{"text_format":"3","workbook":"xlsx","n_sheets":101,"sheets":["Cover","Condensed Consolidated Balance ","Condensed Consolidated Balanc_2","Condensed Consolidated Statemen","Condensed Consolidated Statem_2","Condensed Consolidated Statem_3","Nature of Business","Summary of Significant Accounti","Fair Value of Financial Assets ","Inventory","Prepaid Expenses and Other Curr","Property and Equipment, Net","Goodwill and Intangible Assets,","Accrued Expenses and Other Curr","Debt","Leases","Commitments and Contingencies","Equity","Stock-Based Compensation","Revenue Recognition","License and Distribution Agreem","Benefit Plan","Income Taxes","Segment Information","Related Party Transactions","Subsequent Events","Summary of Significant Accoun_2","Summary of Significant Accoun_3","Fair Value of Financial Asset_2","Inventory (Tables)","Prepaid Expenses and Other Cu_2","Property and Equipment, Net (Ta","Goodwill and Intangible Asset_2","Accrued Expenses and Other Cu_2","Debt (Tables)","Leases (Tables)","Equity (Tables)","Stock-Based Compensation (Table","Revenue Recognition (Tables)","Income Taxes (Tables)","Segment Information (Tables)","Nature of Business (Details Nar","Schedule of Property and Equipm","Schedule of Basic and Diluted N","Schedule of Potentially Dilutiv","Summary of Significant Accoun_4","Schedule of Financial Assets an","Schedule of Reconciliation of C","Schedule of Roll-forward of the","Schedule of Fair Value of Liabi","Schedule of Sponsor Warrants (D","Schedule of May 2022 PIPE Warra","Schedule of Convertible Note Va","Schedule of Reconciliation of t","Schedule of Reconciliation of Y","Schedule of Yorkville Short-ter","Fair Value of Financial Asset_3","Schedule of Major Classes of In","Schedule of Inventory Reserves ","Inventory (Details Narrative)","Schedule of Prepaid Expenses an","Schedule of Property and Equi_2","Property and Equipment, Net (De","Schedule Of Carrying Values Of ","Schedule of Intangible Assets, ","Schedule of Aggregate Amortizat","Goodwill and Intangible Asset_3","Schedule of Accrued Expenses an","Debt (Details Narrative)","Schedule of Lease Costs (Detail","Schedule of Cash and Non-cash A","Schedule of Future Minimum Paym","Leases (Details Narrative)","Commitments and Contingencies (","Summary of the Warrants (Detail","Summary of the Warrants (Deta_2","Equity (Details Narrative)","Schedule of Weighted Average Gr","Schedule of Stock Option Activi","Schedule of Activity Related to","Schedule of Stock-based Compens","Stock-Based Compensation (Detai","Schedule of Disaggregated Reven","Schedule of Changes in Deferred","License and Distribution Agre_2","Benefit Plan (Details Narrative","Schedule of Current and Deferre","Schedule of Reconciliation of_2","Schedule of Deferred tax assets","Schedule of Unrecognized Tax Be","Income Taxes (Details Narrative","Schedule of Financial Informati","Segment Information (Details Na","Related Party Transactions (Det","Schedule Of Antidilutive Securi","Schedule of Reconciliation of_3","Schedule of Reconciliation of W","Schedule of January 20224 Bridg","Schedule of Debt (Details)","Schedule of Changes in Deferr_2","Subsequent Events (Details Narr"],"cells_cut":1,"read":"whole","date_system":"1900"}

{"sheet":"Cover","index":0,"n_rows":27,"n_cols":2,"rows_kept":27,"merged":[[0,0,1,0]]}
["Cover","9 Months Ended"]
[null,"Sep. 30, 2024"]
["Entity Addresses [Line Items]"," "]
["Document Type","S-1"]
["Amendment Flag","false"]
["Entity Registrant Name","CELULARITY\nINC."]
["Entity Central Index Key","0001752828"]
["Entity Tax Identification Number","83-1702591"]
["Entity Incorporation, State or Country Code","DE"]
["Entity Address, Address Line One","170\nPark Avenue"]
["Entity Address, City or Town","Florham\nPark"]
["Entity Address, State or Province","NJ"]
["Entity Address, Postal Zip Code","07932"]
["City Area Code","(908)"]
["Local Phone Number","768-2170"]
["Entity Filer Category","Non-accelerated Filer"]
["Entity Small Business","true"]
["Entity Emerging Growth Company","false"]
["Business Contact [Member]"," "]
["Entity Addresses [Line Items]"," "]
["Entity Address, Address Line One","170\nPark Avenue"]
["Entity Address, City or Town","Florham\nPark"]
["Entity Address, State or Province","NJ"]
["Entity Address, Postal Zip Code","07932"]
["City Area Code","(908)"]
["Local Phone Number","768-2170"]
["Contact Personnel Name","Robert\nJ. Hariri,"]

{"sheet":"Condensed Consolidated Balance ","index":1,"n_rows":84,"n_cols":4,"rows_kept":84}
["Condensed Consolidated Balance Sheets - USD ($) $ in Thousands","Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Current assets:"," "," "," "]
["Cash and cash equivalents",{"v":133,"d":"$ 133"},{"v":227,"d":"$ 227"},{"v":13966,"d":"$ 13,966"}]
["Accounts receivable, net of allowance",{"v":8770,"d":"8,770 "},{"v":10046,"d":"10,046 "},{"v":4452,"d":"4,452 "}]
["Notes receivable"," ",{"v":2072,"d":"2,072 "},{"v":2514,"d":"2,514 "}]
["Inventory",{"v":3963,"d":"3,963 "},{"v":5753,"d":"5,753 "},{"v":5308,"d":"5,308 "}]
["Prepaid expenses and other current assets",{"v":1636,"d":"1,636 "},{"v":1695,"d":"1,695 "},{"v":7262,"d":"7,262 "}]
["Total current assets",{"v":14502,"d":"14,502 "},{"v":19793,"d":"19,793 "},{"v":33502,"d":"33,502 "}]
["Property and equipment, net",{"v":63208,"d":"63,208 "},{"v":67828,"d":"67,828 "},{"v":75655,"d":"75,655 "}]
["Goodwill",{"v":7347,"d":"7,347 "},{"v":7347,"d":"7,347 "},{"v":119694,"d":"119,694 "}]
["Intangible assets, net",{"v":9624,"d":"9,624 "},{"v":11001,"d":"11,001 "},{"v":120994,"d":"120,994 "}]
["Right-of-use assets - operating leases",{"v":10865,"d":"10,865 "},{"v":10990,"d":"10,990 "},{"v":13060,"d":"13,060 "}]
["Restricted cash",{"v":10163,"d":"10,163 "},{"v":9936,"d":"9,936 "},{"v":14836,"d":"14,836 "}]
["Inventory, net of current portion",{"v":12844,"d":"12,844 "},{"v":16657,"d":"16,657 "},{"v":22949,"d":"22,949 "}]
["Other long-term assets",{"v":287,"d":"287 "},{"v":337,"d":"337 "},{"v":376,"d":"376 "}]
["Total assets",{"v":128840,"d":"128,840 "},{"v":143889,"d":"143,889 "},{"v":401066,"d":"401,066 "}]
["Current liabilities:"," "," "," "]
["Accounts payable",{"v":15400,"d":"15,400 "},{"v":14144,"d":"14,144 "},{"v":5810,"d":"5,810 "}]
["Accrued expenses and other current liabilities",{"v":14466,"d":"14,466 "},{"v":7580,"d":"7,580 "},{"v":9069,"d":"9,069 "}]
["Accrued R&D software"," ",{"v":3500,"d":"3,500 "},{"v":7333,"d":"7,333 "}]
["Short-term debt - Yorkville ($17,223 at fair value and $16,623 unpaid principal balance at December 31, 2023 and $37,603 at fair value and $37,000 unpaid principal balance at December 31, 2022)"," ",{"v":17223,"d":"17,223 "},{"v":37603,"d":"37,603 "}]
["Short-term debt - unaffiliated (includes debt measured at fair value of $3,695 at September 30, 2024 and $17,223 at December 31, 2023, respectively)",{"v":3695,"d":"3,695 "},{"v":19331,"d":"19,331 "}," "]
["Other short-term debt"," ",{"v":2108,"d":"2,108 "}," "]
["Short-term debt - related party"," ",{"v":1419,"d":"1,419 "}," "]
["Short-term debt - related parties - C.V. Starr and RWI"," ",{"v":18490,"d":"18,490 "}," "]
["Short-term debt - related parties",{"v":38915,"d":"38,915 "},{"v":19909,"d":"19,909 "}," "]
["Deferred revenue",{"v":3693,"d":"3,693 "},{"v":2834,"d":"2,834 "},{"v":2273,"d":"2,273 "}]
["Total current liabilities",{"v":76169,"d":"76,169 "},{"v":67298,"d":"67,298 "},{"v":62088,"d":"62,088 "}]
["Deferred revenue, net of current portion",{"v":2639,"d":"2,639 "},{"v":3186,"d":"3,186 "},{"v":2219,"d":"2,219 "}]
["Acquisition-related contingent consideration",{"v":1606,"d":"1,606 "},{"v":1606,"d":"1,606 "},{"v":105945,"d":"105,945 "}]
["Noncurrent lease liabilities - operating",{"v":26451,"d":"26,451 "},{"v":26177,"d":"26,177 "},{"v":27985,"d":"27,985 "}]
["Warrant liabilities",{"v":4403,"d":"4,403 "},{"v":4359,"d":"4,359 "},{"v":3598,"d":"3,598 "}]
["Deferred income tax liabilities",{"v":9,"d":"9 "},{"v":9,"d":"9 "},{"v":9,"d":"9 "}]
["Other liabilities",{"v":283,"d":"283 "},{"v":294,"d":"294 "},{"v":321,"d":"321 "}]
["Total liabilities",{"v":111560,"d":"111,560 "},{"v":102929,"d":"102,929 "},{"v":202165,"d":"202,165 "}]
["Commitments and contingencies (Note 9)"," "," "," "]
["Stockholders’ equity"," "," "," "]
["Preferred stock, value"," "," "," "]
["Common stock, value",{"v":2,"d":"2 "},{"v":19,"d":"19 "},{"v":15,"d":"15 "}]
["Additional paid-in capital",{"v":903670,"d":"903,670 "},{"v":882732,"d":"882,732 "},{"v":844373,"d":"844,373 "}]
["Accumulated other comprehensive loss",{"v":-2,"d":"(2)"}," ",{"v":9,"d":"9 "}]
["Accumulated deficit",{"v":-886390,"d":"(886,390)"},{"v":-841791,"d":"(841,791)"},{"v":-645496,"d":"(645,496)"}]
["Total stockholders’ equity",{"v":17280,"d":"17,280 "},{"v":40960,"d":"40,960 "},{"v":198901,"d":"198,901 "}]
["Total liabilities and stockholders’ equity",{"v":128840,"d":"$ 128,840"},{"v":143889,"d":"143,889 "},{"v":401066,"d":"$ 401,066"}]
["Previously Reported [Member]"," "," "," "]
["Current assets:"," "," "," "]
["Cash and cash equivalents"," ",{"v":227,"d":"227 "}," "]
["Accounts receivable, net of allowance"," ",{"v":10046,"d":"10,046 "}," "]
["Notes receivable"," ",{"v":2072,"d":"2,072 "}," "]
["Inventory"," ",{"v":5753,"d":"5,753 "}," "]
["Prepaid expenses and other current assets"," ",{"v":1695,"d":"1,695 "}," "]
["Total current assets"," ",{"v":19793,"d":"19,793 "}," "]
["Property and equipment, net"," ",{"v":67828,"d":"67,828 "}," "]
["Goodwill"," ",{"v":7347,"d":"7,347 "}," "]
["Intangible assets, net"," ",{"v":11001,"d":"11,001 "}," "]
["Right-of-use assets - operating leases"," ",{"v":10990,"d":"10,990 "}," "]
["Restricted cash"," ",{"v":9936,"d":"9,936 "}," "]
["Inventory, net of current portion"," ",{"v":16657,"d":"16,657 "}," "]
["Other long-term assets"," ",{"v":337,"d":"337 "}," "]
["Total assets"," ",{"v":143889,"d":"143,889 "}," "]
["Current liabilities:"," "," "," "]
["Accounts payable"," ",{"v":14144,"d":"14,144 "}," "]
["Accrued expenses and other current liabilities"," ",{"v":7580,"d":"7,580 "}," "]
["Accrued R&D software"," ",{"v":3500,"d":"3,500 "}," "]
["Short-term debt - unaffiliated (includes debt measured at fair value of $3,695 at September 30, 2024 and $17,223 at December 31, 2023, respectively)"," ",{"v":19331,"d":"19,331 "}," "]
["Short-term debt - related parties"," ",{"v":19909,"d":"19,909 "}," "]
["Deferred revenue"," ",{"v":2834,"d":"2,834 "}," "]
["Total current liabilities"," ",{"v":67298,"d":"67,298 "}," "]
["Deferred revenue, net of current portion"," ",{"v":3186,"d":"3,186 "}," "]
["Acquisition-related contingent consideration"," ",{"v":1606,"d":"1,606 "}," "]
["Noncurrent lease liabilities - operating"," ",{"v":26177,"d":"26,177 "}," "]
["Warrant liabilities"," ",{"v":4359,"d":"4,359 "}," "]
["Deferred income tax liabilities"," ",{"v":9,"d":"9 "}," "]
["Other liabilities"," ",{"v":294,"d":"294 "}," "]
["Total liabilities"," ",{"v":102929,"d":"102,929 "}," "]
["Commitments and contingencies (Note 9)"," "," "," "]
["Stockholders’ equity"," "," "," "]
["Preferred stock, value"," "," "," "]
["Common stock, value"," ",{"v":2,"d":"2 "}," "]
["Additional paid-in capital"," ",{"v":882749,"d":"882,749 "}," "]
["Accumulated other comprehensive loss"," "," "," "]
["Accumulated deficit"," ",{"v":-841791,"d":"(841,791)"}," "]
["Total stockholders’ equity"," ",{"v":40960,"d":"40,960 "}," "]
["Total liabilities and stockholders’ equity"," ",{"v":143889,"d":"$ 143,889"}," "]

{"sheet":"Condensed Consolidated Balanc_2","index":2,"n_rows":13,"n_cols":4,"rows_kept":13}
["Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands","Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Statement of Financial Position [Abstract]"," "," "," "]
["Accounts receivable, net of allowance",{"v":6059,"d":"$ 6,059"},{"v":5837,"d":"$ 5,837"},{"v":1789,"d":"$ 1,789"}]
["Short-term debt, fair value",{"v":3695,"d":"$ 3,695"},{"v":17223,"d":"17,223 "},{"v":37603,"d":"37,603 "}]
["Short-term debt, unpaid principal balance"," ",{"v":16623,"d":"$ 16,623"},{"v":37000,"d":"$ 37,000"}]
["Preferred stock par value",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Preferred stock, shares authorized",{"v":10000000,"d":"10,000,000 "},{"v":10000000,"d":"10,000,000 "},{"v":10000000,"d":"10,000,000 "}]
["Preferred stock, shares issued",{"v":0,"d":"0 "},{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Preferred stock, shares outstanding",{"v":0,"d":"0 "},{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Common stock, par value",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, shares authorized",{"v":730000000,"d":"730,000,000 "},{"v":730000000,"d":"730,000,000 "},{"v":730000000,"d":"730,000,000 "}]
["Common stock, shares issued",{"v":21984614,"d":"21,984,614 "},{"v":19378192,"d":"19,378,192 "},{"v":14892129,"d":"14,892,129 "}]
["Common stock, shares outstanding",{"v":21984614,"d":"21,984,614 "},{"v":19378192,"d":"19,378,192 "},{"v":14892129,"d":"14,892,129 "}]

{"sheet":"Condensed Consolidated Statemen","index":3,"n_rows":48,"n_cols":7,"rows_kept":48,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[0,5,0,6]]}
["Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)","3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Revenues"," "," "," "," "," "," "]
["Total net revenues",{"v":9296000,"d":"$ 9,296,000"},{"v":3786000,"d":"$ 3,786,000"},{"v":36088000,"d":"$ 36,088,000"},{"v":10659000,"d":"$ 10,659,000"},{"v":22771000,"d":"$ 22,771,000"},{"v":17975000,"d":"$ 17,975,000"}]
["Operating expenses"," "," "," "," "," "," "]
["Cost of revenues",{"v":3883000,"d":"3,883,000 "},{"v":3602000,"d":"3,602,000 "},{"v":7646000,"d":"7,646,000 "},{"v":6407000,"d":"6,407,000 "}," "," "]
["Research and development",{"v":3915000,"d":"3,915,000 "},{"v":5182000,"d":"5,182,000 "},{"v":13558000,"d":"13,558,000 "},{"v":30737000,"d":"30,737,000 "},{"v":30465000,"d":"30,465,000 "},{"v":78363000,"d":"78,363,000 "}]
["Software cease-use costs"," ",{"v":243000,"d":"243,000 "}," ",{"v":24161000,"d":"24,161,000 "}," "," "]
["Selling, general and administrative",{"v":12650000,"d":"12,650,000 "},{"v":10748000,"d":"10,748,000 "},{"v":42585000,"d":"42,585,000 "},{"v":37508000,"d":"37,508,000 "},{"v":50576000,"d":"50,576,000 "},{"v":66021000,"d":"66,021,000 "}]
["Change in fair value of contingent consideration liability"," "," "," ",{"v":-104339000,"d":"(104,339,000)"},{"v":-104339000,"d":"(104,339,000)"},{"v":-126277000,"d":"(126,277,000)"}]
["Goodwill impairment"," ",{"v":82714000,"d":"82,714,000 "}," ",{"v":112347000,"d":"112,347,000 "},{"v":112347000,"d":"112,347,000 "},{"v":3610000,"d":"3,610,000 "}]
["IPR&D impairment"," "," "," ",{"v":107800000,"d":"107,800,000 "},{"v":107800000,"d":"107,800,000 "}," "]
["Amortization of acquired intangible assets",{"v":375000,"d":"375,000 "},{"v":553000,"d":"553,000 "},{"v":1377000,"d":"1,377,000 "},{"v":1640000,"d":"1,640,000 "},{"v":2193000,"d":"2,193,000 "},{"v":2193000,"d":"2,193,000 "}]
["Total operating expenses",{"v":20823000,"d":"20,823,000 "},{"v":103042000,"d":"103,042,000 "},{"v":65166000,"d":"65,166,000 "},{"v":216261000,"d":"216,261,000 "},{"v":215058000,"d":"215,058,000 "},{"v":43575000,"d":"43,575,000 "}]
["Loss from operations",{"v":-11527000,"d":"(11,527,000)"},{"v":-99256000,"d":"(99,256,000)"},{"v":-29078000,"d":"(29,078,000)"},{"v":-205602000,"d":"(205,602,000)"},{"v":-192287000,"d":"(192,287,000)"},{"v":-25600000,"d":"(25,600,000)"}]
["Other income (expense):"," "," "," "," "," "," "]
["Interest income",{"v":77000,"d":"77,000 "},{"v":23000,"d":"23,000 "},{"v":254000,"d":"254,000 "},{"v":205000,"d":"205,000 "},{"v":320000,"d":"320,000 "},{"v":365000,"d":"365,000 "}]
["Interest expense",{"v":-1752000,"d":"(1,752,000)"},{"v":-971000,"d":"(971,000)"},{"v":-4452000,"d":"(4,452,000)"},{"v":-2352000,"d":"(2,352,000)"},{"v":-3015000,"d":"(3,015,000)"}," "]
["Change in fair value of warrant liabilities",{"v":714000,"d":"714,000 "},{"v":5187000,"d":"5,187,000 "},{"v":-1156000,"d":"(1,156,000)"},{"v":6788000,"d":"6,788,000 "},{"v":6164000,"d":"6,164,000 "},{"v":42109000,"d":"42,109,000 "}]
["Change in fair value of debt",{"v":-708000,"d":"(708,000)"},{"v":2003000,"d":"2,003,000 "},{"v":-694000,"d":"(694,000)"},{"v":-354000,"d":"(354,000)"},{"v":-1177000,"d":"(1,177,000)"},{"v":-2522000,"d":"(2,522,000)"}]
["Loss on debt extinguishment"," "," ",{"v":-3908000,"d":"(3,908,000)"}," "," "," "]
["Other expense, net",{"v":-2902000,"d":"(2,902,000)"},{"v":-862000,"d":"(862,000)"},{"v":-5565000,"d":"(5,565,000)"},{"v":-4527000,"d":"(4,527,000)"},{"v":-6290000,"d":"(6,290,000)"},{"v":-147000,"d":"(147,000)"}]
["Total other income (expense)",{"v":-4571000,"d":"(4,571,000)"},{"v":5380000,"d":"5,380,000 "},{"v":-15521000,"d":"(15,521,000)"},{"v":-240000,"d":"(240,000)"},{"v":-3998000,"d":"(3,998,000)"},{"v":39805000,"d":"39,805,000 "}]
["Loss before income taxes",{"v":-16098000,"d":"(16,098,000)"},{"v":-93876000,"d":"(93,876,000)"},{"v":-44599000,"d":"(44,599,000)"},{"v":-205842000,"d":"(205,842,000)"},{"v":-196285000,"d":"(196,285,000)"},{"v":14205000,"d":"14,205,000 "}]
["Income tax expense (benefit)"," "," "," "," ",{"v":10000,"d":"10,000 "},{"v":13000,"d":"13,000 "}]
["Net loss",{"v":-16098000,"d":"(16,098,000)"},{"v":-93876000,"d":"(93,876,000)"},{"v":-44599000,"d":"(44,599,000)"},{"v":-205842000,"d":"(205,842,000)"},{"v":-196295000,"d":"(196,295,000)"},{"v":14192000,"d":"14,192,000 "}]
["Change in fair value of debt due to change in credit risk, net of tax",{"v":-2000,"d":"(2,000)"}," ",{"v":-2000,"d":"(2,000)"},{"v":2541000,"d":"2,541,000 "},{"v":146000,"d":"146,000 "},{"v":9000,"d":"9,000 "}]
["Other comprehensive (loss) income",{"v":-2000,"d":"(2,000)"}," ",{"v":-2000,"d":"(2,000)"},{"v":2541000,"d":"2,541,000 "},{"v":146000,"d":"146,000 "},{"v":9000,"d":"9,000 "}]
["Comprehensive loss",{"v":-16100000,"d":"$ (16,100,000)"},{"v":-93876000,"d":"$ (93,876,000)"},{"v":-44601000,"d":"$ (44,601,000)"},{"v":-203301000,"d":"$ (203,301,000)"},{"v":-196149000,"d":"$ (196,149,000)"},{"v":14201000,"d":"$ 14,201,000"}]
["Net (loss) income per share - basic",{"v":-0.73,"d":"$ (0.73)"},{"v":-4.98,"d":"$ (4.98)"},{"v":-2.05,"d":"$ (2.05)"},{"v":-11.86,"d":"$ (11.86)"},{"v":-11.02,"d":"$ (11.02)"},{"v":1.01,"d":"$ 1.01"}]
["Weighted average shares outstanding - basic",{"v":21976339,"d":"21,976,339 "},{"v":18831713,"d":"18,831,713 "},{"v":21756498,"d":"21,756,498 "},{"v":17353605,"d":"17,353,605 "},{"v":17813044,"d":"17,813,044 "},{"v":13990703,"d":"13,990,703 "}]
["Net (loss) income per share - diluted",{"v":-0.73,"d":"$ (0.73)"},{"v":-4.98,"d":"$ (4.98)"},{"v":-2.05,"d":"$ (2.05)"},{"v":-11.86,"d":"$ (11.86)"},{"v":-11.02,"d":"$ (11.02)"},{"v":0.95,"d":"$ 0.95"}]
["Weighted average shares outstanding - diluted",{"v":21976339,"d":"21,976,339 "},{"v":18831713,"d":"18,831,713 "},{"v":21756498,"d":"21,756,498 "},{"v":17353605,"d":"17,353,605 "},{"v":17813044,"d":"17,813,044 "},{"v":14983002,"d":"14,983,002 "}]
["Product [Member]"," "," "," "," "," "," "]
["Revenues"," "," "," "," "," "," "]
["Total net revenues",{"v":3393000,"d":"$ 3,393,000"},{"v":1684000,"d":"$ 1,684,000"},{"v":26199000,"d":"$ 26,199,000"},{"v":3633000,"d":"$ 3,633,000"},{"v":13149000,"d":"$ 13,149,000"},{"v":3749000,"d":"$ 3,749,000"}]
["Operating expenses"," "," "," "," "," "," "]
["Cost of revenues",{"v":547000,"d":"547,000 "},{"v":557000,"d":"557,000 "},{"v":2888000,"d":"2,888,000 "},{"v":1486000,"d":"1,486,000 "},{"v":8628000,"d":"8,628,000 "},{"v":2353000,"d":"2,353,000 "}]
["Service [Member]"," "," "," "," "," "," "]
["Revenues"," "," "," "," "," "," "]
["Total net revenues",{"v":1292000,"d":"1,292,000 "},{"v":1427000,"d":"1,427,000 "},{"v":3857000,"d":"3,857,000 "},{"v":4062000,"d":"4,062,000 "},{"v":5441000,"d":"5,441,000 "},{"v":5512000,"d":"5,512,000 "}]
["Operating expenses"," "," "," "," "," "," "]
["Cost of revenues",{"v":238000,"d":"238,000 "},{"v":398000,"d":"398,000 "},{"v":952000,"d":"952,000 "},{"v":1355000,"d":"1,355,000 "},{"v":1650000,"d":"1,650,000 "},{"v":3536000,"d":"3,536,000 "}]
["License Royalty And Other [Member]"," "," "," "," "," "," "]
["Revenues"," "," "," "," "," "," "]
["Total net revenues",{"v":4611000,"d":"4,611,000 "},{"v":675000,"d":"675,000 "},{"v":6032000,"d":"6,032,000 "},{"v":2964000,"d":"2,964,000 "},{"v":4181000,"d":"4,181,000 "},{"v":8714000,"d":"8,714,000 "}]
["Operating expenses"," "," "," "," "," "," "]
["Cost of revenues",{"v":3098000,"d":"$ 3,098,000"},{"v":2647000,"d":"$ 2,647,000"},{"v":3806000,"d":"$ 3,806,000"},{"v":3566000,"d":"$ 3,566,000"},{"v":5738000,"d":"$ 5,738,000"},{"v":13776000,"d":"$ 13,776,000"}]

{"sheet":"Condensed Consolidated Statem_2","index":4,"n_rows":162,"n_cols":11,"rows_kept":162}
["Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands","Common Stock [Member]","Common Stock [Member] Previously Reported [Member]","Additional Paid-in Capital [Member]","Additional Paid-in Capital [Member] Previously Reported [Member]","Retained Earnings [Member]","Retained Earnings [Member] Previously Reported [Member]","AOCI Including Portion Attributable to Noncontrolling Interest [Member]","AOCI Including Portion Attributable to Noncontrolling Interest [Member] Previously Reported [Member]","Total","Previously Reported [Member]"]
["Balances at Dec. 31, 2021",{"v":12,"d":"$ 12"}," ",{"v":763087,"d":"$ 763,087"}," ",{"v":-663681,"d":"$ (663,681)"}," "," "," ",{"v":99418,"d":"$ 99,418"}," "]
["Balance, shares at Dec. 31, 2021",{"v":12430788,"d":"12,430,788 "}," "," "," "," "," "," "," "," "," "]
["Cumulative effect adjustment ASU 2016-02"," "," "," "," ",{"v":3993,"d":"3,993 "}," "," "," ",{"v":3993,"d":"3,993 "}," "]
["Reclassification of previously exercised stock options"," "," ",{"v":441,"d":"441 "}," "," "," "," "," ",{"v":441,"d":"441 "}," "]
["Reclassification of previously exercised stock options, shares",{"v":13125,"d":"13,125 "}," "," "," "," "," "," "," "," "," "]
["Exercise of stock options"," "," ",{"v":948,"d":"948 "}," "," "," "," "," ",{"v":948,"d":"948 "}," "]
["Exercise of stock options, shares",{"v":171047,"d":"171,047 "}," "," "," "," "," "," "," "," "," "]
["Purchase and retirement of common shares"," "," ",{"v":-86,"d":"(86)"}," "," "," "," "," ",{"v":-86,"d":"(86)"}," "]
["Purchase and retirement of common shares, shares",{"v":-1050,"d":"(1,050)"}," "," "," "," "," "," "," "," "," "]
["Exercise of warrants",{"v":2,"d":"$ 2"}," ",{"v":46489,"d":"46,489 "}," "," "," "," "," ",{"v":46491,"d":"46,491 "}," "]
["Exercise of warrants, shares",{"v":1328189,"d":"1,328,189 "}," "," "," "," "," "," "," "," "," "]
["Common stock issued pursuant to short-term debt conversion",{"v":1,"d":"$ 1"}," ",{"v":4098,"d":"4,098 "}," "," "," ",{"v":-11,"d":"(11)"}," ",{"v":4088,"d":"4,088 "}," "]
["Common stock issued pursuant to short-term debt conversion, shares",{"v":262797,"d":"262,797 "}," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units"," "," "," "," "," "," "," "," ",{"v":0,"d":"0 "}," "]
["Vesting of restricted stock units, in shares",{"v":23252,"d":"23,252 "}," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units"," "," ",{"v":-132,"d":"(132)"}," "," "," "," "," ",{"v":-132,"d":"(132)"}," "]
["Tax withholding on vesting of restricted stock units, shares",{"v":-7067,"d":"(7,067)"}," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," ",{"v":15856,"d":"15,856 "}," "," "," "," "," ",{"v":15856,"d":"15,856 "}," "]
["Issuance of common stock and warrants in PIPE Offering, net of offering expenses"," "," ",{"v":7651,"d":"7,651 "}," "," "," "," "," ",{"v":7651,"d":"7,651 "}," "]
["Issuance of common stock and warrants in PIPE Offering, net of offering expenses, in shares",{"v":405406,"d":"405,406 "}," "," "," "," "," "," "," "," "," "]
["Issuance of common stock in ATM offering, net of commissions and offering expenses"," "," ",{"v":6021,"d":"6,021 "}," "," "," "," "," ",{"v":6021,"d":"6,021 "}," "]
["Issuance of common stock in ATM offering, net of commissions and offering expenses, shares",{"v":265641,"d":"265,641 "}," "," "," "," "," "," "," "," "," "]
["Change in fair value of debt due to change in credit risk, net of tax"," "," "," "," "," "," ",{"v":20,"d":"20 "}," ",{"v":20,"d":"20 "}," "]
["Net income (loss)"," "," "," "," ",{"v":14192,"d":"14,192 "}," "," "," ",{"v":14192,"d":"14,192 "}," "]
["Balances at Dec. 31, 2022",{"v":15,"d":"$ 15"},{"v":1,"d":"$ 1"},{"v":844373,"d":"844,373 "},{"v":844387,"d":"$ 844,387"},{"v":-645496,"d":"(645,496)"},{"v":-645496,"d":"$ (645,496)"},{"v":9,"d":"9 "},{"v":9,"d":"$ 9"},{"v":198901,"d":"198,901 "},{"v":198901,"d":"$ 198,901"}]
["Balance, shares at Dec. 31, 2022",{"v":14892129,"d":"14,892,129 "}," "," "," "," "," "," "," "," "," "]
["Exercise of stock options"," "," "," ",{"v":300,"d":"300 "}," "," "," "," "," ",{"v":300,"d":"300 "}]
["Exercise of stock options, shares",{"v":107100,"d":"107,100 "}," "," "," "," "," "," "," "," "," "]
["Common stock issued pursuant to short-term debt conversion"," "," "," ",{"v":3510,"d":"3,510 "}," "," "," ",{"v":-152,"d":"(152)"}," ",{"v":3358,"d":"3,358 "}]
["Common stock issued pursuant to short-term debt conversion, shares",{"v":365612,"d":"365,612 "}," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units"," "," "," ",{"v":-53,"d":"(53)"}," "," "," "," "," ",{"v":-53,"d":"(53)"}]
["Tax withholding on vesting of restricted stock units, shares",{"v":-8110,"d":"(8,110)"}," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," "," ",{"v":3988,"d":"3,988 "}," "," "," "," "," ",{"v":3988,"d":"3,988 "}]
["Change in fair value of debt due to change in credit risk, net of tax"," "," "," "," "," "," "," ",{"v":2810,"d":"2,810 "}," ",{"v":2810,"d":"2,810 "}]
["Net income (loss)"," "," "," "," "," ",{"v":-64017,"d":"(64,017)"}," "," "," ",{"v":-64017,"d":"(64,017)"}]
["Issuance of common stock for stem-cells to be used in research and development"," "," "," ",{"v":1000,"d":"1,000 "}," "," "," "," "," ",{"v":1000,"d":"1,000 "}]
["Issuance of common stock for stem-cells to be used in research and development, shares",{"v":169492,"d":"169,492 "}," "," "," "," "," "," "," "," "," "]
["Issuance of warrants on senior secured bridge loan"," "," "," ",{"v":274,"d":"274 "}," "," "," "," "," ",{"v":274,"d":"274 "}]
["Vesting of restricted stock units"," "," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units, shares",{"v":25339,"d":"25,339 "}," "," "," "," "," "," "," "," "," "]
["Issuance of common stock in PIPE Offering, net of offering expenses"," "," "," ",{"v":8931,"d":"8,931 "}," "," "," "," "," ",{"v":8931,"d":"8,931 "}]
["Issuance of common stock in PIPE Offering, net of offering expenses, shares",{"v":938183,"d":"938,183 "}," "," "," "," "," "," "," "," "," "]
["Issuance of common stock under ATM Agreement"," "," "," ",{"v":136,"d":"136 "}," "," "," "," "," ",{"v":136,"d":"136 "}]
["Issuance of common stock under ATM Agreement, shares",{"v":13296,"d":"13,296 "}," "," "," "," "," "," "," "," "," "]
["Balances at Mar. 31, 2023",{"v":1,"d":"$ 1"}," ",{"v":862473,"d":"862,473 "}," ",{"v":-709513,"d":"(709,513)"}," ",{"v":2667,"d":"2,667 "}," ",{"v":155628,"d":"155,628 "}," "]
["Balance, shares at Mar. 31, 2023",{"v":16503041,"d":"16,503,041 "}," "," "," "," "," "," "," "," "," "]
["Balances at Dec. 31, 2022",{"v":15,"d":"$ 15"},{"v":1,"d":"1 "},{"v":844373,"d":"844,373 "},{"v":844387,"d":"844,387 "},{"v":-645496,"d":"(645,496)"},{"v":-645496,"d":"(645,496)"},{"v":9,"d":"9 "},{"v":9,"d":"9 "},{"v":198901,"d":"198,901 "},{"v":198901,"d":"198,901 "}]
["Balance, shares at Dec. 31, 2022",{"v":14892129,"d":"14,892,129 "}," "," "," "," "," "," "," "," "," "]
["Net income (loss)"," "," "," "," "," "," "," "," ",{"v":-205842,"d":"(205,842)"}," "]
["Balances at Sep. 30, 2023",{"v":2,"d":"$ 2"}," ",{"v":879188,"d":"879,188 "}," ",{"v":-851338,"d":"(851,338)"}," ",{"v":2395,"d":"2,395 "}," ",{"v":30247,"d":"30,247 "}," "]
["Balance, shares at Sep. 30, 2023",{"v":19365913,"d":"19,365,913 "}," "," "," "," "," "," "," "," "," "]
["Balances at Dec. 31, 2022",{"v":15,"d":"$ 15"},{"v":1,"d":"1 "},{"v":844373,"d":"844,373 "},{"v":844387,"d":"844,387 "},{"v":-645496,"d":"(645,496)"},{"v":-645496,"d":"(645,496)"},{"v":9,"d":"9 "},{"v":9,"d":"9 "},{"v":198901,"d":"198,901 "},{"v":198901,"d":"198,901 "}]
["Balance, shares at Dec. 31, 2022",{"v":14892129,"d":"14,892,129 "}," "," "," "," "," "," "," "," "," "]
["Exercise of stock options"," "," ",{"v":304,"d":"304 "}," "," "," "," "," ",{"v":304,"d":"304 "}," "]
["Exercise of stock options, shares",{"v":108637,"d":"108,637 "}," "," "," "," "," "," "," "," "," "]
["Common stock issued pursuant to short-term debt conversion",{"v":1,"d":"$ 1"}," ",{"v":4598,"d":"4,598 "}," "," "," ",{"v":-155,"d":"(155)"}," ",{"v":4444,"d":"4,444 "}," "]
["Common stock issued pursuant to short-term debt conversion, shares",{"v":559481,"d":"559,481 "}," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units"," "," ",{"v":-101,"d":"(101)"}," "," "," "," "," ",{"v":-101,"d":"(101)"}," "]
["Tax withholding on vesting of restricted stock units, shares",{"v":-19130,"d":"(19,130)"}," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," ",{"v":15017,"d":"15,017 "}," "," "," "," "," ",{"v":15017,"d":"15,017 "}," "]
["Change in fair value of debt due to change in credit risk, net of tax"," "," "," "," "," "," ",{"v":146,"d":"146 "}," ",{"v":146,"d":"146 "}," "]
["Net income (loss)"," "," "," "," ",{"v":-196295,"d":"(196,295)"}," "," "," ",{"v":-196295,"d":"(196,295)"}," "]
["Issuance of common stock in Registered Direct Offering, net of offering expenses",{"v":2,"d":"$ 2"}," ",{"v":1320,"d":"1,320 "}," "," "," "," "," ",{"v":1322,"d":"1,322 "}," "]
["Issuance of common stock in Registered Direct Offering, net of offering expenses, shares",{"v":1780220,"d":"1,780,220 "}," "," "," "," "," "," "," "," "," "]
["Common stock issued pursuant to short-term debt maturity extension"," "," ",{"v":712,"d":"712 "}," "," "," "," "," ",{"v":712,"d":"712 "}," "]
["Common stock issued pursuant to short-term debt maturity extension, shares",{"v":270731,"d":"270,731 "}," "," "," "," "," "," "," "," "," "]
["Fair value of warrant modification for professional services"," "," ",{"v":403,"d":"403 "}," "," "," "," "," ",{"v":403,"d":"403 "}," "]
["Issuance of common stock for stem-cells to be used in research and development"," "," ",{"v":1000,"d":"1,000 "}," "," "," "," "," ",{"v":1000,"d":"1,000 "}," "]
["Issuance of common stock for stem-cells to be used in research and development, shares",{"v":169492,"d":"169,492 "}," "," "," "," "," "," "," "," "," "]
["Issuance of warrants on senior secured bridge loan"," "," ",{"v":2016,"d":"2,016 "}," "," "," "," "," ",{"v":2016,"d":"2,016 "}," "]
["Vesting of restricted stock units"," "," "," "," "," "," "," "," ",{"v":0,"d":"0 "}," "]
["Vesting of restricted stock units, shares",{"v":83759,"d":"83,759 "}," "," "," "," "," "," "," "," "," "]
["Issuance of common stock in PIPE Offering, net of offering expenses",{"v":1,"d":"$ 1"}," ",{"v":12680,"d":"12,680 "}," "," "," "," "," ",{"v":12681,"d":"12,681 "}," "]
["Issuance of common stock in PIPE Offering, net of offering expenses, shares",{"v":1519579,"d":"1,519,579 "}," "," "," "," "," "," "," "," "," "]
["Issuance of common stock under ATM Agreement"," "," ",{"v":136,"d":"136 "}," "," "," "," "," ",{"v":136,"d":"136 "}," "]
["Issuance of common stock under ATM Agreement, shares",{"v":13296,"d":"13,296 "}," "," "," "," "," "," "," "," "," "]
["Issuance of warrants (C.V. Starr & RWI)"," "," ",{"v":274,"d":"274 "}," "," "," "," "," ",{"v":274,"d":"274 "}," "]
["Balances at Dec. 31, 2023",{"v":19,"d":"$ 19"},{"v":2,"d":"2 "},{"v":882732,"d":"882,732 "},{"v":882749,"d":"882,749 "},{"v":-841791,"d":"(841,791)"},{"v":-841791,"d":"(841,791)"}," "," ",{"v":40960,"d":"40,960 "},{"v":40960,"d":"40,960 "}]
["Balance, shares at Dec. 31, 2023",{"v":19378192,"d":"19,378,192 "}," "," "," "," "," "," "," "," "," "]
["Balances at Mar. 31, 2023",{"v":1,"d":"$ 1"}," ",{"v":862473,"d":"862,473 "}," ",{"v":-709513,"d":"(709,513)"}," ",{"v":2667,"d":"2,667 "}," ",{"v":155628,"d":"155,628 "}," "]
["Balance, shares at Mar. 31, 2023",{"v":16503041,"d":"16,503,041 "}," "," "," "," "," "," "," "," "," "]
["Exercise of stock options"," "," ",{"v":4,"d":"4 "}," "," "," "," "," ",{"v":4,"d":"4 "}," "]
["Exercise of stock options, shares",{"v":1537,"d":"1,537 "}," "," "," "," "," "," "," "," "," "]
["Common stock issued pursuant to short-term debt conversion"," "," ",{"v":282,"d":"282 "}," "," "," ",{"v":-10,"d":"(10)"}," ",{"v":272,"d":"272 "}," "]
["Common stock issued pursuant to short-term debt conversion, shares",{"v":38085,"d":"38,085 "}," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units"," "," ",{"v":-33,"d":"(33)"}," "," "," "," "," ",{"v":-33,"d":"(33)"}," "]
["Tax withholding on vesting of restricted stock units, shares",{"v":-4589,"d":"(4,589)"}," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," ",{"v":3856,"d":"3,856 "}," "," "," "," "," ",{"v":3856,"d":"3,856 "}," "]
["Change in fair value of debt due to change in credit risk, net of tax"," "," "," "," "," "," ",{"v":-269,"d":"(269)"}," ",{"v":-269,"d":"(269)"}," "]
["Net income (loss)"," "," "," "," ",{"v":-47949,"d":"(47,949)"}," "," "," ",{"v":-47949,"d":"(47,949)"}," "]
["Issuance of common stock in Registered Direct Offering, net of offering expenses",{"v":1,"d":"$ 1"}," ",{"v":1225,"d":"1,225 "}," "," "," "," "," ",{"v":1226,"d":"1,226 "}," "]
["Issuance of common stock in Registered Direct Offering, net of offering expenses, shares",{"v":923077,"d":"923,077 "}," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units"," "," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units, shares",{"v":39178,"d":"39,178 "}," "," "," "," "," "," "," "," "," "]
["Issuance of common stock in PIPE Offering, net of offering expenses"," "," ",{"v":3750,"d":"3,750 "}," "," "," "," "," ",{"v":3750,"d":"3,750 "}," "]
["Issuance of common stock in PIPE Offering, net of offering expenses, shares",{"v":581395,"d":"581,395 "}," "," "," "," "," "," "," "," "," "]
["Issuance of warrants (C.V. Starr & RWI)"," "," ",{"v":2016,"d":"2,016 "}," "," "," "," "," ",{"v":2016,"d":"2,016 "}," "]
["Balances at Jun. 30, 2023",{"v":2,"d":"$ 2"}," ",{"v":873573,"d":"873,573 "}," ",{"v":-757462,"d":"(757,462)"}," ",{"v":2388,"d":"2,388 "}," ",{"v":118501,"d":"118,501 "}," "]
["Balance, shares at Jun. 30, 2023",{"v":18081724,"d":"18,081,724 "}," "," "," "," "," "," "," "," "," "]
["Common stock issued pursuant to short-term debt conversion"," "," ",{"v":807,"d":"807 "}," "," "," ",{"v":7,"d":"7 "}," ",{"v":814,"d":"814 "}," "]
["Common stock issued pursuant to short-term debt conversion, shares",{"v":155785,"d":"155,785 "}," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units"," "," ",{"v":-1,"d":"(1)"}," "," "," "," "," ",{"v":-1,"d":"(1)"}," "]
["Tax withholding on vesting of restricted stock units, shares",{"v":-275,"d":"(275)"}," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," ",{"v":3598,"d":"3,598 "}," "," "," "," "," ",{"v":3598,"d":"3,598 "}," "]
["Net income (loss)"," "," "," "," ",{"v":-93876,"d":"(93,876)"}," "," "," ",{"v":-93876,"d":"(93,876)"}," "]
["Issuance of common stock in Registered Direct Offering, net of offering expenses"," "," ",{"v":96,"d":"96 "}," "," "," "," "," ",{"v":96,"d":"96 "}," "]
["Issuance of common stock in Registered Direct Offering, net of offering expenses, shares",{"v":857143,"d":"857,143 "}," "," "," "," "," "," "," "," "," "]
["Common stock issued pursuant to short-term debt maturity extension"," "," ",{"v":712,"d":"712 "}," "," "," "," "," ",{"v":712,"d":"712 "}," "]
["Common stock issued pursuant to short-term debt maturity extension, shares",{"v":270731,"d":"270,731 "}," "," "," "," "," "," "," "," "," "]
["Fair value of warrant modification for professional services"," "," ",{"v":403,"d":"403 "}," "," "," "," "," ",{"v":403,"d":"403 "}," "]
["Vesting of restricted stock units"," "," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units, shares",{"v":805,"d":"805 "}," "," "," "," "," "," "," "," "," "]
["Balances at Sep. 30, 2023",{"v":2,"d":"$ 2"}," ",{"v":879188,"d":"879,188 "}," ",{"v":-851338,"d":"(851,338)"}," ",{"v":2395,"d":"2,395 "}," ",{"v":30247,"d":"30,247 "}," "]
["Balance, shares at Sep. 30, 2023",{"v":19365913,"d":"19,365,913 "}," "," "," "," "," "," "," "," "," "]
["Balances at Dec. 31, 2023",{"v":19,"d":"$ 19"},{"v":2,"d":"2 "},{"v":882732,"d":"882,732 "},{"v":882749,"d":"882,749 "},{"v":-841791,"d":"(841,791)"},{"v":-841791,"d":"(841,791)"}," "," ",{"v":40960,"d":"40,960 "},{"v":40960,"d":"40,960 "}]
["Balance, shares at Dec. 31, 2023",{"v":19378192,"d":"19,378,192 "}," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units"," "," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units, in shares",{"v":233361,"d":"233,361 "}," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units"," "," "," ",{"v":-357,"d":"(357)"}," "," "," "," "," ",{"v":-357,"d":"(357)"}]
["Tax withholding on vesting of restricted stock units, shares",{"v":-80672,"d":"(80,672)"}," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," "," ",{"v":2966,"d":"2,966 "}," "," "," "," "," ",{"v":2966,"d":"2,966 "}]
["Issuance of common stock and warrants in PIPE Offering, net of offering expenses"," "," "," ",{"v":6000,"d":"6,000 "}," "," "," "," "," ",{"v":6000,"d":"6,000 "}]
["Issuance of common stock and warrants in PIPE Offering, net of offering expenses, in shares",{"v":2141098,"d":"2,141,098 "}," "," "," "," "," "," "," "," "," "]
["Net income (loss)"," "," "," "," "," ",{"v":-22013,"d":"(22,013)"}," "," "," ",{"v":-22013,"d":"(22,013)"}]
["Issuance of common stock to Yorkville for debt extension and SEPA commitment fee"," "," "," ",{"v":317,"d":"317 "}," "," "," "," "," ",{"v":317,"d":"317 "}]
["Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, in shares",{"v":116964,"d":"116,964 "}," "," "," "," "," "," "," "," "," "]
["Issuance and modification of warrants to RWI and C.V. Starr"," "," "," ",{"v":3322,"d":"3,322 "}," "," "," "," "," ",{"v":3322,"d":"3,322 "}]
["Issuance of warrants to Palantir as consideration for settlement agreement"," "," "," ",{"v":50,"d":"50 "}," "," "," "," "," ",{"v":50,"d":"50 "}]
["Issuance of warrants to Palantir as consideration for settlement agreement, in shares",{"v":20000,"d":"20,000 "}," "," "," "," "," "," "," "," "," "]
["Retirement of shares in connection with reverse stock split"," "," "," "," "," "," "," "," "," "," "]
["Retirement of shares in connection with reverse stock split, in shares",{"v":-191,"d":"(191)"}," "," "," "," "," "," "," "," "," "]
["Balances at Mar. 31, 2024",{"v":2,"d":"$ 2"}," ",{"v":895047,"d":"895,047 "}," ",{"v":-863804,"d":"(863,804)"}," "," "," ",{"v":31245,"d":"31,245 "}," "]
["Balance, shares at Mar. 31, 2024",{"v":21808752,"d":"21,808,752 "}," "," "," "," "," "," "," "," "," "]
["Balances at Dec. 31, 2023",{"v":19,"d":"$ 19"},{"v":2,"d":"$ 2"},{"v":882732,"d":"882,732 "},{"v":882749,"d":"$ 882,749"},{"v":-841791,"d":"(841,791)"},{"v":-841791,"d":"$ (841,791)"}," "," ",{"v":40960,"d":"40,960 "},{"v":40960,"d":"$ 40,960"}]
["Balance, shares at Dec. 31, 2023",{"v":19378192,"d":"19,378,192 "}," "," "," "," "," "," "," "," "," "]
["Net income (loss)"," "," "," "," "," "," "," "," ",{"v":-44599,"d":"(44,599)"}," "]
["Balances at Sep. 30, 2024",{"v":2,"d":"$ 2"}," ",{"v":903670,"d":"903,670 "}," ",{"v":-886390,"d":"(886,390)"}," ",{"v":-2,"d":"(2)"}," ",{"v":17280,"d":"17,280 "}," "]
["Balance, shares at Sep. 30, 2024",{"v":21984614,"d":"21,984,614 "}," "," "," "," "," "," "," "," "," "]
["Balances at Mar. 31, 2024",{"v":2,"d":"$ 2"}," ",{"v":895047,"d":"895,047 "}," ",{"v":-863804,"d":"(863,804)"}," "," "," ",{"v":31245,"d":"31,245 "}," "]
["Balance, shares at Mar. 31, 2024",{"v":21808752,"d":"21,808,752 "}," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units"," "," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units, in shares",{"v":87180,"d":"87,180 "}," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units"," "," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units, shares",{"v":-2655,"d":"(2,655)"}," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," ",{"v":2990,"d":"2,990 "}," "," "," "," "," ",{"v":2990,"d":"2,990 "}," "]
["Net income (loss)"," "," "," "," ",{"v":-6488,"d":"(6,488)"}," "," "," ",{"v":-6488,"d":"(6,488)"}," "]
["Issuance and modification of warrants to RWI and C.V. Starr"," "," ",{"v":-61,"d":"(61)"}," "," "," "," "," ",{"v":-61,"d":"(61)"}," "]
["Issuance of warrants to Palantir as consideration for settlement agreement"," "," ",{"v":125,"d":"125 "}," "," "," "," "," ",{"v":125,"d":"125 "}," "]
["Issuance of warrants to Palantir as consideration for settlement agreement, in shares",{"v":40584,"d":"40,584 "}," "," "," "," "," "," "," "," "," "]
["Balances at Jun. 30, 2024",{"v":2,"d":"$ 2"}," ",{"v":898101,"d":"898,101 "}," ",{"v":-870292,"d":"(870,292)"}," "," "," ",{"v":27811,"d":"27,811 "}," "]
["Balance, shares at Jun. 30, 2024",{"v":21933861,"d":"21,933,861 "}," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units"," "," "," "," "," "," "," "," "," "," "]
["Vesting of restricted stock units, in shares",{"v":75472,"d":"75,472 "}," "," "," "," "," "," "," "," "," "]
["Tax withholding on vesting of restricted stock units"," "," ",{"v":-73,"d":"(73)"}," "," "," "," "," ",{"v":-73,"d":"(73)"}," "]
["Tax withholding on vesting of restricted stock units, shares",{"v":-24719,"d":"(24,719)"}," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," ",{"v":2672,"d":"2,672 "}," "," "," "," "," ",{"v":2672,"d":"2,672 "}," "]
["Change in fair value of debt due to change in credit risk, net of tax"," "," "," "," "," "," ",{"v":-2,"d":"(2)"}," ",{"v":-2,"d":"(2)"}," "]
["Net income (loss)"," "," "," "," ",{"v":-16098,"d":"(16,098)"}," "," "," ",{"v":-16098,"d":"(16,098)"}," "]
["Reclassification of warrants from liability classified to equity classified"," "," ",{"v":2970,"d":"2,970 "}," "," "," "," "," ",{"v":2970,"d":"2,970 "}," "]
["Balances at Sep. 30, 2024",{"v":2,"d":"$ 2"}," ",{"v":903670,"d":"$ 903,670"}," ",{"v":-886390,"d":"$ (886,390)"}," ",{"v":-2,"d":"$ (2)"}," ",{"v":17280,"d":"$ 17,280"}," "]
["Balance, shares at Sep. 30, 2024",{"v":21984614,"d":"21,984,614 "}," "," "," "," "," "," "," "," "," "]

{"sheet":"Condensed Consolidated Statem_3","index":5,"n_rows":80,"n_cols":5,"rows_kept":80,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Condensed Consolidated Statements of Cash Flows - USD ($)","9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Cash flow from operating activities:"," "," "," "," "]
["Net loss",{"v":-44599000,"d":"$ (44,599,000)"},{"v":-205842000,"d":"$ (205,842,000)"},{"v":-196295000,"d":"$ (196,295,000)"},{"v":14192000,"d":"$ 14,192,000"}]
["Adjustments to reconcile net loss to net cash used in operating activities:"," "," "," "," "]
["Depreciation and amortization",{"v":6046000,"d":"6,046,000 "},{"v":7028000,"d":"7,028,000 "},{"v":9324000,"d":"9,324,000 "},{"v":9436000,"d":"9,436,000 "}]
["Non cash lease expense",{"v":125000,"d":"125,000 "},{"v":-62000,"d":"(62,000)"},{"v":-13000,"d":"(13,000)"},{"v":-59000,"d":"(59,000)"}]
["Deferred income taxes"," "," "," ",{"v":-1000,"d":"(1,000)"}]
["Provision for credit losses",{"v":222000,"d":"222,000 "},{"v":456000,"d":"456,000 "},{"v":1233000,"d":"1,233,000 "},{"v":1877000,"d":"1,877,000 "}]
["Provision for inventory obsolescence",{"v":-50000,"d":"(50,000)"}," ",{"v":1328000,"d":"1,328,000 "}," "]
["Change in fair value of warrant liabilities",{"v":1156000,"d":"1,156,000 "},{"v":-6788000,"d":"(6,788,000)"},{"v":-6164000,"d":"(6,164,000)"},{"v":-42109000,"d":"(42,109,000)"}]
["Inventory impairment"," "," ",{"v":5384000,"d":"5,384,000 "},{"v":904000,"d":"904,000 "}]
["Goodwill impairment"," ",{"v":112347000,"d":"112,347,000 "},{"v":112347000,"d":"112,347,000 "},{"v":3610000,"d":"3,610,000 "}]
["IPR&D impairment"," ",{"v":107800000,"d":"107,800,000 "},{"v":107800000,"d":"107,800,000 "}," "]
["Stock-based compensation expense",{"v":8628000,"d":"8,628,000 "},{"v":11442000,"d":"11,442,000 "},{"v":15017000,"d":"15,017,000 "},{"v":15856000,"d":"15,856,000 "}]
["Change in fair value of contingent consideration"," ",{"v":-104339000,"d":"(104,339,000)"},{"v":-104339000,"d":"(104,339,000)"},{"v":-126277000,"d":"(126,277,000)"}]
["Acquired in-process research and development"," ",{"v":3000000,"d":"3,000,000 "},{"v":3000000,"d":"3,000,000 "}," "]
["Issuance of common stock for stem-cells to be used in research and development"," ",{"v":1000000,"d":"1,000,000 "},{"v":1000000,"d":"1,000,000 "}," "]
["Issuance of common stock to Palantir as consideration for settlement agreement",{"v":175000,"d":"175,000 "}," "," "," "]
["Issuance of common stock relating to Yorkville debt extension"," "," ",{"v":712000,"d":"712,000 "}," "]
["Discounts arising from RWI loan arrangement - related party"," ",{"v":2151000,"d":"2,151,000 "},{"v":2151000,"d":"2,151,000 "}," "]
["Fair value of warrant modification for professional services"," ",{"v":403000,"d":"403,000 "},{"v":403000,"d":"403,000 "}," "]
["Change in fair value of debt",{"v":694000,"d":"694,000 "},{"v":354000,"d":"354,000 "},{"v":1177000,"d":"1,177,000 "},{"v":2522000,"d":"2,522,000 "}]
["Change in fair value of contingent stock consideration"," ",{"v":-159000,"d":"(159,000)"},{"v":-159000,"d":"(159,000)"},{"v":186000,"d":"186,000 "}]
["Other, net",{"v":-285000,"d":"(285,000)"},{"v":2012000,"d":"2,012,000 "},{"v":4157000,"d":"4,157,000 "},{"v":-37000,"d":"(37,000)"}]
["Issuance of common stock to Yorkville for debt extension and SEPA commitment fee",{"v":317000,"d":"317,000 "},{"v":712000,"d":"712,000 "}," "," "]
["Loss on extinguishment of debt",{"v":3908000,"d":"3,908,000 "}," "," "," "]
["Non cash interest expense",{"v":3217000,"d":"3,217,000 "}," "," "," "]
["Changes in assets and liabilities:"," "," "," "," "]
["Accounts receivable",{"v":1054000,"d":"1,054,000 "},{"v":-118000,"d":"(118,000)"},{"v":-6827000,"d":"(6,827,000)"},{"v":-3584000,"d":"(3,584,000)"}]
["Inventory",{"v":5653000,"d":"5,653,000 "},{"v":-1605000,"d":"(1,605,000)"},{"v":-865000,"d":"(865,000)"},{"v":-16891000,"d":"(16,891,000)"}]
["Prepaid expenses and other assets",{"v":109000,"d":"109,000 "},{"v":2179000,"d":"2,179,000 "},{"v":5606000,"d":"5,606,000 "},{"v":49000,"d":"49,000 "}]
["Accounts payable",{"v":1312000,"d":"1,312,000 "},{"v":6754000,"d":"6,754,000 "},{"v":8497000,"d":"8,497,000 "},{"v":-2948000,"d":"(2,948,000)"}]
["Accrued expenses and other liabilities",{"v":7237000,"d":"7,237,000 "},{"v":1533000,"d":"1,533,000 "},{"v":-1128000,"d":"(1,128,000)"},{"v":-2623000,"d":"(2,623,000)"}]
["Accrued R&D software",{"v":-3500000,"d":"(3,500,000)"},{"v":24161000,"d":"24,161,000 "},{"v":-3834000,"d":"(3,834,000)"},{"v":7333000,"d":"7,333,000 "}]
["Right-of-use assets and lease liabilities"," "," ",{"v":275000,"d":"275,000 "},{"v":263000,"d":"263,000 "}]
["Lease liabilities - operating",{"v":274000,"d":"274,000 "},{"v":172000,"d":"172,000 "}," "," "]
["Deferred revenue",{"v":312000,"d":"312,000 "},{"v":1065000,"d":"1,065,000 "},{"v":1528000,"d":"1,528,000 "},{"v":425000,"d":"425,000 "}]
["Net cash used in operating activities",{"v":-7995000,"d":"(7,995,000)"},{"v":-34344000,"d":"(34,344,000)"},{"v":-38685000,"d":"(38,685,000)"},{"v":-137876000,"d":"(137,876,000)"}]
["Cash flow from investing activities:"," "," "," "," "]
["Capital expenditures",{"v":-105000,"d":"(105,000)"},{"v":-468000,"d":"(468,000)"},{"v":-1048000,"d":"(1,048,000)"},{"v":-5236000,"d":"(5,236,000)"}]
["Proceeds from Sanuwave convertible note receivable",{"v":2175000,"d":"2,175,000 "}," "," "," "]
["Purchase of acquired in-process research and development"," ",{"v":-3000000,"d":"(3,000,000)"},{"v":-3000000,"d":"(3,000,000)"}," "]
["Net cash provided by (used in) investing activities",{"v":2070000,"d":"2,070,000 "},{"v":-3468000,"d":"(3,468,000)"},{"v":-4048000,"d":"(4,048,000)"},{"v":-5236000,"d":"(5,236,000)"}]
["Cash flow from financing activities:"," "," "," "," "]
["Proceeds from RWI senior secured bridge loan and warrants - related party"," "," ",{"v":12375000,"d":"12,375,000 "},{"v":46491000,"d":"46,491,000 "}]
["Proceeds from warrants and short-term debt - related parties",{"v":15000000,"d":"15,000,000 "},{"v":18369000,"d":"18,369,000 "}," "," "]
["Proceeds from issuance of short-term debt - unaffiliated",{"v":2993000,"d":"2,993,000 "},{"v":2000000,"d":"2,000,000 "}," "," "]
["Principal payments of Yorkville short-term debt"," "," ",{"v":-16811000,"d":"(16,811,000)"}," "]
["Proceeds from issuance of senior secured C.V. Starr bridge loan and warrants - related party"," "," ",{"v":4994000,"d":"4,994,000 "}," "]
["Proceeds from short-term debt"," "," "," ",{"v":39200000,"d":"39,200,000 "}]
["Proceeds from the sale of common stock in ATM offering"," ",{"v":136000,"d":"136,000 "},{"v":136000,"d":"136,000 "},{"v":6519000,"d":"6,519,000 "}]
["Payments of ATM offering costs and commissions"," "," "," ",{"v":-498000,"d":"(498,000)"}]
["Repayments of short-term debt - unaffiliated",{"v":-17374000,"d":"(17,374,000)"},{"v":-16811000,"d":"(16,811,000)"}," "," "]
["Payment of SEPA commitment fee",{"v":-25000,"d":"(25,000)"}," "," "," "]
["Repayments of short-term debt - related parties",{"v":-106000,"d":"(106,000)"}," "," "," "]
["Proceeds from other short-term debt"," "," ",{"v":2000000,"d":"2,000,000 "}," "]
["Proceeds from other short-term debt - related party"," "," ",{"v":1000000,"d":"1,000,000 "}," "]
["Proceeds from PIPE financing",{"v":6000000,"d":"6,000,000 "},{"v":12750000,"d":"12,750,000 "},{"v":12750000,"d":"12,750,000 "},{"v":30000000,"d":"30,000,000 "}]
["Proceeds from the exercise of stock options"," ",{"v":304000,"d":"304,000 "},{"v":304000,"d":"304,000 "},{"v":862000,"d":"862,000 "}]
["Tax withholding on vesting of restricted stock units",{"v":-430000,"d":"(430,000)"},{"v":-87000,"d":"(87,000)"},{"v":-101000,"d":"(101,000)"},{"v":-132000,"d":"(132,000)"}]
["Proceeds from registered direct offering"," ",{"v":9000000,"d":"9,000,000 "},{"v":9000000,"d":"9,000,000 "}," "]
["Payments of PIPE and other issuance costs"," ",{"v":-1553000,"d":"(1,553,000)"},{"v":-1553000,"d":"(1,553,000)"},{"v":-2604000,"d":"(2,604,000)"}]
["Net cash provided by financing activities",{"v":6058000,"d":"6,058,000 "},{"v":24108000,"d":"24,108,000 "},{"v":24094000,"d":"24,094,000 "},{"v":119838000,"d":"119,838,000 "}]
["Net increase (decrease) in cash, cash equivalents and restricted cash",{"v":133000,"d":"133,000 "},{"v":-13704000,"d":"(13,704,000)"},{"v":-18639000,"d":"(18,639,000)"},{"v":-23274000,"d":"(23,274,000)"}]
["Cash, cash equivalents and restricted cash at beginning of period",{"v":10163000,"d":"10,163,000 "},{"v":28802000,"d":"28,802,000 "},{"v":28802000,"d":"28,802,000 "},{"v":52076000,"d":"52,076,000 "}]
["Cash, cash equivalents and restricted cash at end of period",{"v":10296000,"d":"10,296,000 "},{"v":15098000,"d":"15,098,000 "},{"v":10163000,"d":"10,163,000 "},{"v":28802000,"d":"28,802,000 "}]
["Supplemental disclosure of cash flow information:"," "," "," "," "]
["Cash paid for interest",{"v":144000,"d":"144,000 "},{"v":1073000,"d":"1,073,000 "},{"v":1073000,"d":"1,073,000 "}," "]
["Supplemental non-cash investing and financing activities:"," "," "," "," "]
["Property and equipment included in accounts payable and accrued expenses",{"v":-56000,"d":"(56,000)"},{"v":-752000,"d":"(752,000)"},{"v":-223000,"d":"(223,000)"},{"v":-683000,"d":"(683,000)"}]
["Common stock issued for short-term debt conversion"," ",{"v":4599000,"d":"4,599,000 "},{"v":4599000,"d":"4,599,000 "},{"v":4099000,"d":"4,099,000 "}]
["Issuance of warrants on senior secured bridge loan"," ",{"v":2002000,"d":"2,002,000 "},{"v":2002000,"d":"2,002,000 "}," "]
["Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification"," ",{"v":-2083000,"d":"(2,083,000)"},{"v":-2083000,"d":"(2,083,000)"}," "]
["PIPE related offering costs included in accrued expenses"," ",{"v":-69000,"d":"(69,000)"},{"v":-69000,"d":"(69,000)"}," "]
["Interest accrued on senior secured loans within long-term debt - related parties"," ",{"v":-1229000,"d":"(1,229,000)"},{"v":-1770000,"d":"(1,770,000)"}," "]
["Reclassification of option liabilities to equity"," "," "," ",{"v":441000,"d":"$ 441,000"}]
["Modification of C.V. Starr warrants in connection with forbearance",{"v":51000,"d":"51,000 "}," "," "," "]
["Issuance of RWI warrants in connection with forbearance",{"v":1162000,"d":"1,162,000 "}," "," "," "]
["Reclassification of warrants from liability classified to equity classified",{"v":2970000,"d":"$ 2,970,000"}," "," "," "]

{"sheet":"Nature of Business","index":6,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Nature of Business","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Accounting Policies [Abstract]"," "," "]
["Nature of Business","1. Nature of Business Celularity\nInc., (“Celularity” or the “Company”), formerly known as GX Acquisition Corp. (“GX”), was a blank\ncheck company incorporated in Delaware on August 24, 2018 On\nJuly 16, 2021 (the “Closing Date”), the Company consummated the previously announced merger pursuant to the Merger Agreement\nand Plan of Reorganization, dated January 8, 2021 (the “Merger Agreement”), by and among GX, Alpha First Merger Sub, Inc.,\na Delaware corporation and a direct, wholly owned subsidiary of GX (“First Merger Sub”), Celularity LLC (f/k/a Alpha Second\nMerger Sub LLC), a Delaware limited liability company and a direct, wholly owned subsidiary of GX (“Second Merger Sub”),\nand the entity formerly known as Celularity Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (“Legacy\nCelularity”). Upon completion of the merger transaction, GX changed its name to Celularity Inc. At\nthe special meeting held on February 22, 2024, the stockholders of Celularity approved an amendment to Celularity’s Second Amended\nand Restated Certificate of Incorporation, as amended, to effect a reverse stock split of Celularity’s Class A common stock, par\nvalue $ 0.0001 1-for-10 Description\nof Business Celularity\nis a cell therapy and regenerative medicine company focused on addressing aging related diseases including cancer and degenerative diseases.\nCelularity is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (“Anthrogenesis”) in\nAugust 2017 from Celgene Corporation (“Celgene”), a global biotechnology company that merged with Bristol Myers Squibb Company.\nPreviously, Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene’s cell therapy division. The\nCompany is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited\nto, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance\nwith governmental regulations and the ability to secure additional capital to fund operations. Drug candidates currently under development\nwill require significant additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory\napproval. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting\ncapabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize\nsignificant revenue from cellular therapy product sales. Going\nConcern The\nCompany has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about\nthe Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements\nare issued. As\nan emerging clinical-stage biotechnology company, Celularity is subject to certain inherent risks and uncertainties associated with the\ndevelopment of an enterprise. In this regard, since the Company’s inception, substantially all of management’s efforts have\nbeen devoted to making investments in research and development including basic scientific research into placentally-derived allogeneic\ncells, pre-clinical studies to support its current and future clinical programs in cellular therapeutics, and clinical development of\nits cell programs as well as facilities and selling, general and administrative expenses that support its core business operations (collectively,\nthe “investments”), all at the expense of the Company’s short-term profitability. The Company has historically funded\nthese investments through limited revenues generated from its biobanking and degenerative disease businesses and issuances of equity\nand debt securities to public and private investors (these issuances are collectively referred to as “outside capital”).\nNotwithstanding these efforts, management can provide no assurance that the Company’s research and development and commercialization\nefforts will be successfully completed, or that adequate protection of the Company’s intellectual property will be adequately maintained.\nEven if these efforts are successful, it is uncertain when, if ever, the Company will generate significant sales or operate in a profitable\nmanner to sustain the Company’s operations without needing to continue to rely on outside capital. As\nof the date the accompanying condensed consolidated financial statements were issued, or the issuance date, management evaluated the\nsignificance of the following adverse conditions and events in considering its ability to continue as a going concern:\n● Since its inception, the Company has incurred significant operating\nlosses and net cash used in operating activities. For the nine months ended September 30, 2024, the Company incurred an operating loss\nof $ 29,078 7,995 886,390\n● The Company expects to incur substantial expenditures to fund\nits investments for the foreseeable future. In order to fund these investments, the Company will need to secure additional sources of\noutside capital. While the Company is actively seeking to secure additional outside capital (and has historically been able to successfully\nsecure such capital), as of the issuance date, additional outside capital sufficient to fund operations for the next 12 months has not\nbeen secured or was deemed probable of being secured. In addition, management can provide no assurance that the Company will be able\nto secure additional outside capital in the future or on terms that are acceptable to the Company. Absent an ability to secure additional\noutside capital in the very near term, the Company will be unable to meet its obligations as they become due over the next 12 months\nbeyond the issuance date.\n● As of the issuance date, the Company had approximately $ 46,050\n● As a result of the Company’s failure to timely file its\nquarterly reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024, it no longer complied with the continued listing\nrequirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1). The Company had regained compliance with the\nNasdaq listing requirements upon filing its Form 10-Q for the period ended June 30, 2024 on November 7, 2024. On November 21, 2024, Nasdaq\nprovided formal notice to the Company that as a result of Company’s failure to timely file its quarterly report on Form 10-Q for\nthe period ended September 30, 2024, the Company was not in compliance with the continued listing requirements under Nasdaq Listing Rule\n5250(c)(1). The Company has 60 days to submit a plan to Nasdaq to regain compliance with the continued listing requirements. If Nasdaq\naccepts the Company’s plan, it may grant an exception of up to 180 days from the filing’s due date, or May 13, 2025, to regain\ncompliance. There can be no assurance that Nasdaq will grant the Company an extension or that the Company will maintain compliance with\nthe Nasdaq listing requirements. If the Company is unable to regain compliance, the Company’s securities will be delisted from\nthe Nasdaq, which such delisting could have a materially adverse effect on the Company’s ability to continue as a going concern.\n● In the event the Company is unable to secure additional outside\ncapital to fund the Company’s obligations when they become due over the next 12 months beyond the issuance date, which includes\nthe funds needed to repay the Company’s outstanding debt, management will be required to seek other strategic alternatives, which\nmay include, among others, a significant curtailment of the Company’s operations, a sale of certain of the Company’s assets,\na sale of the entire Company to strategic or financial investors, and/or allowing the Company to become insolvent by filing for bankruptcy\nprotection under the provisions of the U.S. Bankruptcy Code. These\nuncertainties raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated\nfinancial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates\nthat the Company will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable\nfuture. Accordingly, the accompanying condensed consolidated financial statements do not include any adjustments that may result from\nthe outcome of these uncertainties. ","1.\nNature of Business Celularity\nInc., (“Celularity” or the “Company”), formerly known as GX Acquisition Corp. (“GX”), was a blank\ncheck company incorporated in Delaware on August 24, 2018 On\nJuly 16, 2021 (the “Closing Date”), the Company consummated the previously announced merger pursuant to the Merger Agreement\nand Plan of Reorganization, dated January 8, 2021 (the “Merger Agreement”), by and among GX, Alpha First Merger Sub, Inc.,\na Delaware corporation and a direct, wholly owned subsidiary of GX (“First Merger Sub”), Celularity LLC (f/k/a Alpha Second\nMerger Sub LLC), a Delaware limited liability company and a direct, wholly owned subsidiary of GX (“Second Merger Sub”),\nand the entity formerly known as Celularity Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (“Legacy\nCelularity”). Upon completion of the merger transaction, GX changed its name to Celularity Inc. At\nthe special meeting held on February 22, 2024, the stockholders of Celularity approved an amendment to Celularity’s Second Amended\nand Restated Certificate of Incorporation, as amended, to effect a reverse stock split of Celularity’s Class A common stock, par\nvalue $ 0.0001 1-for-10 Description\nof Business Celularity\nis a cell therapy and regenerative medicine company focused on addressing aging related diseases including cancer and degenerative\ndiseases. Celularity develops and markets off-the-shelf placental-derived allogeneic advanced biomaterial products including allografts\nand connective tissue matrices for soft tissue repair and reconstructive procedures in the treatment of degenerative disorders and diseases\nincluding those associated with aging. Celularity is developing a pipeline of off-the-shelf placental-derived allogeneic cell therapy\nproduct candidates including T cells engineered with a chimeric antigen receptor (“CAR”), natural killer (“NK”)\ncells, and mesenchymal-like adherent stromal cells (“MLASCs”) and exosomes. These therapeutic candidates may potentially\ntarget indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique\nbiology and ready availability, it will be able to develop therapeutic solutions that address a significant unmet global need for effective,\naccessible and affordable therapeutics. Celularity’s biomaterials business today is comprised primarily of the sale of its Biovance\n3L products, directly or through its distribution network. Biovance 3L is a tri-layer decellularized, dehydrated human amniotic membrane\nderived from the placenta of a healthy, full-term pregnancy. It is an intact, natural extracellular matrix that provides a foundation\nfor the wound regeneration process and acts as a scaffold for restoration of functional tissue. Celularity is developing new placental\nbiomaterial products to deepen the commercial pipeline. The Company also plans to leverage its core expertise in cellular therapeutic\ndevelopment and manufacturing to generate revenues by providing contract manufacturing and development services to third parties. The\ninitial focus of this new service offering will be to assist development stage cell therapy companies with the development and manufacturing\nof their therapeutic candidates for clinical trials. Celularity\nis headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (“Anthrogenesis”) in August 2017\nfrom Celgene Corporation (“Celgene”), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously,\nAnthrogenesis operated as Celgene Cellular Therapeutics, Celgene’s cell therapy division. The\nCelularity IMPACT ( IM P A Cellular\ntherapy 147,215 From\na single source material, the postpartum human placenta, the Company derives four allogeneic cell or extracellular vesicle types: T\ncells, NK cells, MLASCs and exosomes, which have the potential to support multiple therapeutic programs. In 2022, the The\nCompany is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited\nto, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance\nwith governmental regulations and the ability to secure additional capital to fund operations. Drug candidates currently under development\nwill require significant additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory\napproval. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting\ncapabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize\nsignificant revenue from product sales. Going\nConcern In\naccordance with Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability\nto Continue as a Going Concern (Subtopic 205-40) (“ASU 205-40”), the Company has evaluated whether there are certain conditions\nand events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern\nwithin one year after the date that the consolidated financial statements are issued. As\nan emerging clinical-stage biotechnology company, Celularity is subject to certain inherent risks and uncertainties associated with the\ndevelopment of an enterprise. In this regard, since the Company’s inception, substantially all of management’s efforts have\nbeen devoted to making investments in research and development including basic scientific research into placentally-derived allogeneic\ncells, pre-clinical studies to support its current and future clinical programs in cellular therapeutics, and clinical development of\nits cell programs as well as facilities and selling, general and administrative expenses that support its core business operations (collectively\nthe “investments”), all at the expense of the Company’s short-term profitability. The Company has historically funded\nthese investments through limited revenues generated from its biobanking and degenerative disease businesses and issuances of equity\nand debt securities to public and private investors (these issuances are collectively referred to as “outside capital”).\nNotwithstanding these efforts, management can provide no assurance that the Company’s research and development and commercialization\nefforts will be successfully completed, or that adequate protection of the Company’s intellectual property will be adequately maintained.\nEven if these efforts are successful, it is uncertain when, if ever, the Company will generate significant sales or operate in a profitable\nmanner to sustain the Company’s operations without needing to continue to rely on outside capital. Continued decline in the Company’s\nshare price could result in impairment of goodwill or long-lived assets in a future period. As\nof the date the accompanying consolidated financial statements were issued (the “issuance date”), management evaluated the\nsignificance of the following adverse conditions and events in accordance with ASU 205-40: ● 192,287 38,685 841,791 ●\nAs of the issuance date, the Company had approximately $ 593 ●\nThe Company expects to incur substantial expenditures to fund its investments for the foreseeable future. In order to fund these\ninvestments, the Company will need to secure additional sources of outside capital. While the Company is actively seeking to secure\nadditional outside capital (and has historically been able to successfully secure such capital), as of the issuance date, no\nadditional outside capital has been secured or was deemed probable of being secured. In addition, ●\nAs of the issuance date, the Company had approximately $ 42,700 ●\nOn April 17, 2024, Nasdaq provided formal notice to the Company that as a result of the Company’s failure to timely file its\n2023 Form 10-K, it no longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq\nListing Rule 5250(c)(1). The Company was required to submit a plan to Nasdaq to regain compliance within 60 calendar days, or by\nJune 17, 2024. On June 18, 2024, Nasdaq indicated that it had received the Company’s plan and granted the Company an extension\nto file this annual report on Form 10-K and the Company’s quarterly report on Form 10-Q for the period ended March 31, 2024 on\nor before August 30, 2024. If the Company is unable to regain compliance, the Company’s securities will be delisted from the\nNasdaq, which such delisting would have a materially adverse effect on the Company’s ability to continue as a going\nconcern. ●\nIn the event the Company is unable to secure additional outside capital to fund the Company’s obligations when they become\ndue, including repayment of the Company’s outstanding debt, over the next 12 months beyond the issuance date, management will\nbe required to seek other strategic alternatives, which may include, among others, a significant curtailment of the Company’s\noperations, a sale of certain of the Company’s assets, a sale of the entire Company to strategic or financial investors,\nand/or allowing the Company to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy\nCode. These\nuncertainties raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated\nfinancial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates\nthat the Company will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable\nfuture. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome\nof these uncertainties. "]

{"sheet":"Summary of Significant Accounti","index":7,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Accounting Policies [Abstract]"," "," "]
["Summary of Significant Accounting Policies","2.\nSummary of Significant Accounting Policies Basis\nof Presentation The\nCompany’s unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally\naccepted in the United States (“GAAP”). The unaudited condensed consolidated financial statements include the accounts of\nwholly owned subsidiaries, after elimination of intercompany accounts and transactions. The unaudited condensed consolidated financial\ninformation presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement\nof consolidated financial position, results of operations and cash flows for the periods presented. The\nCompany’s condensed consolidated financial statements are prepared in accordance with the U.S. Securities and Exchange Commission’s\n(“SEC”) rules for the presentation of interim financial statements, which permit certain disclosures to be condensed or omitted.\nThese financial statements should be read in conjunction with the Company’s annual financial statements as of and for the year\nended December 31, 2023 included in the Annual Report on Form 10-K filed with the SEC on July 30, 2024, (the “2023 Form 10-K”). In\nthe opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist\nprimarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s\nconsolidated financial position as of September 30, 2024, and its consolidated results of operations and cash flows for the nine months\nended September 30, 2024 and 2023. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative\nof the results that may be expected for the year ending December 31, 2024. Use\nof Estimates The\npreparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates\nand assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the\ndate of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period.\nSignificant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to,\nassumptions related to the Company’s goodwill and intangible asset impairment assessments, determination of incremental borrowing\nrates, accrual of research and development expenses, and the valuations of inventory, contingent consideration, short-term debt, stock\noptions and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other\nrelevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when\nthere are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.\nActual results could differ from those estimates. Fair\nValue Measurements Certain\nassets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be\nreceived for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability\nin an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize\nthe use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are\nto be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered\nobservable and the last is considered unobservable:\n● Level\n1 — Quoted prices in active markets for identical assets or liabilities.\n● Level\n2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in\nactive markets for similar assets or liabilities, quoted prices in markets that are not active\nfor identical or similar assets or liabilities, or other inputs that are observable or can\nbe corroborated by observable market data.\n● Level\n3 — Unobservable inputs that are supported by little or no market activity that are\nsignificant to determining the fair value of the assets or liabilities, including pricing\nmodels, discounted cash flow methodologies and similar techniques. Comprehensive\nIncome (Loss) Comprehensive\nincome (loss) refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded\nfrom net income (loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The\nCompany’s only component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of\nindebtedness accounted for under the fair value option that is attributable to changes in instrument-specific credit risk. During the\nnine months ended September 30, 2024, the Company recorded instrument-specific credit risk loss of $ 2 2,541 155 Income\nTaxes The\nCompany accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities\nfor the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in\nthe Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement\nand tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.\nChanges in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that\nits deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available\nevidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance\nis established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future\ntaxable profits expected and considering prudent and feasible tax planning strategies. No income tax expense was incurred during the\nnine months ended September 30, 2024 and 2023. Net\nIncome (Loss) per Share Basic\nnet income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common\nstock outstanding during each period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential\nexercise or conversion of securities, such as redeemable convertible preferred stock, convertible debt, stock options, restricted stock\nunits and warrants, which would result in the issuance of incremental shares of common stock. However, potential common shares are excluded\nif their effect is anti-dilutive. For diluted net loss per share when the Company has a net loss, the weighted-average number of shares\nof common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included\nin the calculation as the impact is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis\nwith Class A common stock in the distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing\nearnings per share, the warrants are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company\ncomputes earnings per share using the two-class method, an earnings allocation method that determines net income (loss) per share (when\nthere are earnings) for common stock and participating securities. No The\nfollowing potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common\nstock outstanding, prior to the use of the two-class method, as they would be anti-dilutive: Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share\n2024 2023\nSeptember 30,\n2024 2023\nStock options 3,455,049 2,961,438\nRestricted stock units 327,359 878,555\nWarrants 10,905,901 7,070,627\nConvertible debt 1,241,291 2,830,177\nAnti-dilutive\nsecurities 15,929,600 13,740,797 Segment\nInformation Operating\nsegments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by\nthe chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company\nmanages its operations through an evaluation of three Allowance\nfor Credit Losses With\nthe adoption of ASU 2016-13 Financial Instruments — Credit Losses, Concentrations\nof Credit Risk and Significant Customers Financial\ninstruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted\ncash, and accounts receivable. The Company generally maintains balances in various operating accounts at financial institutions that\nmanagement believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced\nany losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk\nbeyond the normal credit risk associated with commercial banking relationships. The\nCompany is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services.\nAll trade accounts receivables are a result from product sales and services performed in the United States. As of September 30, 2024,\ntwo of the Company’s customers, each of which individually comprised at least 10 33 10 63 15 21 10 15 Emerging\nGrowth Company Section\n102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being\nrequired to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities\nAct registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934,\nas amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth\ncompany can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies\nbut any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which\nexpires December 31, 2026 unless the Company is otherwise disqualified. Accordingly, when a standard is issued or revised and it has\ndifferent application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised\nstandard at the time private companies adopt the new or revised standard. This\nmay make comparison of the Company’s condensed consolidated financial statements with another public company that is neither an\nemerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible\nbecause of the potential differences in accounting standards used. Reclassifications Certain\nprior period amounts have been reclassified to conform with current year presentation. On the condensed consolidated balance sheets,\nshort-term debt - Yorkville and other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related\nparty and short-term debt - related parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 7 for\nfurther information. Recently\nAdopted Accounting Pronouncements In\nJune 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13,\nFinancial Instruments — Credit Losses adopted ASU 2016-13 January 1, 2023 no Recently\nIssued Accounting Pronouncements In\nNovember 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In\nDecember 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures In\nNovember 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures\n(Subtopic 220-40): Disaggregation of Income Statement Expenses ",{"$cut":{"chars":32767,"head":"2.\nSummary of Significant Accounting Policies Basis\nof Presentation The\nCompany’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United\nStates (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination\nof intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information\nthat, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for\nthe periods presented. Use\nof Estimates The\npreparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and\nassumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date\nof the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates\nand assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related to the Company’s\ngoodwill and intangible impairment assessment, the valuation of inventory, contingent consideration, short-term debt, determination of\nincremental borrowing rates, accrual of research and development expenses, and the valuations of stock options and stock warrants. The\nCompany based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes\nto be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances,\nfacts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those\nestimates. Fair\nValue Measurements Certain\nassets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would\nbe received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset\nor liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure\nfair value ●\nLevel 1 — Quoted prices in active markets for identical assets or liabilities. ●\nLevel 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or\nliabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are\nobservable or can be corroborated by observable market data. ●\nLevel 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair\nvalue of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Cash\nand Cash Equivalents Cash\nand cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having\nan original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or\nless at the date of acquisition to be cash equivalents. At December 31, 2023 and 2022, substantially all cash and cash equivalents were\nheld in either commercial bank accounts or money market funds. Restricted\nCash As\nof December 31, 2023 and 2022, the Company maintained a letter of credit of $ 9,936 14,836 Inventory Inventory\nis stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out basis. Prior to\ninitial approval from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the\nperiod incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related\nto the product. The Company continues to expense costs associated with clinical trial supply co"}}]

{"sheet":"Fair Value of Financial Assets ","index":8,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Fair Value of Financial Assets and Liabilities","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Fair Value Disclosures [Abstract]"," "," "]
["Fair Value of Financial Assets and Liabilities","3. Fair Value of Financial Assets and Liabilities The\nfollowing tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring\nbasis and indicate the level of the fair value hierarchy used to determine such fair values: Schedule of Financial Assets and Liabilities Measures at Fair Value\nLevel 1 Level 2 Level 3 Total\nFair Value Measurements as of September 30, 2024\nLevel 1 Level 2 Level 3 Total\nLiabilities:\nAcquisition-related contingent consideration obligations $ — $ — $ 1,606 $ 1,606\nContingent stock consideration — — 27 27\nShort-term debt - Yorkville convertible note — — 3,695 3,695\nWarrant liability - July 2023 Registered Direct Warrants — — 1,748 1,748\nWarrant liability - April 2023 Registered Direct Warrants — — 1,670 1,670\nWarrant liability - May 2022 PIPE Warrants — — 809 809\nWarrant liability - Sponsor Warrants — — 32 32\nWarrant liability - Public Warrants 144 — — 144\nTotal\nfair value liabilities $ 144 $ — $ 9,587 $ 9,731\nLevel 1 Level 2 Level 3 Total\nFair Value Measurements as of December 31, 2023\nLevel 1 Level 2 Level 3 Total\nAssets:\nConvertible note receivable $ — $ — $ 2,072 $ 2,072\nTotal\nfair value assets $ — $ — $ 2,072 $ 2,072\nLiabilities:\nAcquisition-related contingent consideration obligations $ — $ — $ 1,606 $ 1,606\nContingent stock consideration — — 27 27\nShort-term debt - Yorkville — — 17,223 17,223\nWarrant liability - July 2023 Registered Direct Warrants — — 1,529 1,529\nWarrant liability - April 2023 Registered Direct Warrants — — 1,487 1,487\nWarrant liability - May 2022 PIPE Warrants — — 708 708\nWarrant liability - Sponsor Warrants — — 60 60\nWarrant liability - Public Warrants 575 — — 575\nTotal\nfair value liabilities $ 575 $ — $ 22,640 $ 23,215 During\nthe nine months ended September 30, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3. The carrying values\nof other current liabilities approximate fair value in the accompanying condensed consolidated financial statements due to the\nshort-term nature of those instruments. Valuation\nof Convertible Note Receivable The\nconvertible note receivable was received in connection with the disposition of the UltraMIST/MIST business in 2020. At any time on or\nafter January 1, 2021, at the sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued\ninterest) may be converted into Sanuwave common stock at a defined rate. The convertible note receivable was to be paid on or before\nAugust 6, 2021. On\nDecember 18, 2023, the Company entered into a forbearance agreement with Sanuwave (“Sanuwave Forbearance Agreement”). Per\nthe Sanuwave Forbearance Agreement, from the period from December 18, 2023 to the earliest of (i) February 28, 2024, (ii) the commencement\nof bankruptcy proceedings for Sanuwave pursuant to the U.S. Bankruptcy Code, (iii) the occurrence of an event of default other than payment\ndefault, or (iv) the failure of Sanuwave to comply with any term, condition or covenant set forth in the forbearance agreement, the Company\nagrees that it will not exercise any remedy available to it under the convertible note receivable, excluding the right to increase the\ninterest rate. As collateral for payments owed to Palantir Technologies, Inc. (“Palantir”), the Company assigned to Palantir\nthe Sanuwave convertible note receivable in the event of default (see Note 9). On May 10, 2024, the Company entered into a letter agreement\nwith Sanuwave to extend the forbearance period from February 28, 2024 June 3, 2024 2,175 100 2,075 The\nfollowing table presents a reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the\nnine months ended September 30, 2024: Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis\nBalance as of Net Purchases, Fair value Balance as of September 30, 2024\nAssets:\nConvertible note receivable $ 2,072 $ — $ (2,072 ) $ — $ — At\nDecember 31, 2023, the fair value of this note was based on a bond valuation which employs a credit default model. The Company\nutilized Level 3 inputs on a probability weighted model based on outcomes of a default, repayment and conversion of the note. The\nmeasurement is based upon unobservable inputs supported by little or no market activity based on the Company’s own\nassumptions. Significant\ninputs for the convertible note valuation model were as follows: Schedule of Convertible\nNote Valuation Model\nDecember 31, 2023\nFace value $ 4,000\nCoupon rate 12 17\nStock price $ 0.23\nTerm (years) 0.51 2.45\nRisk-free interest rate 5.47 %\nVolatility n/a Valuation\nof Contingent Consideration The\nfair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted\nincome approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s\nown assumptions. The\nfollowing table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs\nfor the nine months ended September 30, 2024: Schedule of Reconciliation of Contingent Consideration Obligations\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nAcquisition-related contingent consideration obligations $ 1,606 $ — $ — $ — $ 1,606 The\nfair value of the liability to make potential future milestone and earn-out payments was estimated by the Company at each reporting date\nbased, in part, on the results of a third-party valuation using a discounted cash flow analysis based on various assumptions, including\nthe probability of achieving specified events, discount rates, and the period of time until earn-out payments are payable and the conditions\ntriggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based\non the actual occurrence of these specified events. At\neach reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair\nvalue as income or expense in the Company’s condensed consolidated statements of operations and comprehensive loss. Changes in\nthe fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing\nand amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent\nconsideration obligations. The change in the fair value of the contingent consideration obligations during the nine months ended September\n30, 2024 was de minimus. The Company has classified all of the contingent consideration as a long-term liability in the condensed consolidated\nbalance sheets as of September 30, 2024 and December 31, 2023. See Note 9 for more information on contingent consideration. Valuation\nof Contingent Stock Consideration The\ncontingent stock consideration liability at September 30, 2024, is comprised of the fair value of potential future issuance of Class\nA common stock to CariCord participating shareholders pursuant to a settlement agreement signed during the year ended December 31, 2021.\nThe fair value measurement of the contingent stock consideration obligation is determined using Level 3 inputs and is based on a probability\nweighted expected return methodology (“PWERM”). The measurement is largely based upon unobservable inputs supported by little\nor no market activity based on the Company’s own assumptions. The\nfollowing table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level\n3 inputs for the nine months ended September 30, 2024: Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nContingent stock consideration $ 27 $ — $ — $ — $ 27 The\nfair value of the liability to issue future shares of Class A common stock was estimated by the Company at each reporting date using\na PWERM based on various inputs and assumptions, including the Company’s common share price, discount rates, and the probability\nof achieving specified future operational targets. The actual settlement of contingent stock consideration could differ from current\nestimates based on the actual achievement of these specified targets and movements in the Company’s common share price. At\neach reporting date, the Company revalues the contingent stock consideration obligation to estimated fair value and records changes in\nfair value as income or expense in the Company’s condensed consolidated statements of operations and comprehensive loss. Changes\nin the fair value of the contingent stock consideration obligation may result from changes in discount rates, changes in the Company’s\ncommon share price, and changes in probability assumptions with respect to the likelihood of achieving specified operational targets.\nThe change in the fair value of the contingent stock consideration obligation during the nine months ended September 30, 2024 was de\nminimus. The Company has classified all of the contingent stock consideration as a current liability in the condensed consolidated balance\nsheets as of September 30, 2024 and December 31, 2023. Valuation\nof Short-Term Debt - Yorkville The\nCompany elected the fair value option to account for the Yorkville PPA signed on September 15, 2022 (see Note 7). As of December 31,\n2023, due to the short-term nature of the debt, the fair value of the Yorkville PPA approximated the settlement amount, which was fully\npaid on January 17, 2024. The Company also elected the fair value option to account for the Yorkville convertible promissory note signed\non March 13, 2024 (see Note 7). The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable\nin the market. Changes in the fair value of debt that is accounted for at fair value, inclusive of related accrued interest expense,\nare presented as gains or losses in the accompanying condensed consolidated statements of operations and comprehensive loss under change\nin fair value of debt. The portion of total changes in fair value of debt attributable to changes in instrument-specific credit risk\nare determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and\nare presented as a component of comprehensive loss in the accompanying condensed consolidated statements of operations and comprehensive\nloss. The actual settlement of the short-term debt could differ from current estimates based on the timing of when and if Yorkville elects\nto convert amounts into common shares, potential cash repayment by the Company prior to maturity, and movements in the Company’s\ncommon share price. The\nfollowing table presents a reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the nine\nmonths ended September 30, 2024: Schedule of Reconciliation\nof Yorkville Debt Measured on a Measured Basis\nLiabilities:\nBalance as of January 1, 2024 $ 17,223\nPrincipal repayments (17,374 )\nIssuance of convertible promissory note 3,150\nFair value adjustment through earnings 694\nFair value adjustment through accumulated other comprehensive income 2\nBalance as of September 30, 2024 $ 3,695 The\nfair value of the Yorkville convertible promissory note is based on a valuation which employs a Monte Carlo model and a credit default\nmodel. The Company utilized Level 3 inputs in a probability weighted model based on outcomes of a default, repayment and conversion of\nthe note. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s own\nassumptions. The fair value of the Yorkville convertible promissory note on March 13, 2024, the date of issuance, was $2,993. Significant\ninputs for the Yorkville convertible promissory note valuation model were as follows: Schedule of Yorkville Short-term Debt Valuation Model\nSeptember 30, 2024 March 13, 2024\n(issuance)\nCommon share price $ 2.97 $ 5.79\nCredit spread 8.00 % 8.50 %\nDividend yield 0 % 0 %\nTerm (years) 0.45 1.00\nRisk-free interest rate 4.30 % 4.90 %\nVolatility 50.0 % 50.0 % Valuation\nof Warrant Liability The\nwarrant liability at September 30, 2024 is comprised of the fair value of warrants to purchase shares of Class A common stock. The Public\nWarrants are recorded at fair value based on the period-end publicly stated close price, which is a Level 1 input. The January 2024 Bridge\nLoan - Tranche #2 Warrants were recorded at fair value based on a Monte Carlo simulation model and the Registered Direct, PIPE and Sponsor\nWarrants are recorded at their respective closing date fair values based on a Black-Scholes option pricing model that utilizes inputs\nfor: (i) value of the underlying asset, (ii) the exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset,\n(v) the dividend yield of the underlying asset and (vi) maturity, which are Level 3 inputs. The Black-Scholes option pricing model’s\nprimary unobservable input utilized in determining the fair values of the warrant liabilities is the expected volatility of the Class\nA common stock. Prior to the merger, Legacy Celularity was a private company and lacked company-specific historical and implied volatility\ninformation for its stock. Therefore, the Company estimates its expected stock price volatility using its volatility since the merger\nand the historical volatility of publicly traded peer companies. The risk-free interest rate is determined by reference to the U.S. Treasury\nyield curve for time periods approximately equal to the estimated remaining term of the warrants. Inputs to the Monte Carlo and Black-Scholes\noption pricing models for the warrants are updated each reporting period to reflect fair value. The\nfollowing table presents a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the nine\nmonths ended September 30, 2024: Schedule\nof Reconciliation of Warrant Liabilities Measured on Recurring Basis\nBalance as of January 1, 2024 $ 3,784\nJanuary 2024 Bridge Loan - Tranche #2 warrant issuance 1,858\nGain recognized in earnings from change in fair value 1,587\nReclassification of warrants from liability classified to equity classified (2,970 )\nBalance as of September 30, 2024 $ 4,259 Significant\ninputs for the May 2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows: Schedule of May 2022 PIPE\nWarrants and 2023 Registered Direct Warrants\nSeptember 30, 2024 December 31, 2023\nCommon share price $ 2.97 $ 2.47\nExercise price $ 3.50 7.50 $ 3.50 7.50\nDividend yield 0 % 0 %\nTerm (years) 4.03 4.34 4.78 5.09\nRisk-free interest rate 3.58 % 3.84 %\nVolatility 97.1 98.1 % 100.1 100.7 % Significant\ninputs for the January 2024 Bridge Loan - Tranche #2 Warrants were as follows: Schedule\nof January 20224 Bridge Loan\nJuly 15, 2024 January\n16, 2024\n(reclassification) (issuance)\nCommon share price $ 3.19 $ 2.00\nTerm to initial exercise date (years) (1) N/A 0.50\nDividend yield 0 % 0 %\nTerm (years) 5.0 5.0\nRisk-free interest rate 4.00 % 3.90 %\nVolatility 112.5 % 107.5 %\n(1) As discussed further\nin Note 7, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July 15, 2024,\nthe warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the Company’s\nown stock. As such, the warrants were marked to fair value as of the initial exercise date and then reclassified from liability classified\nto equity classified. Significant\ninputs for the Sponsor Warrants were as follows: Schedule of Sponsor Warrants\nSeptember 30, 2024 December 31, 2023\nCommon share price $ 2.97 $ 2.47\nExercise price $ 115.00 $ 115.00\nDividend yield 0 % 0 %\nTerm (years) 1.8 2.5\nRisk-free interest rate 3.66 % 4.12 %\nVolatility 105.9 % 100.7 % ","3.\nFair Value of Financial Assets and Liabilities The\nfollowing tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring\nbasis and indicate the level of the fair value hierarchy used to determine such fair values: Schedule of Financial Assets and Liabilities Measures at Fair Value\nLevel 1 Level 2 Level 3 Total\nFair Value Measurements as of December 31, 2023\nLevel 1 Level 2 Level 3 Total\nAssets:\nCash equivalents - money market funds $ — $ — $ — $ —\nConvertible note receivable — — 2,072 2,072\nTotal\nfair value assets $ — $ — $ 2,072 $ 2,072\nLiabilities:\nAcquisition-related contingent consideration obligations $ — $ — $ 1,606 $ 1,606\nContingent stock consideration — — 27 27\nShort-term debt - Yorkville — — 17,223 17,223\nWarrant liability - July 2023 Registered Direct Warrants — — 1,529 1,529\nWarrant liability - April 2023 Registered Direct Warrants — — 1,487 1,487\nWarrant liability - May 2022 PIPE Warrants — — 708 708\nWarrant liability - Sponsor Warrants — — 60 60\nWarrant liability - Public Warrants 575 — — 575\nTotal\nfair value liabilities $ 575 $ — $ 22,640 $ 23,215\nLevel 1 Level 2 Level 3 Total\nFair Value Measurements as of December 31, 2022\nLevel 1 Level 2 Level 3 Total\nAssets:\nCash equivalents – money market funds $ 12,174 $ — $ — $ 12,174\nConvertible note receivable — — 2,514 2,514\nTotal\nfair value assets $ 12,174 $ — $ 2,514 $ 14,688\nLiabilities:\nAcquisition-related contingent consideration obligations $ — $ — $ 105,945 $ 105,945\nContingent stock consideration — — 186 186\nShort-term debt - Yorkville — — 37,603 37,603\nWarrant liability - May 2022 PIPE Warrants — — 1,402 1,402\nWarrant liability - Sponsor Warrants — — 1,190 1,190\nWarrant liability - Public Warrants 1,006 — — 1,006\nTotal\nfair value liabilities $ 1,006 $ — $ 146,326 $ 147,332 During\nthe years ended December 31, 2023 and 2022, there were no The\nCompany’s cash equivalents consisted of a money market funds. The money market fund was valued using inputs observable in active\nmarkets for similar securities, which represents a Level 1 measurement in the fair value hierarchy. The carrying values of accounts receivable,\naccounts payable, deferred revenue and other current liabilities approximate fair value in the accompanying consolidated financial statements\ndue to the short-term nature of those instruments. Valuation\nof Contingent Consideration The\nfair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted\nincome approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company’s\nown assumptions. The\nfollowing table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs\nas of December 31, 2023 and 2022: Schedule of Reconciliation of Contingent Consideration Obligations\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nAcquisition-related contingent consideration obligations $ 105,945 $ — $ — $ (104,339 ) $ 1,606\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nAcquisition-related contingent consideration obligations $ 232,222 $ — $ — $ (126,277 ) $ 105,945 The\nfair value of the liability to make potential future milestone and earn-out payments was estimated by the Company at each reporting date\nbased, in part, on the results of a third-party valuation using a discounted cash flow analysis based on various assumptions, including\nthe probability of achieving specified events, discount rates, and the period of time until earn-out payments are payable and the conditions\ntriggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based\non the actual occurrence of these specified events. At\neach reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair\nvalue as income or expense in the Company’s consolidated statements of operations. Changes in the fair value of the contingent\nconsideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates\nand changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations.\nThe Company has classified all of the contingent consideration as a long-term liability in the consolidated balance sheets as of December\n31, 2023 and 2022. See Note 11, “Commitment and Contingencies”, for more information on contingent consideration. Valuation\nof Warrant Liability The\nwarrant liability at December 31, 2023 is composed of the fair value of warrants to purchase shares of Class A Common Stock. The Liability\nWarrants were recorded at their respective closing date fair values based on a Black-Scholes option pricing model that utilizes inputs\nfor: (i) value of the underlying asset, (ii) the exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset,\n(v) the dividend yield of the underlying asset and (vi) maturity. The Black-Scholes option pricing model’s primary unobservable\ninput utilized in determining the fair value of the Liability Warrants is the expected volatility of the Class A Common Stock. Prior\nto the Mergers, Legacy Celularity was historically a private company and lacks company-specific historical and implied volatility information\nfor its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer\ncompanies. Inputs to the Black-Scholes option pricing model for the warrants are updated each reporting period to reflect fair value.\nThe public warrants (the “Public Warrants”) were recorded at the closing date fair value based on the close price of such\nwarrants. Each subsequent reporting period, the Public Warrants are marked-to-market based on the period-end close price. As\nof December 31, 2023 and 2022, the fair value of the warrant liabilities was $ 4,359 3,598 The\nfollowing table provides a roll-forward of the aggregate fair values of the Company’s warrant liabilities for which fair values\nare determined using Level 3 inputs: Schedule of Roll-forward of the Aggregate Fair\nValues of Company’s Warrant Liabilities\nBalance as of December 31, 2021 $ 25,962\nMay 2022 PIPE warrant issuance 19,745\nApril 2023 Registered Direct warrant issuance 4,280\nJuly 2023 Registered Direct warrant issuance 2,645\nGain recognized in earnings from change in fair value (42,109 )\nBalance as of December 31, 2022 $ 3,598\nBalance as of December 31, 2022 $ 3,598\nApril 2023 Registered Direct warrant issuance 4,280\nJuly 2023 Registered Direct warrant issuance 2,645\nGain recognized in earnings from change in fair value (6,164 )\nBalance as of December 31, 2023 $ 4,359 The\nfair value of the Liability Warrants are as follows: Schedule of Fair Value of\nLiability Warrants\nDecember 31, December 31,\nPublic Warrants $ 575 $ 1,006\nSponsor Warrants 60 1,190\n2023 Registered Direct Warrants 3,016 —\nMay 2022 PIPE Warrants 708 1,402\nTotal $ 4,359 $ 3,598 Significant\ninputs for the Sponsor Warrants are as follows: Schedule of Sponsor Warrants\nDecember 31, December 31,\nCommon share price $ 2.47 $ 12.90\nExercise price $ 115.00 $ 115.00\nDividend yield 0 % 0 %\nTerm (years) 2.5 3.5\nRisk-free interest rate 4.12 % 4.16 %\nVolatility 100.7 % 75.0 % Significant\ninputs for the May 2022 PIPE Warrants and the 2023 Registered Direct Warrants are as follows: Schedule of May 2022 PIPE\nWarrants and 2023 Registered Direct Warrants\nDecember 31, December 31,\nCommon share price $ 2.47 $ 12.90\nExercise price $ 3.50 7.50 $ 82.5\nDividend yield 0 % 0 %\nTerm (years) 5.03 5.34 4.4\nRisk-free interest rate 4.60 % 3.99 %\nVolatility 97.0 % 81.2 % Valuation\nof the Note Receivable The\nconvertible note receivable was received in connection with the disposition of the UltraMIST/MIST business in 2020. At any time on or\nafter January 1, 2021, at the sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued\ninterest) may be converted into Sanuwave common stock at a defined rate. The convertible promissory note was to be paid on or before\nAugust 6, 2021, however, remains outstanding in full as of December 31, 2023 and 2022. The fair value of this note was based on a bond\nvaluation which employs a credit default model. The Company utilized Level 3 inputs on a probability weighted model based on outcomes\nof a default, repayment and conversion of the note. The measurement is based upon unobservable inputs supported by little or no market\nactivity based on the Company’s own assumptions. Significant\ninputs for the convertible note valuation model are as follows: Schedule of Convertible\nNote Valuation Model\nDecember 31, 2023 December 31, 2022\nFace value $ 4,000 $ 4,000\nCoupon rate 12 17 12 17\nStock price $ 0.2 $ 0.2\nTerm (years) 0.51 2.45 1.01 3.45\nRisk-free interest rate 5.47 % 4.73 %\nVolatility n/a n/a On\nDecember 18, 2023, the Company entered into a forbearance agreement with Sanuwave (“Sanuwave Forbearance Agreement”).\nPer the agreement, from the period from December 18, 2023 to the earliest of (i) February 28, 2024, (ii) the commencement of\nbankruptcy proceeds for Sanuwave pursuant to the U.S. Bankruptcy Code, (iii) the occurrence of an event of default other than\npayment default, (iv) the failure of Sanuwave to comply with any term, condition or covenant set forth in the agreement, the\nCompany agrees that it will not, exercise any remedy available to it under the Convertible Note Receivable, excluding the right to\nincrease the interest rate. As collateral for payments owed to Palantir, the Company assigned the Sanuwave convertible note in the\nevent of default (see Note 11). On May 10, 2024, the Company entered into a letter agreement with Sanuwave to extend the forbearance\nperiod from February 28, 2024 June 3, 2024 2,175 100 2,075 Valuation\nof the Contingent Stock Consideration The\ncontingent stock consideration liability at December 31, 2023, is comprised of the fair value of potential future issuance of Class A\nCommon Stock to CariCord participating shareholders pursuant to a settlement agreement signed during the year ended December 31, 2021\n(see Note 11). The fair value measurement of the contingent stock consideration obligation is determined using Level 3 inputs and is\nbased on a probability-weighted expected return methodology (“PWERM”). The measurement is largely based upon unobservable\ninputs supported by little or no market activity based on the Company’s own assumptions. As of December 31, 2021, the applicable\nprocurement targets were not probable of being achieved. The\nfollowing table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level\n3 inputs as of December 31, 2023 and 2022: Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nContingent stock consideration $ 186 $ — $ — $ (159 ) $ 27 The\nfair value of the liability to issue future shares of Class A Common Stock was estimated by the Company at each reporting date using\na PWERM based on various inputs and assumptions, including the Company’s common share price, discount rates, and the probability\nof achieving specified future operational targets. The actual settlement of contingent stock consideration could differ from current\nestimates based on the actual achievement of these specified targets and movements in the Company’s common share price. At\neach reporting date, the Company revalues the contingent stock consideration obligation to estimated fair value and records changes in\nfair value as income or expense in the Company’s consolidated statements of operations. Changes in the fair value of the contingent\nstock consideration obligation may result from changes in discount rates, changes in the Company’s common share price, and changes\nin probability assumptions with respect to the likelihood of achieving specified operational targets. The Company has classified all\nof the contingent stock consideration within accrued expenses and other current liabilities in the consolidated balance sheets as of\nDecember 31, 2023. See Note 11, “Commitments and Contingencies”, for more information on contingent stock consideration. Valuation\nof Short-Term Debt - Yorkville The\nCompany elected the fair value option to account for the financial instrument with Yorkville signed on September 15, 2022 (see Note 9).\nAs of December 31, 2023, due to the short term nature of the debt, the fair value approximates the settlement amount which was fully\npaid on January 17, 2024. As of December 31, 2022, the estimate of the fair value was determined using a binomial lattice model. The\nfair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair\nvalue of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in\nthe accompanying consolidated statements of operations and comprehensive income (loss) under change in fair value of debt. The portion\nof total changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement\nof periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive\nincome (loss) in the accompanying consolidated statements of operations and comprehensive income (loss). The actual settlement of the\nshort-term debt could differ from current estimates based on the timing of when and if Yorkville elects to convert amounts into common\nshares, potential cash repayment by the Company prior to maturity, and movements in the Company’s common share price. The\nfollowing table presents a reconciliation of the Yorkville debt measured on a recurring basis using Level 3 inputs as of the initial\nvaluation date of September 15, 2022 and as of December 31, 2023: Schedule of Reconciliation\nof Yorkville Debt Measured on a Measured Basis\nLiabilities:\nBalance as of December 31, 2022 $ 37,603\nConversion of debt into common shares (4,599 )\nPrincipal repayments (16,811 )\nIssuance of convertible promissory note 3,150\nFair value adjustment through earnings 354\nFair value adjustment through accumulated other comprehensive income (146 )\nFair value adjustment through interest accrual 822\nBalance as of December 31, 2023 $ 17,223 The\nYorkville debt was settled on January 17, 2024, the loan was paid in full. Due to the short term nature, the fair value of the debt as\nof December 31, 2023 was deemed to be settlement amount. Significant\ninputs for the Yorkville short-term debt valuation model as of December 31, 2022 were as follows: Schedule of Yorkville Short-term Debt Valuation Model\nDecember 31, 2022\nCommon share price $ 12.90\nCredit spread 13.71 %\nDividend yield 0 %\nTerm (years) 0.71\nRisk-free interest rate 4.75 %\nVolatility 45.0 %\nDiscount yield 18.46 % "]

{"sheet":"Inventory","index":9,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Inventory","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Inventory Disclosure [Abstract]"," "," "]
["Inventory","4. Inventory The\nCompany’s major classes of inventory were as follows: Schedule of Major Classes of Inventories\nSeptember 30, December 31,\nRaw materials $ 42 $ 3,081\nWork in progress 10,284 10,696\nFinished goods 8,720 10,922\nInventory, gross 19,046 24,699\nLess: inventory reserves (2,239 ) (2,289 )\nInventory, net $ 16,807 $ 22,410\nBalance Sheet Classification:\nInventory $ 3,963 $ 5,753\nInventory, net of current portion 12,844 16,657\nInventory,\nnet $ 16,807 $ 22,410 Inventory,\nnet of current portion includes inventory expected to remain on-hand beyond one year from each balance sheet date presented. ","4.\nInventory The\nCompany’s major classes of inventories were as follows: Schedule of Major Classes of Inventories\n2023 2022\nDecember 31,\n2023 2022\nRaw materials $ 3,081 $ 7,719\nWork in progress 10,696 12,381\nFinished goods 10,922 9,256\nInventory, gross 24,699 29,356\nLess: inventory reserves (2,289 ) (1,099 )\nInventory, net $ 22,410 $ 28,257\nBalance Sheet Classification:\nInventory 5,753 5,308\nInventory, net of current portion 16,657 22,949\nInventory,\nnet $ 22,410 $ 28,257 Inventory,\nnet of current portion includes inventory expected to remain on-hand beyond one year from each balance sheet date presented. The\nCompany recognized a $ 5,384 2,129 3,255 No A\nschedule of the activity in the inventory reserves is as follows: Schedule of Inventory Reserves\nBalance at January 1, 2022 $ 48\nAdditions for obsolete inventory 1,051\nBalance at December 31, 2022 1,099\nAdditions for obsolete inventory 7,627\nWrite-offs (6,437 )\nBalance at December 31, 2023 $ 2,289 "]

{"sheet":"Prepaid Expenses and Other Curr","index":10,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Prepaid Expenses and Other Current Assets","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Prepaid Expenses And Other Current Assets"," "]
["Prepaid Expenses and Other Current Assets","5.\nPrepaid Expenses and Other Current Assets Prepaid\nexpenses and other current assets consisted of the following: Schedule of Prepaid Expenses and Other Current Assets\n2023 2022\nDecember 31,\n2023 2022\nPrepaid clinical expenses $ 688 $ 5,836\nPrepaid insurance expense 678 377\nOther 329 1,049\nPrepaid\nexpenses and other current assets $ 1,695 $ 7,262 "]

{"sheet":"Property and Equipment, Net","index":11,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Property and Equipment, Net","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Property, Plant and Equipment [Abstract]"," "," "]
["Property and Equipment, Net","5. Property and Equipment, Net Property\nand equipment, net consisted of the following: Schedule of Property and Equipment, Net\nSeptember 30, December 31,\nLeasehold improvements $ 73,211 $ 73,211\nLaboratory and production equipment 14,093 14,093\nMachinery, equipment and fixtures 7,781 7,781\nConstruction in progress 70 21\nProperty and equipment 95,155 95,106\nLess: Accumulated depreciation and amortization (31,947 ) (27,278 )\nProperty and equipment, net $ 63,208 $ 67,828 Depreciation\nand amortization expense was $ 1,519 1,790 4,669 5,388 ","6. Property\nand Equipment, Net Property\nand equipment, net consisted of the following: Schedule of Property and Equipment, Net\n2023 2022\nDecember 31,\n2023 2022\nLeasehold improvements $ 73,211 $ 70,113\nLaboratory and production equipment 14,093 14,433\nMachinery, equipment and fixtures 7,781 7,780\nConstruction in progress 21 3,660\nProperty and equipment 95,106 95,986\nLess: Accumulated depreciation and amortization (27,278 ) (20,331 )\nProperty and equipment, net $ 67,828 $ 75,655 Depreciation\nexpense was $ 7,131 7,243 "]

{"sheet":"Goodwill and Intangible Assets,","index":12,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Goodwill and Intangible Assets, Net","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Goodwill and Intangible Assets Disclosure [Abstract]"," "," "]
["Goodwill and Intangible Assets, Net","6. Goodwill and Intangible Assets, Net Goodwill During\nthe nine months ended September 30, 2023, the Company experienced a sustained decline in its stock price resulting in its market capitalization\nbeing less than the carrying value of its combined reporting units. The Company concluded the sustained decline in its stock price combined\nwith the decision to discontinue certain Cell Therapy clinical trials and development were triggering events and performed a quantitative\nimpairment test on goodwill and acquired IPR&D assets. Based on the results of the impairment analysis, the Company recognized an\n$ 82,714 112,347 no 7,347 Intangible\nAssets, Net Intangible\nassets, net consisted of the following: Schedule of Intangible Assets, Net\nSeptember 30, December 31, Estimated\nAmortizable intangible assets:\nDeveloped technology $ 16,810 $ 16,810 11 16\nCustomer relationships 2,413 2,413 10\nTrade names & trademarks 570 570 10 13\nReacquired rights 4,200 4,200 6\n23,993 23,993\nLess accumulated amortization:\nDeveloped technology (8,600 ) (7,722 )\nCustomer relationships (1,898 ) (1,700 )\nTrade names & trademarks (371 ) (330 )\nReacquired rights (4,200 ) (3,940 )\n(15,069 ) (13,692 )\nAmortizable intangible assets, net 8,924 10,301\nNon-amortized intangible assets\nAcquired IPR&D product rights 700 700 indefinite\n$ 9,624 $ 11,001 For\nthe three months ended September 30, 2024 and 2023, amortization expense for intangible assets was $ 375 553 1,377 1,640 No 107,800 ","7.\nGoodwill and Intangible Assets, Net The\nCompany performs its annual goodwill impairment test in the fourth quarter of every year for all of our reporting units, and more frequently\nif events or circumstances indicate a potential impairment. During the quarter ended December 31, 2023, management identified various\nqualitative and quantitative factors which collectively indicated a triggering event had occurred and performed an impairment test. Based\non the results of the impairment analysis, the Degenerative Disease reporting unit had a carrying amount that exceeded its fair value\ndue to lower forecasted sales and growth and it was determined that all of the goodwill for the Degenerative Disease reporting unit was\nimpaired as of December 31, 2023. The\nCompany tests its goodwill for impairment on an annual basis in the fourth quarter of each year for all of its reporting units, or more\nfrequently if events or circumstances indicate a potential impairment. The Company manages its operations through an evaluation of three During\nannual impairment tests and for any period in which the Company identifies an impairment trigger, the Company’s methodology includes\ninternally generated separate cash flow projections for each reporting unit based on the different drivers that affect each reporting\nunit. The Company compares the fair values of each of its reporting units to their respective carrying amounts. If the carrying value\nof the reporting unit exceeds its estimated fair value, a goodwill impairment charge is recorded for the difference, with the impairment\nloss limited to the total amount of goodwill allocated to that reporting unit. The fair values of each of the Company’s reporting\nunits were derived using the income approach, specifically the discounted cash flow method. The use of a discounted cash flow analysis\nrequires significant judgment to estimate the future cash flows and the period of time over which those cash flows will be realized,\nas well as to determine the appropriate discount rate. The discounted cash flow model reflects management’s assumptions regarding\nrevenue growth rates, risk-adjusted discount rates, terminal period growth rates, economic and market trends, and other expectations\nabout the anticipated operating results of the Company’s reporting units. As part of the goodwill impairment test, the Company\nalso considers its market capitalization in assessing the reasonableness of the combined fair values estimated for its reporting units.\nSubstantial changes in the cash flows assumptions of the different reporting units may lead to a future impairment or may alter the implied\ndistribution of value between the different reporting units. A material decline in the Company’s stock price may affect the imputed\ndiscount rate and the distribution of value between the reporting units, which may also lead to a future impairment. For\nthe year ended December 31, 2023, the Company recognized $ 112,347 During\nthe first quarter 2023, as a result of a sustained decrease in its stock price and market capitalization, and its decision to cease recruitment\nin its GBM and HER2+ gastric trials, the Company tested for impairment due to these triggering events. Based on the results of the impairment\nanalysis, the carrying value exceeded the fair value on the Cell Therapy reporting unit. The Company recognized a $ 29,633 During\nthe second quarter of 2023, the Company’s stock price and market capitalization continued to decline, and the Company also\ndetermined to cease active recruitment in its AML trial and halted all NK programs. The AML trial was the Company’s most\nadvanced clinical program with a relatively large addressable patient population given the high unmet medical need in relapsed and\nrefractory AML. After the Company ceased recruitment, it removed all associated cash flows relating to that program including all\nother NK related programs as well. As a result of these triggering events, the Company fully impaired the IPR&D assets\nassociated with these product candidates, and performed a goodwill impairment test on its Cell Therapy reporting unit. At June 30,\n2023, the estimated fair value of the Cell Therapy reporting unit was determined to be at breakeven compared to the carrying value\nusing a discount rate commensurate with the risks associated with the cash flows for preclinical product candidates. The Company\nalso performed a reconciliation of the aggregate fair value of each reporting unit to the market capitalization of the Company. The\nanalysis showed the fair value of the reporting units approximated our market capitalization, indicating an insignificant control\npremium. Based on the results of the impairment analysis, the Company did no During\nthe third quarter of 2023, the Company’s stock price and market capitalization continued to further decline. The Company also elected\nto terminate development of CYCART-19 for B-cell malignancies during the quarter, as well as paused development in exosomes. Therefore,\nthe Company tested for impairment due to these triggering events. Based on the results of the impairment analysis, the carrying value\nexceeded the fair value on the Cell Therapy reporting unit. The Company recognized a goodwill impairment charge for the remaining goodwill\nbalance on the Cell Therapy reporting unit of $ 82,714 At\nDecember 31, 2023, the estimated fair value of the Biobanking reporting unit was substantially in excess of its book value. The relative\nstability of the expected cash flows of the Biobanking reporting unit makes an impairment of goodwill in the future less likely. During\nthe quarter ended December 31, 2022, management identified various qualitative and quantitative factors which collectively indicated\na triggering event had occurred and performed an impairment test. Based on the results of the impairment analysis, the Degenerative Disease\nreporting unit had a carrying amount that exceeded its fair value due to lower forecasted sales and growth and it was determined that\nall of the goodwill, $ 3,610 The\ncarrying values of goodwill assigned to the Company’s reporting units are as follows: Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments\nCell Therapy Degenerative Biobanking Total\nBalance at December 31, 2021 $ 112,347 $ 3,610 $ 7,347 $ 123,304\nImpairment — (3,610 ) — (3,610 )\nBalance at December 31, 2022 $ 112,347 $ — $ 7,347 $ 119,694\nImpairment (112,347 ) — — (112,347 )\nBalance at December 31, 2023 $ — $ — $ 7,347 $ 7,347 Intangible\nAssets, Net Intangible\nassets, net consisted of the following: Schedule of Intangible Assets, Net\nDecember 31, December 31, Estimated Useful\nAmortizable intangible assets:\nDeveloped technology $ 16,810 $ 16,810 11 16\nCustomer relationships 2,413 2,413 10\nTrade names & trademarks 570 570 10 13\nReacquired rights 4,200 4,200 6\n23,993 23,993\nLess: accumulated amortization\nDeveloped technology (7,722 ) (6,549 )\nCustomer relationships (1,700 ) (1,435 )\nTrade names & trademarks (330 ) (275 )\nReacquired rights (3,940 ) (3,240 )\n(13,692 ) (11,499 )\nAmortizable intangible assets, net 10,301 12,494\nNon-amortized intangible assets\nAcquired IPR&D product rights 700 108,500 indefinite\n$ 11,001 $ 120,994 Amortization\nexpense for intangible assets was $ 2,193 2,193 Aggregate\namortization expense for each of the five succeeding years related to intangible assets held as of December 31, 2023 is estimated as\nfollows: Schedule of Aggregate Amortization Expense Related to Intangible Assets\n2024 $ 1,753\n2025 $ 1,493\n2026 $ 1,356\n2027 $ 1,258\n2028 $ 1,208 "]

{"sheet":"Accrued Expenses and Other Curr","index":13,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Accrued Expenses and Other Current Liabilities","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Payables and Accruals [Abstract]"," "]
["Accrued Expenses and Other Current Liabilities","8.\nAccrued Expenses and Other Current Liabilities Accrued\nexpenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities\n2023 2022\nDecember 31,\n2023 2022\nAccrued clinical trial expense $ 189 $ 2,659\nAccrued professional fees 573 880\nAccrued wages, bonuses, commissions and vacation 3,011 2,576\nAccruals for construction in progress 214 322\nAccrued compliance fee 1,145 —\nOther 2,448 2,632\nTotal\naccrued expenses $ 7,580 $ 9,069 "]

{"sheet":"Debt","index":14,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Debt","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Debt Disclosure [Abstract]"," "," "]
["Debt","7. Debt Debt\nconsisted of the following: Schedule\nof Debt\nSeptember 30, December 31,\nShort-term debt - unaffiliated:\nYorkville - PPA (measured at fair value) $ - $ 17,223\nYorkville - convertible promissory note (measured at fair value) 3,695 -\nShort-term debt - other - 2,108\nTotal short-term debt - unaffiliated 3,695 19,331\nShort-term debt - related parties:\nC.V. Starr Bridge Loan, net of discount 5,640 5,523\nRWI Bridge Loan, net of discount 29,482 12,967\nCEO promissory note 3,793 1,419\nTotal short-term debt - related parties 38,915 19,909\nTotal debt $ 42,610 $ 39,240 Yorkville\nPPA On\nSeptember 15, 2022, the Company entered into a Pre-Paid Advance Agreement (“PPA”) with YA II PN, Ltd. (“Yorkville”),\npursuant to which the Company could request advances of up to $ 40,000 18 150,000 2.0 6.0 15.0 7.50 19.9 4.99 6,000 7.50 6,000 5.0 10.0 7.50 0.50 20.0 In\nconnection with the entry into the PPA, the Company received the initial Pre-Paid Advance of $ 40,000 39,200 12 During\nthe fourth quarter of 2022, Yorkville elected to convert $ 3,000 694 262,797 3,889 400 559,481 18,724 16,811 1,073 840 17,223 16,623 On\nJanuary 12, 2024, the Company and Yorkville entered into a forbearance agreement (“Forbearance Agreement”), pursuant to which\nYorkville agreed to restrain from enforcing its rights and remedies as a result of the event of default during the forbearance period.\nThe forbearance period was to continue until the earlier of January 19, 2024 or the date the Company fully repaid all amounts outstanding\nunder the PPA (“Forbearance Period”). During the Forbearance Period, interest accrued at 15.0 17,348 7 100,000 100,000 On\nMarch 13, 2024, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) with Yorkville (see Note 10). Yorkville\nConvertible Promissory Note Upon\nentry into the SEPA, the Company issued Yorkville a $ 3,150 2,993 5 8.0 18.0 March 13, 2025 6.3171 2.7546 19.9 4.99 18.0 The\nCompany determined that the convertible note included embedded derivatives that would otherwise require bifurcation as derivative liabilities,\nand neither the debt instrument nor the embedded features are required to be classified as equity. Therefore, at inception, the Company\nelected to carry the convertible promissory note comprised of the debt host and the embedded derivative liabilities at fair value on\na recurring basis as permitted under ASC 825, Financial Instruments 157 3,695 3,150 Short-Term\nDebt - Other and CEO Promissory Note On\nAugust 21, 2023, the Company entered into a loan agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two\nunaffiliated lenders, providing for a loan in the aggregate principal amount of $ 3,000 1,000 15.0 August 21, 2024 4,500 On\nOctober 12, 2023, in order to further address the Company’s immediate working capital requirements, Dr. Robert Hariri and the Company\nsigned a promissory note for $ 285 15.0 12 As\nof September 30, 2024, there was no other short-term debt and the carrying value of the CEO promissory note inclusive of accrued interest\nwas $ 3,793 2,108 1,419 Short-Term\nDebt – Related Parties - C.V. Starr and RWI C.V.\nStarr & Co., Inc On\nMarch 17, 2023, the Company entered into a loan agreement (the “Starr Bridge Loan”) with C.V. Starr & Co., Inc. (“C.V.\nStarr”), a stockholder of the Company, for an aggregate principal amount of $ 5,000 100 12.0 15.0 March 17, 2025 75,000 1.25 94 five-year 7.10 In\nJune 2023, in connection with the Amended RWI Loan (as defined below), the Company granted C.V. Starr additional warrants to acquire\nup to an aggregate 50,000 5-year 8.10 Debt with Conversion and Other Options Derivatives\nand Hedging Under\nthe terms of the Starr Bridge Loan, the Company agreed to customary negative covenants restricting its ability to repay indebtedness,\npay dividends to stockholders, repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest\nin any of the Company’s assets, other than as permitted, or hold cash and cash equivalents less than $ 3,000 3,000 On\nJanuary 12, 2024, the Company entered into an amendment which terminated the minimum $ 3,000 On\nMarch 13, 2024, the Company and C.V. Starr entered into a forbearance agreement (“Starr Forbearance Agreement”) with respect\nto the Starr Bridge Loan. Under the Starr Forbearance Agreement, (i) C.V. Starr agreed not to exercise its rights and remedies upon the\noccurrence of any default under the Starr Bridge Loan until the Company’s obligations in respect of the Yorkville convertible promissory\nnote have been indefeasibly paid in full, (ii) C.V. Starr consented to the Company’s incurrence of indebtedness under the Yorkville\nconvertible promissory note, (iii) C.V. Starr consented to cash payments required to be made under the SEPA and the Yorkville convertible\npromissory note, (iv) the Company agreed to increase the interest rate on the loan outstanding under the Starr Bridge Loan by 100 75,000 7.10 March 17, 2028 50,000 8.10 June 20, 2028 5.895 13.0 10 16.0 As\nof September 30, 2024 and December 31, 2023, the carrying value of Starr Bridge Loan, inclusive of accrued interest and net of discount,\nwas $ 5,640 5,523 Resorts\nWorld Inc Pte Ltd On\nMay 16, 2023, with written consent provided by Yorkville, the Company entered into a senior secured loan agreement (“RWI Bridge\nLoan”) with Resorts World Inc Pte Ltd, (“RWI”) providing for an initial loan in the aggregate principal amount of $ 6,000 120 12.5 15.5 June 14, 2023 On\nJune 21, 2023, the Company closed on an amended and restated senior secured loan agreement (“Amended RWI Loan”), to amend\nand restate the previous senior secured loan agreement, in its entirety. The Amended RWI Loan provided for an additional loan in the\naggregate principal amount of $ 6,000 678 12.5 15.5 March 17, 2025 300,000 1.25 375 five-year 8.10 Pursuant\nto the terms of the Amended RWI Loan, the Company was required to apply the net proceeds to the trigger payments due to Yorkville pursuant\nto the PPA. In addition, the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends\nto stockholders, repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of its\nassets, other than as permitted, or hold cash and cash equivalents less than $ 3,000 3,000 3,000 The\nCompany accounted for the Amended RWI Loan in accordance with ASC 470-20, Debt with Conversion and Other Options Derivatives and Hedging 2,151 On\nJanuary 12, 2024, the Company entered into a second amended and restated senior secured loan agreement (“RWI Second Amended Bridge\nLoan”), to amend and restate the previously announced senior secured loan agreement with RWI dated as of May 16, 2023, as amended\non June 20, 2023, in its entirety. The RWI Second Amended Bridge Loan provided for an additional loan in the aggregate principal amount\nof $ 15,000 3,750 12.5 July 16, 2025 5-year 1,650,000 1,350,000 5 2.4898 2.988 Pursuant\nto the terms of the RWI Second Amended Bridge Loan, the Company was required to apply the proceeds of the additional loan (i) to the\npayment in full of all outstanding amounts owed to Yorkville under the PPA, (ii) to the payment of invoices of certain critical vendors,\n(iii) to the first settlement payment owed to Palantir (see Note 9), and (iv) for working capital and other purposes pre-approved by\nRWI. Pursuant to the terms of the RWI Second Amended Bridge Loan, the Company agreed to customary negative covenants restricting its\nability to pay dividends to stockholders, repay or incur other indebtedness other than as permitted, or grant or suffer to exist a security\ninterest in any of the Company’s assets, other than as permitted. In addition, the Company agreed to apply net revenues received\nthrough the sale of its products/provision of services in connection with or related to its distribution and manufacturing agreement\nwith Genting Innovation Pte Ltd (“Genting Innovation”), a related party, as a prepayment towards the loan. The\nRWI Second Amended Bridge Loan resulted in an extinguishment of the Amended RWI Loan, since the change in cash flows exceeds 10%. As\na result, the Company record a loss on extinguishment equal to the difference between (i) the fair values of the new loan and Tranche\n#1 and Tranche #2 Warrants and (ii) the previous carrying amount of the Amended RWI Loan, or $ 3,908 Derivatives and Hedging Fair Value\nOption for Financial Instruments Distinguishing Liabilities from Equity The\nCompany and RWI also entered into an investor rights agreement dated as of January 12, 2024. The investor rights agreement provides RWI\ncertain information and audit rights, as well as registration rights with respect to the shares underlying the Tranche #1 Warrant and\nTranche #2 Warrant, including both the undertaking to file a registration statement within 45 days of filing of the 2023 Form 10-K, “piggyback”\nregistration rights, as well as the right to request up to three demand rights for underwritten offerings per year; in each case subject\nto customary “underwriter cutback” language as well as any objections raised by the Securities and Exchange Commission to\ninclusion of securities. If the initial registration statement was not filed on or prior to May 15, 2024, the investor rights agreement\nprovided for partial liquidating damages equal to 1.0 6.0 18.0 On\nMarch 13, 2024, the Company and RWI entered into a second forbearance agreement (“RWI 2nd Forbearance Agreement”). Under\nthe RWI 2nd Forbearance Agreement, (i) RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the\nRWI Second Amended Bridge Loan until the Company’s obligations in respect of the Yorkville convertible promissory note have been\nindefeasibly paid in full or March 13, 2025, whichever occurs first, (ii) RWI consented to the Company’s incurrence of indebtedness\nunder the Yorkville convertible promissory note, (iii) RWI consented to cash payments required to be made under the SEPA and the Yorkville\nconvertible promissory note, (iv) the Company agreed to increase the interest rate on the loan outstanding under the RWI Loan Agreement\nby 100 12.5 13.5 300,000 5.895 10 1,162 13,700 16.5 As\nof September 30, 2024 and December 31, 2023, the carrying value of the RWI Second Amended Bridge Loan and Amended RWI Loan, inclusive\nof interest and net of discount was $ 29,482 12,967 ","9. Debt Short-Term\nDebt - Yorkville On\nSeptember 15, 2022, the Company entered into a Pre-Paid Advance Agreement (“PPA”) with Yorkville, pursuant to which the Company\nmay request advances of up to $ 40,000 18 150,000 2 6 15 7.50 19.9 4.99 6,000 7.50 6,000 5.0 10 7.50 In\nconnection with the entry into the PPA, the Company received the initial Pre-Paid Advance of $ 40,000 39,200 12 During\nthe year ended December 31, 2023, Yorkville elected to convert $ 3,889 400 559,481 155 17,223 16,623 37,603 37,000 On\nFebruary 22, 2023, Yorkville provided notice to the Company that a “triggering event” under the terms of the PPA occurred\non February 21, 2023 and approximately $ 6,500 5 On\nMarch 24, 2023, the Company paid $ 1,950 In\nApril 2023, the Company and Yorkville agreed that Yorkville would not accelerate any amounts outstanding under the PPA provided that\n(i) the Company pays the remaining balance on the first trigger payment of approximately $ 4,600 two 6,500 5,500 900 On\nMay 16, 2023, the Company used the net proceeds from the RWI Bridge Loan (as defined below) to repay the remaining balance on the second\ntrigger payment for approximately $ 5,600 Further,\non June 21, 2023, the Company used the net proceeds from the Amended RWI Loan (as defined below) to repay $ 5,700 18,724 16,811 1,073 840 0.50 On\nAugust 2, 2023, Yorkville provided notice to the Company that a “triggering event” under the term of the PPA occurred on\nAugust 1, 2023. The Company was not able to make the August trigger payment of $ 6,340 On\nSeptember 18, 2023, the Company and Yorkville entered into a letter agreement to extend the maturity date of the PPA to December 31,\n2023, and Yorkville agreed not to declare an event of default, as defined in the PPA, until January 1, 2024. The Company further agreed\nto issue 270,730 712 2,000 500 On\nJanuary 12, 2024, the Company and Yorkville entered into a forbearance agreement (“Forbearance Agreement”) in which Yorkville\nagreed to restrain from enforcing its rights and remedies as a result of the event of default during the forbearance period. The forbearance\nperiod shall continue until the earliest of the January 19, 2024 or the date the Company fully repaid all amounts outstanding under the\nPPA (“Forbearance Period”). During the Forbearance Period, interest shall accrue at 15 17,348 7 100,000 100,000 On\nMarch 13, 2024, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) with Yorkville (Note 12). Upon\nentry into the SEPA, the Company issued Yorkville a $ 3.15 2.99 5 8.0 18.0 March 13, 2025 6.3171 2.4898 19.9 4.99 Short-Term\nDebt - Other and Related Party On\nAugust 21, 2023, the Company entered into a loan agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two\nunaffiliated lenders, providing for a loan in the aggregate principal amount of $ 3,000 1,000 15 August 21, 2024 4,500 On\nOctober 12, 2023, in order to further address the Company’s immediate working capital requirements, Robert Hariri, M.D., Ph.D.,\nthe Company’s Chairman and Chief Executive Officer, and the Company signed a promissory note (“CEO Promissory Note”)\nfor $ 285 15.0 twelve months As\nof December 31, 2023, the carrying value of the Loan and the CEO Promissory Note inclusive of accrued interest is $ 3,527 1,419 2,108 Short-Term\nDebt – Related Parties - C.V. Starr and RWI C.V.\nStarr & Co., Inc On\nMarch 17, 2023, the Company entered into a loan agreement (the “Starr Bridge Loan”) with C.V. Starr & Co., Inc. (“C.V.\nStarr”), a stockholder of the Company, for an aggregate principal amount of $ 5,000 100 12.0 15.0 March 17, 2025 75,000 1.25 94 five-year 7.10 In\nJune 2023, in connection with the Amended RWI Loan (as defined below), the Company granted C.V. Starr additional warrants to acquire\nup to an aggregate 50,000 5-year 8.10 ASC 470-20, Debt with Conversion and Other Options\nASC 815, Derivatives and Hedging ASC 815-10-15-74(a) 5,523 Under\nthe terms of the Starr Bridge Loan, the Company agreed to customary negative covenants restricting its ability to repay indebtedness,\npay dividends to stockholders, repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest\nin any of the Company’s assets, other than as permitted, or hold cash and cash equivalents less than $ 3,000 During the year ended December 31, 2023, the Company’s cash and cash equivalents fell below the $ 3,000 On\nJanuary 12, 2024, the Company entered into an amendment (“Starr Bridge First Amendment”), which terminated the minimum\n$ 3,000 includes\ncustomary events of default and the Company granted C.V. Starr a senior security interest in all of its assets, pari passu with RWI\n(as defined below). On\nMarch 13, 2024, the Company and C.V. Starr, entered into a forbearance agreement (“Starr Forbearance Agreement”), with respect\nto the Starr Bridge Loan. Under the Starr Forbearance Agreement, (i) Starr agreed not to exercise its rights and remedies upon the occurrence\nof any default under the Starr Loan Agreement until the Company’s obligations in respect of the Yorkville convertible note have\nbeen indefeasibly paid in full, (ii) Starr consented to the Company’s incurrence of indebtedness under the Yorkville convertible\nnote, (iii) Starr consented to cash payments required to be made under the SEPA and the Yorkville convertible note, (iv) the Company\nagreed to increase the interest rate on the loan outstanding under the Starr Bridge Loan by 100 75,000 7.10 March 17, 2028 50,000 8.10 June 20,\n2028 5.895 13 Resorts\nWorld Inc Pte Ltd On\nMay 16, 2023, with written consent provided by Yorkville, the Company entered into a senior secured loan agreement (“RWI Bridge\nLoan”) with Resorts World Inc Pte Ltd, (“RWI”) providing for an initial loan in the aggregate principal amount of $ 6,000 120 12.5 15.5 June 14, 2023 On\nJune 21, 2023, the Company closed on an amended and restated senior secured loan agreement (“Amended RWI Loan”), to amend\nand restate the previous senior secured loan agreement, in its entirety. The Amended RWI Loan provided for an additional loan in the\naggregate principal amount of $ 6,000 678 12.5 15.5 March 17, 2025 300,000 1.25 375 5-year 8.10 The\nCompany applied the guidance for this transaction in accordance with ASC 470-20, Debt with Conversion and Other Options ASC\n815, Derivatives and Hedging 2,151 ASC 815-10-15-74(a) 12,967 Pursuant\nto the terms of the Amended RWI Loan, the Company was required to apply the net proceeds to the trigger payments due to Yorkville pursuant\nto the PPA. RWI is affiliated with Lim Kok Thay, a former member of the Company’s board of directors. In addition, the Company\nagreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders, repay or incur other\nindebtedness other than as permitted, grant or suffer to exist a security interest in any of its assets, other than as permitted, or\nhold cash and cash equivalents less than $ 3,000 3,000 Pursuant\nto the amendment on January 12, 2024, see below, the amendment terminated the minimum $ 3,000 On\nJanuary 12, 2024, the Company entered into a second amended and restated senior secured loan agreement (“RWI Second Amended\nBridge Loan”), to amend and restate the previously announced senior secured loan agreement with RWI dated as of May 16, 2023,\nas amended on June 20, 2023, in its entirety. The RWI Second Amended Bridge Loan provided for an additional loan in the 15,000 3,750 12.5 July 16, 2025 5-year 1,650,000 1,350,000 5 2.4898 Pursuant\nto the terms of the RWI Second Amended Bridge Loan, the Company was required to apply the proceeds of the additional loan (i) to the\npayment in full of all outstanding amounts owed to Yorkville under the PPA, (ii) to the payment of invoices of certain critical vendors,\n(iii) to the first settlement payment owed to Palantir Technologies, Inc., and (iv) for working capital and other purposes pre-approved\nby RWI. Pursuant to the terms of the RWI Second Amended Bridge Loan, the Company agreed to customary negative covenants restricting its\nability to pay dividends to stockholders, repay or incur other indebtedness other than as permitted, or grant or suffer to exist a security\ninterest in any of the Company’s assets, other than as permitted. In addition, the Company agreed to apply net revenues received\nthrough the sale of our products/provision of services in connection with or related to its distribution and manufacturing agreement\nwith Genting Innovation Pte Ltd (“Genting Innovation”), a related party, as a prepayment towards the loan. On\nMarch 13, 2024, the Company and RWI entered into a second forbearance agreement (“RWI 2nd Forbearance Agreement”). Under\nthe RWI 2nd Forbearance Agreement, (i) RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the\nRWI Loan Agreement until the Company’s obligations in respect of the Yorkville convertible note have been indefeasibly paid in\nfull or March 13, 2025, whichever occurs first, (ii) RWI consented to the Company’s incurrence of indebtedness under the Yorkville\nconvertible note, (iii) RWI consented to cash payments required to be made under the SEPA and the Yorkville convertible note, (iv) the\nCompany agreed to increase the interest rate on the loan outstanding under the RWI Loan Agreement by 100 300,000 June 20,\n2028 5.895 Schedule\nof Debt "]

{"sheet":"Leases","index":15,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Leases","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Leases"," "," "]
["Leases","8. Leases Lease\nAgreements ROU\nassets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s\nobligation to make lease payments arising from the lease. The Company’s lease ROU assets and liabilities are recognized at the\nlease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments,\nthe Company uses its incremental borrowing rate based on the information available at the lease commencement date to determine the appropriate\ndiscount rate by multiple asset classes. Variable lease payments that are not based on an index or that result from changes to an index\nsubsequent to the initial measurement of the corresponding lease liability are not included in the measurement of lease ROU assets or\nliabilities and instead are recognized in earnings in the period in which the obligation for those payments is incurred. Lease terms\nmay include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease\nexpense is recognized on a straight-line basis over the expected lease term. Rent expense was $ 1,114 892 3,333 2,687 On\nMarch 13, 2019, Legacy Celularity entered into a lease agreement for a 147,215 2036 five-year March 1, 2020 230 14,722 14,722 On\nSeptember 14, 2023, the Company entered into a lease amendment on the Company’s Florham Park, New Jersey facility to reduce the\nletter of credit by approximately $ 4,900 9,883 400 2,083 The\ncomponents of the Company’s lease costs are classified on its condensed consolidated statements of operations and comprehensive\nloss as follows: Schedule of Lease Costs\n2024 2023 2024 2023\nThree Months Ended Nine Months Ended\n2024 2023 2024 2023\nOperating lease cost $ 978 $ 759 $ 2,933 $ 2,278\nVariable lease cost 348 320 1,026 911\nTotal operating lease cost $ 1,326 $ 1,079 $ 3,959 $ 3,189 The\ntable below shows the cash and non-cash activity related to the Company’s lease liabilities during the period: Schedule of Cash and\nNon-cash Activity Related to the lease Liabilities\n2024 2023\nNine Months Ended September 30,\n2024 2023\nCash paid related to lease liabilities:\nOperating cash flows from operating leases $ 2,534 $ 2,168 As\nof September 30, 2024, the maturities of the Company’s operating lease liabilities were as follows: Schedule of Future Minimum Payments under\nNon-Cancelable Operating Leases\n2024 (remaining three months) $ 845\nRemaining year $ 845\n2025 3,452\nYear one 3,452\n2026 3,526\nYear two 3,526\n2027 3,599\nYear three 3,599\n2028 3,673\nYear four 3,673\nThereafter 84,568\nYear four Thereafter 84,568\nTotal lease payments 99,663\nLess imputed interest (73,212 )\nTotal $ 26,451 As\nof September 30, 2024, the weighted average remaining lease term of the Company’s operating lease was 21.5 14.24 ","10.\nLeases Lease\nAgreements ROU\nassets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s\nobligation to make lease payments arising from the lease. The Company’s lease ROU assets and liabilities are recognized at the\nlease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments,\nthe Company uses its incremental borrowing rate based on the information available at the lease commencement date to determine the appropriate\ndiscount rate by multiple asset classes. Variable lease payments that are not based on an index or that result from changes to an index\nsubsequent to the initial measurement of the corresponding lease liability are not included in the measurement of lease ROU assets or\nliabilities and instead are recognized in earnings in the period in which the obligation for those payments is incurred. Lease terms\nmay include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease\nexpense is recognized on a straight-line basis over the expected lease term. Lease expense was $ 3,750 3,803 On\nMarch 13, 2019, Legacy Celularity entered into a lease agreement for a 147,215 2036 five-year March 1, 2020 230 14,722 14,722 On\nSeptember 14, 2023, the Company entered into a lease amendment on the Company’s Florham Park, New Jersey facility to reduce\nthe letter of credit by approximately $ 4,900 9,883 400 2,083 The\ncomponents of the Company’s lease costs are classified on its consolidated statements of operations as follows: Schedule of Lease Costs\n2023 2022\nYear Ended December 31,\n2023 2022\nOperating lease cost $ 3,256 $ 3,038\nVariable lease cost 1,132 1,598\nTotal operating lease cost $ 4,388 $ 4,636\nShort term lease cost $ - $ 126 The\ntable below shows the cash and non-cash activity related to the Company’s lease liabilities during the year ended December 31,\n2023: Schedule of Cash and\nNon-cash Activity Related to the lease Liabilities\n2023 2022\nYear Ended December 31,\n2023 2022\nCash paid related to lease liabilities:\nOperating cash flows from operating leases $ 2,995 $ 2,834\nNon-cash lease liability activity:\nRight-of-use assets obtained in exchange for lease obligations:\nOperating leases $ - $ - As\nof December 31, 2023, the maturities of the Company’s operating lease liabilities were as follows: Schedule of Future Minimum Payments under\nNon-Cancelable Operating Leases\nRemaining year\n2024 $ 3,378\nYear one $ 3,378\n2025 3,452\nYear two 3,452\n2026 3,526\nYear three 3,526\n2027 3,599\nYear four 3,599\n2028 3,673\nYear five 3,673\nYear four Thereafter\nThereafter 84,568\nYear five Thereafter 84,568\nTotal lease payments 102,196\nLess imputed interest (76,019 )\nTotal $ 26,177 As\nof December 31, 2023, the weighted average remaining lease term of the Company’s operating lease was 22.3 14.24 "]

{"sheet":"Commitments and Contingencies","index":16,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Commitments and Contingencies","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Commitments and Contingencies Disclosure [Abstract]"," "," "]
["Commitments and Contingencies","9. Commitments and Contingencies Contingent\nConsideration Related to Business Combinations In\nconnection with Legacy Celularity’s acquisition in 2017 of HLI Cellular Therapeutics, LLC and Anthrogenesis, the Company has agreed\nto pay future consideration to the sellers upon the achievement of certain regulatory and commercial milestones. As a result, the Company\nrecorded $ 1,606 Indemnification\nAgreements In\nthe ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners\nand other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from\nintellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements\nwith members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them\nagainst certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount\nof future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date,\nthe Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification\nclaims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of September\n30, 2024 or December 31, 2023. Agreement\nwith Palantir Technologies Inc. On\nMay 5, 2021, Legacy Celularity executed a Master Subscription Agreement (the “Palantir MSA”) with Palantir under which it\nagreed to pay $ 40,000 five years Exit or Disposal Costs 24,161 3,500 Arbitration Demand no 3,500 Sirion\nLicense Agreement In\nDecember 2021, the Company entered into a license agreement (“Sirion License”) with Sirion Biotech GmbH (“Sirion”).\nUnder the Sirion License, Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (“Licensed\nProduct”). As part of the Sirion License, the Company paid Sirion $ 136 113 5,099 10 30 Legal\nProceedings At\neach reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably\nestimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred\nthe costs related to such legal proceedings. Civil\nInvestigative Demand The\nCompany received a Civil Investigative Demand (the “Demand”) under the False Claims Act, 31 U.S.C. § 3729, dated August\n14, 2022, from the U.S. Attorney’s Office for the Eastern District of Pennsylvania. The Demand requests documents and information\nrelating to claims submitted to Medicare, Medicaid, or other federal insurers for services or procedures involving injectable human tissue\ntherapy products derived from amniotic fluid or birth tissue and includes Interfyl, a biomaterials product. The Company is cooperating\nwith the request and is engaged in an ongoing dialogue with the Assistant U.S. Attorneys handling the Demand. The matter is still in\npreliminary stages and there is uncertainty as to whether the Demand will result in any liability. Arbitration\nDemand from Palantir Technologies Inc. On\nApril 20, 2023, Palantir commenced an arbitration with JAMS Arbitration asserting claims for declaratory relief and breach of contract\nrelating to the Palantir MSA, seeking damages in an amount equal to the full value of the contract. The Company responded to the arbitration\ndemand and asserted counterclaims for breach of contract, breach of warranty, fraudulent inducement, violation of California’s\nUnfair Competition Law, amongst others, in relation to the Palantir MSA. On\nDecember 21, 2023, the Company and Palantir entered into the Palantir Settlement Agreement to resolve the JAMS Arbitration. The Palantir\nSettlement Agreement was subsequently amended on January 10, 2024 and May 6, 2024. Both parties agreed to dismiss the arbitration proceeding\nand dispute and provide for mutual releases upon the Company’s satisfaction of a settlement payment obligation. Through June 3,\n2024, the Company made total settlement payments of $ 3,500 60,584 Celularity\nInc. v. Evolution Biologyx, LLC, et al. On\nApril 17, 2023, the Company filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC (collectively,\n“Evolution”) in the United States District Court for the District of New Jersey to recover unpaid invoice amounts for the\nsale of its biomaterial products in the amount of approximately $ 2,350 TargetCW\nv. Celularity Inc. On\nMarch 27, 2024, WMBE Payrolling, Inc., dba TCWGlobal, filed a complaint in the United States District Court for the Southern District\nof California alleging a breach of contract and account stated claims relating to a Master Services Agreement dated May 4, 2020, or the\nTCWGlobal MSA, for the provision of certain leased workers to perform services on our behalf. The complaint alleges that the Company\nbreached the TCWGlobal MSA by failing to make payments on certain invoices for the services of the leased workers. On May 7, 2024, the\nCompany entered into a settlement agreement and mutual release with TCWGlobal whereupon the Company agreed to pay $ 500 ","11.\nCommitments and Contingencies Contingent\nConsideration Related to Business Combinations In\nconnection with the Company’s acquisition of HLI Cellular Therapeutics, LLC and Anthrogenesis, the Company has agreed to pay future\nconsideration to the sellers upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded\n$ 1,606 105,945 Indemnification\nAgreements In\nthe ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business\npartners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of\nsuch agreements or from intellectual property\ninfringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its\nboard of directors and its executive officers that will require the Company, among other things, to indemnify them against certain\nliabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future\npayments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the\nCompany has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any\nindemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as\nof December 31, 2023 and 2022. Agreement\nwith Palantir Technologies Inc. On\nMay 5, 2021, Legacy Celularity executed a Master Subscription Agreement (“MSA”) with Palantir under which it will pay $ 40,000 five years 24,402 3,500 3,500 7,333 8,000 Sirion\nLicense Agreement In\nDecember 2021, the Company entered into a license agreement (“Sirion License”) with Sirion Biotech GmbH (“Sirion”).\nUnder the Sirion License, Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (“Licensed\nProduct”). As part of the Sirion License, the Company paid Sirion $ 136 113 5,099 10 30 Legal\nProceedings At\neach reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably\nestimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred\nthe costs related to such legal proceedings. Civil\nInvestigative Demand The\nCompany received a Civil Investigative Demand (the “Demand”) under the False Claims Act, 31 U.S.C. § 3729, dated August\n14, 2022, from the U.S. Attorney’s Office for the Eastern District of Pennsylvania. The Demand requests documents and information\nrelating to claims submitted to Medicare, Medicaid, or other federal insurers for services or procedures involving injectable human tissue\ntherapy products derived from amniotic fluid or birth tissue and includes Interfyl. The Company is cooperating with the request and is\nengaged in an ongoing dialogue with the Assistant U.S. Attorneys handling the Demand. The matter is still in preliminary stages and there\nis uncertainty as to whether the Demand will result in any liability. Arbitration\nDemand from Palantir Technologies Inc. On\nApril 20, 2023, Palantir Technologies Inc. (“Palantir”), commenced an arbitration with JAMS Arbitration asserting claims\nfor declaratory relief and breach of contract relating to the May 5, 2021 Master Service Agreement (the “Palantir MSA”),\nseeking damages in an amount equal to the full value of the contract. The Company has responded to the arbitration demand and\nasserted counterclaims for breach of contract,\nbreach of warranty, fraudulent inducement, violation of California’s Unfair Competition Law, amongst others, in relation to\nthe Palantir MSA. On\nDecember 21, 2023, the Company and Palantir entered into a settlement and release agreement pursuant to the JAMS arbitration proceeding\nasserting claims for declaratory relief and breach of contract relating to the Palantir MSA. Both parties agreed to dismiss the arbitration\nproceeding and dispute and provide for mutual releases upon the Company’s satisfaction of a settlement payment obligation. Through\nJune 3, 2024, the Company made total settlement payments of $ 3.5 60,584 Celularity\nInc. v. Evolution Biologyx, LLC, et al. On\nApril 17, 2023, the Company filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC (collectively,\n“Evolution”) in the United States District Court for the District of New Jersey to recover unpaid invoice amounts for the\nsale of its biomaterial products in the amount of approximately $ 2.35 "]

{"sheet":"Equity","index":17,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Equity","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Equity [Abstract]"," "," "]
["Equity","10. Equity Common\nStock As\nof September 30, 2024 and December 31, 2023, the Company’s certificate of incorporation, as amended and restated, authorized the\nCompany to issue 730,000,000 0.0001 21,984,614 19,378,192 Voting\nPower Except\nas otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders\nof common stock possess all voting power for the election of the Company’s directors and all other matters requiring stockholder\naction. Holders of common stock are entitled to one vote per share Dividends Holders\nof Class A common stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company’s\nboard of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or\ncombinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally\nand identically. Liquidation,\nDissolution and Winding Up In\nthe event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders\nof the common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available\nfor distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. Preemptive\nor Other Rights The\nCompany’s stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable\nto common stock. Election\nof Directors The\nCompany’s board of directors is divided into three classes, Class I, Class II and Class III, with only one class of directors being\nelected in each year and each class serving a three-year term, except with respect to the election of directors at the special meeting\nheld in connection with the merger with GX, Class I directors are elected to an initial one-year term (and three-year terms subsequently),\nthe Class II directors are elected to an initial two-year term (and three-year terms subsequently) and the Class III directors are elected\nto an initial three-year term (and three-year terms subsequently). There is no cumulative voting with respect to the election of directors,\nwith the result that the holders of more than 50.0 Preferred\nStock The\nCompany’s Certificate of Incorporation authorized 10,000,000 no ATM\nAgreement On\nSeptember 8, 2022, the Company entered into an At-the-Market Sales Agreement (the “ATM Agreement”) with BTIG, LLC, Oppenheimer\n& Co. Inc. and B. Riley Securities, Inc., acting as sales agents and/or principals, pursuant to which the Company may offer and sell,\nfrom time to time in its sole discretion, shares of its common stock, having an aggregate offering price of up to $ 150,000 Any\nshares offered and sold in the at-the-market offering will be issued pursuant to the Company’s shelf registration statement on\nForm S-3 and the related prospectus supplement. Under the ATM Agreement, the sales agents may sell shares of common stock by any method\npermitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933. The\nCompany will pay the sales agents a commission rate of up to 3.0 During\nthe nine months ended September 30, 2023, the Company received gross and net proceeds of $ 141 136 13,296 10.60 March\n2023 PIPE On\nMarch 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief\nExecutive Officer, Dr. Robert Hariri, providing for the private placement of (i) 938,184 938,183 8.34 1.25 9,000 2,000 30.00 five years 61 The\nCompany accounted for the March 2023 PIPE Warrants and common stock as a single non-arm’s length transaction. The Company applied\nthe guidance for this transaction in accordance with ASU 2020-06, (Subtopic 470-20): Debt - Debt with Conversion and Other Options,\nASC 815 Derivatives and Hedging, ASC 480 Distinguishing Liabilities from Equity 1,650 On\nSeptember 14, 2023, the Company entered into a warrant amendment on the March 2023 PIPE Warrants with the unaffiliated investor to reduce\nthe exercise price from $ 30.00 10.00 729,698 Stock-Based Compensation, 402 Registered\nDirect Offerings On\nApril 10, 2023, the Company closed on a registered direct offering of 923,077 923,076 6.50 6,000 7.50 five years 5,505 4,280 Upon\nthe closing of the registered direct offering on April 10, 2023, the Company amended the existing May 2022 PIPE Warrants, to reduce the\nexercise price from $ 82.50 7.50 date to five and one-half years following the closing of the\noffering 1,389 On\nJuly 31, 2023, the Company closed on a registered direct offering of 857,143 857,142 3.50 3,000 3.50 five years 2,740 2,645 In\nconnection with the July 31, 2023 registered direct offering described above, the Company also entered into an amendment to certain existing\nwarrants to purchase up to an aggregate of 892,856 7.50 3.50 511 May\n2023 PIPE On\nMay 18, 2023, the Company closed on a securities purchase agreement with a group of accredited investors, providing for the private placement\nof an aggregate (i) 581,395 581,394 1.25 3,750 10.00 May 17, 2028 61 January\n2024 PIPE On\nJanuary 12, 2024, the Company entered into a securities purchase agreement with an existing investor, Dragasac Limited (“Dragasac”),\nproviding for the private placement of (i) 2,141,098 0.0001 535,274 2.4898 1.25 6,000 January 16, 2024 2.4898 January 16, 2029 five years The\nCompany accounted for the January 2024 PIPE Warrant and common stock as a single non-arm’s length transaction recognized in equity.\nThe Company applied the guidance for this transaction in accordance with ASU 2020-06, (Subtopic 470-20): Debt - Debt with Conversion\nand Other Options, ASC 815 Derivatives and Hedging, ASC 480 Distinguishing Liabilities from Equity 909 652,981 67.70 2.4898 524 In\nconnection with the execution of the securities purchase agreement, the Company also entered into an investor rights agreement with Dragasac\ndated as of January 12, 2024. The investor rights agreement provides Dragasac certain information and audit rights, as well as registration\nrights with respect to the shares (and shares underlying the January 2024 PIPE Warrant), including both the undertaking to file a registration\nstatement within 45 days of filing of the 2023 Form 10-K, “piggyback” registration rights, as well as the right to request\nup to three demand rights for underwritten offerings per year; in each case subject to customary “underwriter cutback” language\nas well as any objections raised by the SEC to inclusion of securities. If the initial registration statement was not filed on or prior\nto May 15, 2024, the investor rights agreement provides for partial liquidating damages equal to 1.0 6.0 18.0 Effective\nFebruary 16, 2024, in order to comply with Section 4.15(a) of the securities purchase agreement, the Company entered into an amended\nemployment agreement with its Chief Administrative Officer (“CAO”), whereby the CAO agreed to decrease his base salary from\n$ 500 425 Warrant\nModifications On\nJanuary 12, 2024, in connection with the January 2024 PIPE, the Company agreed to amend the exercise price of legacy warrants held by\nDragasac to purchase 652,981 March 16, 2025 67.70 2.4898 300,000 June 20, 2028 5.895 75,000 March 17, 2028 7.10 5.895 50,000 June 20, 2028 8.10 5.895 Standby\nEquity Purchase Agreement On\nMarch 13, 2024, the Company and Yorkville entered into a SEPA. Under the SEPA, the Company has the right to sell to Yorkville up to $ 10,000 0.0001 Upon\nthe satisfaction of the conditions precedent in the SEPA, which include having a resale shelf for shares of common stock issued to Yorkville\ndeclared effective, the Company has the right to direct Yorkville to purchase a specified number of shares of common stock by delivering\nwritten notice (“Advance”). An Advance may not exceed 100 five Yorkville\nwill generally purchase shares pursuant to an Advance at a price per share equal to 97 The\nSEPA will automatically terminate on the earliest to occur of (i) the first day of the month next following the 36-month anniversary\nof the date of the SEPA or (ii) the date on which Yorkville shall have made payment for shares of common stock equal to $ 10,000 As\nconsideration for Yorkville’s commitment to purchase the shares of common stock pursuant to the SEPA, the Company paid Yorkville\na $ 25 16,964 125 In\nconnection with the entry into the SEPA, on March 13, 2024, the Company entered into a registration rights agreement with Yorkville,\npursuant to which the Company agreed to file with the SEC no later than May 3, 2024, a registration statement for the resale by Yorkville\nof the shares of common stock issued under the SEPA (including the commitment fee shares). The Company agreed to use commercially reasonable\nefforts to have such registration statement declared effective within 45 days of such filing and to maintain the effectiveness of such\nregistration statement during the 36-month commitment period. The Company will not have the ability to request any Advances under the\nSEPA (nor may Yorkville convert the Initial Advance into common stock) until such resale registration statement is declared effective\nby the SEC. The Company has not yet filed a registration statement with the SEC for the resale by Yorkville of the shares of common stock\nissued under the SEPA, which is deemed an event of default under the SEPA and as a result, the interest rate on the on the Yorkville\nconvertible promissory note (see Note 7) increased to 18.0 The\nCompany determined that the SEPA should be accounted for as a derivative measured at fair value, with changes in the fair value recognized\nin earnings. Because the Company has not yet filed a registration statement and no shares can currently be issued under the SEPA, the\nSEPA is deemed to have no value as of the issuance date and as of September 30, 2024. Warrants As\nof September 30, 2024, the Company had 10,905,901 Summary of the Warrants\nNumber of Exercise Expiration\nDragasac Warrant (1) 652,981 $ 2.4898 March 16, 2025\nPublic Warrants (2) 1,437,447 $ 115.00 July 16, 2026\nSponsor Warrants (2) 849,999 $ 115.00 July 16, 2026\nMay 2022 PIPE Warrants 405,405 $ 3.50 October 10, 2028\nMarch 2023 PIPE Warrants 208,485 $ 30.00 March 27, 2028\nMarch 2023 PIPE Warrants (modified) 729,698 $ 10.00 March 27, 2028\nMarch 2023 Loan Warrants (3) 75,000 $ 5.895 March 17, 2028\nApril 2023 Registered Direct Warrants 435,625 $ 7.50 October 10, 2028\nApril 2023 Registered Direct Warrants (modified) 487,451 $ 3.50 October 10, 2028\nMay 2023 PIPE Warrants 581,394 $ 10.00 May 17, 2028\nJune 2023 Warrants (3) 50,000 $ 5.895 June 20, 2028\nJune 2023 Loan Warrants 300,000 $ 8.10 June 20, 2028\nJuly 2023 Registered Direct Warrants 857,142 $ 3.50 January 31, 2029\nJanuary 2024 PIPE Warrants 535,274 $ 2.4898 January 16, 2029\nJanuary 2024 Bridge Loan - Tranche #1 Warrants 1,650,000 $ 2.4898 January 16, 2029\nJanuary 2024 Bridge Loan - Tranche #2 Warrants 1,350,000 $ 2.988 July 15, 2029\nMarch 2024 RWI Forbearance Warrants 300,000 $ 5.895 June 20, 2028\n10,905,901\n(1) In connection with the execution of the January 2024 PIPE\ndescribed above, the Company agreed to reprice 652,981 67.70 2.4898\n(2) The number of Public Warrants and Sponsor Warrants outstanding\nwas not adjusted for the reverse stock split. There are 14,374,478 8,499,999 115.00\n(3) In connection with the execution of the Starr Forbearance\nAgreement on March 13, 2024, described above under Warrant Modification and further in Note 7, the Company agreed to reprice 75,000 7.10 50,000 8.10 5.895 ","12.\nEquity Common\nStock As\nof December 31, 2023 and 2022, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue\n730,000,000 0.0001 Voting\nPower Except\nas otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders\nof common stock possess all voting power for the election of the Company’s directors and all other matters requiring stockholder\naction. Holders of common stock are entitled to one vote per share Dividends Holders\nof Class A Common Stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company’s\nboard of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or\ncombinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally\nand identically. Liquidation,\nDissolution and Winding Up In\nthe event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders\nof the common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available\nfor distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. Preemptive\nor Other Rights The\nCompany’s stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable\nto common stock. Election\nof Directors The\nCompany’s board of directors is divided into three classes, Class I, Class II and Class III, with only one class of directors being\nelected in each year and each class serving a three-year term, except with respect to the election of directors at the special meeting\nheld in connection with the merger with GX. Class I directors are elected to an initial one-year term (and three-year terms subsequently),\nthe Class II directors are elected to an initial two-year term (and three-year terms subsequently) and the Class III directors are elected\nto an initial three-year term (and three-year terms subsequently). There is no cumulative voting with respect to the election of directors,\nwith the result that the holders of more than 50 Preferred\nStock The\nCompany’s Certificate of Incorporation authorized 10,000,000 no May\n2022 PIPE On\nMay 18, 2022, the Company entered into a securities purchase agreement with an institutional accredited investor providing for the private\nplacement of (i) 405,405 405,405 74.0 30,000 27,396 2,604 7,651 82.50 May 20, 2027 five years May 20, 2022 19,745 On\nApril 10, 2023, upon the closing of a registered direct offering (see further discussion below), the Company amended the existing May\n2022 PIPE Warrants, to reduce the exercise price from $ 82.50 7.50 date to five and one-half\nyears following the closing of the offering 1,389 3.50 892,857 405,405 487,451 511 ATM\nAgreement On\nSeptember 8, 2022, the Company entered into an At-the-Market Sales Agreement (the “ATM Agreement”) with BTIG, LLC, Oppenheimer\n& Co. Inc. and B. Riley Securities, Inc., acting as sales agents and/or principals, pursuant to which the Company may offer and sell,\nfrom time to time in its sole discretion, shares of its common stock, having an aggregate offering price of up to $ 150,000 Any\nshares offered and sold in the at-the-market offering will be issued pursuant to the Company’s effective shelf registration statement\non Form S-3 and the related prospectus supplement. Under the ATM Agreement, the sales agents may sell shares of common stock by any method\npermitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act. The Company\nwill pay the sales agents a commission rate of up to 3 During\nthe year ended December 31, 2023, the Company received gross and net proceeds of $ 141 136 13,296 10.60 March\n2023 PIPE On\nMarch 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief\nExecutive Officer, Dr. Robert Hariri, providing for the private placement of (i) 938,183 938,183 83.43 1.25 9,000 2,000 30.00 March 27, 2028 five years 61 The\nCompany accounted for the March 2023 PIPE Warrants and common stock as a single non-arm’s length transaction. The Company applied\nthe guidance for this transaction in accordance with ASU 2020-06, (Subtopic 470-20): Debt - Debt with Conversion and Other Options,\nASC 815 Derivatives and Hedging, ASC 480 Distinguishing Liabilities from Equity 1,650 ASC 815-10-15-74(a) On\nSeptember 14, 2023, the Company entered into a warrant amendment on the March 2023 PIPE Warrants with the unaffiliated investor to reduce\nthe exercise price from $ 30.00 10.00 729,698 ASC 718 Stock-Based Compensation 402 Registered\nDirect Offerings On\nApril 10, 2023, the Company closed on a registered direct offering of 923,076 923,076 6.50 6,000 7.50 five years 5,505 4,280 On\nJuly 31, 2023, the Company closed on a registered direct offering of 857,142 857,142 3.50 3,000 3.50 five years 2,740 2,645 In\nconnection with the July 31, 2023 registered direct offering described above, the Company also entered into an amendment to certain existing\nwarrants to purchase up to an aggregate of 892,856 7.50 3.50 511 May\n2023 PIPE On\nMay 18, 2023, the Company closed on a securities purchase agreement with a group of accredited investors, providing for the private placement\nof an aggregate (i) 581,394 581,394 5.20 1.25 3,750 10.00 May 18, 2028 five years 61 ASC 815-10-15-74(a) Warrants On\nMarch 1, 2022, Celularity and certain of the related party investors amended and restated the investors’ respective Legacy Celularity\nWarrants to (i) reduce the exercise price per share from $ 75.30 35.00 1,328,138 1,328,138 46,485 15,985 As\nof December 31, 2023, the Company had outstanding warrants to purchase 7,070,627 Summary of the Warrants\nNumber of Exercise Expiration\nDragasac Warrant(1) 652,981 $ 67.70 March 16, 2025\nPublic Warrants(2) 1,437,447 $ 115.00 July 16, 2026\nSponsor Warrants(2) 849,999 $ 115.00 July 16, 2026\nMay 2022 PIPE Warrants 405,405 $ 3.50 October 10, 2028\nMarch 2023 PIPE Warrants 208,485 $ 30.00 March 27, 2028\nMarch 2023 PIPE Warrants (modified) 729,698 $ 10.00 March 27, 2028\nMarch 2023 Loan Warrants 75,000 $ 7.10 March 17, 2028\nApril 2023 Registered Direct Warrants 435,625 $ 7.50 October 10, 2028\nApril 2023 Registered Direct Warrants (modified) 487,451 $ 3.50 October 10, 2028\nMay 2023 PIPE Warrants 581,394 $ 10.00 May 17, 2028\nJune 2023 Warrants 50,000 $ 8.10 June 20, 2028\nJune 2023 Loan Warrants 300,000 $ 8.10 June 20, 2028\nJuly 2023 Registered Direct Warrants 857,142 $ 3.50 January 31, 2029\n7,070,627\n(1) The exercise price is the lesser of $ 67.70 80\n(2) The number of\nPublic Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are 14,374,478 8,499,999 115.00 2024\nWarrant Repricing In\nconnection with the execution of the private placement on January 12, 2024 described below, the Company agreed to reprice 652,981 67.70 2.4898 January\n2024 PIPE Warrants On\nJanuary 12, 2024, the Company entered into a securities purchase agreement with an existing investor, Dragasac Limited, providing for\nthe private placement of (i) 2,141,098 0.0001 535,274 2.4898 1.25 6,000 January 16, 2024 2.4898 January 16, 2029 five years Effective\nFebruary 16, 2024, in order to comply with Section 4.15(a) of the securities purchase agreement, the Company entered into an amended\nemployment agreement with its Chief Administrative Officer (“CAO”), whereby the CAO agreed to decrease his base salary from\n$ 500 425 Warrant\nModifications On\nMarch 13, 2024, in connection with the RWI Forbearance Agreement (See Note 10), the Company agreed to issue RWI a warrant to acquire\nup to 300,000 June 20, 2028 5.895 75,000 March 17, 2028 7.10 5.895 50,000 June 20, 2028 8.10 5.895 Standby\nEquity Purchase Agreement On\nMarch 13, 2024, the Company and Yorkville entered into a SEPA. Under the SEPA, the Company has the right to sell to Yorkville up to $ 10,000,000 0.0001 Upon\nthe satisfaction of the conditions precedent in the SEPA, which include having a resale shelf for shares of common stock issued to Yorkville\ndeclared effective, the Company has the right to direct Yorkville to purchase a specified number of shares of common stock by delivering\nwritten notice (“Advance”). An Advance may not exceed 100 five Yorkville\nwill generally purchase shares pursuant to an Advance at a price per share equal to 97 three The\nSEPA will automatically terminate on the earliest to occur of (i) the first day of the month next following the 36-month anniversary\nof the date of the SEPA or (ii) the date on which Yorkville shall have made payment of for shares of common stock equal to $ 10.0 As\nconsideration for Yorkville’s commitment to purchase the shares of common stock pursuant to the SEPA, the Company paid Yorkville\na $ 25 16,964 In\nconnection with the entry into the SEPA, on March 13, 2024, the Company entered into a registration rights agreement with Yorkville,\npursuant to which the Company agreed to file with the Securities and Exchange Commission (“SEC”) no later than May 3, 2024,\na registration statement for the resale by Yorkville of the shares of Common Stock issued under the SEPA (including the commitment fee\nshares). The Company agreed to use commercially reasonable efforts to have such registration statement declared effective within 45 days\nof such filing and to maintain the effectiveness of such registration statement during the 36-month commitment period. The Company will\nnot have the ability to request any Advances under the SEPA (nor may Yorkville convert the Initial Advance into Common Stock) until such\nresale registration statement is declared effective by the SEC. Delaware\nSection 205 Proceeding On\nJuly 14, 2021, Celularity, then operating as GX Acquisition Corp. (“Pre-Merger Company”), held a special meeting of stockholders\n(the “Special Meeting”) to approve certain matters related to the business combination between the Pre-Merger Company and\nCelularity Operations, Inc. (“Legacy Celularity”), including a proposal to adopt a certificate of amendment to the Pre-Merger\nCompany’s amended and restated certificate of incorporation (the “Pre-Merger Charter”) to increase the number of authorized\nshares of its common stock from 110,000,000 730,000,000 A\nrecent decision by the Court of Chancery of the State of Delaware (the “Court”) in Garfield v. Boxed, Inc. In re Celularity,\nInc. On\nMarch 29, 2023, the Court of Chancery held a hearing in the Section 205 Action and orally granted the Petition, and, later that same\nday, the Court issued an order in the Section 205 Action, in which it validated and declared effective the Increase Amendment and the\nCertificate of Incorporation as of 10:00 a.m. (EDT) on July 16, 2021, and all shares of capital stock of the Company issued in reliance\non the effectiveness of the Increase Amendment and the Certificate of Incorporation as of the date and time of the original issuance\nof such shares. The Courts order has addressed and eliminated the uncertainty created by the Garfield "]

{"sheet":"Stock-Based Compensation","index":18,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Stock-Based Compensation","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Share-Based Payment Arrangement [Abstract]"," "," "]
["Stock-Based Compensation","11. Stock-Based Compensation 2021\nEquity Incentive Plan In\nJuly 2021, the Company’s board of directors adopted, and the Company’s stockholders approved the 2021 Equity Incentive Plan\n(the “2021 Plan”). The 2021 Plan provides for the grant of incentive stock options (“ISOs”) to employees and\nfor the grant of nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock\nunit awards, performance awards and other forms of stock awards to employees, directors and consultants. The\nnumber of shares of Class A Common Stock initially reserved for issuance under the 2021 Plan is 2,091,528 1,254,803 10 4.0 The\n2021 Plan is administered by the Company’s board of directors. The Company’s board of directors, or a duly authorized committee\nthereof, may delegate to one or more officers the authority to (i) designate employees other than officers to receive specified stock\nawards and (ii) determine the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan administrator\nhas the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any,\nthe number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together\nwith any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms\nand conditions of the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards\nunder the 2021 Plan. Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment,\nthe plan administrator may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel\nany award with an exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining\nthe approval of the Company’s stockholders. 2017\nEquity Incentive Plan The\n2017 Equity Incentive Plan (the “2017 Plan”) adopted by Legacy Celularity’s board of directors and approved by Legacy\nCelularity’s stockholders provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy\nCelularity. In connection with the closing of the merger and effectiveness of the 2021 Plan, no further grants will be made under the\n2017 Plan. The\ntotal number of stock options that could have been issued under the 2017 Plan was 3,234,204 The\n2017 Plan is administered by the Company’s board of directors or, at the discretion of the Company’s board of directors,\nby a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy\nCelularity’s board of directors, or its committee if so delegated, except that the exercise price per share of stock options could\nnot be less than 100 ten years three four Stock\nOption Valuation Awards\nwith Service Conditions The\nfair value of each option is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs\nsuch as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price\nvolatility, risk-free interest rate, and dividend yield. The fair value of each grant of stock options was determined by the Company\nusing the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.\n● The expected term of employee stock options with service-based\nvesting is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting\nterm and the original contractual term of the option due to the Company’s lack of sufficient historical data. The expected term\nof non-employee options is equal to the contractual term or its estimated term based on the underlying agreement.\n● The expected stock price volatility is based on historical\nvolatilities of comparable public entities within the Company’s industry.\n● The risk-free interest rate is based on the interest rate payable\non U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the respective expected term or contractual\nterm.\n● The expected dividend yield is 0 The\nfollowing table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the\ngrant-date fair value of stock options granted during the nine months ended September 30, 2024 and 2023: Schedule\nof Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model\nNine Months Ended September 30,\n2024 2023\nRisk-free interest rate 4.5 % 4.1 %\nExpected term (in years) 5.5 5.6\nExpected volatility 110.8 % 86.5 %\nExpected dividend yield 0 % 0 % The\nweighted average grant-date fair value per share of stock options granted during the nine months ended September 30, 2024 and 2023 was\n$ 3.10 0.39 The\nfollowing table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan: Schedule of Stock Option Activity\nOptions Weighted Weighted Aggregate\nOutstanding at January 1, 2024 2,820,187 $ 40.16 5.6 $ —\nGranted 879,664 3.76\nExercised — —\nForfeited (289,802 ) 31.47\nOutstanding at September 30, 2024* 3,410,049 $ 31.51 6.0 $ 115\nVested and expected to vest September 30, 2024 3,410,049 $ 31.51 6.0 $ 115\nExercisable at September 30, 2024 2,513,584 $ 38.00 4.9 $ 113\n* Options outstanding\nat September 30, 2024 under the 2021 Plan and 2017 Plan were 1,979,953 1,475,096 45,000 The\naggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value\nof the Company’s Class A common stock for those options that had exercise prices lower than the fair value of Class A common stock. The\nCompany recorded stock-based compensation expense relating to option awards with service conditions of $ 2,077 6,306 2,255 6,952 8,370 2.62 Awards\nwith Performance Conditions In\nconnection with the advisory agreement signed with Robin L. Smith, MD (see Note 15), the Company awarded options under the 2021 Plan\nto acquire a total of 105,000 29.90 25,000 80,000 20,000 79.9 2.95 five 0 60,000 no Awards\nwith Market Conditions In\nSeptember 2021, the Company awarded options to acquire a total of 246,928 63.20 vest\nin up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the\neffective date Restricted\nStock Units The\nCompany issues restricted stock units (“RSUs”) to employees that generally vest over a four-year 25.0 The\nfollowing table summarizes activity related to RSU stock-based payment awards under the 2021 Plan: Schedule\nof Activity Related to RSU Stock-Based Payment Awards\nNumber of Shares Weighted\nOutstanding at January 1, 2024 823,332 $ 13.77\nGranted — —\nVested (395,996 ) 11.50\nForfeited (99,977 ) 13.24\nOutstanding at September 30, 2024 327,359 $ 16.68 The\nCompany recorded stock-based compensation expense of $ 595 2,322 1,343 4,490 4,086 2.20 Stock\nUnits with Market Condition Vesting In\nJuly 2023, the Company granted 174,500 one three years 145,833 28,667 5.00 Stock-Based\nCompensation Expense The\nCompany recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations\nand comprehensive loss: Schedule\nof Stock-based Compensation Expense\n2024 2023 2024 2023\nThree Months Ended Nine Months Ended\n2024 2023 2024 2023\nCost of revenues $ 90 $ 166 $ 285 $ 462\nResearch and development 182 379 903 1,384\nSelling, general and administrative 2,400 3,053 7,440 9,596\nStock-based\ncompensation expense $ 2,672 $ 3,598 $ 8,628 $ 11,442 ","13.\nStock-Based Compensation 2021\nEquity Incentive Plan In\nJuly 2021, the Company’s board of directors adopted and the Company’s stockholders approved the 2021 Equity Incentive Plan\n(the “2021 Plan”). The 2021 Plan provides for the grant of incentive stock options (“ISOs”) to employees and\nfor the grant of nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock\nunit awards, performance awards and other forms of stock awards to employees, directors and consultants. The\nnumber of shares of Class A Common Stock initially reserved for issuance under the 2021 Plan is 2,091,528 821,789 10 4 The\n2021 Plan is administered by the Company’s board of directors. The Company’s board of directors, or a duly authorized committee\nthereof, may delegate to one or more officers the authority to (i) designate employees other than officers to receive specified stock\nawards and (ii) determine the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan administrator\nhas the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any,\nthe number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together\nwith any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms\nand conditions of the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards\nunder the 2021 Plan. Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment,\nthe plan administrator may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel\nany award with an exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining\nthe approval of the Company’s stockholders. 2017\nEquity Incentive Plan The\n2017 Equity Incentive Plan (the “2017 Plan”) adopted by Legacy Celularity’s board of directors and approved by Legacy\nCelularity’s stockholders provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy\nCelularity. In connection with the closing of the Business Combination and effectiveness of the 2021 Plan, no further grants will be\nmade under the 2017 Plan. The\ntotal number of stock options that could have been issued under the 2017 Plan was 3,234,204 The\n2017 Plan is administered by the Company’s board of directors or, at the discretion of the Company’s board of directors,\nby a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy\nCelularity’s board of directors, or its committee if so delegated, except that the exercise price per share of stock options could\nnot be less than 100 ten years three four year Stock\nOption Valuation Awards\nwith Service Conditions The\nfair value of each option is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs\nsuch as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price\nvolatility, risk-free interest rate, and dividend yield. The fair value of each grant of stock options was determined by the Company\nusing the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine. ● ● ●\nThe risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a\nperiod that is commensurate with the respective expected term or contractual term. ● The\nexpected dividend yield is 0 The\nfollowing table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the\ngrant-date fair value of stock options granted during the years ended December 31, 2023 and 2022: Schedule\nof Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model\nYear Ended\n2023 2022\nRisk-free interest rate 4.1 % 2.7 %\nExpected term (in years) 5.6 5.9\nExpected volatility 86.5 % 77.1 %\nExpected dividend yield — % — % The\nweighted average grant-date fair value per share of stock options granted during the years ended December 31, 2023 and 2022 was $ 5.35 5.43 The\nfollowing table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan: Schedule of Stock Option Activity\nOptions Weighted Weighted Aggregate\nOutstanding at December 31, 2022 2,514,452 $ 49.08 6.1 $ 7,851\nGranted 741,634 5.35\nExercised (108,637 ) 2.80\nForfeited/Expired (327,262 ) 42.23\nOutstanding at December 31, 2023 2,820,187 $ 40.16 5.6 $ —\nVested and expected to vest December 31, 2023 2,820,187 $ 40.16 5.6 $ —\nExercisable at December 31, 2023 2,025,287 $ 46.01 4.5 $ — The\naggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value\nof the Company’s Class A Common Stock for those options that had exercise prices lower than the fair value of the Company’s\nClass A Common Stock. The\nCompany recorded stock-based compensation expense relating to awards with service conditions of $ 9,293 10,702 0 7,997 13,449 2.59 Awards\nwith Performance Conditions In\nconnection with the advisory agreement signed with Robin L. Smith, MD (see Note 19), the Company awarded options to acquire a total of\n105,000 29.90 25,000 80,000 20,000 79.9 2.95 5 0 60,000 0 881 1,175 Awards\nwith Market Conditions In\nSeptember 2021, the Company awarded options to acquire a total of 246,928 63.20 vest\nin up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the\neffective date 1,167 1,681 Restricted\nStock Units The\nCompany issues RSUs to employees that generally vest over a two-year 50 50 The\nfollowing table summarizes activity related to RSU stock-based payment awards: Schedule\nof Activity Related to RSU Stock-Based Payment Awards\nNumber of Shares Weighted\nOutstanding at December 31, 2022 227,013 $ 73.35\nGranted 954,931 $ 6.29\nReleased (83,759 ) $ 65.05\nForfeited (274,853 ) $ 21.37\nOutstanding at December 31, 2023 823,332 $ 13.77 The\nCompany recorded stock-based compensation expense of $ 5,724 4,787 7,732 2.06 Performance\nStock Units In\nJuly 2023, the Company granted 174,500 5.00 one three years 871 1.79 no Stock-Based\nCompensation Expense The\nCompany recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations: Schedule\nof Stock-based Compensation Expense\n2023 2022\nYear Ended December 31,\n2023 2022\nCost of revenues $ 580 $ 410\nResearch and development 1,832 2,118\nSelling, general and administrative 12,605 13,328\nStock-based\ncompensation expense $ 15,017 $ 15,856 "]

{"sheet":"Revenue Recognition","index":19,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Revenue Recognition","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Revenue from Contract with Customer [Abstract]"," "," "]
["Revenue Recognition","12. Revenue Recognition The\nfollowing table provides information about disaggregated revenue by product and services: Schedule\nof Disaggregated Revenue by Product And Services\n2024 2023 2024 2023\nThree Months Ended September 30, Nine Months Ended September 30,\n2024 2023 2024 2023\nProduct sales, net $ 3,393 $ 1,684 $ 26,199 $ 3,633\nServices 1,292 1,427 3,857 4,062\nLicense, royalty and other 4,611 675 6,032 2,964\nTotal net revenues $ 9,296 $ 3,786 $ 36,088 $ 10,659 Net\nrevenues include: (i) sales of biomaterial products, including Biovance, Biovance 3L, Rebound TM The\nfollowing table provides changes in deferred revenue from contract liabilities: Schedule of Changes in Deferred Revenue from Contract Liabilities\n2024 2023\nBalance at January 1 $ 6,020 $ 4,492\nBeginning Balance $ 6,020 $ 4,492\nDeferral of revenue (1) 3,931 4,579\nRecognition of unearned revenue (2) (3,619 ) (3,514 )\nBalance at September 30 $ 6,332 $ 5,557\nEnding Balance $ 6,332 $ 5,557\n(1) Deferral of revenue includes\n$ 3,736 3,818\n(2) Recognition of unearned revenue\nincludes $ 2,271 2,274 ","14.\nRevenue Recognition The\nfollowing table provides information about disaggregated revenue by product and services: Schedule\nof Disaggregated Revenue by Product And Services\n2023 2022\nYear Ended December 31,\n2023 2022\nProduct sales and rentals $ 13,149 $ 3,749\nServices 5,441 5,512\nLicense, royalty and other 4,181 8,714\nNet revenues $ 22,771 $ 17,975 The\nfollowing table provides changes in deferred revenue from contract liabilities: Schedule of Changes in Deferred Revenue from Contract Liabilities\n2023 2022\nBalance at January 1 $ 4,492 $ 4,067\nDeferral of revenue * 6,266 5,004\nRecognition of unearned revenue (4,738 ) (4,579 )\nBalance at December 31 $ 6,020 $ 4,492\n* Deferral of revenue\nresulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue\nunder the contract as performance is completed. Also includes up-front payment incurred in connection with signing of the Regeneron Services\nAgreement in August 2023 (see Note 15 below). "]

{"sheet":"License and Distribution Agreem","index":20,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["License and Distribution Agreements","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["License And Distribution Agreements"," "," "]
["License and Distribution Agreements","13. License and Distribution Agreements Sequence\nLifeScience, Inc. Independent Distribution Agreement On\nAugust 23, 2024, the Company entered into an Independent Distributor Agreement (the “Distribution Agreement”) with Sequence\nLifeScience, Inc. (“Sequence”), which provides the Company exclusive rights to market, sell and distribute Rebound TM Regeneron\nResearch Collaboration Services Agreement On\nAugust 25, 2023, the Company entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc.\n(“Regeneron”), pursuant to which the Company will support the research effort of Regeneron’s allogeneic cell therapy\ncandidates (the “Regeneron Services Agreement”). The Regeneron Services Agreement’s initial focus is the research on\na targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation\nand potency against solid tumors. Payments to the Company under the Regeneron Services Agreement included a non-refundable up-front payment\nand payments based upon the achievement of defined milestones according to written statements of work. The Regeneron Services Agreement\nwill expire five years 30 The\nRegeneron Services Agreement grants Regeneron a royalty-free, fully-paid up, worldwide, non-exclusive license, with the right to grant\nsublicenses, to the Company’s intellectual property (“IP”) to the extent that any such license is necessary for Regeneron\nto fully use the Company’s research services. The Company determined that the (1) research licenses and (2) the research activities\nperformed by the Company represent a single combined performance obligation under the Regeneron Services Agreement. The Company determined\nthat Regeneron cannot benefit from the licenses separately from the research activities because these services are specialized and rely\non the Company’s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised\ngoods and services represent one combined performance obligation and the entire transaction price was allocated to that single combined\nperformance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities. The\nupfront payment of $ 750 Sorrento\nTherapeutics, Inc. License and Transfer Agreement The\nCompany and Sorrento Therapeutics, Inc. (“Sorrento”), a related party through September 30, 2023, are party to a License\nand Transfer Agreement for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived\ncells for the treatment of any disease or disorder (the “2020 Sorrento License Agreement”). The Company retains the right\nto sublicense the rights granted under the agreement with Sorrento’s prior written consent. As consideration for the license, the\nCompany is obligated to pay Sorrento a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and\na royalty equal to low double-digit percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License\nAgreement will remain in effect until terminated by either the Company or Sorrento for uncured material breach upon 90 days written notice\nor, after the first anniversary of the effective date of the 2020 Sorrento License Agreement, by the Company for convenience upon six\nmonths’ written notice to Sorrento. On October 19, 2023, Sorrento filed a Plan of Reorganization under Chapter 11 of the U.S. Bankruptcy\nCode in the U.S. Bankruptcy Court for the Southern District of Texas which plan contemplates a liquidation of the debtor. If the Plan\nis confirmed by the Bankruptcy Court, the Company believes that Sorrento will not be able to perform under the license and that any rights\nthe Company might have under the license would be unenforceable. After assessing the status of the IND to determine an optional path\nforward for the program, the Company elected to terminate development of CYCART-19 for B-cell malignancies during the third quarter of\n2023. The Company may continue pre-clinical development of other T-cell candidates. Genting\nInnovation PTE LTD Distribution Agreement On\nMay 4, 2018, concurrently with Dragasac’s equity investment in Legacy Celularity, Legacy Celularity entered into a distribution\nagreement with Genting Innovation pursuant to which Genting Innovation was granted supply and distribution rights to certain Company\nproducts in select Asia markets (the “Genting Agreement”). The Genting Agreement grants Genting Innovation limited distribution\nrights to the Company’s then-current portfolio of degenerative disease products and provides for the automatic rights to future\nproducts developed by or on behalf of the Company. The\nterm of the Genting Agreement was renewed on January 31, 2023, and automatically renews for successive 12 month terms unless: Genting\nprovides written notice of its intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise\nterminated by either party for cause. Genting\nInnovation and Dragasac are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled\nin Malaysia. On\nJune 14, 2023, the Genting Agreement was amended and restated to include manufacturing rights in the territories covered under the agreement,\nexpanded to include two new countries, and a commitment by the Company to provide technology transfer pursuant to the plan established\nby a Joint Steering Committee. On January 17, 2024, the Company further amended the Genting Agreement to include distribution and manufacturing\nrights to certain of the Company’s cell therapy products, including PSC-100, PDA-001, PDA-002, pEXO-001, APPL-001 and CYNK-001.\nAs of September 30, 2024, the Company has not recognized any revenue under the Genting Agreement. Celgene\nCorporation License Agreement The\nCompany is party to a license agreement with Celgene (the “Celgene Agreement”) pursuant to which the Company granted Celgene\ntwo separate licenses to certain intellectual property. The Celgene Agreement grants Celgene a royalty-free, fully-paid up, worldwide,\nnon-exclusive license to the certain intellectual property (“IP”) for pre-clinical research purposes in all fields and a\nroyalty-free, fully-paid up, worldwide license, with the right to grant sublicenses, for the development, manufacture, commercialization\nand exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte or NK cell to express\nsuch a CAR, and/or the use of such CARs or T-lymphocytes or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic\nuses thereof. The Celgene Agreement will remain in effect until its termination by either party for cause. Pulthera,\nLLC Binding Term Sheet Concurrent\nwith the entry into the securities purchase agreement for the private placement described in Note 7 above, the Company executed a binding\nterm sheet to negotiate and enter into a sublicense agreement of certain assets from an affiliate of Pulthera, LLC (the “sublicensor”).\nPursuant to the binding term sheet, the Company paid sublicensor $ 3,000 1,000 169,492 3,000 License\nAgreement with BioCellgraft, Inc. On\nDecember 11, 2023, the Company and BioCellgraft, Inc. (“BioCellgraft”) entered into a license agreement whereby the Company\ngranted an exclusive license to BioCellgraft, with the right to sublicense, to develop and commercialize certain licensed products to\nthe dental market in the United States over an initial four two years 5,000 two 300 300 ","15.\nLicense and Distribution Agreements Regeneron\nResearch Collaboration Services Agreement On\nAugust 25, 2023, the Company entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc.\n(“Regeneron”), pursuant to which the Company will support the research effort of Regeneron’s allogeneic cell therapy\ncandidates (the “Regeneron Services Agreement”). The Regeneron Services Agreement’s initial focus is the research on\na targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation\nand potency against solid tumors. Payments to the Company under the Regeneron Services Agreement included a nonrefundable up-front payment\nand payments based upon the achievement of defined milestones according to written statements of work. The Regeneron Services Agreement\nwill expire five years 30 The\nRegeneron Services Agreement grants Regeneron a royalty-free, fully-paid up, worldwide, non-exclusive license, with the right to grant\nsublicenses, to the Company’s intellectual property (“IP”) to the extent that any such license is necessary for Regeneron\nto fully use the Company’s research services. The Company determined that the (1) research licenses and (2) the research activities\nperformed by the Company represent a single combined performance obligation under the Regeneron Services Agreement. The Company determined\nthat Regeneron cannot benefit from the licenses separately from the research activities because these services are specialized and rely\non the Company’s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised\ngoods and services represent one combined performance obligation and the entire transaction price was allocated to that single combined\nperformance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities. The\nupfront payment of $ 750 Sorrento\nTherapeutics, Inc. License and Transfer Agreement The\nCompany and Sorrento Therapeutics, Inc. (“Sorrento”), a related party through September 30, 2023, are party to a License\nand Transfer Agreement for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord\nblood-derived cells for the treatment of any disease or disorder (the “2020 Sorrento License Agreement”). The Company\nretains the right to sublicense the rights granted under the agreement with Sorrento’s prior written consent. As consideration\nfor the license, the Company is obligated to pay Sorrento a royalty equal to low single-digit percentage of net sales (as defined\nwithin the agreement) and a royalty equal to low double-digit percentage of all sublicensing revenues (as defined within the\nagreement). The 2020 Sorrento License Agreement will remain in effect until terminated by either the Company or Sorrento for uncured\nmaterial breach upon 90 days written notice or, after the first anniversary of the effective date of the 2020 Sorrento License\nAgreement, by the Company for convenience upon six months’ written notice to Sorrento. On October 19, 2023, Sorrento filed a\nPlan of Reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas\nwhich plan contemplates a liquidation of the debtor. If the Plan is confirmed by the Bankruptcy Court, the Company believes that\nSorrento will not be able to perform under the license and that any rights the Company might have under the license would be\nunenforceable. After assessing the status of the IND to determine an optional path forward for the program, the Company has elected\nto terminate development of CYCART-19 for B-cell malignancies during the third quarter of 2023. The Company may continue\npre-clinical development of other T-cell candidates. Genting\nInnovation PTE LTD Distribution Agreement On\nMay 4, 2018, concurrently with Dragasac’s equity investment in Legacy Celularity, Legacy Celularity entered into a distribution\nagreement with Genting Innovation pursuant to which Genting Innovation was granted supply and distribution rights to certain Company\nproducts in select Asia markets (the “Genting Agreement”). The Genting Agreement grants Genting Innovation limited distribution\nrights to the Company’s then-current portfolio of degenerative disease products and provides for the automatic rights to future\nproducts developed by or on behalf of the Company. The\nterm of the Genting Agreement was renewed on January 31, 2023, and automatically renews for successive twelve month terms unless: Genting\nprovides written notice of its intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise\nterminated by either party for cause. Genting\nInnovation and Dragasac are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled\nin Malaysia. On\nJune 14, 2023, the Genting Agreement was amended and restated to include manufacturing rights in the territories covered under the agreement,\nexpanded to include two new countries, and a commitment by the Company to provide technology transfer pursuant to the plan established\nby a Joint Steering Committee. On January 17, 2024, the Company further amended the Genting Agreement to distribution and manufacturing\nrights to certain of the Company’s cell therapy products, including PSC-100, PDA-001, PDA-002, pEXO-001, APPL-001 and CYNK-001. Celgene\nCorporation License Agreement The\nCompany is party to a license agreement with Celgene (the “Celgene Agreement”) pursuant to which the Company granted Celgene\ntwo separate licenses to certain intellectual property. The Celgene Agreement grants Celgene a royalty-free, fully-paid up, worldwide,\nnon-exclusive license to the certain intellectual property (“IP”) for pre-clinical research purposes in all fields and a\nroyalty-free, fully-paid up, worldwide license, with the right to grant sublicenses, for the development, manufacture, commercialization\nand exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte or NK cell to express\nsuch a CAR, and/or the use of such CARs or T-lymphocytes or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic\nuses thereof. The Celgene Agreement will remain in effect until its termination by either party for cause. Exclusive\nSupply and Distribution Agreements On\nMay 7, 2021, the Company entered into a six-year two-year twelve months 2 forty-five\ndays thirty days On\nSeptember 1, 2021, the Company entered into a three-year April 13, 2023 2.35 Pulthera,\nLLC Binding Term Sheet Concurrent\nwith the entry into the securities purchase agreement for the private placement described in Note 9 above, the Company executed a binding\nterm sheet to negotiate and enter into a sublicense agreement of certain assets from an affiliate of Pulthera, LLC (the “sublicensor”).\nPursuant to the binding term sheet, the Company paid sublicensor $ 3,000 1,000 169,492 3,000 License\nAgreement with BioCellgraft, Inc. On\nDecember 11, 2023, the Company and BioCellgraft, Inc. (“BioCellgraft”) entered into a license agreement whereby the Company\ngranted an exclusive license to BioCellgraft, with the right to sublicense, to develop and commercialize certain licensed products to\nthe dental market in the United States over an initial four year two years 5,000 two year 300 "]

{"sheet":"Benefit Plan","index":21,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Benefit Plan","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Retirement Benefits [Abstract]"," "]
["Benefit Plan","16.\nBenefit Plan The\nCompany established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all employees\nwho meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis.\nMatching contributions to the plan may be made at the discretion of the Company’s board of directors. During the year ended December\n31, 2023, the Company made contributions of $ 198 1,159 "]

{"sheet":"Income Taxes","index":22,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Income Taxes","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Income Tax Disclosure [Abstract]"," "]
["Income Taxes","17.\nIncome Taxes A\nsummary of the Company’s current and deferred tax provision is as follows: Schedule\nof Current and Deferred Tax Provision\nYear Ended December 31,\n2023 2022\nCurrent income tax expense:\nFederal $ - $ -\nState 10 13\nTotal current income tax expense 10 13\nDeferred income tax expense (benefit):\nFederal 1 1\nState (1 ) (1 )\nTotal deferred tax expense — —\nTotal expense from income taxes $ 10 $ 13 A\nreconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows: Schedule\nof Reconciliation of the U.S federal statutory income tax\nYear Ended December 31,\n2023 2022\nFederal statutory income tax rate 21.0 % 21.0 %\nState income taxes, net of federal benefits 1.4 % (38.9 )%\nInterest accretion expense 11.0 % (186.9 )%\nChange in valuation allowance (20.0 )% 269.1 %\nMark to market warrant 0.5 % (58.5 )%\nDeferred true-up (2.4 )% 0.2 %\nStock-based compensation (0.0 )% (8.2 )%\nImpairment (12.0 )% 5.3 %\nOther permanent items 0.5 % (3.1 )%\nEffective income tax rate (0.0 )% (0.0 )% Net\ndeferred tax liabilities as of December 31, 2023 and 2022 consisted of the following: Schedule\nof Deferred tax assets and liabilities\n2023 2022\nYear Ended December 31,\n2023 2022\nDeferred tax assets:\nNet operating loss carryforwards $ 109,544 $ 102,723\nResearch and development tax credit carryforwards 5,674 5,674\nStock-based compensation expense 16,539 14,321\nStartup costs 498 588\nIntangible assets 3,442 3,905\nDeferred revenue 1,441 1,135\nUnicap 5 6\nImputed interest on contingent payments 110 5,654\nLegal fee capitalization and amortization 1,171 1,342\nCapitalized research and development 26,613 19,318\nOther 4,751 3,121\nTotal deferred tax assets 169,788 157,787\nDeferred tax liabilities:\nIn-process research and development — (27,271 )\nTotal deferred tax liabilities — (27,271 )\nValuation allowance (169,797 ) (130,525 )\nNet deferred tax liabilities $ (9 ) $ (9 ) A\nreconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: Schedule\nof Unrecognized Tax Benefits\nUnrecognized\nBalance at December 31, 2021 $ 1,270\nDecrease related to current year tax provisions (242 )\nBalance at December 31, 2022 $ 1,028\nDecrease related to current year tax provisions —\nBalance at December 31, 2023 $ 1,028 As\nof December 31, 2023 and 2022, the Company had U.S. federal and state net operating loss carryforwards of $ 109,544 102,723 2040 5,674 2032 Utilization\nof the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject\nto an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law,\ndue to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the\namount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership\nchange, as defined by Section 382, results from transactions increasing the ownership of certain stockholders in the stock of a\ncorporation by more than 50% over a three-year period. A corporation that experiences an ownership change is subject to an annual\nlimitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the\nownership change by the applicable long-term tax-exempt rate subject to additional adjustments, as required. The Company experienced\nan ownership change on August 15, 2017. The annual limitation from the ownership change is not expected to result in the expiration\nof net operating losses or research and development credits before utilization. The\nrealization of deferred tax assets is dependent upon the Company’s ability to generate taxable income in future years. ASC 740-10,\nIncome Taxes, At\nDecember 31, 2023, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the benefits\nof the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded valuation allowance against its\nfederal and state gross deferred tax assets. The valuation allowance increased by $ 39,272 The\nimpact of an uncertain income tax position is recognized at the largest amount that is “more likely than not” to be sustained\nupon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of\nbeing sustained. As\nof December 31, 2023 and 2022, the Company had gross unrecognized tax benefits of $ 1,028 "]

{"sheet":"Segment Information","index":23,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Segment Information","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Segment Reporting [Abstract]"," "," "]
["Segment Information","14. Segment Information The\nCompany regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. The Company\nmanages its operations through an evaluation of three The\nreportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers\nto therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development.\nDegenerative Disease produces, sells and licenses products used in surgical and wound care markets. BioBanking collects stem cells from\numbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The\nCompany manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not\nregularly review any asset information or related income statement effects by operating segment and, accordingly, asset information is\nnot reported by operating segment. Total assets were $ 128,840 143,889 Financial\ninformation by segment for the three months ended September 30, 2024 and 2023 is as follows: Schedule\nof Financial Information by Segment\nCell BioBanking Degenerative Other Total\nThree Months Ended September 30, 2024\nCell BioBanking Degenerative Other Total\nNet revenues $ - $ 1,292 $ 8,004 $ - $ 9,296\nCost of revenues (excluding amortization of acquired intangible assets) - 238 3,645 - 3,883\nDirect expenses 3,496 353 4,187 8,529 16,565\nSegment contribution $ (3,496 ) $ 701 $ 172 $ (8,529 ) $ (11,152 )\nIndirect expenses 375 (a) 375\nLoss from operations $ (11,527 )\n(a) Components of other\nAmortization 375\nTotal other $ 375\nCell BioBanking Degenerative Other Total\nThree Months Ended September 30, 2023\nCell BioBanking Degenerative Other Total\nNet revenues $ - $ 1,427 $ 2,359 $ - $ 3,786\nCost of revenues (excluding amortization of acquired intangible assets) - 398 3,204 - 3,602\nDirect expenses 4,887 350 1,901 9,074 16,212\nSegment contribution $ (4,887 ) $ 679 $ (2,746 ) $ (9,074 ) $ (16,028 )\nIndirect expenses 83,228 (b) 83,228\nLoss from operations $ (99,256 )\n(b) Components of other\nChange in fair value of contingent stock consideration (39 )\nGoodwill impairment 82,714\nAmortization 553\nTotal other $ 83,228 Financial\ninformation by segment for the nine months ended September 30, 2024 and 2023 is as follows:\nCell BioBanking Degenerative Other Total\nNine Months Ended September 30, 2024\nCell BioBanking Degenerative Other Total\nNet revenues $ - $ 3,857 $ 32,231 $ - $ 36,088\nCost of revenues (excluding amortization of acquired intangible assets) - 952 6,694 - 7,646\nDirect expenses 12,383 1,216 14,385 28,159 56,143\nSegment contribution $ (12,383 ) $ 1,689 $ 11,152 $ (28,159 ) $ (27,701 )\nIndirect expenses 1,377 (a) 1,377\nLoss from operations $ (29,078 )\n(a) Components of other\nAmortization 1,377\nTotal other $ 1,377\nCell BioBanking Degenerative Other ``Total\nNine Months Ended September 30, 2023\nCell BioBanking Degenerative Other Total\nNet revenues $ - $ 4,062 $ 6,597 $ - $ 10,659\nCost of revenues (excluding amortization of acquired intangible assets) - 1,355 5,052 - 6,407\nDirect expenses 53,505 780 6,799 31,481 92,565\nSegment contribution $ (53,505 ) $ 1,927 $ (5,254 ) $ (31,481 ) $ (88,313 )\nIndirect expenses 117,289 (b) 117,289\nLoss from operations $ (205,602 )\n(b) Components of other\nChange in fair value of contingent consideration liability (104,339 )\nChange in fair value of contingent stock consideration (159 )\nGoodwill impairment 112,347\nIPR&D impairment 107,800\nAmortization 1,640\nTotal other $ 117,289 ","18.\nSegment Information The\nCompany regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. Prior to the\nthird quarter of 2020, Legacy Celularity managed operations as one three The\nreportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers\nto therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development.\nDegenerative Disease produces, sells and licenses products used in surgical and wound care markets. Biobanking collects stem cells from\numbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The\nCompany manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not\nregularly review any asset information by operating segment and, accordingly, asset information is not reported by operating segment.\nTotal assets were approximately $ 143,889 401,066 Financial\ninformation by segment is as follows: Schedule\nof Financial Information by Segment\nCell BioBanking Degenerative Disease Other Total\nYear Ended December 31, 2023\nCell BioBanking Degenerative Disease Other Total\nNet revenues $ — $ 5,441 $ 17,330 $ — $ 22,771\nGross profit — 3,791 2,964 — 6,755\nDirect expenses 28,694 1,752 9,720 40,876 81,041\nSegment contribution (28,694 ) 2,039 (6,756 ) (40,876 ) (74,286 )\nIndirect expenses 118,001 (a) 118,001\nLoss from operations $ (192,287 )\n(a) Components of other\nChange in fair value of contingent consideration liability (104,339 )\nGoodwill impairment 112,347\nIPR&D impairment 107,800\nAmortization 2,193\nTotal other $ 118,001\nCell BioBanking Degenerative Other Total\nYear Ended December 31, 2022\nCell BioBanking Degenerative Other Total\nNet revenues $ — $ 5,512 $ 12,463 $ — $ 17,975\nGross profit — 1,976 (3,666 ) — (1,690 )\nDirect expenses 75,379 1,699 10,859 56,261 144,198\nSegment contribution (75,379 ) 277 (14,525 ) (56,261 ) (145,888 )\nIndirect expenses (120,288 ) (b) (120,288 )\nLoss from operations $ (25,600 )\n(b) Components of other\nChange in fair value of contingent consideration liability (126,277 )\nChange in fair value of contingent stock consideration 186\nGoodwill impairment 3,610\nAmortization 2,193\nTotal other $ (120,288 ) "]

{"sheet":"Related Party Transactions","index":24,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Related Party Transactions","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Related Party Transactions [Abstract]"," "," "]
["Related Party Transactions","15. Related Party Transactions Amended\nand Restated Employment Agreement with Dr. Robert Hariri On\nJanuary 25, 2023, in order to address the Company’s current working capital requirements, Robert Hariri, M.D., Ph.D., the Company’s\nChairman and Chief Executive Officer, agreed to temporarily reduce payment of his salary pursuant to his employment agreement to minimum\nwage level with the remaining salary deferred until December 31, 2023. As of September 30, 2024, $ 1,432 In\norder to comply with the Securities Purchase Agreement dated January 12, 2024 1,088 21,000 125 85 February 16,\n2024 180 January 1, 2025 March\n2023 PIPE On\nMarch 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief\nExecutive Officer, Dr. Robert Hariri, for an aggregate purchase price of $ 9,000 2,000 Loan\nAgreement with Dr. Robert Hariri On\nAugust 21, 2023, the Company entered into a $ 1,000 15 On\nOctober 12, 2023, in order to further address the Company’s immediate working capital requirements, Robert Hariri, M.D., Ph.D.,\nthe Company’s Chairman and Chief Executive Officer, and the Company signed a promissory note for $ 285 15.0 Consulting\n& Advisory Agreements with Dr. Andrew Pecora On\nAugust 31, 2022, Dr. Pecora resigned as the Company’s President, and subsequently entered into a consulting agreement with the\nCompany dated September 21, 2022, to receive a $ 10 10 125 four years Advisory\nAgreement with Robin L. Smith MD On\nAugust 16, 2022, the Company entered into an advisory agreement with Robin L. Smith, MD, a then member of the Company’s board of\ndirectors, to receive $ 20 105,000 25,000 20,000 1,500 0 20 COTA,\nInc In\nNovember 2020, Legacy Celularity and COTA, Inc. (“COTA”) entered into an Order Schedule (the “Order Schedule No. 2”),\nto the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide\nthe licensed data in connection with AML patients. The COTA Order Schedule No. 2 will terminate on the one-year anniversary following\nthe final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity’s former President, is the Founder and Chairman\nof the Board of COTA and Dr. Robin L. Smith, a former member of the Company’s board of directors, is an investor in COTA. The Company\ndid no Cryoport\nSystems, Inc During\nthe nine months ended September 30, 2024 and 2023, the Company made payments totaling $ 2 33 C.V.\nStarr Loan On\nMarch 17, 2023 the Company entered into a $ 5,000 125,000 1,528,138 Employment\nof an Immediate Family Member Alexandra\nHariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and Chief Executive Officer, is employed by Celularity\nas an Executive Director, Corporate Strategy & Business Development. Ms. Hariri’s annual base salary for 2024 and 2023 was\n$ 265 Fountain\nLife Management LLC On\nNovember 7, 2024, the Company entered into a Technology Services Agreement with Fountain Life Management LLC (“Fountain Life”)\nunder which the Company agreed to process and store mononuclear cells isolated from blood samples collected by Fountain Life or its authorized\nrepresentatives in accordance with the Company’s adult banking enrollment processes. In consideration of the services, Fountain\nLife will pay the Company a one-time fee of two thousand five hundred dollars per sample collected and stored. The initial term of the\nagreement is one year and automatically extends for one-year periods unless earlier terminated by either party. The Company’s Chairman\nand Chief Executive Officer, Dr. Robert Hariri, M.D, Ph.D., and director, Peter Diamandis, M.D., are founding partners of Fountain Life. ","19.\nRelated Party Transactions The\nrelated party transactions described below do not have any associated balances on the consolidated balance sheets as of December 31,\n2023 and 2022. Amended\nand Restated Employment Agreement with Dr. Robert Hariri On\nJanuary 25, 2023, in order to address the Company’s current working capital requirements, Dr. Robert Hariri, M.D., Ph.D., the Company’s\nChairman and Chief Executive Officer, agreed to temporarily reduce payment of his salary pursuant to his employment agreement to minimum\nwage level with the remaining salary deferred until December 31, 2023. As of December 31, 2023, $ 1,088 In\norder to comply with the Securities Purchase Agreement dated January 12, 2024 1,088 21.0 125 85 February 16, 2024 180 January 1, 2025 March\n2023 PIPE On\nMarch 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief\nExecutive Officer, Dr. Robert Hariri, for an aggregate purchase price of $ 9,000 2,000 Loan\nAgreement with Dr. Robert Hariri On\nAugust 21, 2023, the Company entered into a $ 1,000 15 On\nOctober 12, 2023, in order to further address the Company’s immediate working capital requirements, Robert Hariri, M.D., Ph.D.,\nthe Company’s Chairman and Chief Executive Officer, and the Company signed a promissory note (“CEO Promissory Note”)\nfor $ 285 15.0 Consulting\n& Advisory Agreements with Dr. Andrew Pecora On\nAugust 31, 2022, Dr. Pecora resigned as the Company’s President, and subsequently entered into a consulting agreement with the\nCompany dated September 21, 2022, to receive a $ 10 10 125 four years Advisory\nAgreement with Robin L. Smith MD On\nAugust 16, 2022, the Company entered into an advisory agreement with Robin L. Smith, MD, a then member of the Company’s board of\ndirectors, to receive $ 20 105,000 25,000 20,000 1,500 20 80 COTA,\nInc In\nNovember 2020, Legacy Celularity and COTA, Inc. (“COTA”) entered into an Order Schedule (the “Order Schedule No. 2”),\nto the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide\nthe licensed data in connection with AML patients. The COTA Order Schedule No. 2 will terminate on the one-year anniversary following\nthe final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity’s former President, is the Founder and Chairman\nof the Board of COTA and Dr. Robin L. Smith, a former member of the Company’s board of directors, is an investor in COTA. The Company\ndid no 86 Cryoport\nSystems, Inc The\nCompany made payments totaling $ 33 70 C.V.\nStarr Loan On\nMarch 17, 2023, the Company entered into a $ 5,000 75,000 50,000 125,000 764,069 Resorts\nWorld Inc Pte Ltd On\nMay 16, 2023, the Company entered into a $ 12,000 300,000 Sorrento\nTherapeutics, Inc. In\nSeptember 2020, the Company entered into the 2020 Sorrento Agreement, with Sorrento. Henry Ji, Ph.D., a former member of Legacy Celularity’s\nboard of directors, previously served as President and Chief Executive Officer of Sorrento. Sorrento was also a significant stockholder\nand invested in the July 2021 PIPE Financing. During the year ended December 31, 2023, the Company did no 1,821 Employment\nof an Immediate Family Member Alexandra\nHariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and Chief Executive Officer, is employed by Celularity\nas an Executive Director, Corporate Strategy & Business Development. For each of the years ended December 31, 2023 and 2022, Ms.\nHariri’s base salary was $ 265 216 "]

{"sheet":"Subsequent Events","index":25,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Subsequent Events","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Subsequent Events [Abstract]"," "," "]
["Subsequent Events","16. Subsequent Events Rebound TM\nOn\nOctober 9, 2024, the Company entered into an asset purchase agreement with Sequence LifeScience, Inc. (“Sequence”) to acquire\nSequence’s Rebound™ full thickness placental-derived allograft matrix product and certain related assets. The aggregate consideration\npaid for the assets was $ 5,500 1,000 4,000 500 20 Concurrently\nwith the execution of the asset purchase agreement, the Company entered into an exclusive supply agreement with Sequence for the manufacture\nand supply of Rebound for a minimum period of six months. Celularity retains the right to manufacture Rebound internally and intends\nto commence a technology transfer as soon as practicable. Unsecured\nSenior Convertible Notes On\nNovember 25, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited\ninvestor exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D promulgated\nthereunder, pursuant to which the Company agreed to sell and issue, in one or more closings, to the investor and other purchasers (the\n“Purchasers”) in a private placement transaction, unsecured senior convertible notes (the “Notes”) and warrants\n(the “Purchaser Warrants”) for an aggregate original principal amount of up to $ 1,000 750 The\nNotes bear interest at an annual rate of 8 10 0.0001 2.85 2,500 1.00 The\nPurchaser Warrants entitle the Purchasers to purchase shares of Common Stock equal to each Purchaser’s subscription amount divided\nby the exercise price of $ 2.85 1.00 5 In\nconnection with the transaction, the Company paid a cash fee equal to 7 1 25 75 5 7 125 There\nare no additional items that have not previously been mentioned elsewhere (see Note 1) requiring disclosure.","20.\nSubsequent Events The\nCompany has evaluated subsequent events through the date of issuance and there are no additional items that have not previously been\nmentioned elsewhere requiring disclosure (see Notes 1, 2, 3, 9, 11, 12, 15, and 19)."]

{"sheet":"Summary of Significant Accoun_2","index":26,"n_rows":34,"n_cols":3,"rows_kept":34,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies (Policies)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Accounting Policies [Abstract]"," "," "]
["Basis of Presentation","Basis\nof Presentation The\nCompany’s unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally\naccepted in the United States (“GAAP”). The unaudited condensed consolidated financial statements include the accounts of\nwholly owned subsidiaries, after elimination of intercompany accounts and transactions. The unaudited condensed consolidated financial\ninformation presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement\nof consolidated financial position, results of operations and cash flows for the periods presented. The\nCompany’s condensed consolidated financial statements are prepared in accordance with the U.S. Securities and Exchange Commission’s\n(“SEC”) rules for the presentation of interim financial statements, which permit certain disclosures to be condensed or omitted.\nThese financial statements should be read in conjunction with the Company’s annual financial statements as of and for the year\nended December 31, 2023 included in the Annual Report on Form 10-K filed with the SEC on July 30, 2024, (the “2023 Form 10-K”). In\nthe opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist\nprimarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s\nconsolidated financial position as of September 30, 2024, and its consolidated results of operations and cash flows for the nine months\nended September 30, 2024 and 2023. Operating results for the three and nine months ended September 30, 2024, are not necessarily indicative\nof the results that may be expected for the year ending December 31, 2024. ","Basis\nof Presentation The\nCompany’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United\nStates (“GAAP”). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination\nof intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information\nthat, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for\nthe periods presented. "]
["Use of Estimates","Use\nof Estimates The\npreparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates\nand assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the\ndate of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period.\nSignificant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to,\nassumptions related to the Company’s goodwill and intangible asset impairment assessments, determination of incremental borrowing\nrates, accrual of research and development expenses, and the valuations of inventory, contingent consideration, short-term debt, stock\noptions and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other\nrelevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when\nthere are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.\nActual results could differ from those estimates. ","Use\nof Estimates The\npreparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and\nassumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date\nof the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates\nand assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related to the Company’s\ngoodwill and intangible impairment assessment, the valuation of inventory, contingent consideration, short-term debt, determination of\nincremental borrowing rates, accrual of research and development expenses, and the valuations of stock options and stock warrants. The\nCompany based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes\nto be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances,\nfacts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those\nestimates. "]
["Fair Value Measurements","Fair\nValue Measurements Certain\nassets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be\nreceived for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability\nin an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize\nthe use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are\nto be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered\nobservable and the last is considered unobservable:\n● Level\n1 — Quoted prices in active markets for identical assets or liabilities.\n● Level\n2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in\nactive markets for similar assets or liabilities, quoted prices in markets that are not active\nfor identical or similar assets or liabilities, or other inputs that are observable or can\nbe corroborated by observable market data.\n● Level\n3 — Unobservable inputs that are supported by little or no market activity that are\nsignificant to determining the fair value of the assets or liabilities, including pricing\nmodels, discounted cash flow methodologies and similar techniques. ","Fair\nValue Measurements Certain\nassets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would\nbe received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset\nor liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure\nfair value ●\nLevel 1 — Quoted prices in active markets for identical assets or liabilities. ●\nLevel 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or\nliabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are\nobservable or can be corroborated by observable market data. ●\nLevel 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair\nvalue of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. "]
["Cash and Cash Equivalents"," ","Cash\nand Cash Equivalents Cash\nand cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having\nan original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or\nless at the date of acquisition to be cash equivalents. At December 31, 2023 and 2022, substantially all cash and cash equivalents were\nheld in either commercial bank accounts or money market funds. "]
["Restricted Cash"," ","Restricted\nCash As\nof December 31, 2023 and 2022, the Company maintained a letter of credit of $ 9,936 14,836 "]
["Inventory"," ","Inventory Inventory\nis stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out basis. Prior to\ninitial approval from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the\nperiod incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related\nto the product. The Company continues to expense costs associated with clinical trial supply costs as research and development expense. The\nCompany periodically analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory\nis (i) expected to expire prior to being sold, (ii) has a cost basis in excess of its net realizable value, (iii) is in excess of expected\nsales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial sale specifications, the inventory is\nwritten-down through a charge to cost of revenues. The determination of whether inventory costs will be realizable requires estimates\nby management of future expected inventory requirements, based on sales forecasts. If actual market conditions are less favorable than\nthose projected by management, inventory write-downs may be required. Inventory, net of current portion on the Company’s consolidated\nbalance sheets includes inventory expected to remain on hand beyond one year. "]
["Property and Equipment"," ","Property\nand Equipment Property\nand equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized\nusing the straight-line method over the estimated useful life of each asset, as follows: Schedule of Property and\nEquipment Estimated Useful Life\nEstimated Useful Life\nBuilding 26\nFurniture and fixtures 5 7\nLab equipment 5\nComputer equipment 3\nSoftware 3\nLeasehold improvements shorter of the estimated useful life or the lease term Estimated\nuseful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred.\nWhen assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated\nfrom the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of operations in the\nperiod of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated\nonce placed into service. "]
["Impairment of Long-Lived Assets"," ","Impairment\nof Long-Lived Assets Long-lived\nassets consist of property, plant and equipment, operating right-of-use assets, and definite-lived intangible assets. Long-lived assets\nto be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount\nof the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include\nsignificant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant\nchanges or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability,\nthe Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived\nasset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future\ncash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on\nthe excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Due to the\ngoodwill impairment recognized during the years ended December 31, 2023 and 2022, as discussed below and in Note 7, the Company performed\na recoverability test on long-lived assets and concluded no additional impairment to be recognized as result of this test. The Company\ndid not record any impairment losses on long-lived assets during the years ended December 31, 2023 and 2022. "]
["Asset Acquisitions"," ","Asset\nAcquisitions The\nCompany measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets,\nwhich includes transaction costs. In an asset acquisition, the cost allocated to acquire IPR&D with no alternative future use is\ncharged to research and development expense at the acquisition date. "]
["In-Process Research and Development"," ","In-Process\nResearch and Development The\nfair value of IPR&D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion\nor abandonment of the related research and development activities. When the related research and development is completed, the asset\nis reclassified to a definite-lived asset and amortized over its estimated useful life. The\nfair value of an IPR&D intangible asset is typically determined using an income approach whereby management forecasts the net cash\nflows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion,\nthe probability of technical success, the projected costs to complete, expected market competition, and an assessment of the asset’s\nlife-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors\nassociated with the cash flow streams. Indefinite-lived\nIPR&D is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment.\nThe Company tests its indefinite-lived IPR&D annually for impairment during the fourth quarter. In testing indefinite-lived IPR&D\nfor impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances\nwould indicate that it is more likely than not that its fair value is less than its carrying amount, or the Company can perform a quantitative\nimpairment analysis to determine the fair value of the indefinite-lived IPR&D without performing a qualitative assessment. Qualitative\nfactors that the Company considers include significant negative industry or economic trends and significant changes or planned changes\nin the use of the assets. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely\nthan not that the fair value of the indefinite-lived IPR&D is less than its carrying amount, the Company would then determine the\nfair value of the indefinite-lived IPR&D. Under either approach, if the fair value of the indefinite-lived IPR&D is less than\nits carrying amount, an impairment charge is recognized in the consolidated statements of operations. During the years ended December\n31, 2023 and 2022, the Company recognized an impairment charge related to its indefinite-lived IPR&D of $ 107,800 0 "]
["Goodwill"," ","Goodwill Goodwill\nrepresents the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible\nassets acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently\nif there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each\nyear. The\nCompany manages its operations through an evaluation of three In\ntesting goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence\nof events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than\nits carrying amount, or the Company can perform a quantitative impairment analysis without performing the qualitative assessment.\nExamples of such events or circumstances considered in the Company’s qualitative assessment include, but are not limited to, a\nsignificant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. If the Company\nchooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of its\nreporting unit is less than its carrying amount, the Company would then perform the quantitative impairment test. The quantitative\ntest starts with comparing the fair value of the reporting unit to the carrying amount of a reporting unit, including goodwill. If\nthe fair value of the reporting unit exceeds the carrying amount, no impairment loss is recognized. However, if the fair value of\nthe reporting unit is less than its carrying value, the Company would recognize an impairment charge for the amount by which the\ncarrying amount exceeds the reporting unit’s fair value, not to exceed the total amount of goodwill allocated to the reporting\nunit. During the years ended December 31, 2023 and 2022, the Company recognized goodwill impairment of $ 112,347 3,610 "]
["Warrant Liabilities"," ","Warrant\nLiabilities The\nCompany accounts for the public warrants, private placement warrants, registered direct warrants, and May 2022 PIPE warrants (collectively,\n“Liability Warrants”) in accordance with the guidance contained in ASC 815-40, “Derivatives and Hedging—Contracts\nin Entity’s Own Equity,” under which the Liability Warrants do not meet the criteria for equity treatment and must be recorded\nas liabilities. Accordingly, the Company classifies the Liability Warrants as liabilities at their fair value and adjusts to fair value\nat each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair\nvalue is recognized as a component of other (expense) income in the consolidated statements of operations. The Liability Warrants excluding\nthe public warrants were initially and subsequently valued using a Black-Scholes option pricing model, which is considered to be a Level\n3 fair value measurement. The public warrants are valued based on the quoted market price as of each relevant reporting date. "]
["Leases"," ","Leases In\naccordance with ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02” or “ASC 842”), the Company classifies leases\nat the lease commencement date. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease\nbased on the circumstances present. Leases with a term greater than one year will be recognized on the consolidated balance sheets as\nright-of-use assets (“ROU”), lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal\noptions to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and\nthe corresponding ROU are recorded based on the present values of lease payments over the terms. The interest rate implicit in lease\ncontracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are\nthe rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar\neconomic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized\nas incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments\nto ROUs may be required for items such as initial direct costs paid, incentives received, or lease prepayments. If significant events,\nchanges in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease\nclassification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU. The\nCompany has elected the “package of 3” practical expedients permitted under the transition guidance, which eliminates the\nrequirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also\nadopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option that the Company\nis reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its consolidated\nbalance sheets. Refer\nto Note 10 for further information. "]
["Short-Term Debt- Yorkville"," ","Short-Term\nDebt- Yorkville The\nCompany elected the fair value option to account for the financial instrument as per the pre-paid advance agreement with YA II PN, Ltd\n(“Yorkville”) (see Note 9). As of December 31, 2023, due to the short term nature of the debt, the fair value approximates\nthe settlement amount which was fully paid on January 17, 2024. As of December 31, 2022, the estimate of the fair value was determined\nusing a binomial lattice model. The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable\nin the market. Changes in the fair value of debt that is accounted for at fair value, inclusive of related accrued interest expense,\nare presented as gains or losses in the accompanying consolidated statements of operations and comprehensive loss under change in fair\nvalue of debt. The portion of total changes in fair value of debt attributable to changes in instrument-specific credit risk are determined\nthrough specific measurement of periodic changes in the discount rate assumption exclusive of base market changes and are presented as\na component of comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive loss. The actual\nsettlement of the short-term debt could differ from current estimates based on the timing of when and if Yorkville elects to convert\namounts into common shares, potential cash repayment by us prior to maturity, and movements in the Company’s common share price. "]
["Revenue Recognition"," ","Revenue\nRecognition The\nCompany generates revenue from its degenerative disease commercial operations (i.e., the sale of Biovance ® ® ® ® Product\nsales and rentals Biovance ®\n® The\nCompany recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration\nit expects to receive from its customers in exchange for those products and services. This process involves identifying the contract\nwith a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price\nto the distinct performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied.\nSales and other taxes collected on behalf of third parties are excluded from revenue. A\nperformance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either\non its own or together with other resources that are readily available to the customer and is separately identified in the contract.\nThe Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning\nthe customer has the ability to use and obtain the benefit of the good or service. Transaction prices of products or services are typically\nbased on contracted rates with customers and to the extent that the transaction price includes variable consideration, the Company estimates\nthe amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most\nlikely amount, depending on the circumstances, to which the Company expects to be entitled. The\nCompany offers volume-based discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the\nvariable consideration model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company\nestimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying\nrevenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value\nmethod, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer\nbasis to estimate what levels of incentives will be earned. At December 31, 2023, the Company had reserves totaling $ 3,270 no The\nCompany provides for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product\nreturns and therefore does not record a provision for returns. Services The\nCompany separately recognizes revenues for services to expectant parents who contract with the Company to collect, process and store\numbilical cord blood and placenta derived cells and tissue for private use. The Company recognizes revenue from collection and processing\nfees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the\ncontractual storage period. Contracted storage periods are generally 18 25 When\ndetermining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before\nor significantly after performance, resulting in a significant financing component. For all plans (annual, lifetime, 18 25 one 24 When\nconsidered over a 24 The\nCompany offers promotional discounts and other various incentives which are accounted for under the variable consideration model. The\nCompany estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period\nthe underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under\nthe expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer\nbasis to estimate what levels of incentives will be earned. As\nthe Company’s processing and storage agreements contain multiple performance obligations, ASC 606 Revenue from Contracts with\nCustomers, License,\nroyalty and other Under\nlicense agreements, the Company assesses whether the related performance obligation is satisfied at a point in time or over time. At\nthe inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones\nare considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount\nmethod. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction\nprice. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered\nprobable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory,\ncommercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable\njudgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent\nreporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts\nits estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues\nand earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company’s\nefforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally\nallocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would\nnot occur. See Note 15 for further discussion of the Company’s license agreements. While\nthe Company’s direct sales of degenerative disease products are included in product sales and rentals, sales through the Company’s\nnetwork of distribution partners are included in license, royalty and other revenues. For certain distribution agreements as described\nin Note 15, the Company will utilize the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount\nto which the entity has a right to invoice so long as the consideration from a customer corresponds directly with the value received.\nThus, the Company will recognize revenue upon invoicing for these agreements (subsequent to receipt of the related purchase order). "]
["Cost of Revenues"," ","Cost\nof Revenues Cost\nof revenues consists of labor, material and overhead costs associated with the Company’s two existing commercial business segments,\nbiobanking and degenerative disease. Biobanking costs, which include the cost of storage and transportation kits for newly banked materials\nas well as tank and facility overhead costs for cord blood and other units in storage, are included in services in cost of revenues.\nDegenerative disease costs, which include costs associated with procuring placentas, qualifying the placental material and processing\nthe placental tissue into a marketable product, are included in product sales or license, royalty and other in cost of revenues depending\non the class of customer. Costs in the degenerative disease segment include labor and overhead costs associated with the production of\nthe Biovance, Biovance 3L and Interfyl product lines. "]
["Research and Development Costs"," ","Research\nand Development Costs The\nCompany has entered into various research and development and other agreements with commercial firms, researchers, universities and\nothers for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as\nresearch and development expense as incurred. Research and development expenses include costs for salaries, employee benefits,\nsubcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees,\nlaboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development\nactivities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company records accruals for\nestimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes\nprogress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs.\nSignificant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results\ncould differ materially from the Company’s estimates. Nonrefundable advance payments for goods or services to be received in\nthe future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as\nan expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the\ngoods will be delivered, or the services rendered. Upfront\npayments, milestone payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred. "]
["Advertising and Marketing Costs"," ","Advertising\nand Marketing Costs Advertising\nand marketing costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses\nand were $ 44 163 "]
["Government Grants"," ","Government\nGrants From\ntime to time, the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants\nas a reduction to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental\nagency. The Company did no "]
["Patent Costs"," ","Patent\nCosts All\npatent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty\nabout the recovery of the expenditure. Amounts incurred are classified in selling, general and administrative expenses. "]
["Stock-Based Compensation"," ","Stock-Based\nCompensation The\nCompany measures all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes\ncompensation expense for those awards, over the requisite service period, which is generally the vesting period of the respective award.\nThe Company typically issues stock-based awards with only service-based vesting conditions and records the expense for these awards using\na straight-line method. The\nCompany’s board of directors may also approve and award performance-based stock options. The performance-based stock options are\nearned based on the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based\nawards over the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses\nthe probability of vesting at each reporting period for performance-based awards and adjusts expense accordingly on a cumulative basis. The\nfair value of each services and performance-based stock option grant is estimated on the date of grant using the Black-Scholes option-pricing\nmodel. The Company historically has been a private company and lacks company-specific historical and implied volatility information for\nits stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies\nand expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock\nprice. The expected term of the Company’s stock options granted to employees is determined utilizing the “simplified”\nmethod for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employee consultants\nis equal to the contractual term of the option award or the Company’s estimated term based on the underlying agreement. The risk-free\ninterest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods\napproximately equal to the expected term of the award. The expected dividend yield is zero based on the fact that the Company has never\npaid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. The\nCompany classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award\nrecipient’s payroll costs are classified or in which the award recipient’s service payments are classified. The Company elects\nto account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure\nto satisfy a service or performance condition is generally reversed in the period of the forfeiture. "]
["Comprehensive Income (Loss)","Comprehensive\nIncome (Loss) Comprehensive\nincome (loss) refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded\nfrom net income (loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The\nCompany’s only component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of\nindebtedness accounted for under the fair value option that is attributable to changes in instrument-specific credit risk. During the\nnine months ended September 30, 2024, the Company recorded instrument-specific credit risk loss of $ 2 2,541 155 ","Comprehensive\nIncome (Loss) Comprehensive\nincome (loss) refers to revenues, expenses, gains and losses that under U.S. GAAP are included in comprehensive income (loss) but are\nexcluded from net income (loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss).\nThe Company’s only component of other comprehensive income (loss) is comprised of the portion of the total change in fair value\nof indebtedness accounted for under the fair value option that is attributable to changes in instrument-specific credit risk. During\nthe year ended December 31, 2023, the Company recorded instrument-specific credit risk income of $ 146 155 20 11 "]
["Income Taxes","Income\nTaxes The\nCompany accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities\nfor the expected future tax consequences of events that have been recognized in the condensed consolidated financial statements or in\nthe Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement\nand tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.\nChanges in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that\nits deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available\nevidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance\nis established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future\ntaxable profits expected and considering prudent and feasible tax planning strategies. No income tax expense was incurred during the\nnine months ended September 30, 2024 and 2023. ","Income\nTaxes The\nCompany accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities\nfor the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s\ntax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis\nof assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in\ndeferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred\ntax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,\nthat it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established\nthrough a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits\nexpected and considering prudent and feasible tax planning strategies. The\nCompany accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to\ndetermine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will\nbe sustained based on the technical merits of the position. If the tax position is deemed more-likely-than-not to be sustained, the tax\nposition is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the\nbenefit that may be recognized is the largest amount that has a greater than 50 "]
["Net Income (Loss) per Share","Net\nIncome (Loss) per Share Basic\nnet income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common\nstock outstanding during each period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential\nexercise or conversion of securities, such as redeemable convertible preferred stock, convertible debt, stock options, restricted stock\nunits and warrants, which would result in the issuance of incremental shares of common stock. However, potential common shares are excluded\nif their effect is anti-dilutive. For diluted net loss per share when the Company has a net loss, the weighted-average number of shares\nof common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included\nin the calculation as the impact is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis\nwith Class A common stock in the distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing\nearnings per share, the warrants are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company\ncomputes earnings per share using the two-class method, an earnings allocation method that determines net income (loss) per share (when\nthere are earnings) for common stock and participating securities. No The\nfollowing potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common\nstock outstanding, prior to the use of the two-class method, as they would be anti-dilutive: Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share\n2024 2023\nSeptember 30,\n2024 2023\nStock options 3,455,049 2,961,438\nRestricted stock units 327,359 878,555\nWarrants 10,905,901 7,070,627\nConvertible debt 1,241,291 2,830,177\nAnti-dilutive\nsecurities 15,929,600 13,740,797 ","Net\nIncome (Loss) per Share Basic\nnet income (loss) per share of common stock is computed by dividing net income (loss) by the weighted-average number of shares of common\nstock outstanding during each period. Diluted net income (loss) per share of common stock includes the effect, if any, from the potential\nexercise or conversion of securities, such as convertible debt, stock options, restricted stock units and warrants, which would result\nin the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive.\nFor diluted net income (loss) per share, the weighted-average number of shares of common stock is the same for basic net income (loss)\nper share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.\nFor the year ended December 31, 2022, the Company was in a net income position and calculated the diluted net income per share by dividing\nthe Company’s net income by the dilutive weighted average number of shares outstanding during the year, determined using the treasury\nstock method. A reconciliation of the numerators and denominators of the basic and diluted net income (loss) per share calculations are\nas follows: Schedule of Basic and\nDiluted Net Income Loss Per Share\n2023 2022\nYear Ended December 31,\n2023 2022\nNumerator:\nNet (loss) income $ (196,295 ) $ 14,192\nDenominator:\nWeighted average shares outstanding, basic 17,813,044 13,990,703\nWeighted average dilutive stock options - 958,602\nWeighted average restricted stock units - 33,697\nWeighted average shares outstanding, diluted 17,813,044 14,983,002\nNet (loss) income, basic $ (11.02 ) $ 1.01\nNet (loss) income, diluted $ (11.02 ) $ 0.95 The\nfollowing potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock\noutstanding, prior to the use of the two-class method, as they would be anti-dilutive: Schedule of Potentially\nDilutive Securities\n2023 2022\nDecember 31,\n2023 2022\nStock options 2,820,187 1,239,219\nRestricted stock units 823,332 128,590\nWarrants 7,070,627 3,345,836\nConvertible debt 549,681 629,101\nAnti-dilutive\nsecurities 11,263,827 5,342,746 "]
["Segment Information","Segment\nInformation Operating\nsegments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by\nthe chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company\nmanages its operations through an evaluation of three ","Segment\nInformation Operating\nsegments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by\nthe chief operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company\nmanages its operations through an evaluation of three "]
["Allowance for Credit Losses","Allowance\nfor Credit Losses With\nthe adoption of ASU 2016-13 Financial Instruments — Credit Losses, ","Allowance\nfor Credit Losses and Concentrations of Credit Risk With\nthe adoption of ASU 2016-13 Financial Instruments — Credit Losses , "]
["Concentrations of Credit Risk and Significant Customers","Concentrations\nof Credit Risk and Significant Customers Financial\ninstruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted\ncash, and accounts receivable. The Company generally maintains balances in various operating accounts at financial institutions that\nmanagement believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced\nany losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk\nbeyond the normal credit risk associated with commercial banking relationships. The\nCompany is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services.\nAll trade accounts receivables are a result from product sales and services performed in the United States. As of September 30, 2024,\ntwo of the Company’s customers, each of which individually comprised at least 10 33 10 63 15 21 10 15 ","Concentrations\nof Credit Risk and Significant Customers Financial\ninstruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted\ncash. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be\nof high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its\ncash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit\nrisk associated with commercial banking relationships. The\nCompany is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services.\nAll trade accounts receivables are a result from product sales and services performed in the United States. As of December 31, 2023,\none of the Company’s customers comprised 23 18 38 33 14 13 37 11 In\nNovember 2017, the FDA provided guidance that established an updated framework for regulation of Human Cell & Tissue Products (“HCT/P”).\nThe Company’s Interfyl products meet the criteria for minimal manipulation and homologous use as outlined within the applicable\nguidance and has an official designation from the FDA as an HCT/P product. As a result, the Company did not stop selling its Interfyl\nproducts when the FDA ended its enforcement discretion on May 31, 2021. However, the Center for Medicare and Medicaid Services (“CMS”)\nbegan rejecting claims for Interfyl submitted by Customer A. The Company believes that CMS is not distinguishing the Interfyl products\nfrom its competitors’ products. While the Company and Customer A continue to work with CMS to resolve the rejected claims, a full\nreserve of $ 2,349 1,762 "]
["Emerging Growth Company","Emerging\nGrowth Company Section\n102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being\nrequired to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities\nAct registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934,\nas amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth\ncompany can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies\nbut any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which\nexpires December 31, 2026 unless the Company is otherwise disqualified. Accordingly, when a standard is issued or revised and it has\ndifferent application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised\nstandard at the time private companies adopt the new or revised standard. This\nmay make comparison of the Company’s condensed consolidated financial statements with another public company that is neither an\nemerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible\nbecause of the potential differences in accounting standards used. ","Emerging\nGrowth Company Section\n102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from\nbeing required to comply with new or revised financial accounting standards until private companies (that is, those that have not\nhad a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities\nExchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act\nprovides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements\nthat apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt\nout of such extended transition period, which means that when a standard is issued or revised and it has different application dates\nfor public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time\nprivate companies adopt the new or revised standard. This\nmay make comparison of the Company’s financial statements with another public company that is neither an emerging growth company\nnor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential\ndifferences in accounting standards used. "]
["Reclassifications","Reclassifications Certain\nprior period amounts have been reclassified to conform with current year presentation. On the condensed consolidated balance sheets,\nshort-term debt - Yorkville and other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related\nparty and short-term debt - related parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 7 for\nfurther information. ","Reclassifications Certain\nprior period amounts have been reclassified to conform with current year presentation on the consolidated balance sheets and consolidated\nstatements of cash flows between accrued expenses and accrued research and development (“R&D”) software to separately\npresent the Palantir liability recorded during the year ended December 31, 2023 (See Note 11 for further information). "]
["Recently Adopted Accounting Pronouncements","Recently\nAdopted Accounting Pronouncements In\nJune 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13,\nFinancial Instruments — Credit Losses adopted ASU 2016-13 January 1, 2023 no ","Recently\nAdopted Accounting Pronouncements In\nJune 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, which changes the accounting for recognizing\nimpairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based\non expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial\nassets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022\n(fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company adopted ASU\n2016-13 effective January 1, 2023. The standard did not have a material impact on the consolidated financial statements. "]
["Recently Issued Accounting Pronouncements","Recently\nIssued Accounting Pronouncements In\nNovember 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In\nDecember 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures In\nNovember 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures\n(Subtopic 220-40): Disaggregation of Income Statement Expenses","Recently\nIssued Accounting Pronouncements In\nNovember 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In\nDecember 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures"]

{"sheet":"Summary of Significant Accoun_3","index":27,"n_rows":6,"n_cols":3,"rows_kept":6,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Accounting Policies [Abstract]"," "," "]
["Schedule of Property and Equipment Estimated Useful Life"," ","Property\nand equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized\nusing the straight-line method over the estimated useful life of each asset, as follows: Schedule of Property and\nEquipment Estimated Useful Life\nEstimated Useful Life\nBuilding 26\nFurniture and fixtures 5 7\nLab equipment 5\nComputer equipment 3\nSoftware 3\nLeasehold improvements shorter of the estimated useful life or the lease term"]
["Schedule of Basic and Diluted Net Income Loss Per Share"," ","Schedule of Basic and\nDiluted Net Income Loss Per Share\n2023 2022\nYear Ended December 31,\n2023 2022\nNumerator:\nNet (loss) income $ (196,295 ) $ 14,192\nDenominator:\nWeighted average shares outstanding, basic 17,813,044 13,990,703\nWeighted average dilutive stock options - 958,602\nWeighted average restricted stock units - 33,697\nWeighted average shares outstanding, diluted 17,813,044 14,983,002\nNet (loss) income, basic $ (11.02 ) $ 1.01\nNet (loss) income, diluted $ (11.02 ) $ 0.95 "]
["Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share","The\nfollowing potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common\nstock outstanding, prior to the use of the two-class method, as they would be anti-dilutive: Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share\n2024 2023\nSeptember 30,\n2024 2023\nStock options 3,455,049 2,961,438\nRestricted stock units 327,359 878,555\nWarrants 10,905,901 7,070,627\nConvertible debt 1,241,291 2,830,177\nAnti-dilutive\nsecurities 15,929,600 13,740,797 ","The\nfollowing potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock\noutstanding, prior to the use of the two-class method, as they would be anti-dilutive: Schedule of Potentially\nDilutive Securities\n2023 2022\nDecember 31,\n2023 2022\nStock options 2,820,187 1,239,219\nRestricted stock units 823,332 128,590\nWarrants 7,070,627 3,345,836\nConvertible debt 549,681 629,101\nAnti-dilutive\nsecurities 11,263,827 5,342,746 "]

{"sheet":"Fair Value of Financial Asset_2","index":28,"n_rows":19,"n_cols":3,"rows_kept":19,"merged":[[0,0,1,0]]}
["Fair Value of Financial Assets and Liabilities (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Class of Warrant or Right [Line Items]"," "," "]
["Schedule of Financial Assets and Liabilities Measures at Fair Value","The\nfollowing tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring\nbasis and indicate the level of the fair value hierarchy used to determine such fair values: Schedule of Financial Assets and Liabilities Measures at Fair Value\nLevel 1 Level 2 Level 3 Total\nFair Value Measurements as of September 30, 2024\nLevel 1 Level 2 Level 3 Total\nLiabilities:\nAcquisition-related contingent consideration obligations $ — $ — $ 1,606 $ 1,606\nContingent stock consideration — — 27 27\nShort-term debt - Yorkville convertible note — — 3,695 3,695\nWarrant liability - July 2023 Registered Direct Warrants — — 1,748 1,748\nWarrant liability - April 2023 Registered Direct Warrants — — 1,670 1,670\nWarrant liability - May 2022 PIPE Warrants — — 809 809\nWarrant liability - Sponsor Warrants — — 32 32\nWarrant liability - Public Warrants 144 — — 144\nTotal\nfair value liabilities $ 144 $ — $ 9,587 $ 9,731\nLevel 1 Level 2 Level 3 Total\nFair Value Measurements as of December 31, 2023\nLevel 1 Level 2 Level 3 Total\nAssets:\nConvertible note receivable $ — $ — $ 2,072 $ 2,072\nTotal\nfair value assets $ — $ — $ 2,072 $ 2,072\nLiabilities:\nAcquisition-related contingent consideration obligations $ — $ — $ 1,606 $ 1,606\nContingent stock consideration — — 27 27\nShort-term debt - Yorkville — — 17,223 17,223\nWarrant liability - July 2023 Registered Direct Warrants — — 1,529 1,529\nWarrant liability - April 2023 Registered Direct Warrants — — 1,487 1,487\nWarrant liability - May 2022 PIPE Warrants — — 708 708\nWarrant liability - Sponsor Warrants — — 60 60\nWarrant liability - Public Warrants 575 — — 575\nTotal\nfair value liabilities $ 575 $ — $ 22,640 $ 23,215 ","The\nfollowing tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring\nbasis and indicate the level of the fair value hierarchy used to determine such fair values: Schedule of Financial Assets and Liabilities Measures at Fair Value\nLevel 1 Level 2 Level 3 Total\nFair Value Measurements as of December 31, 2023\nLevel 1 Level 2 Level 3 Total\nAssets:\nCash equivalents - money market funds $ — $ — $ — $ —\nConvertible note receivable — — 2,072 2,072\nTotal\nfair value assets $ — $ — $ 2,072 $ 2,072\nLiabilities:\nAcquisition-related contingent consideration obligations $ — $ — $ 1,606 $ 1,606\nContingent stock consideration — — 27 27\nShort-term debt - Yorkville — — 17,223 17,223\nWarrant liability - July 2023 Registered Direct Warrants — — 1,529 1,529\nWarrant liability - April 2023 Registered Direct Warrants — — 1,487 1,487\nWarrant liability - May 2022 PIPE Warrants — — 708 708\nWarrant liability - Sponsor Warrants — — 60 60\nWarrant liability - Public Warrants 575 — — 575\nTotal\nfair value liabilities $ 575 $ — $ 22,640 $ 23,215\nLevel 1 Level 2 Level 3 Total\nFair Value Measurements as of December 31, 2022\nLevel 1 Level 2 Level 3 Total\nAssets:\nCash equivalents – money market funds $ 12,174 $ — $ — $ 12,174\nConvertible note receivable — — 2,514 2,514\nTotal\nfair value assets $ 12,174 $ — $ 2,514 $ 14,688\nLiabilities:\nAcquisition-related contingent consideration obligations $ — $ — $ 105,945 $ 105,945\nContingent stock consideration — — 186 186\nShort-term debt - Yorkville — — 37,603 37,603\nWarrant liability - May 2022 PIPE Warrants — — 1,402 1,402\nWarrant liability - Sponsor Warrants — — 1,190 1,190\nWarrant liability - Public Warrants 1,006 — — 1,006\nTotal\nfair value liabilities $ 1,006 $ — $ 146,326 $ 147,332 "]
["Schedule of Reconciliation of Contingent Consideration Obligations","The\nfollowing table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs\nfor the nine months ended September 30, 2024: Schedule of Reconciliation of Contingent Consideration Obligations\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nAcquisition-related contingent consideration obligations $ 1,606 $ — $ — $ — $ 1,606 ","The\nfollowing table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs\nas of December 31, 2023 and 2022: Schedule of Reconciliation of Contingent Consideration Obligations\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nAcquisition-related contingent consideration obligations $ 105,945 $ — $ — $ (104,339 ) $ 1,606\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nAcquisition-related contingent consideration obligations $ 232,222 $ — $ — $ (126,277 ) $ 105,945 "]
["Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants","The\nfollowing table presents a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the nine\nmonths ended September 30, 2024: Schedule\nof Reconciliation of Warrant Liabilities Measured on Recurring Basis\nBalance as of January 1, 2024 $ 3,784\nJanuary 2024 Bridge Loan - Tranche #2 warrant issuance 1,858\nGain recognized in earnings from change in fair value 1,587\nReclassification of warrants from liability classified to equity classified (2,970 )\nBalance as of September 30, 2024 $ 4,259 ","The\nfollowing table provides a roll-forward of the aggregate fair values of the Company’s warrant liabilities for which fair values\nare determined using Level 3 inputs: Schedule of Roll-forward of the Aggregate Fair\nValues of Company’s Warrant Liabilities\nBalance as of December 31, 2021 $ 25,962\nMay 2022 PIPE warrant issuance 19,745\nApril 2023 Registered Direct warrant issuance 4,280\nJuly 2023 Registered Direct warrant issuance 2,645\nGain recognized in earnings from change in fair value (42,109 )\nBalance as of December 31, 2022 $ 3,598\nBalance as of December 31, 2022 $ 3,598\nApril 2023 Registered Direct warrant issuance 4,280\nJuly 2023 Registered Direct warrant issuance 2,645\nGain recognized in earnings from change in fair value (6,164 )\nBalance as of December 31, 2023 $ 4,359 "]
["Schedule of Fair Value of Liability Warrants"," ","The\nfair value of the Liability Warrants are as follows: Schedule of Fair Value of\nLiability Warrants\nDecember 31, December 31,\nPublic Warrants $ 575 $ 1,006\nSponsor Warrants 60 1,190\n2023 Registered Direct Warrants 3,016 —\nMay 2022 PIPE Warrants 708 1,402\nTotal $ 4,359 $ 3,598 "]
["Schedule of Sponsor Warrants","Significant\ninputs for the January 2024 Bridge Loan - Tranche #2 Warrants were as follows: Schedule\nof January 20224 Bridge Loan\nJuly 15, 2024 January\n16, 2024\n(reclassification) (issuance)\nCommon share price $ 3.19 $ 2.00\nTerm to initial exercise date (years) (1) N/A 0.50\nDividend yield 0 % 0 %\nTerm (years) 5.0 5.0\nRisk-free interest rate 4.00 % 3.90 %\nVolatility 112.5 % 107.5 %\n(1) As discussed further\nin Note 7, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July 15, 2024,\nthe warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the Company’s\nown stock. As such, the warrants were marked to fair value as of the initial exercise date and then reclassified from liability classified\nto equity classified."," "]
["Schedule of Convertible Note Valuation Model","Significant\ninputs for the convertible note valuation model were as follows: Schedule of Convertible\nNote Valuation Model\nDecember 31, 2023\nFace value $ 4,000\nCoupon rate 12 17\nStock price $ 0.23\nTerm (years) 0.51 2.45\nRisk-free interest rate 5.47 %\nVolatility n/a ","Significant\ninputs for the convertible note valuation model are as follows: Schedule of Convertible\nNote Valuation Model\nDecember 31, 2023 December 31, 2022\nFace value $ 4,000 $ 4,000\nCoupon rate 12 17 12 17\nStock price $ 0.2 $ 0.2\nTerm (years) 0.51 2.45 1.01 3.45\nRisk-free interest rate 5.47 % 4.73 %\nVolatility n/a n/a "]
["Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis","The\nfollowing table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level\n3 inputs for the nine months ended September 30, 2024: Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nContingent stock consideration $ 27 $ — $ — $ — $ 27 ","The\nfollowing table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level\n3 inputs as of December 31, 2023 and 2022: Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis\nBalance as of Net Purchases, Fair value Balance as of\nLiabilities:\nContingent stock consideration $ 186 $ — $ — $ (159 ) $ 27 "]
["Schedule of Reconciliation of Yorkville Debt Measured on a Measured Basis","The\nfollowing table presents a reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the nine\nmonths ended September 30, 2024: Schedule of Reconciliation\nof Yorkville Debt Measured on a Measured Basis\nLiabilities:\nBalance as of January 1, 2024 $ 17,223\nPrincipal repayments (17,374 )\nIssuance of convertible promissory note 3,150\nFair value adjustment through earnings 694\nFair value adjustment through accumulated other comprehensive income 2\nBalance as of September 30, 2024 $ 3,695 ","The\nfollowing table presents a reconciliation of the Yorkville debt measured on a recurring basis using Level 3 inputs as of the initial\nvaluation date of September 15, 2022 and as of December 31, 2023: Schedule of Reconciliation\nof Yorkville Debt Measured on a Measured Basis\nLiabilities:\nBalance as of December 31, 2022 $ 37,603\nConversion of debt into common shares (4,599 )\nPrincipal repayments (16,811 )\nIssuance of convertible promissory note 3,150\nFair value adjustment through earnings 354\nFair value adjustment through accumulated other comprehensive income (146 )\nFair value adjustment through interest accrual 822\nBalance as of December 31, 2023 $ 17,223 "]
["Schedule of Yorkville Short-term Debt Valuation Model","Significant\ninputs for the Yorkville convertible promissory note valuation model were as follows: Schedule of Yorkville Short-term Debt Valuation Model\nSeptember 30, 2024 March 13, 2024\n(issuance)\nCommon share price $ 2.97 $ 5.79\nCredit spread 8.00 % 8.50 %\nDividend yield 0 % 0 %\nTerm (years) 0.45 1.00\nRisk-free interest rate 4.30 % 4.90 %\nVolatility 50.0 % 50.0 %","Significant\ninputs for the Yorkville short-term debt valuation model as of December 31, 2022 were as follows: Schedule of Yorkville Short-term Debt Valuation Model\nDecember 31, 2022\nCommon share price $ 12.90\nCredit spread 13.71 %\nDividend yield 0 %\nTerm (years) 0.71\nRisk-free interest rate 4.75 %\nVolatility 45.0 %\nDiscount yield 18.46 %"]
["Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis","The\nfollowing table presents a reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the\nnine months ended September 30, 2024: Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis\nBalance as of Net Purchases, Fair value Balance as of September 30, 2024\nAssets:\nConvertible note receivable $ 2,072 $ — $ (2,072 ) $ — $ — "," "]
["GX Sponsor Warrants [Member]"," "," "]
["Class of Warrant or Right [Line Items]"," "," "]
["Schedule of Sponsor Warrants","Significant\ninputs for the Sponsor Warrants were as follows: Schedule of Sponsor Warrants\nSeptember 30, 2024 December 31, 2023\nCommon share price $ 2.97 $ 2.47\nExercise price $ 115.00 $ 115.00\nDividend yield 0 % 0 %\nTerm (years) 1.8 2.5\nRisk-free interest rate 3.66 % 4.12 %\nVolatility 105.9 % 100.7 %","Significant\ninputs for the Sponsor Warrants are as follows: Schedule of Sponsor Warrants\nDecember 31, December 31,\nCommon share price $ 2.47 $ 12.90\nExercise price $ 115.00 $ 115.00\nDividend yield 0 % 0 %\nTerm (years) 2.5 3.5\nRisk-free interest rate 4.12 % 4.16 %\nVolatility 100.7 % 75.0 %"]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member]"," "," "]
["Class of Warrant or Right [Line Items]"," "," "]
["Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants","Significant\ninputs for the May 2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows: Schedule of May 2022 PIPE\nWarrants and 2023 Registered Direct Warrants\nSeptember 30, 2024 December 31, 2023\nCommon share price $ 2.97 $ 2.47\nExercise price $ 3.50 7.50 $ 3.50 7.50\nDividend yield 0 % 0 %\nTerm (years) 4.03 4.34 4.78 5.09\nRisk-free interest rate 3.58 % 3.84 %\nVolatility 97.1 98.1 % 100.1 100.7 %","Significant\ninputs for the May 2022 PIPE Warrants and the 2023 Registered Direct Warrants are as follows: Schedule of May 2022 PIPE\nWarrants and 2023 Registered Direct Warrants\nDecember 31, December 31,\nCommon share price $ 2.47 $ 12.90\nExercise price $ 3.50 7.50 $ 82.5\nDividend yield 0 % 0 %\nTerm (years) 5.03 5.34 4.4\nRisk-free interest rate 4.60 % 3.99 %\nVolatility 97.0 % 81.2 %"]

{"sheet":"Inventory (Tables)","index":29,"n_rows":5,"n_cols":3,"rows_kept":5,"merged":[[0,0,1,0]]}
["Inventory (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Inventory Disclosure [Abstract]"," "," "]
["Schedule of Major Classes of Inventories","The\nCompany’s major classes of inventory were as follows: Schedule of Major Classes of Inventories\nSeptember 30, December 31,\nRaw materials $ 42 $ 3,081\nWork in progress 10,284 10,696\nFinished goods 8,720 10,922\nInventory, gross 19,046 24,699\nLess: inventory reserves (2,239 ) (2,289 )\nInventory, net $ 16,807 $ 22,410\nBalance Sheet Classification:\nInventory $ 3,963 $ 5,753\nInventory, net of current portion 12,844 16,657\nInventory,\nnet $ 16,807 $ 22,410 ","The\nCompany’s major classes of inventories were as follows: Schedule of Major Classes of Inventories\n2023 2022\nDecember 31,\n2023 2022\nRaw materials $ 3,081 $ 7,719\nWork in progress 10,696 12,381\nFinished goods 10,922 9,256\nInventory, gross 24,699 29,356\nLess: inventory reserves (2,289 ) (1,099 )\nInventory, net $ 22,410 $ 28,257\nBalance Sheet Classification:\nInventory 5,753 5,308\nInventory, net of current portion 16,657 22,949\nInventory,\nnet $ 22,410 $ 28,257 "]
["Schedule of Inventory Reserves"," ","A\nschedule of the activity in the inventory reserves is as follows: Schedule of Inventory Reserves\nBalance at January 1, 2022 $ 48\nAdditions for obsolete inventory 1,051\nBalance at December 31, 2022 1,099\nAdditions for obsolete inventory 7,627\nWrite-offs (6,437 )\nBalance at December 31, 2023 $ 2,289 "]

{"sheet":"Prepaid Expenses and Other Cu_2","index":30,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Prepaid Expenses and Other Current Assets (Tables)","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Prepaid Expenses And Other Current Assets"," "]
["Schedule of Prepaid Expenses and Other Current Assets","Prepaid\nexpenses and other current assets consisted of the following: Schedule of Prepaid Expenses and Other Current Assets\n2023 2022\nDecember 31,\n2023 2022\nPrepaid clinical expenses $ 688 $ 5,836\nPrepaid insurance expense 678 377\nOther 329 1,049\nPrepaid\nexpenses and other current assets $ 1,695 $ 7,262 "]

{"sheet":"Property and Equipment, Net (Ta","index":31,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Property and Equipment, Net (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Property, Plant and Equipment [Abstract]"," "," "]
["Schedule of Property and Equipment, Net","Property\nand equipment, net consisted of the following: Schedule of Property and Equipment, Net\nSeptember 30, December 31,\nLeasehold improvements $ 73,211 $ 73,211\nLaboratory and production equipment 14,093 14,093\nMachinery, equipment and fixtures 7,781 7,781\nConstruction in progress 70 21\nProperty and equipment 95,155 95,106\nLess: Accumulated depreciation and amortization (31,947 ) (27,278 )\nProperty and equipment, net $ 63,208 $ 67,828 ","Property\nand equipment, net consisted of the following: Schedule of Property and Equipment, Net\n2023 2022\nDecember 31,\n2023 2022\nLeasehold improvements $ 73,211 $ 70,113\nLaboratory and production equipment 14,093 14,433\nMachinery, equipment and fixtures 7,781 7,780\nConstruction in progress 21 3,660\nProperty and equipment 95,106 95,986\nLess: Accumulated depreciation and amortization (27,278 ) (20,331 )\nProperty and equipment, net $ 67,828 $ 75,655 "]

{"sheet":"Goodwill and Intangible Asset_2","index":32,"n_rows":6,"n_cols":3,"rows_kept":6,"merged":[[0,0,1,0]]}
["Goodwill and Intangible Assets, Net (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Goodwill and Intangible Assets Disclosure [Abstract]"," "," "]
["Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments"," ","The\ncarrying values of goodwill assigned to the Company’s reporting units are as follows: Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments\nCell Therapy Degenerative Biobanking Total\nBalance at December 31, 2021 $ 112,347 $ 3,610 $ 7,347 $ 123,304\nImpairment — (3,610 ) — (3,610 )\nBalance at December 31, 2022 $ 112,347 $ — $ 7,347 $ 119,694\nImpairment (112,347 ) — — (112,347 )\nBalance at December 31, 2023 $ — $ — $ 7,347 $ 7,347 "]
["Schedule of Intangible Assets, Net","Intangible\nassets, net consisted of the following: Schedule of Intangible Assets, Net\nSeptember 30, December 31, Estimated\nAmortizable intangible assets:\nDeveloped technology $ 16,810 $ 16,810 11 16\nCustomer relationships 2,413 2,413 10\nTrade names & trademarks 570 570 10 13\nReacquired rights 4,200 4,200 6\n23,993 23,993\nLess accumulated amortization:\nDeveloped technology (8,600 ) (7,722 )\nCustomer relationships (1,898 ) (1,700 )\nTrade names & trademarks (371 ) (330 )\nReacquired rights (4,200 ) (3,940 )\n(15,069 ) (13,692 )\nAmortizable intangible assets, net 8,924 10,301\nNon-amortized intangible assets\nAcquired IPR&D product rights 700 700 indefinite\n$ 9,624 $ 11,001 ","Intangible\nassets, net consisted of the following: Schedule of Intangible Assets, Net\nDecember 31, December 31, Estimated Useful\nAmortizable intangible assets:\nDeveloped technology $ 16,810 $ 16,810 11 16\nCustomer relationships 2,413 2,413 10\nTrade names & trademarks 570 570 10 13\nReacquired rights 4,200 4,200 6\n23,993 23,993\nLess: accumulated amortization\nDeveloped technology (7,722 ) (6,549 )\nCustomer relationships (1,700 ) (1,435 )\nTrade names & trademarks (330 ) (275 )\nReacquired rights (3,940 ) (3,240 )\n(13,692 ) (11,499 )\nAmortizable intangible assets, net 10,301 12,494\nNon-amortized intangible assets\nAcquired IPR&D product rights 700 108,500 indefinite\n$ 11,001 $ 120,994 "]
["Schedule of Aggregate Amortization Expense Related to Intangible Assets"," ","Aggregate\namortization expense for each of the five succeeding years related to intangible assets held as of December 31, 2023 is estimated as\nfollows: Schedule of Aggregate Amortization Expense Related to Intangible Assets\n2024 $ 1,753\n2025 $ 1,493\n2026 $ 1,356\n2027 $ 1,258\n2028 $ 1,208 "]

{"sheet":"Accrued Expenses and Other Cu_2","index":33,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Accrued Expenses and Other Current Liabilities (Tables)","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Payables and Accruals [Abstract]"," "]
["Schedule of Accrued Expenses and Other Current Liabilities","Accrued\nexpenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities\n2023 2022\nDecember 31,\n2023 2022\nAccrued clinical trial expense $ 189 $ 2,659\nAccrued professional fees 573 880\nAccrued wages, bonuses, commissions and vacation 3,011 2,576\nAccruals for construction in progress 214 322\nAccrued compliance fee 1,145 —\nOther 2,448 2,632\nTotal\naccrued expenses $ 7,580 $ 9,069 "]

{"sheet":"Debt (Tables)","index":34,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Debt (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Debt Disclosure [Abstract]"," "," "]
["Schedule of Debt","Debt\nconsisted of the following: Schedule\nof Debt\nSeptember 30, December 31,\nShort-term debt - unaffiliated:\nYorkville - PPA (measured at fair value) $ - $ 17,223\nYorkville - convertible promissory note (measured at fair value) 3,695 -\nShort-term debt - other - 2,108\nTotal short-term debt - unaffiliated 3,695 19,331\nShort-term debt - related parties:\nC.V. Starr Bridge Loan, net of discount 5,640 5,523\nRWI Bridge Loan, net of discount 29,482 12,967\nCEO promissory note 3,793 1,419\nTotal short-term debt - related parties 38,915 19,909\nTotal debt $ 42,610 $ 39,240 "," Schedule\nof Debt"]

{"sheet":"Leases (Tables)","index":35,"n_rows":6,"n_cols":3,"rows_kept":6,"merged":[[0,0,1,0]]}
["Leases (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Leases"," "," "]
["Schedule of Lease Costs","The\ncomponents of the Company’s lease costs are classified on its condensed consolidated statements of operations and comprehensive\nloss as follows: Schedule of Lease Costs\n2024 2023 2024 2023\nThree Months Ended Nine Months Ended\n2024 2023 2024 2023\nOperating lease cost $ 978 $ 759 $ 2,933 $ 2,278\nVariable lease cost 348 320 1,026 911\nTotal operating lease cost $ 1,326 $ 1,079 $ 3,959 $ 3,189 ","The\ncomponents of the Company’s lease costs are classified on its consolidated statements of operations as follows: Schedule of Lease Costs\n2023 2022\nYear Ended December 31,\n2023 2022\nOperating lease cost $ 3,256 $ 3,038\nVariable lease cost 1,132 1,598\nTotal operating lease cost $ 4,388 $ 4,636\nShort term lease cost $ - $ 126 "]
["Schedule of Cash and Non-cash Activity Related to the lease Liabilities","The\ntable below shows the cash and non-cash activity related to the Company’s lease liabilities during the period: Schedule of Cash and\nNon-cash Activity Related to the lease Liabilities\n2024 2023\nNine Months Ended September 30,\n2024 2023\nCash paid related to lease liabilities:\nOperating cash flows from operating leases $ 2,534 $ 2,168 ","The\ntable below shows the cash and non-cash activity related to the Company’s lease liabilities during the year ended December 31,\n2023: Schedule of Cash and\nNon-cash Activity Related to the lease Liabilities\n2023 2022\nYear Ended December 31,\n2023 2022\nCash paid related to lease liabilities:\nOperating cash flows from operating leases $ 2,995 $ 2,834\nNon-cash lease liability activity:\nRight-of-use assets obtained in exchange for lease obligations:\nOperating leases $ - $ - "]
["Schedule of Future Minimum Payments under Non-Cancelable Operating Leases","As\nof September 30, 2024, the maturities of the Company’s operating lease liabilities were as follows: Schedule of Future Minimum Payments under\nNon-Cancelable Operating Leases\n2024 (remaining three months) $ 845\nRemaining year $ 845\n2025 3,452\nYear one 3,452\n2026 3,526\nYear two 3,526\n2027 3,599\nYear three 3,599\n2028 3,673\nYear four 3,673\nThereafter 84,568\nYear four Thereafter 84,568\nTotal lease payments 99,663\nLess imputed interest (73,212 )\nTotal $ 26,451 ","As\nof December 31, 2023, the maturities of the Company’s operating lease liabilities were as follows: Schedule of Future Minimum Payments under\nNon-Cancelable Operating Leases\nRemaining year\n2024 $ 3,378\nYear one $ 3,378\n2025 3,452\nYear two 3,452\n2026 3,526\nYear three 3,526\n2027 3,599\nYear four 3,599\n2028 3,673\nYear five 3,673\nYear four Thereafter\nThereafter 84,568\nYear five Thereafter 84,568\nTotal lease payments 102,196\nLess imputed interest (76,019 )\nTotal $ 26,177 "]

{"sheet":"Equity (Tables)","index":36,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Equity (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Equity [Abstract]"," "," "]
["Summary of the Warrants","Summary of the Warrants\nNumber of Exercise Expiration\nDragasac Warrant (1) 652,981 $ 2.4898 March 16, 2025\nPublic Warrants (2) 1,437,447 $ 115.00 July 16, 2026\nSponsor Warrants (2) 849,999 $ 115.00 July 16, 2026\nMay 2022 PIPE Warrants 405,405 $ 3.50 October 10, 2028\nMarch 2023 PIPE Warrants 208,485 $ 30.00 March 27, 2028\nMarch 2023 PIPE Warrants (modified) 729,698 $ 10.00 March 27, 2028\nMarch 2023 Loan Warrants (3) 75,000 $ 5.895 March 17, 2028\nApril 2023 Registered Direct Warrants 435,625 $ 7.50 October 10, 2028\nApril 2023 Registered Direct Warrants (modified) 487,451 $ 3.50 October 10, 2028\nMay 2023 PIPE Warrants 581,394 $ 10.00 May 17, 2028\nJune 2023 Warrants (3) 50,000 $ 5.895 June 20, 2028\nJune 2023 Loan Warrants 300,000 $ 8.10 June 20, 2028\nJuly 2023 Registered Direct Warrants 857,142 $ 3.50 January 31, 2029\nJanuary 2024 PIPE Warrants 535,274 $ 2.4898 January 16, 2029\nJanuary 2024 Bridge Loan - Tranche #1 Warrants 1,650,000 $ 2.4898 January 16, 2029\nJanuary 2024 Bridge Loan - Tranche #2 Warrants 1,350,000 $ 2.988 July 15, 2029\nMarch 2024 RWI Forbearance Warrants 300,000 $ 5.895 June 20, 2028\n10,905,901\n(1) In connection with the execution of the January 2024 PIPE\ndescribed above, the Company agreed to reprice 652,981 67.70 2.4898\n(2) The number of Public Warrants and Sponsor Warrants outstanding\nwas not adjusted for the reverse stock split. There are 14,374,478 8,499,999 115.00\n(3) In connection with the execution of the Starr Forbearance\nAgreement on March 13, 2024, described above under Warrant Modification and further in Note 7, the Company agreed to reprice 75,000 7.10 50,000 8.10 5.895","Summary of the Warrants\nNumber of Exercise Expiration\nDragasac Warrant(1) 652,981 $ 67.70 March 16, 2025\nPublic Warrants(2) 1,437,447 $ 115.00 July 16, 2026\nSponsor Warrants(2) 849,999 $ 115.00 July 16, 2026\nMay 2022 PIPE Warrants 405,405 $ 3.50 October 10, 2028\nMarch 2023 PIPE Warrants 208,485 $ 30.00 March 27, 2028\nMarch 2023 PIPE Warrants (modified) 729,698 $ 10.00 March 27, 2028\nMarch 2023 Loan Warrants 75,000 $ 7.10 March 17, 2028\nApril 2023 Registered Direct Warrants 435,625 $ 7.50 October 10, 2028\nApril 2023 Registered Direct Warrants (modified) 487,451 $ 3.50 October 10, 2028\nMay 2023 PIPE Warrants 581,394 $ 10.00 May 17, 2028\nJune 2023 Warrants 50,000 $ 8.10 June 20, 2028\nJune 2023 Loan Warrants 300,000 $ 8.10 June 20, 2028\nJuly 2023 Registered Direct Warrants 857,142 $ 3.50 January 31, 2029\n7,070,627\n(1) The exercise price is the lesser of $ 67.70 80\n(2) The number of\nPublic Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are 14,374,478 8,499,999 115.00"]

{"sheet":"Stock-Based Compensation (Table","index":37,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0]]}
["Stock-Based Compensation (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Share-Based Payment Arrangement [Abstract]"," "," "]
["Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model","The\nfollowing table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the\ngrant-date fair value of stock options granted during the nine months ended September 30, 2024 and 2023: Schedule\nof Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model\nNine Months Ended September 30,\n2024 2023\nRisk-free interest rate 4.5 % 4.1 %\nExpected term (in years) 5.5 5.6\nExpected volatility 110.8 % 86.5 %\nExpected dividend yield 0 % 0 %","The\nfollowing table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the\ngrant-date fair value of stock options granted during the years ended December 31, 2023 and 2022: Schedule\nof Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model\nYear Ended\n2023 2022\nRisk-free interest rate 4.1 % 2.7 %\nExpected term (in years) 5.6 5.9\nExpected volatility 86.5 % 77.1 %\nExpected dividend yield — % — %"]
["Schedule of Stock Option Activity","The\nfollowing table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan: Schedule of Stock Option Activity\nOptions Weighted Weighted Aggregate\nOutstanding at January 1, 2024 2,820,187 $ 40.16 5.6 $ —\nGranted 879,664 3.76\nExercised — —\nForfeited (289,802 ) 31.47\nOutstanding at September 30, 2024* 3,410,049 $ 31.51 6.0 $ 115\nVested and expected to vest September 30, 2024 3,410,049 $ 31.51 6.0 $ 115\nExercisable at September 30, 2024 2,513,584 $ 38.00 4.9 $ 113\n* Options outstanding\nat September 30, 2024 under the 2021 Plan and 2017 Plan were 1,979,953 1,475,096 45,000","The\nfollowing table summarizes option activity with service conditions under the 2021 Plan and the 2017 Plan: Schedule of Stock Option Activity\nOptions Weighted Weighted Aggregate\nOutstanding at December 31, 2022 2,514,452 $ 49.08 6.1 $ 7,851\nGranted 741,634 5.35\nExercised (108,637 ) 2.80\nForfeited/Expired (327,262 ) 42.23\nOutstanding at December 31, 2023 2,820,187 $ 40.16 5.6 $ —\nVested and expected to vest December 31, 2023 2,820,187 $ 40.16 5.6 $ —\nExercisable at December 31, 2023 2,025,287 $ 46.01 4.5 $ — "]
["Schedule of Activity Related to RSU Stock-Based Payment Awards","The\nfollowing table summarizes activity related to RSU stock-based payment awards under the 2021 Plan: Schedule\nof Activity Related to RSU Stock-Based Payment Awards\nNumber of Shares Weighted\nOutstanding at January 1, 2024 823,332 $ 13.77\nGranted — —\nVested (395,996 ) 11.50\nForfeited (99,977 ) 13.24\nOutstanding at September 30, 2024 327,359 $ 16.68 ","The\nfollowing table summarizes activity related to RSU stock-based payment awards: Schedule\nof Activity Related to RSU Stock-Based Payment Awards\nNumber of Shares Weighted\nOutstanding at December 31, 2022 227,013 $ 73.35\nGranted 954,931 $ 6.29\nReleased (83,759 ) $ 65.05\nForfeited (274,853 ) $ 21.37\nOutstanding at December 31, 2023 823,332 $ 13.77 "]
["Schedule of Stock-based Compensation Expense","The\nCompany recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations\nand comprehensive loss: Schedule\nof Stock-based Compensation Expense\n2024 2023 2024 2023\nThree Months Ended Nine Months Ended\n2024 2023 2024 2023\nCost of revenues $ 90 $ 166 $ 285 $ 462\nResearch and development 182 379 903 1,384\nSelling, general and administrative 2,400 3,053 7,440 9,596\nStock-based\ncompensation expense $ 2,672 $ 3,598 $ 8,628 $ 11,442 ","The\nCompany recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations: Schedule\nof Stock-based Compensation Expense\n2023 2022\nYear Ended December 31,\n2023 2022\nCost of revenues $ 580 $ 410\nResearch and development 1,832 2,118\nSelling, general and administrative 12,605 13,328\nStock-based\ncompensation expense $ 15,017 $ 15,856 "]

{"sheet":"Revenue Recognition (Tables)","index":38,"n_rows":5,"n_cols":3,"rows_kept":5,"merged":[[0,0,1,0]]}
["Revenue Recognition (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Revenue from Contract with Customer [Abstract]"," "," "]
["Schedule of Disaggregated Revenue by Product And Services","The\nfollowing table provides information about disaggregated revenue by product and services: Schedule\nof Disaggregated Revenue by Product And Services\n2024 2023 2024 2023\nThree Months Ended September 30, Nine Months Ended September 30,\n2024 2023 2024 2023\nProduct sales, net $ 3,393 $ 1,684 $ 26,199 $ 3,633\nServices 1,292 1,427 3,857 4,062\nLicense, royalty and other 4,611 675 6,032 2,964\nTotal net revenues $ 9,296 $ 3,786 $ 36,088 $ 10,659 ","The\nfollowing table provides information about disaggregated revenue by product and services: Schedule\nof Disaggregated Revenue by Product And Services\n2023 2022\nYear Ended December 31,\n2023 2022\nProduct sales and rentals $ 13,149 $ 3,749\nServices 5,441 5,512\nLicense, royalty and other 4,181 8,714\nNet revenues $ 22,771 $ 17,975 "]
["Schedule of Changes in Deferred Revenue from Contract Liabilities","The\nfollowing table provides changes in deferred revenue from contract liabilities: Schedule of Changes in Deferred Revenue from Contract Liabilities\n2024 2023\nBalance at January 1 $ 6,020 $ 4,492\nBeginning Balance $ 6,020 $ 4,492\nDeferral of revenue (1) 3,931 4,579\nRecognition of unearned revenue (2) (3,619 ) (3,514 )\nBalance at September 30 $ 6,332 $ 5,557\nEnding Balance $ 6,332 $ 5,557\n(1) Deferral of revenue includes\n$ 3,736 3,818\n(2) Recognition of unearned revenue\nincludes $ 2,271 2,274","The\nfollowing table provides changes in deferred revenue from contract liabilities: Schedule of Changes in Deferred Revenue from Contract Liabilities\n2023 2022\nBalance at January 1 $ 4,492 $ 4,067\nDeferral of revenue * 6,266 5,004\nRecognition of unearned revenue (4,738 ) (4,579 )\nBalance at December 31 $ 6,020 $ 4,492\n* Deferral of revenue\nresulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue\nunder the contract as performance is completed. Also includes up-front payment incurred in connection with signing of the Regeneron Services\nAgreement in August 2023 (see Note 15 below)."]

{"sheet":"Income Taxes (Tables)","index":39,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Income Taxes (Tables)","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Income Tax Disclosure [Abstract]"," "]
["Schedule of Current and Deferred Tax Provision","A\nsummary of the Company’s current and deferred tax provision is as follows: Schedule\nof Current and Deferred Tax Provision\nYear Ended December 31,\n2023 2022\nCurrent income tax expense:\nFederal $ - $ -\nState 10 13\nTotal current income tax expense 10 13\nDeferred income tax expense (benefit):\nFederal 1 1\nState (1 ) (1 )\nTotal deferred tax expense — —\nTotal expense from income taxes $ 10 $ 13 "]
["Schedule of Reconciliation of the U.S federal statutory income tax","A\nreconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows: Schedule\nof Reconciliation of the U.S federal statutory income tax\nYear Ended December 31,\n2023 2022\nFederal statutory income tax rate 21.0 % 21.0 %\nState income taxes, net of federal benefits 1.4 % (38.9 )%\nInterest accretion expense 11.0 % (186.9 )%\nChange in valuation allowance (20.0 )% 269.1 %\nMark to market warrant 0.5 % (58.5 )%\nDeferred true-up (2.4 )% 0.2 %\nStock-based compensation (0.0 )% (8.2 )%\nImpairment (12.0 )% 5.3 %\nOther permanent items 0.5 % (3.1 )%\nEffective income tax rate (0.0 )% (0.0 )%"]
["Schedule of Deferred tax assets and liabilities","Net\ndeferred tax liabilities as of December 31, 2023 and 2022 consisted of the following: Schedule\nof Deferred tax assets and liabilities\n2023 2022\nYear Ended December 31,\n2023 2022\nDeferred tax assets:\nNet operating loss carryforwards $ 109,544 $ 102,723\nResearch and development tax credit carryforwards 5,674 5,674\nStock-based compensation expense 16,539 14,321\nStartup costs 498 588\nIntangible assets 3,442 3,905\nDeferred revenue 1,441 1,135\nUnicap 5 6\nImputed interest on contingent payments 110 5,654\nLegal fee capitalization and amortization 1,171 1,342\nCapitalized research and development 26,613 19,318\nOther 4,751 3,121\nTotal deferred tax assets 169,788 157,787\nDeferred tax liabilities:\nIn-process research and development — (27,271 )\nTotal deferred tax liabilities — (27,271 )\nValuation allowance (169,797 ) (130,525 )\nNet deferred tax liabilities $ (9 ) $ (9 )"]
["Schedule of Unrecognized Tax Benefits","A\nreconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: Schedule\nof Unrecognized Tax Benefits\nUnrecognized\nBalance at December 31, 2021 $ 1,270\nDecrease related to current year tax provisions (242 )\nBalance at December 31, 2022 $ 1,028\nDecrease related to current year tax provisions —\nBalance at December 31, 2023 $ 1,028 "]

{"sheet":"Segment Information (Tables)","index":40,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0]]}
["Segment Information (Tables)","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Segment Reporting [Abstract]"," "," "]
["Schedule of Financial Information by Segment","Financial\ninformation by segment for the three months ended September 30, 2024 and 2023 is as follows: Schedule\nof Financial Information by Segment\nCell BioBanking Degenerative Other Total\nThree Months Ended September 30, 2024\nCell BioBanking Degenerative Other Total\nNet revenues $ - $ 1,292 $ 8,004 $ - $ 9,296\nCost of revenues (excluding amortization of acquired intangible assets) - 238 3,645 - 3,883\nDirect expenses 3,496 353 4,187 8,529 16,565\nSegment contribution $ (3,496 ) $ 701 $ 172 $ (8,529 ) $ (11,152 )\nIndirect expenses 375 (a) 375\nLoss from operations $ (11,527 )\n(a) Components of other\nAmortization 375\nTotal other $ 375\nCell BioBanking Degenerative Other Total\nThree Months Ended September 30, 2023\nCell BioBanking Degenerative Other Total\nNet revenues $ - $ 1,427 $ 2,359 $ - $ 3,786\nCost of revenues (excluding amortization of acquired intangible assets) - 398 3,204 - 3,602\nDirect expenses 4,887 350 1,901 9,074 16,212\nSegment contribution $ (4,887 ) $ 679 $ (2,746 ) $ (9,074 ) $ (16,028 )\nIndirect expenses 83,228 (b) 83,228\nLoss from operations $ (99,256 )\n(b) Components of other\nChange in fair value of contingent stock consideration (39 )\nGoodwill impairment 82,714\nAmortization 553\nTotal other $ 83,228 Financial\ninformation by segment for the nine months ended September 30, 2024 and 2023 is as follows:\nCell BioBanking Degenerative Other Total\nNine Months Ended September 30, 2024\nCell BioBanking Degenerative Other Total\nNet revenues $ - $ 3,857 $ 32,231 $ - $ 36,088\nCost of revenues (excluding amortization of acquired intangible assets) - 952 6,694 - 7,646\nDirect expenses 12,383 1,216 14,385 28,159 56,143\nSegment contribution $ (12,383 ) $ 1,689 $ 11,152 $ (28,159 ) $ (27,701 )\nIndirect expenses 1,377 (a) 1,377\nLoss from operations $ (29,078 )\n(a) Components of other\nAmortization 1,377\nTotal other $ 1,377\nCell BioBanking Degenerative Other ``Total\nNine Months Ended September 30, 2023\nCell BioBanking Degenerative Other Total\nNet revenues $ - $ 4,062 $ 6,597 $ - $ 10,659\nCost of revenues (excluding amortization of acquired intangible assets) - 1,355 5,052 - 6,407\nDirect expenses 53,505 780 6,799 31,481 92,565\nSegment contribution $ (53,505 ) $ 1,927 $ (5,254 ) $ (31,481 ) $ (88,313 )\nIndirect expenses 117,289 (b) 117,289\nLoss from operations $ (205,602 )\n(b) Components of other\nChange in fair value of contingent consideration liability (104,339 )\nChange in fair value of contingent stock consideration (159 )\nGoodwill impairment 112,347\nIPR&D impairment 107,800\nAmortization 1,640\nTotal other $ 117,289 ","Financial\ninformation by segment is as follows: Schedule\nof Financial Information by Segment\nCell BioBanking Degenerative Disease Other Total\nYear Ended December 31, 2023\nCell BioBanking Degenerative Disease Other Total\nNet revenues $ — $ 5,441 $ 17,330 $ — $ 22,771\nGross profit — 3,791 2,964 — 6,755\nDirect expenses 28,694 1,752 9,720 40,876 81,041\nSegment contribution (28,694 ) 2,039 (6,756 ) (40,876 ) (74,286 )\nIndirect expenses 118,001 (a) 118,001\nLoss from operations $ (192,287 )\n(a) Components of other\nChange in fair value of contingent consideration liability (104,339 )\nGoodwill impairment 112,347\nIPR&D impairment 107,800\nAmortization 2,193\nTotal other $ 118,001\nCell BioBanking Degenerative Other Total\nYear Ended December 31, 2022\nCell BioBanking Degenerative Other Total\nNet revenues $ — $ 5,512 $ 12,463 $ — $ 17,975\nGross profit — 1,976 (3,666 ) — (1,690 )\nDirect expenses 75,379 1,699 10,859 56,261 144,198\nSegment contribution (75,379 ) 277 (14,525 ) (56,261 ) (145,888 )\nIndirect expenses (120,288 ) (b) (120,288 )\nLoss from operations $ (25,600 )\n(b) Components of other\nChange in fair value of contingent consideration liability (126,277 )\nChange in fair value of contingent stock consideration 186\nGoodwill impairment 3,610\nAmortization 2,193\nTotal other $ (120,288 ) "]

{"sheet":"Nature of Business (Details Nar","index":41,"n_rows":20,"n_cols":10,"rows_kept":20,"merged":[[0,0,1,0],[0,2,0,3],[0,4,0,5],[0,6,0,7]]}
["Nature of Business (Details Narrative) $ / shares in Units, $ in Thousands",null,"3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Feb. 22, 2024 $ / shares","Sep. 30, 2024 USD ($) $ / shares","Sep. 30, 2023 USD ($)","Sep. 30, 2024 USD ($) $ / shares","Sep. 30, 2023 USD ($)","Dec. 31, 2023 USD ($) ft² $ / shares","Dec. 31, 2022 USD ($) $ / shares","Nov. 25, 2024 $ / shares","Jul. 29, 2024 USD ($)"]
["Date of incorporation"," "," "," ","Aug. 24,  2018"," ","Aug. 24,  2018"," "," "," "]
["Common stock, par value | $ / shares"," ",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}," "," "]
["Area of building | ft²"," "," "," "," "," ",{"v":147215,"d":"147,215 "}," "," "," "]
["Net operating loss"," ",{"v":11527,"d":"$ 11,527"},{"v":99256,"d":"$ 99,256"},{"v":29078,"d":"$ 29,078"},{"v":205602,"d":"$ 205,602"},{"v":192287,"d":"$ 192,287"},{"v":25600,"d":"$ 25,600"}," "," "]
["Net cash used in operating activities"," "," "," ",{"v":7995,"d":"7,995 "},{"v":34344,"d":"$ 34,344"},{"v":38685,"d":"38,685 "},{"v":137876,"d":"137,876 "}," "," "]
["Accumulated deficit"," ",{"v":886390,"d":"886,390 "}," ",{"v":886390,"d":"886,390 "}," ",{"v":841791,"d":"841,791 "},{"v":645496,"d":"$ 645,496"}," "," "]
["Debt outstanding"," ",{"v":42610,"d":"42,610 "}," ",{"v":42610,"d":"42,610 "}," ",{"v":39240,"d":"$ 39,240"}," "," ",{"v":42700,"d":"$ 42,700"}]
["Debt outstanding"," ",{"v":46050,"d":"$ 46,050"}," ",{"v":46050,"d":"$ 46,050"}," "," "," "," "," "]
["Forecast [Member]"," "," "," "," "," "," "," "," "," "]
["Unrestricted cash and cash equivalent"," "," "," "," "," "," "," "," ",{"v":593,"d":"$ 593"}]
["Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares"," "," "," "," "," "," "," ",{"v":0.0001,"d":"$ 0.0001"}," "]
["Common Class A [Member]"," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}," "," "]
["Reverse stock split ratio","1-for-10"," "," "," "," "," "," "," "," "]
["Common Class A [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares",{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "," "," "," "]
["Reverse stock split ratio","1-for-10"," "," "," "," "," "," "," "," "]

{"sheet":"Schedule of Property and Equipm","index":42,"n_rows":22,"n_cols":2,"rows_kept":22}
["Schedule of Property and Equipment Estimated Useful Life (Details)","Dec. 31, 2023"]
["Building [Member]"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property and equipment expected useful lives","26 years"]
["Office Equipment And Furniture [Member] | Minimum [Member]"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property and equipment expected useful lives","5 years"]
["Furniture and Fixtures [Member] | Maximum [Member]"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property and equipment expected useful lives","7 years"]
["Equipment [Member]"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property and equipment expected useful lives","5 years"]
["Computer Equipment [Member]"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property and equipment expected useful lives","3 years"]
["Software Development [Member]"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property and equipment expected useful lives","3 years"]
["Leasehold Improvements [Member]"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]","Useful Life, Shorter of Lease Term or Asset Utility [Member]"]

{"sheet":"Schedule of Basic and Diluted N","index":43,"n_rows":10,"n_cols":7,"rows_kept":10,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[0,5,0,6]]}
["Schedule of Basic and Diluted Net Income Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands","3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Accounting Policies [Abstract]"," "," "," "," "," "," "]
["Net (loss) income",{"v":-16098,"d":"$ (16,098)"},{"v":-93876,"d":"$ (93,876)"},{"v":-44599,"d":"$ (44,599)"},{"v":-205842,"d":"$ (205,842)"},{"v":-196295,"d":"$ (196,295)"},{"v":14192,"d":"$ 14,192"}]
["Weighted average shares outstanding, basic",{"v":21976339,"d":"21,976,339 "},{"v":18831713,"d":"18,831,713 "},{"v":21756498,"d":"21,756,498 "},{"v":17353605,"d":"17,353,605 "},{"v":17813044,"d":"17,813,044 "},{"v":13990703,"d":"13,990,703 "}]
["Weighted average dilutive stock options"," "," "," "," "," ",{"v":958602,"d":"958,602 "}]
["Weighted average restricted stock units"," "," "," "," "," ",{"v":33697,"d":"33,697 "}]
["Weighted average shares outstanding, diluted",{"v":21976339,"d":"21,976,339 "},{"v":18831713,"d":"18,831,713 "},{"v":21756498,"d":"21,756,498 "},{"v":17353605,"d":"17,353,605 "},{"v":17813044,"d":"17,813,044 "},{"v":14983002,"d":"14,983,002 "}]
["Net (loss) income, basic",{"v":-0.73,"d":"$ (0.73)"},{"v":-4.98,"d":"$ (4.98)"},{"v":-2.05,"d":"$ (2.05)"},{"v":-11.86,"d":"$ (11.86)"},{"v":-11.02,"d":"$ (11.02)"},{"v":1.01,"d":"$ 1.01"}]
["Net (loss) income, diluted",{"v":-0.73,"d":"$ (0.73)"},{"v":-4.98,"d":"$ (4.98)"},{"v":-2.05,"d":"$ (2.05)"},{"v":-11.86,"d":"$ (11.86)"},{"v":-11.02,"d":"$ (11.02)"},{"v":0.95,"d":"$ 0.95"}]

{"sheet":"Schedule of Potentially Dilutiv","index":44,"n_rows":16,"n_cols":5,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Schedule of Potentially Dilutive Securities (Details) - shares","9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":15929600,"d":"15,929,600 "},{"v":13740797,"d":"13,740,797 "},{"v":11263827,"d":"11,263,827 "},{"v":5342746,"d":"5,342,746 "}]
["Share-Based Payment Arrangement, Option [Member]"," "," "," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":3455049,"d":"3,455,049 "},{"v":2961438,"d":"2,961,438 "},{"v":2820187,"d":"2,820,187 "},{"v":1239219,"d":"1,239,219 "}]
["Restricted Stock Units (RSUs) [Member]"," "," "," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":327359,"d":"327,359 "},{"v":878555,"d":"878,555 "},{"v":823332,"d":"823,332 "},{"v":128590,"d":"128,590 "}]
["Warrant [Member]"," "," "," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":10905901,"d":"10,905,901 "},{"v":7070627,"d":"7,070,627 "},{"v":7070627,"d":"7,070,627 "},{"v":3345836,"d":"3,345,836 "}]
["Convertible Debt Securities [Member]"," "," "," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":1241291,"d":"1,241,291 "},{"v":2830177,"d":"2,830,177 "},{"v":549681,"d":"549,681 "},{"v":629101,"d":"629,101 "}]

{"sheet":"Summary of Significant Accoun_4","index":45,"n_rows":67,"n_cols":10,"rows_kept":67,"merged":[[0,0,1,0],[0,1,0,5],[0,6,0,7],[0,8,0,9]]}
["Summary of Significant Accounting Policies (Details Narrative)","3 Months Ended",{"$nulls":4},"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024 USD ($)","Sep. 30, 2023 USD ($)","Jun. 30, 2023 USD ($)","Mar. 31, 2023 USD ($)","Dec. 31, 2022 USD ($)","Sep. 30, 2024 USD ($) Integer Segment","Sep. 30, 2023 USD ($)","Dec. 31, 2023 USD ($) Integer","Dec. 31, 2022 USD ($)"]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Restricted cash",{"v":10163000,"d":"$ 10,163,000"}," "," "," ",{"v":14836000,"d":"$ 14,836,000"},{"v":10163000,"d":"$ 10,163,000"}," ",{"v":9936000,"d":"$ 9,936,000"},{"v":14836000,"d":"$ 14,836,000"}]
["Indefinite-lived IPR&D"," "," "," "," "," "," ",{"v":107800000,"d":"$ 107,800,000"},{"v":107800000,"d":"$ 107,800,000"}," "]
["Operating segments"," "," "," "," "," ",{"v":3,"d":"3 "}," ",{"v":3,"d":"3 "}," "]
["Goodwill impairment"," ",{"v":82714000,"d":"$ 82,714,000"},{"v":0,"d":"$ 0"},{"v":29633000,"d":"$ 29,633,000"},{"v":3610000,"d":"3,610,000 "}," ",{"v":112347000,"d":"112,347,000 "},{"v":112347000,"d":"$ 112,347,000"},{"v":3610000,"d":"3,610,000 "}]
["Accounts receivable",{"v":6059000,"d":"$ 6,059,000"}," "," "," ",{"v":1789000,"d":"1,789,000 "},{"v":6059000,"d":"$ 6,059,000"}," ",{"v":5837000,"d":"5,837,000 "},{"v":1789000,"d":"1,789,000 "}]
["Marketing and advertising expenses"," "," "," "," "," "," "," ",{"v":44000,"d":"44,000 "},{"v":163000,"d":"163,000 "}]
["Grant monies"," "," "," "," "," "," "," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Instrument-specific credit risk income"," "," "," "," "," "," ",{"v":2541000,"d":"2,541,000 "},{"v":146000,"d":"146,000 "},{"v":20000,"d":"20,000 "}]
["Accumulated other comprehensive income"," "," "," "," "," "," ",{"v":155000,"d":"155,000 "},{"v":155000,"d":"$ 155,000"},{"v":11000,"d":"11,000 "}]
["Tax authority percentage"," "," "," "," "," "," "," ",{"v":0.5,"d":"50%"}," "]
["Business segments | Integer"," "," "," "," "," ",{"v":3,"d":"3 "}," ",{"v":3,"d":"3 "}," "]
["Instrument-specific credit risk income"," "," "," "," "," "," "," ",{"v":2000,"d":"$ 2,000"}," "]
["Income (loss) from allocated to warrants"," "," "," "," "," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}," "," "]
["Change In Accounting Principle Accounting Standards Update Adopted","true"," "," "," "," ","true"," "," "," "]
["Accounting Standards Update [Extensible Enumeration]"," "," "," "," "," ","Accounting Standards Update [Extensible Enumeration]"," "," "," "]
["Change In Accounting Principle Accounting Standards Update Adoption Date","Jan.  01,  2023"," "," "," "," ","Jan.  01,  2023"," "," "," "]
["Change In Accounting Principle Accounting Standards Update Immaterial Effect","true"," "," "," "," ","true"," "," "," "]
["One Customer [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Accounts receivable"," "," "," "," ",{"v":1762000,"d":"1,762,000 "}," "," ",{"v":2349000,"d":"$ 2,349,000"},{"v":1762000,"d":"$ 1,762,000"}]
["One Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage"," "," "," "," "," "," "," ",{"v":0.23,"d":"23%"}," "]
["One Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage"," "," "," "," "," "," "," ",{"v":0.14,"d":"14%"}," "]
["Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage"," "," "," "," "," "," "," ",{"v":0.18,"d":"18%"},{"v":0.38,"d":"38%"}]
["Customer A [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage"," "," "," "," "," "," "," "," ",{"v":0.11,"d":"11%"}]
["Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage"," "," "," "," "," ",{"v":0.33,"d":"33%"}," ",{"v":0.63,"d":"63%"},{"v":0.33,"d":"33%"}]
["Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage"," "," "," "," "," "," "," ",{"v":0.13,"d":"13%"},{"v":0.37,"d":"37%"}]
["Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage"," ",{"v":0.15,"d":"15%"}," "," "," ",{"v":0.15,"d":"15%"},{"v":0.21,"d":"21%"}," "," "]
["Minimum [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Contracted storage periods"," "," "," "," "," "," "," ","18 years"," "]
["Pay over time for a period"," "," "," "," "," "," "," ","1 month"," "]
["Minimum [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "," "]
["Minimum [Member] | Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Concentration percentage"," "," "," "," "," ",{"v":0.1,"d":"10%"}," ",{"v":0.1,"d":"10%"}," "]
["Maximum [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Contracted storage periods"," "," "," "," "," "," "," ","25 years"," "]
["Pay over time for a period"," "," "," "," "," "," "," ","24 months"," "]
["Biovance 3L [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Accounts receivable"," "," "," "," ",{"v":0,"d":"$ 0"}," "," ",{"v":3270000,"d":"$ 3,270,000"},{"v":0,"d":"$ 0"}]
["Cell Therapy [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Goodwill impairment"," "," "," "," "," "," "," ",{"v":112347000,"d":"$ 112,347,000"}," "]
["Degenerative Disease [Member]"," "," "," "," "," "," "," "," "," "]
["Product Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Goodwill impairment"," "," "," "," "," "," "," "," ",{"v":3610000,"d":"$ 3,610,000"}]

{"sheet":"Schedule of Financial Assets an","index":46,"n_rows":60,"n_cols":4,"rows_kept":60}
["Schedule of Financial Assets and Liabilities Measures at Fair Value (Details) - USD ($) $ in Thousands","Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Assets:"," "," "," "]
["Cash equivalents – money market funds"," "," ",{"v":12174,"d":"$ 12,174"}]
["Convertible note receivable"," ",{"v":2072,"d":"2,072 "},{"v":2514,"d":"2,514 "}]
["Total fair value assets"," ",{"v":2072,"d":"2,072 "},{"v":14688,"d":"14,688 "}]
["Liabilities:"," "," "," "]
["Acquisition-related contingent consideration obligations",{"v":1606,"d":"1,606 "},{"v":1606,"d":"1,606 "},{"v":105945,"d":"105,945 "}]
["Contingent stock consideration",{"v":27,"d":"27 "},{"v":27,"d":"27 "},{"v":186,"d":"186 "}]
["Short-term debt - Yorkville",{"v":3695,"d":"3,695 "},{"v":17223,"d":"17,223 "},{"v":37603,"d":"37,603 "}]
["Warrant liability - July 2023 Registered Direct Warrants",{"v":1748,"d":"1,748 "},{"v":1529,"d":"1,529 "}," "]
["Warrant liability - April 2023 Registered Direct Warrants",{"v":1670,"d":"1,670 "},{"v":1487,"d":"1,487 "}," "]
["Warrant liability - May 2022 PIPE Warrants",{"v":809,"d":"809 "},{"v":708,"d":"708 "},{"v":1402,"d":"1,402 "}]
["Warrant liability - Sponsor Warrants",{"v":32,"d":"32 "},{"v":60,"d":"60 "},{"v":1190,"d":"1,190 "}]
["Warrant liability - Public Warrants",{"v":144,"d":"144 "},{"v":575,"d":"575 "},{"v":1006,"d":"1,006 "}]
["Total fair value liabilities",{"v":9731,"d":"9,731 "},{"v":23215,"d":"23,215 "},{"v":147332,"d":"147,332 "}]
["Fair Value, Inputs, Level 1 [Member]"," "," "," "]
["Assets:"," "," "," "]
["Cash equivalents – money market funds"," "," ",{"v":12174,"d":"12,174 "}]
["Convertible note receivable"," "," "," "]
["Total fair value assets"," "," ",{"v":12174,"d":"12,174 "}]
["Liabilities:"," "," "," "]
["Acquisition-related contingent consideration obligations"," "," "," "]
["Contingent stock consideration"," "," "," "]
["Short-term debt - Yorkville"," "," "," "]
["Warrant liability - July 2023 Registered Direct Warrants"," "," "," "]
["Warrant liability - April 2023 Registered Direct Warrants"," "," "," "]
["Warrant liability - May 2022 PIPE Warrants"," "," "," "]
["Warrant liability - Sponsor Warrants"," "," "," "]
["Warrant liability - Public Warrants",{"v":144,"d":"144 "},{"v":575,"d":"575 "},{"v":1006,"d":"1,006 "}]
["Total fair value liabilities",{"v":144,"d":"144 "},{"v":575,"d":"575 "},{"v":1006,"d":"1,006 "}]
["Fair Value, Inputs, Level 2 [Member]"," "," "," "]
["Assets:"," "," "," "]
["Cash equivalents – money market funds"," "," "," "]
["Convertible note receivable"," "," "," "]
["Total fair value assets"," "," "," "]
["Liabilities:"," "," "," "]
["Acquisition-related contingent consideration obligations"," "," "," "]
["Contingent stock consideration"," "," "," "]
["Short-term debt - Yorkville"," "," "," "]
["Warrant liability - July 2023 Registered Direct Warrants"," "," "," "]
["Warrant liability - April 2023 Registered Direct Warrants"," "," "," "]
["Warrant liability - May 2022 PIPE Warrants"," "," "," "]
["Warrant liability - Sponsor Warrants"," "," "," "]
["Warrant liability - Public Warrants"," "," "," "]
["Total fair value liabilities"," "," "," "]
["Fair Value, Inputs, Level 3 [Member]"," "," "," "]
["Assets:"," "," "," "]
["Cash equivalents – money market funds"," "," "," "]
["Convertible note receivable"," ",{"v":2072,"d":"2,072 "},{"v":2514,"d":"2,514 "}]
["Total fair value assets"," ",{"v":2072,"d":"2,072 "},{"v":2514,"d":"2,514 "}]
["Liabilities:"," "," "," "]
["Acquisition-related contingent consideration obligations",{"v":1606,"d":"1,606 "},{"v":1606,"d":"1,606 "},{"v":105945,"d":"105,945 "}]
["Contingent stock consideration",{"v":27,"d":"27 "},{"v":27,"d":"27 "},{"v":186,"d":"186 "}]
["Short-term debt - Yorkville",{"v":3695,"d":"3,695 "},{"v":17223,"d":"17,223 "},{"v":37603,"d":"37,603 "}]
["Warrant liability - July 2023 Registered Direct Warrants",{"v":1748,"d":"1,748 "},{"v":1529,"d":"1,529 "}," "]
["Warrant liability - April 2023 Registered Direct Warrants",{"v":1670,"d":"1,670 "},{"v":1487,"d":"1,487 "}," "]
["Warrant liability - May 2022 PIPE Warrants",{"v":809,"d":"809 "},{"v":708,"d":"708 "},{"v":1402,"d":"1,402 "}]
["Warrant liability - Sponsor Warrants",{"v":32,"d":"32 "},{"v":60,"d":"60 "},{"v":1190,"d":"1,190 "}]
["Warrant liability - Public Warrants"," "," "," "]
["Total fair value liabilities",{"v":9587,"d":"$ 9,587"},{"v":22640,"d":"$ 22,640"},{"v":146326,"d":"$ 146,326"}]

{"sheet":"Schedule of Reconciliation of C","index":47,"n_rows":8,"n_cols":4,"rows_kept":8,"merged":[[0,0,1,0],[0,2,0,3]]}
["Schedule of Reconciliation of Contingent Consideration Obligations (Details) - USD ($) $ in Thousands","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Fair Value Disclosures [Abstract]"," "," "," "]
["Beginning balance",{"v":1606,"d":"$ 1,606"},{"v":105945,"d":"$ 105,945"},{"v":232222,"d":"$ 232,222"}]
["Net transfers into (out of) Level 3"," "," "," "]
["Purchases, settlements and other net"," "," "," "]
["Fair value adjustments"," ",{"v":-104339,"d":"(104,339)"},{"v":-126277,"d":"(126,277)"}]
["Ending balance",{"v":1606,"d":"$ 1,606"},{"v":1606,"d":"$ 1,606"},{"v":105945,"d":"$ 105,945"}]

{"sheet":"Schedule of Roll-forward of the","index":48,"n_rows":11,"n_cols":4,"rows_kept":11,"merged":[[0,0,1,0],[0,2,0,3]]}
["Schedule of Roll-forward of the Aggregate Fair Values of Company’s Warrant Liabilities (Details) - USD ($) $ in Thousands","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Fair Value Disclosures [Abstract]"," "," "," "]
["Fair value, Beginning Balance",{"v":3784,"d":"$ 3,784"},{"v":3598,"d":"$ 3,598"},{"v":25962,"d":"$ 25,962"}]
["May 2022 PIPE warrant issuance"," "," ",{"v":19745,"d":"19,745 "}]
["April 2023 Registered Direct warrant issuance"," ",{"v":4280,"d":"4,280 "}," "]
["July 2023 Registered Direct warrant issuance"," ",{"v":2645,"d":"2,645 "}," "]
["Gain recognized in earnings from change in fair value",{"v":1587,"d":"1,587 "},{"v":-6164,"d":"(6,164)"},{"v":-42109,"d":"(42,109)"}]
["Fair Value, Ending Balance",{"v":4259,"d":"4,259 "},{"v":3784,"d":"3,784 "},{"v":3598,"d":"3,598 "}]
["Fair value, Beginning Balance",{"v":4359,"d":"$ 4,359"},{"v":3598,"d":"3,598 "}," "]
["Fair Value, Ending Balance"," ",{"v":4359,"d":"$ 4,359"},{"v":3598,"d":"$ 3,598"}]

{"sheet":"Schedule of Fair Value of Liabi","index":49,"n_rows":16,"n_cols":3,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2]]}
["Schedule of Fair Value of Liability Warrants (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2023","Dec. 31, 2022"]
["Class of Warrant or Right [Line Items]"," "," "]
["Total",{"v":4359,"d":"$ 4,359"},{"v":3598,"d":"$ 3,598"}]
["Public Warrants [Member]"," "," "]
["Class of Warrant or Right [Line Items]"," "," "]
["Total",{"v":575,"d":"575 "},{"v":1006,"d":"1,006 "}]
["Sponsors Warrants [Member]"," "," "]
["Class of Warrant or Right [Line Items]"," "," "]
["Total",{"v":60,"d":"60 "},{"v":1190,"d":"1,190 "}]
["Two Thousand Twenty Three Registered Direct Warrants [Member]"," "," "]
["Class of Warrant or Right [Line Items]"," "," "]
["Total",{"v":3016,"d":"3,016 "}," "]
["May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member]"," "," "]
["Class of Warrant or Right [Line Items]"," "," "]
["Total",{"v":708,"d":"$ 708"},{"v":1402,"d":"$ 1,402"}]

{"sheet":"Schedule of Sponsor Warrants (D","index":50,"n_rows":17,"n_cols":6,"rows_kept":17}
["Schedule of Sponsor Warrants (Details)","Sep. 30, 2024 $ / shares","Mar. 13, 2024 $ / shares","Dec. 31, 2023 $ / shares","Apr. 10, 2023 $ / shares","Dec. 31, 2022 $ / shares"]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "]
["Exercise price"," ",{"v":8.1,"d":"$ 8.10"}," ",{"v":7.5,"d":"$ 7.50"}," "]
["Sponsors Warrants [Member]"," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "]
["Common share price",{"v":2.97,"d":"$ 2.97"}," ",{"v":2.47,"d":"$ 2.47"}," ",{"v":12.9,"d":"$ 12.90"}]
["Exercise price",{"v":115,"d":"$ 115"}," ",{"v":115,"d":"$ 115"}," ",{"v":115,"d":"$ 115"}]
["Term (years)","1 year 9 months 18 days"," ","2 years 6 months"," ","3 years 6 months"]
["Sponsors Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]"," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "]
["Warrant and right outstanding measurement input",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}]
["Sponsors Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]"," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "]
["Warrant and right outstanding measurement input",3.66," ",4.12," ",4.16]
["Sponsors Warrants [Member] | Measurement Input, Price Volatility [Member]"," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "]
["Warrant and right outstanding measurement input",105.9," ",100.7," ",{"v":75,"d":"75 "}]

{"sheet":"Schedule of May 2022 PIPE Warra","index":51,"n_rows":46,"n_cols":7,"rows_kept":46}
["Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)","Sep. 30, 2024 $ / shares","Mar. 13, 2024 $ / shares","Dec. 31, 2023 $ / shares","Jul. 31, 2023 $ / shares","Apr. 10, 2023 $ / shares","Dec. 31, 2022 $ / shares"]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Exercise price"," ",{"v":8.1,"d":"$ 8.10"}," "," ",{"v":7.5,"d":"$ 7.50"}," "]
["Minimum [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Exercise price"," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "]
["Maximum [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Exercise price"," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Common share price",{"v":2.97,"d":"$ 2.97"}," ",{"v":2.47,"d":"$ 2.47"}," "," ",{"v":12.9,"d":"$ 12.90"}]
["Exercise price"," "," "," "," "," ",{"v":82.5,"d":"$ 82.5"}]
["Term (years)"," "," "," "," "," ","4 years 4 months 24 days"]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Warrant and right outstanding measurement input",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}," "," ",{"v":0,"d":"0 "}]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Warrant and right outstanding measurement input"," "," ",{"v":4.6,"d":"4.60"}," "," ",3.99]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member] | Measurement Input, Price Volatility [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Warrant and right outstanding measurement input"," "," ",{"v":97,"d":"97 "}," "," ",81.2]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member] | Minimum [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Exercise price",{"v":3.5,"d":"$ 3.50"}," ",{"v":3.5,"d":"$ 3.50"}," "," "," "]
["Term (years)"," "," ","5 years 10 days"," "," "," "]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Warrant and right outstanding measurement input",97.1," ",100.1," "," "," "]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member] | Maximum [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Exercise price",{"v":7.5,"d":"$ 7.50"}," ",{"v":7.5,"d":"$ 7.50"}," "," "," "]
["Term (years)"," "," ","5 years 4 months 2 days"," "," "," "]
["May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Warrant and right outstanding measurement input",98.1," ",100.7," "," "," "]
["May Two Thousand Twenty Two Private Investmentin Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Warrant and right outstanding measurement input",3.58," ",3.84," "," "," "]
["May Two Thousand Twenty Two Private Investmentin Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrants [Member] | Minimum [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Term (years)","4 years 10 days"," ","4 years 9 months 10 days"," "," "," "]
["May Two Thousand Twenty Two Private Investmentin Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrants [Member] | Maximum [Member]"," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "]
["Term (years)","4 years 4 months 2 days"," ","5 years 1 month 2 days"," "," "," "]

{"sheet":"Schedule of Convertible Note Va","index":52,"n_rows":17,"n_cols":3,"rows_kept":17,"merged":[[0,0,1,0],[0,1,0,2]]}
["Schedule of Convertible Note Valuation Model (Details) - USD ($) $ / shares in Units, $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2023","Dec. 31, 2022"]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "]
["Face value",{"v":4000,"d":"$ 4,000"},{"v":4000,"d":"$ 4,000"}]
["Stock price",{"v":0.23,"d":"$ 0.23"}," "]
["Measurement Input, Risk Free Interest Rate [Member]"," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "]
["Risk-free interest rate",{"v":0.0547,"d":"5.47%"},{"v":0.0473,"d":"4.73%"}]
["Minimum [Member]"," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "]
["Coupon rate",{"v":0.12,"d":"12%"},{"v":0.12,"d":"12%"}]
["Term (years)","6 months 3 days","1 year 3 days"]
["Maximum [Member]"," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "]
["Coupon rate",{"v":0.17,"d":"17%"},{"v":0.17,"d":"17%"}]
["Stock price",{"v":0.2,"d":"$ 0.2"},{"v":0.2,"d":"$ 0.2"}]
["Term (years)","2 years 5 months 12 days","3 years 5 months 12 days"]

{"sheet":"Schedule of Reconciliation of t","index":53,"n_rows":13,"n_cols":5,"rows_kept":13,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details) - USD ($) $ in Thousands","9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Business Acquisition, Contingent Consideration [Line Items]"," "," "," "," "]
["Net transfers into (out of) Level 3"," "," "," "," "]
["Purchases, settlements and other net"," "," "," "," "]
["Fair value adjustments"," ",{"v":-159,"d":"$ (159)"},{"v":-159,"d":"(159)"},{"v":186,"d":"186 "}]
["Contingent Stock Consideration [Member]"," "," "," "," "]
["Business Acquisition, Contingent Consideration [Line Items]"," "," "," "," "]
["Beginning balance",{"v":27,"d":"27 "},{"v":186,"d":"$ 186"},{"v":186,"d":"186 "}," "]
["Net transfers into (out of) Level 3"," "," "," "," "]
["Purchases, settlements and other net"," "," "," "," "]
["Fair value adjustments"," "," ",{"v":-159,"d":"(159)"}," "]
["Ending balance",{"v":27,"d":"$ 27"}," ",{"v":27,"d":"$ 27"},{"v":186,"d":"$ 186"}]

{"sheet":"Schedule of Reconciliation of Y","index":54,"n_rows":16,"n_cols":3,"rows_kept":16,"merged":[[0,0,1,0]]}
["Schedule of Reconciliation of Yorkville Debt Measured on a Measured Basis (Details) - USD ($) $ in Thousands","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Line of Credit Facility [Line Items]"," "," "]
["Balance",{"v":17223,"d":"$ 17,223"},{"v":37603,"d":"$ 37,603"}]
["Principal repayments",{"v":-2072,"d":"(2,072)"}," "]
["Balance"," ",{"v":17223,"d":"17,223 "}]
["Yorkville [Member]"," "," "]
["Line of Credit Facility [Line Items]"," "," "]
["Balance",{"v":17223,"d":"17,223 "},{"v":37603,"d":"37,603 "}]
["Conversion of debt into common shares"," ",{"v":-4599,"d":"(4,599)"}]
["Principal repayments",{"v":-17374,"d":"(17,374)"},{"v":-16811,"d":"(16,811)"}]
["Issuance of convertible promissory note",{"v":3150,"d":"3,150 "}," "]
["Fair value adjustment through earnings",{"v":694,"d":"694 "},{"v":354,"d":"354 "}]
["Fair value adjustment through accumulated other comprehensive income",{"v":2,"d":"2 "},{"v":-146,"d":"(146)"}]
["Fair value adjustment through interest accrual"," ",{"v":822,"d":"822 "}]
["Balance",{"v":3695,"d":"$ 3,695"},{"v":17223,"d":"$ 17,223"}]

{"sheet":"Schedule of Yorkville Short-ter","index":55,"n_rows":14,"n_cols":4,"rows_kept":14,"merged":[[0,0,1,0]]}
["Schedule of Yorkville Short-term Debt Valuation Model (Details)",null,"9 Months Ended","12 Months Ended"]
[null,"Mar. 13, 2024 $ / shares","Sep. 30, 2024 $ / shares","Dec. 31, 2022 $ / shares"]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "]
["Common share price",{"v":5.79,"d":"$ 5.79"},{"v":2.97,"d":"$ 2.97"},{"v":12.9,"d":"$ 12.90"}]
["Credit spread",{"v":8.5,"d":"8.50"},{"v":8,"d":"8 "},13.71]
["Volatility",{"v":0,"d":"0%"},{"v":0,"d":"0%"},{"v":0,"d":"0%"}]
["Term (years)","1 year","5 months 12 days","8 months 15 days"]
["Discount yield"," "," ",{"v":0.1846,"d":"18.46%"}]
["Measurement Input, Risk Free Interest Rate [Member]"," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "]
["Volatility",{"v":0.049,"d":"4.90%"},{"v":0.043,"d":"4.30%"},{"v":0.0475,"d":"4.75%"}]
["Measurement Input, Price Volatility [Member]"," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "]
["Volatility",{"v":0.5,"d":"50%"},{"v":0.5,"d":"50%"},{"v":0.45,"d":"45%"}]

{"sheet":"Fair Value of Financial Asset_3","index":56,"n_rows":27,"n_cols":9,"rows_kept":27,"merged":[[0,0,1,0],[0,3,0,4]]}
["Fair Value of Financial Assets and Liabilities (Details Narrative) - USD ($)",null,null,"12 Months Ended"]
[null,"Jun. 03, 2024","May 10, 2024","Dec. 31, 2023","Dec. 31, 2022","Sep. 30, 2024","Jul. 31, 2023","Apr. 10, 2023","Dec. 31, 2021"]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "," "," "]
["Fair value, assets, level 1 to level 2 transfers, amount"," "," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}," "," "," "," "]
["Fair value, assets, level 2 to level 1 transfers, amount"," "," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "," "," "," "]
["Fair value, assets, transfers into level 3, amount"," "," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "," "," "," "]
["Fair value, assets, transfers out of level 3, amount"," "," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "," "," "," "]
["Fair value of the warrant liabilities"," "," ",{"v":4359000,"d":"4,359,000 "}," "," "," "," "," "]
["Fair value of the warrant liabilities"," "," ",{"v":3784000,"d":"$ 3,784,000"},{"v":3598000,"d":"$ 3,598,000"},{"v":4259000,"d":"$ 4,259,000"},{"v":2645000,"d":"$ 2,645,000"},{"v":4280000,"d":"$ 4,280,000"},{"v":25962000,"d":"$ 25,962,000"}]
["Sanuwave Forbearance Agreement [Member] | Minimum [Member] | Letter Agreement [Member]"," "," "," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "," "," "]
["Forbearance extend period"," ","Feb. 28,  2024"," "," "," "," "," "," "]
["Increased total note payments"," ",{"v":2175000,"d":"$ 2,175,000"}," "," "," "," "," "," "]
["Initial note payment"," ",{"v":100000,"d":"$ 100,000"}," "," "," "," "," "," "]
["Second note payment",{"v":2075000,"d":"$ 2,075,000"}," "," "," "," "," "," "," "]
["Sanuwave Forbearance Agreement [Member] | Minimum [Member] | Subsequent Event [Member] | Letter Agreement [Member]"," "," "," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "," "," "]
["Forbearance extend period"," ","Feb. 28,  2024"," "," "," "," "," "," "]
["Increased total note payments"," ",{"v":2175000,"d":"$ 2,175,000"}," "," "," "," "," "," "]
["Initial note payment"," ",{"v":100000,"d":"100,000 "}," "," "," "," "," "," "]
["Second note payment"," ",{"v":2075000,"d":"$ 2,075,000"}," "," "," "," "," "," "]
["Sanuwave Forbearance Agreement [Member] | Maximum [Member] | Letter Agreement [Member]"," "," "," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "," "," "]
["Forbearance extend period"," ","Jun.  03,  2024"," "," "," "," "," "," "]
["Sanuwave Forbearance Agreement [Member] | Maximum [Member] | Subsequent Event [Member] | Letter Agreement [Member]"," "," "," "," "," "," "," "," "]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "," "," "," "," "," "," "]
["Forbearance extend period"," ","Jun.  03,  2024"," "," "," "," "," "," "]

{"sheet":"Schedule of Major Classes of In","index":57,"n_rows":10,"n_cols":5,"rows_kept":10}
["Schedule of Major Classes of Inventories (Details) - USD ($) $ in Thousands","Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022","Dec. 31, 2021"]
["Inventory Disclosure [Abstract]"," "," "," "," "]
["Raw materials",{"v":42,"d":"$ 42"},{"v":3081,"d":"$ 3,081"},{"v":7719,"d":"$ 7,719"}," "]
["Work in progress",{"v":10284,"d":"10,284 "},{"v":10696,"d":"10,696 "},{"v":12381,"d":"12,381 "}," "]
["Finished goods",{"v":8720,"d":"8,720 "},{"v":10922,"d":"10,922 "},{"v":9256,"d":"9,256 "}," "]
["Inventory, gross",{"v":19046,"d":"19,046 "},{"v":24699,"d":"24,699 "},{"v":29356,"d":"29,356 "}," "]
["Less: inventory reserves",{"v":-2239,"d":"(2,239)"},{"v":-2289,"d":"(2,289)"},{"v":-1099,"d":"(1,099)"},{"v":-48,"d":"$ (48)"}]
["Inventory, net",{"v":16807,"d":"16,807 "},{"v":22410,"d":"22,410 "},{"v":28257,"d":"28,257 "}," "]
["Inventory",{"v":3963,"d":"3,963 "},{"v":5753,"d":"5,753 "},{"v":5308,"d":"5,308 "}," "]
["Inventory, net of current portion",{"v":12844,"d":"$ 12,844"},{"v":16657,"d":"$ 16,657"},{"v":22949,"d":"$ 22,949"}," "]

{"sheet":"Schedule of Inventory Reserves ","index":58,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Schedule of Inventory Reserves (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2023","Dec. 31, 2022"]
["Inventory Disclosure [Abstract]"," "," "]
["Beginning balance",{"v":1099,"d":"$ 1,099"},{"v":48,"d":"$ 48"}]
["Additions for obsolete inventory",{"v":7627,"d":"7,627 "},{"v":1051,"d":"1,051 "}]
["Write-offs",{"v":-6437,"d":"(6,437)"}," "]
["Ending balance",{"v":2289,"d":"$ 2,289"},{"v":1099,"d":"$ 1,099"}]

{"sheet":"Inventory (Details Narrative)","index":59,"n_rows":9,"n_cols":3,"rows_kept":9}
["Inventory (Details Narrative) - USD ($) $ in Thousands","Dec. 31, 2023","Dec. 31, 2022"]
["Inventory [Line Items]"," "," "]
["Inventory impairment charge",{"v":5384,"d":"$ 5,384"},{"v":0,"d":"$ 0"}]
["Due To Lower Of Cost Or Market Adjustments For Work In Progress Goods [Member]"," "," "]
["Inventory [Line Items]"," "," "]
["Inventory impairment charge",{"v":2129,"d":"2,129 "}," "]
["Due To Lower Of Cost Or Market Adjustments For Finished Goods [Member]"," "," "]
["Inventory [Line Items]"," "," "]
["Inventory impairment charge",{"v":3255,"d":"$ 3,255"}," "]

{"sheet":"Schedule of Prepaid Expenses an","index":60,"n_rows":6,"n_cols":4,"rows_kept":6}
["Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands","Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Prepaid Expenses And Other Current Assets"," "," "," "]
["Prepaid clinical expenses"," ",{"v":688,"d":"$ 688"},{"v":5836,"d":"$ 5,836"}]
["Prepaid insurance expense"," ",{"v":678,"d":"678 "},{"v":377,"d":"377 "}]
["Other"," ",{"v":329,"d":"329 "},{"v":1049,"d":"1,049 "}]
["Prepaid expenses and other current assets",{"v":1636,"d":"$ 1,636"},{"v":1695,"d":"$ 1,695"},{"v":7262,"d":"$ 7,262"}]

{"sheet":"Schedule of Property and Equi_2","index":61,"n_rows":17,"n_cols":4,"rows_kept":17}
["Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands","Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Property, Plant and Equipment [Line Items]"," "," "," "]
["Property and equipment",{"v":95155,"d":"$ 95,155"},{"v":95106,"d":"$ 95,106"},{"v":95986,"d":"$ 95,986"}]
["Less: Accumulated depreciation and amortization",{"v":-31947,"d":"(31,947)"},{"v":-27278,"d":"(27,278)"},{"v":-20331,"d":"(20,331)"}]
["Property and equipment, net",{"v":63208,"d":"63,208 "},{"v":67828,"d":"67,828 "},{"v":75655,"d":"75,655 "}]
["Leasehold Improvements [Member]"," "," "," "]
["Property, Plant and Equipment [Line Items]"," "," "," "]
["Property and equipment",{"v":73211,"d":"73,211 "},{"v":73211,"d":"73,211 "},{"v":70113,"d":"70,113 "}]
["Laboratory And Production Equipment [Member]"," "," "," "]
["Property, Plant and Equipment [Line Items]"," "," "," "]
["Property and equipment",{"v":14093,"d":"14,093 "},{"v":14093,"d":"14,093 "},{"v":14433,"d":"14,433 "}]
["Machinery Equipment And Fixtures [Member]"," "," "," "]
["Property, Plant and Equipment [Line Items]"," "," "," "]
["Property and equipment",{"v":7781,"d":"7,781 "},{"v":7781,"d":"7,781 "},{"v":7780,"d":"7,780 "}]
["Construction in Progress [Member]"," "," "," "]
["Property, Plant and Equipment [Line Items]"," "," "," "]
["Property and equipment",{"v":70,"d":"$ 70"},{"v":21,"d":"$ 21"},{"v":3660,"d":"$ 3,660"}]

{"sheet":"Property and Equipment, Net (De","index":62,"n_rows":5,"n_cols":7,"rows_kept":5,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[0,5,0,6]]}
["Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands","3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Property, Plant and Equipment [Abstract]"," "," "," "," "," "," "]
["Depreciation expense"," "," "," "," ",{"v":7131,"d":"$ 7,131"},{"v":7243,"d":"$ 7,243"}]
["Depreciation and amortization expense",{"v":1519,"d":"$ 1,519"},{"v":1790,"d":"$ 1,790"},{"v":4669,"d":"$ 4,669"},{"v":5388,"d":"$ 5,388"}," "," "]

{"sheet":"Schedule Of Carrying Values Of ","index":63,"n_rows":21,"n_cols":3,"rows_kept":21,"merged":[[0,0,1,0],[0,1,0,2]]}
["Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2023","Dec. 31, 2022"]
["Indefinite-Lived Intangible Assets [Line Items]"," "," "]
["Balance at beginning of year",{"v":119694,"d":"$ 119,694"},{"v":123304,"d":"$ 123,304"}]
["Goodwill impairment",{"v":-112347,"d":"(112,347)"},{"v":-3610,"d":"(3,610)"}]
["Balance at beginning of year",{"v":7347,"d":"7,347 "},{"v":119694,"d":"119,694 "}]
["Cell Therapy [Member]"," "," "]
["Indefinite-Lived Intangible Assets [Line Items]"," "," "]
["Balance at beginning of year",{"v":112347,"d":"112,347 "},{"v":112347,"d":"112,347 "}]
["Goodwill impairment",{"v":-112347,"d":"(112,347)"}," "]
["Balance at beginning of year"," ",{"v":112347,"d":"112,347 "}]
["Degenerative Disease [Member]"," "," "]
["Indefinite-Lived Intangible Assets [Line Items]"," "," "]
["Balance at beginning of year"," ",{"v":3610,"d":"3,610 "}]
["Goodwill impairment"," ",{"v":-3610,"d":"(3,610)"}]
["Balance at beginning of year"," "," "]
["Biobanking [Member]"," "," "]
["Indefinite-Lived Intangible Assets [Line Items]"," "," "]
["Balance at beginning of year",{"v":7347,"d":"7,347 "},{"v":7347,"d":"7,347 "}]
["Goodwill impairment"," "," "]
["Balance at beginning of year",{"v":7347,"d":"$ 7,347"},{"v":7347,"d":"$ 7,347"}]

{"sheet":"Schedule of Intangible Assets, ","index":64,"n_rows":39,"n_cols":4,"rows_kept":39,"merged":[[0,0,1,0],[0,2,0,3]]}
["Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Amortizable intangible assets",{"v":23993,"d":"$ 23,993"},{"v":23993,"d":"$ 23,993"},{"v":23993,"d":"$ 23,993"}]
["Less: Accumulated amortization",{"v":-15069,"d":"(15,069)"},{"v":-13692,"d":"(13,692)"},{"v":-11499,"d":"(11,499)"}]
["Amortizable intangible assets, net",{"v":8924,"d":"8,924 "},{"v":10301,"d":"10,301 "},{"v":12494,"d":"12,494 "}]
["Acquired IPR&D product rights",{"v":700,"d":"$ 700"},{"v":700,"d":"$ 700"},{"v":108500,"d":"$ 108,500"}]
["Estimated useful lives","indefinite","indefinite","indefinite"]
["Intangible assets, net",{"v":9624,"d":"$ 9,624"},{"v":11001,"d":"$ 11,001"},{"v":120994,"d":"$ 120,994"}]
["Developed Technology Rights [Member]"," "," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Amortizable intangible assets",{"v":16810,"d":"16,810 "},{"v":16810,"d":"16,810 "},{"v":16810,"d":"16,810 "}]
["Less: Accumulated amortization",{"v":-8600,"d":"$ (8,600)"},{"v":-7722,"d":"$ (7,722)"},{"v":-6549,"d":"$ (6,549)"}]
["Developed Technology Rights [Member] | Minimum [Member]"," "," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Estimated useful lives","11 years","11 years","11 years"]
["Developed Technology Rights [Member] | Maximum [Member]"," "," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Estimated useful lives","16 years","16 years","16 years"]
["Customer Relationships [Member]"," "," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Amortizable intangible assets",{"v":2413,"d":"$ 2,413"},{"v":2413,"d":"$ 2,413"},{"v":2413,"d":"$ 2,413"}]
["Estimated useful lives","10 years","10 years","10 years"]
["Less: Accumulated amortization",{"v":-1898,"d":"$ (1,898)"},{"v":-1700,"d":"$ (1,700)"},{"v":-1435,"d":"$ (1,435)"}]
["Trademarks and Trade Names [Member]"," "," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Amortizable intangible assets",{"v":570,"d":"570 "},{"v":570,"d":"570 "},{"v":570,"d":"570 "}]
["Less: Accumulated amortization",{"v":-371,"d":"$ (371)"},{"v":-330,"d":"$ (330)"},{"v":-275,"d":"$ (275)"}]
["Trademarks and Trade Names [Member] | Minimum [Member]"," "," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Estimated useful lives","10 years","10 years","10 years"]
["Trademarks and Trade Names [Member] | Maximum [Member]"," "," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Estimated useful lives","13 years","13 years","13 years"]
["Reacquired Rights [Member]"," "," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "," "]
["Amortizable intangible assets",{"v":4200,"d":"$ 4,200"},{"v":4200,"d":"$ 4,200"},{"v":4200,"d":"$ 4,200"}]
["Estimated useful lives","6 years","6 years","6 years"]
["Less: Accumulated amortization",{"v":-4200,"d":"$ (4,200)"},{"v":-3940,"d":"$ (3,940)"},{"v":-3240,"d":"$ (3,240)"}]

{"sheet":"Schedule of Aggregate Amortizat","index":65,"n_rows":7,"n_cols":2,"rows_kept":7}
["Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details) $ in Thousands","Dec. 31, 2023 USD ($)"]
["Goodwill and Intangible Assets Disclosure [Abstract]"," "]
["2024",{"v":1753,"d":"$ 1,753"}]
["2025",{"v":1493,"d":"1,493 "}]
["2026",{"v":1356,"d":"1,356 "}]
["2027",{"v":1258,"d":"1,258 "}]
["2028",{"v":1208,"d":"$ 1,208"}]

{"sheet":"Goodwill and Intangible Asset_3","index":66,"n_rows":14,"n_cols":11,"rows_kept":14,"merged":[[0,0,1,0],[0,1,0,5],[0,6,0,7],[0,8,0,9]]}
["Goodwill and Intangible Assets, Net (Details Narrative)","3 Months Ended",{"$nulls":4},"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024 USD ($)","Sep. 30, 2023 USD ($)","Jun. 30, 2023 USD ($)","Mar. 31, 2023 USD ($)","Dec. 31, 2022 USD ($)","Sep. 30, 2024 USD ($)","Sep. 30, 2023 USD ($)","Dec. 31, 2023 USD ($) Integer","Dec. 31, 2022 USD ($)","Dec. 31, 2021 USD ($)"]
["Indefinite-Lived Intangible Assets [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Number of reporting units | Integer"," "," "," "," "," "," "," ",{"v":3,"d":"3 "}," "," "]
["Goodwill, impairment loss"," ",{"v":82714000,"d":"$ 82,714,000"},{"v":0,"d":"$ 0"},{"v":29633000,"d":"$ 29,633,000"},{"v":3610000,"d":"$ 3,610,000"}," ",{"v":112347000,"d":"$ 112,347,000"},{"v":112347000,"d":"$ 112,347,000"},{"v":3610000,"d":"$ 3,610,000"}," "]
["Amortization of acquired intangible assets",{"v":375000,"d":"375,000 "},{"v":553000,"d":"553,000 "}," "," "," ",{"v":1377000,"d":"1,377,000 "},{"v":1640000,"d":"1,640,000 "},{"v":2193000,"d":"2,193,000 "},{"v":2193000,"d":"2,193,000 "}," "]
["Goodwill",{"v":7347000,"d":"7,347,000 "}," "," "," ",{"v":119694000,"d":"$ 119,694,000"},{"v":7347000,"d":"7,347,000 "}," ",{"v":7347000,"d":"7,347,000 "},{"v":119694000,"d":"119,694,000 "},{"v":123304000,"d":"$ 123,304,000"}]
["Impairment of intangible assets",{"v":0,"d":"$ 0"}," "," "," "," ",{"v":0,"d":"$ 0"}," "," "," "," "]
["Other [Member]"," "," "," "," "," "," "," "," "," "," "]
["Indefinite-Lived Intangible Assets [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Goodwill, impairment loss"," ",{"v":82714000,"d":"82,714,000 "}," "," "," "," ",{"v":112347000,"d":"112,347,000 "},{"v":112347000,"d":"$ 112,347,000"},{"v":3610000,"d":"$ 3,610,000"}," "]
["Cell Therapy Clinical Trial Update [Member] | In Process Research and Development [Member]"," "," "," "," "," "," "," "," "," "," "]
["Indefinite-Lived Intangible Assets [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Impairment of intangible assets"," ",{"v":107800000,"d":"$ 107,800,000"}," "," "," "," ",{"v":107800000,"d":"$ 107,800,000"}," "," "," "]

{"sheet":"Schedule of Accrued Expenses an","index":67,"n_rows":9,"n_cols":3,"rows_kept":9}
["Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands","Dec. 31, 2023","Dec. 31, 2022"]
["Payables and Accruals [Abstract]"," "," "]
["Accrued clinical trial expense",{"v":189,"d":"$ 189"},{"v":2659,"d":"$ 2,659"}]
["Accrued professional fees",{"v":573,"d":"573 "},{"v":880,"d":"880 "}]
["Accrued wages, bonuses, commissions and vacation",{"v":3011,"d":"3,011 "},{"v":2576,"d":"2,576 "}]
["Accruals for construction in progress",{"v":214,"d":"214 "},{"v":322,"d":"322 "}]
["Accrued compliance fee",{"v":1145,"d":"1,145 "}," "]
["Other",{"v":2448,"d":"2,448 "},{"v":2632,"d":"2,632 "}]
["Total accrued expenses",{"v":7580,"d":"$ 7,580"},{"v":9069,"d":"$ 9,069"}]

{"sheet":"Debt (Details Narrative)","index":68,"n_rows":267,"n_cols":36,"rows_kept":267,"merged":[[0,0,1,0],[0,20,0,21],[0,22,0,24]]}
["Debt (Details Narrative) - USD ($)",{"$nulls":18},"3 Months Ended","9 Months Ended",null,"12 Months Ended"]
[null,"Nov. 25, 2024","Mar. 13, 2024","Feb. 12, 2024","Jan. 12, 2024","Oct. 12, 2023","Sep. 18, 2023","Aug. 21, 2023","Jul. 31, 2023","Jun. 21, 2023","May 16, 2023","May 14, 2023","Apr. 14, 2023","Apr. 11, 2023","Apr. 10, 2023","Mar. 24, 2023","Mar. 17, 2023","Feb. 21, 2023","Sep. 15, 2022","Dec. 31, 2022","Sep. 30, 2024","Sep. 30, 2023","Oct. 13, 2024","Dec. 31, 2023","Dec. 31, 2022","Sep. 13, 2024","Aug. 05, 2024","Jul. 15, 2024","May 01, 2024","Apr. 15, 2024","Jan. 16, 2024","Oct. 31, 2023","Oct. 05, 2023","Aug. 02, 2023","Jun. 30, 2023","Mar. 20, 2023"]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Instrument-specific credit risk income"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2541000,"d":"$ 2,541,000"}," ",{"v":146000,"d":"$ 146,000"},{"v":20000,"d":"$ 20,000"}," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt, unpaid principal balance"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":37000000,"d":"$ 37,000,000"}," "," "," ",{"v":16623000,"d":"16,623,000 "},{"v":37000000,"d":"37,000,000 "}," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument payment"," "," "," "," "," "," "," ",{"v":2740000,"d":"$ 2,740,000"}," "," "," "," "," ",{"v":5505000,"d":"$ 5,505,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Repayments of short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":16811000,"d":"$ 16,811,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Issue of common stock"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":14892129,"d":"14,892,129 "},{"v":21984614,"d":"21,984,614 "}," "," ",{"v":19378192,"d":"19,378,192 "},{"v":14892129,"d":"14,892,129 "}," "," "," "," "," "," "," "," "," "," "," "]
["Gross proceeds"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2000000,"d":"$ 2,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":37603000,"d":"$ 37,603,000"}," "," "," ",{"v":17223000,"d":"17,223,000 "},{"v":37603000,"d":"37,603,000 "}," "," "," "," "," "," "," "," "," "," "," "]
["Other short term debt due to related party"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1419000,"d":"1,419,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Other short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2108000,"d":"2,108,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," "," "," "," "," "," "," ",{"v":892856,"d":"892,856 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," "," "," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":8.34,"d":"$ 8.34"}]
["Exercise per share price (in Dollars per share)"," ",{"v":8.1,"d":"$ 8.10"}," "," "," "," "," "," "," "," "," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Cash and cash equivalents"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":13966000,"d":"13,966,000 "},{"v":133000,"d":"$ 133,000"}," "," ",{"v":227000,"d":"227,000 "},{"v":13966000,"d":"13,966,000 "}," "," "," "," "," "," "," "," "," "," "," "]
["Discount on warrant amount"," "," "," "," "," "," "," "," "," ",{"v":2151000,"d":"$ 2,151,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt - related parties"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":18490000,"d":"$ 18,490,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Daily interest accruing rate"," "," "," ",{"v":0.18,"d":"18%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maximum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":83.43,"d":"$ 83.43"}]
["Exercise per share price (in Dollars per share)"," "," "," "," "," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Initial And Second Tranche [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of partial liquidating damages on purchase price"," "," "," ",{"v":0.01,"d":"1%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Daily interest accruing rate"," "," "," ",{"v":0.18,"d":"18%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Initial And Second Tranche [Member] | Maximum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of partial liquidating damages on subscription amount"," "," "," ",{"v":0.06,"d":"6%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issue of common stock"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":21984614,"d":"21,984,614 "}," "," ",{"v":19378192,"d":"19,378,192 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," "," "," "," "," "," "," ",{"v":857142,"d":"857,142 "}," "," "," "," "," ",{"v":923076,"d":"923,076 "}," "," "," "," "," ",{"v":10905901,"d":"10,905,901 "}," "," ",{"v":7070627,"d":"7,070,627 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," "," "," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," ",{"v":6.5,"d":"$ 6.50"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Chairman And Chief Executive Officer [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," "," "," "," ",{"v":285000,"d":"$ 285,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2108000,"d":"$ 2,108,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Loan Agreement [Member] | Chairman And Chief Executive Officer [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maturity date"," "," "," "," "," "," ","Aug. 21,  2024"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," "," "," "," "," "," ",{"v":3000000,"d":"$ 3,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument contribution amount"," "," "," "," "," "," ",{"v":1000000,"d":"$ 1,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Default rate"," "," "," "," "," "," ",{"v":0.15,"d":"15%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Gross proceeds"," "," "," "," "," "," ",{"v":4500000,"d":"$ 4,500,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Ceo Promissory Note [Member] | Chairman And Chief Executive Officer [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Pre-paid advance maturity period"," "," "," "," ","12 months"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," "," "," "," ",{"v":285000,"d":"$ 285,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Interest rate"," ",{"v":0.15,"d":"15%"}," "," ",{"v":0.15,"d":"15%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.15,"d":"15%"}," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3793000,"d":"$ 3,793,000"}," "," ",{"v":3527000,"d":"3,527,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Other short term debt due to related party"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1419000,"d":"1,419,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Other short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2108000,"d":"2,108,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Bridge Loan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt"," "," "," ",{"v":3908000,"d":"$ 3,908,000"}," "," "," "," "," ",{"v":12967000,"d":"$ 12,967,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Cash and cash equivalents"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3000,"d":"3,000 "}," "," ",{"v":3000000,"d":"3,000,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Fall in cash and cash equivalents"," "," "," ",{"v":3000000,"d":"3,000,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3000,"d":"3,000 "}," "," ",{"v":3000000,"d":"3,000,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Discount on warrant amount"," "," "," ",{"v":2151000,"d":"$ 2,151,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt - related parties"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":29482000,"d":"29,482,000 "}," "," ",{"v":12967000,"d":"12,967,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Bridge Loan [Member] | Common Class A [Member] | Tranche One Warrant [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," "," "," ",{"v":1650000,"d":"1,650,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)"," "," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2.988,"d":"$ 2.988"}," "," ",{"v":2.4898,"d":"$ 2.4898"}," "," "," "," "," "]
["Bridge Loan [Member] | Warrant [Member] | Maximum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Variable interest rate"," ",{"v":0.135,"d":"13.50%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of changes in cash flow"," ",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Bridge Loan [Member] | Warrant [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," "," "," ",{"v":1350000,"d":"1,350,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Bridge Loan [Member] | Initial Loan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maturity date"," "," "," "," "," "," "," "," "," ","Jun. 14,  2023"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," "," "," "," "," "," "," "," "," ",{"v":6000000,"d":"$ 6,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Interest rate"," "," "," "," "," "," "," "," "," ",{"v":0.125,"d":"12.50%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Discount"," "," "," "," "," "," "," "," ",{"v":678000,"d":"$ 678,000"},{"v":120000,"d":"$ 120,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Interest rate"," "," "," "," "," "," "," "," "," ",{"v":0.155,"d":"15.50%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Bridge Loan [Member] | Additional Loan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maturity date"," "," "," ","Jul. 16,  2025"," "," "," "," ","Mar. 17,  2025"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," "," "," ",{"v":15000000,"d":"$ 15,000,000"}," "," "," "," ",{"v":6000000,"d":"$ 6,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Interest rate"," "," "," ",{"v":0.125,"d":"12.50%"}," "," "," "," ",{"v":0.125,"d":"12.50%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Original issue discount"," "," "," ",{"v":3750000,"d":"$ 3,750,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," "," "," "," "," "," "," "," ",{"v":300000,"d":"300,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," "," "," "," "," "," "," "," ",{"v":1.25,"d":"$ 1.25"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Share issued purchase price"," "," "," "," "," "," "," "," ",{"v":375,"d":"$ 375"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)"," "," "," ","5 years"," "," "," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," "," "," "," "," "," "," "," ",{"v":8.1,"d":"$ 8.10"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Discount"," "," "," "," "," "," "," "," ",{"v":678000,"d":"$ 678,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Interest rate"," "," "," "," "," "," "," "," ",{"v":0.155,"d":"15.50%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Annual interest rate",{"v":0.08,"d":"8%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of credit increase in interest rate during period in event of default",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)",{"v":2.85,"d":"$ 2.85"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Member] | Bridge Loan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Fall in cash and cash equivalents"," "," "," ",{"v":3000000,"d":"$ 3,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Member] | Bridge Loan [Member] | Common Class A [Member] | Tranche One Warrant [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," "," "," ",{"v":1650000,"d":"1,650,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)"," "," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2.4898,"d":"$ 2.4898"}," "," "," "," "," "]
["Subsequent Event [Member] | Bridge Loan [Member] | Warrant [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," "," "," ",{"v":1350000,"d":"1,350,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Member] | Bridge Loan [Member] | Additional Loan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maturity date"," "," "," ","Jul. 16,  2025"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," "," "," ",{"v":15000000,"d":"$ 15,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Interest rate"," "," "," ",{"v":0.125,"d":"12.50%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Original issue discount"," "," "," ",{"v":3750000,"d":"$ 3,750,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)"," "," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Forbearance Agreement [Member] | Bridge Loan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," ",{"v":300000,"d":"300,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Variable interest rate"," ",{"v":1,"d":"100%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Forbearance Agreement [Member] | Bridge Loan [Member] | Warrant [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Forbearance Agreement [Member] | Bridge Loan [Member] | Warrant [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":13700000,"d":"$ 13,700,000"}," "," "," "," "," "," "," "," "," "]
["Variable interest rate"," ",{"v":0.125,"d":"12.50%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument default interest rate"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.165,"d":"16.50%"}," "," "," "," "," "," "," "," "," "]
["Debt instrument, unamortized discount"," ",{"v":1162000,"d":"$ 1,162,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Forbearance Agreement [Member] | Subsequent Event [Member] | Bridge Loan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," ",{"v":300000,"d":"300,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Variable interest rate"," ",{"v":1,"d":"100%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrant expiration date"," ","Jun. 20,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Yorkville [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument payment"," "," "," "," "," "," "," "," ",{"v":18724000,"d":"$ 18,724,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":37603000,"d":"37,603,000 "},{"v":3695000,"d":"$ 3,695,000"}," "," ",{"v":17223000,"d":"17,223,000 "},{"v":37603000,"d":"37,603,000 "}," "," "," "," "," "," "," "," "," "," "," "]
["Yorkville [Member] | Pre Paid Advance Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maximum advance amount"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":40000000,"d":"$ 40,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Pre-paid advance period"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","18 months"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of credit aggregate limitation amount"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":150000000,"d":"$ 150,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Pre-paid advance issued discount percentage"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.02,"d":"2%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Annual interest rate"," "," ",{"v":0.15,"d":"15%"},{"v":0.15,"d":"15%"}," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.06,"d":"6%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of credit increase in interest rate during period in event of default"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.15,"d":"15%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issuance of common stock minimum option price per share"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maximum percentage of common stock issued"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.199,"d":"19.90%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of beneficial ownership limitation"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.0499,"d":"4.99%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Minimum number of shares of common stock purchase"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":6000,"d":"6,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Minimum required daily volume weighted average price"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":6000000,"d":"$ 6,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Redemption premium percentage if volume weighted average price is less than $0.75"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.05,"d":"5%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Redemption premium percentage if volume weighted average price more than $0.75"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Proceeds from pre-paid advance gross"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":40000000,"d":"$ 40,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Proceeds from pre-paid advance"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":39200000,"d":"$ 39,200,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Pre-paid advance maturity period"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","12 months"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt conversion, principal amount"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3000000,"d":"3,000,000 "}," "," "," ",{"v":3889000,"d":"3,889,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt conversion, accrued interest amount"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":694000,"d":"$ 694,000"}," "," "," ",{"v":400000,"d":"$ 400,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt conversion, number of shares issued"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":262797,"d":"262,797 "}," "," "," ",{"v":559481,"d":"559,481 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Instrument-specific credit risk income"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":155,"d":"$ 155"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Fair value of debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":37603000,"d":"$ 37,603,000"}," "," "," ",{"v":17223000,"d":"17,223,000 "},{"v":37603000,"d":"37,603,000 "}," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt, unpaid principal balance"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":37000000,"d":"$ 37,000,000"}," "," "," ",{"v":16623000,"d":"16,623,000 "},{"v":37000000,"d":"$ 37,000,000"}," "," "," "," "," "," "," "," "," "," "," "]
["Amount of monthly repayment"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":6500000,"d":"$ 6,500,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of premium principal amount"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.05,"d":"5%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument payment"," "," "," "," "," "," "," "," ",{"v":5700000,"d":"5,700,000 "}," "," "," ",{"v":5600000,"d":"$ 5,600,000"}," ",{"v":1950000,"d":"$ 1,950,000"}," "," "," "," "," "," "," ",{"v":18724000,"d":"18,724,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument payment remaining balance"," "," "," "," "," "," "," "," "," "," ",{"v":6500000,"d":"$ 6,500,000"},{"v":4600000,"d":"$ 4,600,000"},{"v":5500000,"d":"5,500,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Business days"," "," "," "," "," "," "," "," "," "," "," ","two"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument payment partial payment"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":900000,"d":"$ 900,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Repayments of short-term debt"," "," "," "," "," "," "," "," ",{"v":16811000,"d":"$ 16,811,000"}," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":16811000,"d":"16,811,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Accrued interest"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1073000,"d":"1,073,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument redemption premium"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":840000,"d":"$ 840,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Share price per share"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.5,"d":"$ 0.50"}," "," "," "," "," "," "," "," "," "," ",{"v":0.5,"d":"$ 0.50"}," "]
["Payment on due"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":6340000,"d":"$ 6,340,000"}," "," "]
["Common stock issued pursuant to short-term debt maturity extension, shares"," "," "," "," "," ",{"v":270730,"d":"270,730 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock issued pursuant to short-term debt maturity extension"," "," "," "," "," ",{"v":712000,"d":"$ 712,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Amount required for payment"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2000000,"d":"$ 2,000,000"}," "," "," "]
["Additional amount required for payment"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":500000,"d":"$ 500,000"}," "," "," "," "]
["Cash payment"," "," ",{"v":17348000,"d":"$ 17,348,000"},{"v":17348000,"d":"$ 17,348,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Diem interest payment for each day"," "," ",{"v":7000,"d":"$ 7,000"},{"v":7000,"d":"$ 7,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issue of common stock"," "," "," ",{"v":100000,"d":"100,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Yorkville [Member] | Pre Paid Advance Agreement [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issuance price percentage"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.2,"d":"20%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Yorkville [Member] | Pre Paid Advance Agreement [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issue of common stock"," "," "," ",{"v":100000,"d":"100,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Yorkville [Member] | Equity Purchase Agreement [Member] | Convertible Promissory Notes [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maximum advance amount"," ",{"v":2993000,"d":"$ 2,993,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of beneficial ownership limitation"," ",{"v":0.0499,"d":"4.99%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Minimum required daily volume weighted average price"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2.7546,"d":"$ 2.7546"}," "," "," "," "," "," "," "," "," "," "]
["Fair value of debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3695000,"d":"$ 3,695,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt, unpaid principal balance"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3150000,"d":"3,150,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issue of Debt"," ",{"v":3150000,"d":"$ 3,150,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Original issue discount"," ",{"v":0.05,"d":"5%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maturity date"," ","Mar. 13,  2025"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Conversion price per share"," ",{"v":6.3171,"d":"$ 6.3171"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of conversion on outstanding common stock"," ",{"v":0.199,"d":"19.90%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument default interest rate"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.18,"d":"18%"}," "," "," "," "," "," "," "]
["Amortization of debt discount (Premium)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":157000,"d":"157,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Yorkville [Member] | Equity Purchase Agreement [Member] | Subsequent Event [Member] | Convertible Promissory Notes [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maximum advance amount"," ",{"v":2990000,"d":"$ 2,990,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Annual interest rate"," ",{"v":0.08,"d":"8%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of credit increase in interest rate during period in event of default"," ",{"v":0.18,"d":"18%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of beneficial ownership limitation"," ",{"v":0.0499,"d":"4.99%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Minimum required daily volume weighted average price"," ",{"v":2.4898,"d":"$ 2.4898"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issue of Debt"," ",{"v":3150000,"d":"$ 3,150,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Original issue discount"," ",{"v":0.05,"d":"5%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maturity date"," ","Mar. 13,  2025"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Conversion price per share"," ",{"v":6.3171,"d":"$ 6.3171"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of conversion on outstanding common stock"," ",{"v":0.199,"d":"19.90%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member] | Loan Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maturity date"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","Mar. 17,  2025"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":5000000,"d":"$ 5,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Default rate"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.12,"d":"12%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":5523000,"d":"$ 5,523,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Original issue discount"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":100000,"d":"$ 100,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument, interest rate, effective percentage in event of default"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.15,"d":"15%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Cash and cash equivalents"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3000000,"d":"3,000,000 "}," "," ",{"v":3000000,"d":"$ 3,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument, covenant compliance description"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","During the year ended December 31, 2023, the Company’s cash and cash equivalents fell below the $3,000\nminimum liquidity covenant, which per the terms of the loan agreement caused an event of default. Therefore, the Company reclassified\nthe loan as a current liability reflected within short-term debt - related parties on the consolidated balance sheets as of December\n31, 2023."," "," "," "," "," "," "," "," "," "," "," "," "]
["Fall in cash and cash equivalents"," "," "," ",{"v":3000000,"d":"$ 3,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3000000,"d":"$ 3,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Short-term debt - related parties"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":5640000,"d":"$ 5,640,000"}," "," ",{"v":5523000,"d":"$ 5,523,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member] | Loan Agreement [Member] | Warrant [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":75000,"d":"75,000 "}," "," "," ",{"v":50000,"d":"50,000 "}," "," ",{"v":50000,"d":"50,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1.25,"d":"$ 1.25"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Share issued purchase price"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":94,"d":"$ 94"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","5 years"," "," "," ","5 years"," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":7.1,"d":"$ 7.10"}," "," "," ",{"v":8.1,"d":"$ 8.10"}," "," ",{"v":8.1,"d":"$ 8.10"}," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member] | Subsequent Event [Member] | Loan Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Fall in cash and cash equivalents"," "," "," ",{"v":3000000,"d":"$ 3,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member] | Forbearance Agreement [Member] | Loan Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Default rate"," ",{"v":0.13,"d":"13%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.16,"d":"16%"}," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," ",{"v":75000,"d":"75,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," ",{"v":7.1,"d":"$ 7.10"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Variable interest rate"," ",{"v":1,"d":"100%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrant expiration date"," ","Mar. 17,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of changes in cash flow"," ",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member] | Forbearance Agreement [Member] | Loan Agreement [Member] | Tranche Two Warrant [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," ",{"v":50000,"d":"50,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," ",{"v":8.1,"d":"$ 8.10"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrant expiration date"," ","Jun. 20,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member] | Forbearance Agreement [Member] | Subsequent Event [Member] | Loan Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Default rate"," ",{"v":0.13,"d":"13%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," ",{"v":75000,"d":"75,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," ",{"v":7.1,"d":"$ 7.10"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise per share price (in Dollars per share)"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Variable interest rate"," ",{"v":1,"d":"100%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrant expiration date"," ","Mar. 17,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member] | Forbearance Agreement [Member] | Subsequent Event [Member] | Loan Agreement [Member] | Tranche Two Warrant [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase Class A common stock"," ",{"v":50000,"d":"50,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share"," ",{"v":8.1,"d":"$ 8.10"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrant expiration date"," ","Jun. 20,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]

{"sheet":"Schedule of Lease Costs (Detail","index":69,"n_rows":7,"n_cols":7,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[0,5,0,6]]}
["Schedule of Lease Costs (Details) - USD ($) $ in Thousands","3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Leases"," "," "," "," "," "," "]
["Operating lease cost",{"v":978,"d":"$ 978"},{"v":759,"d":"$ 759"},{"v":2933,"d":"$ 2,933"},{"v":2278,"d":"$ 2,278"},{"v":3256,"d":"$ 3,256"},{"v":3038,"d":"$ 3,038"}]
["Variable lease cost",{"v":348,"d":"348 "},{"v":320,"d":"320 "},{"v":1026,"d":"1,026 "},{"v":911,"d":"911 "},{"v":1132,"d":"1,132 "},{"v":1598,"d":"1,598 "}]
["Total operating lease cost",{"v":1326,"d":"$ 1,326"},{"v":1079,"d":"$ 1,079"},{"v":3959,"d":"$ 3,959"},{"v":3189,"d":"$ 3,189"},{"v":4388,"d":"4,388 "},{"v":4636,"d":"4,636 "}]
["Short term lease cost"," "," "," "," "," ",{"v":126,"d":"$ 126"}]

{"sheet":"Schedule of Cash and Non-cash A","index":70,"n_rows":4,"n_cols":5,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Schedule of Cash and Non-cash Activity Related to the lease Liabilities (Details) - USD ($) $ in Thousands","9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Leases"," "," "," "," "]
["Operating cash flows from operating leases",{"v":2534,"d":"$ 2,534"},{"v":2168,"d":"$ 2,168"},{"v":2995,"d":"$ 2,995"},{"v":2834,"d":"$ 2,834"}]

{"sheet":"Schedule of Future Minimum Paym","index":71,"n_rows":13,"n_cols":3,"rows_kept":13}
["Schedule of Future Minimum Payments under Non-Cancelable Operating Leases (Details) - USD ($) $ in Thousands","Sep. 30, 2024","Dec. 31, 2023"]
["Leases"," "," "]
["Remaining year",{"v":845,"d":"$ 845"}," "]
["Year one",{"v":3452,"d":"3,452 "},{"v":3378,"d":"$ 3,378"}]
["Year two",{"v":3526,"d":"3,526 "},{"v":3452,"d":"3,452 "}]
["Year three",{"v":3599,"d":"3,599 "},{"v":3526,"d":"3,526 "}]
["Year four",{"v":3673,"d":"3,673 "},{"v":3599,"d":"3,599 "}]
["Year five"," ",{"v":3673,"d":"3,673 "}]
["Year four Thereafter",{"v":84568,"d":"84,568 "}," "]
["Year five Thereafter"," ",{"v":84568,"d":"84,568 "}]
["Total lease payments",{"v":99663,"d":"99,663 "},{"v":102196,"d":"102,196 "}]
["Less imputed interest",{"v":-73212,"d":"(73,212)"},{"v":-76019,"d":"(76,019)"}]
["Total",{"v":26451,"d":"$ 26,451"},{"v":26177,"d":"$ 26,177"}]

{"sheet":"Leases (Details Narrative)","index":72,"n_rows":24,"n_cols":9,"rows_kept":24,"merged":[[0,0,1,0],[0,3,0,4],[0,5,0,6],[0,7,0,8]]}
["Leases (Details Narrative) $ in Thousands",null,null,"3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 14, 2023 USD ($)","Mar. 13, 2019 USD ($) ft²","Sep. 30, 2024 USD ($)","Sep. 30, 2023 USD ($)","Sep. 30, 2024 USD ($)","Sep. 30, 2023 USD ($)","Dec. 31, 2023 USD ($) ft²","Dec. 31, 2022 USD ($)"]
["Property, Plant and Equipment [Line Items]"," "," "," "," "," "," "," "," "]
["Rent expense"," "," ",{"v":1114,"d":"$ 1,114"},{"v":892,"d":"$ 892"},{"v":3333,"d":"$ 3,333"},{"v":2687,"d":"$ 2,687"},{"v":3750,"d":"$ 3,750"},{"v":3803,"d":"$ 3,803"}]
["Area of building | ft²"," "," "," "," "," "," ",{"v":147215,"d":"147,215 "}," "]
["Restricted cash"," "," ",{"v":10163,"d":"10,163 "}," ",{"v":10163,"d":"10,163 "}," ",{"v":9936,"d":"$ 9,936"},{"v":14836,"d":"14,836 "}]
["Operating lease liability"," "," ",{"v":26451,"d":"$ 26,451"}," ",{"v":26451,"d":"$ 26,451"}," ",{"v":26177,"d":"$ 26,177"}," "]
["Weighted average remaining lease term"," "," ","21 years 6 months"," ","21 years 6 months"," ","22 years 3 months 18 days"," "]
["Weighted average discount rate"," "," ",{"v":0.1424,"d":"14.24%"}," ",{"v":0.1424,"d":"14.24%"}," ",{"v":0.1424,"d":"14.24%"}," "]
["Florham Park New Jersey [Member]"," "," "," "," "," "," "," "," "]
["Property, Plant and Equipment [Line Items]"," "," "," "," "," "," "," "," "]
["Reduction in line of credit",{"v":4900,"d":"$ 4,900"}," "," "," "," "," "," "," "]
["New line of credit",{"v":9883,"d":"9,883 "}," "," "," "," "," "," "," "]
["Base rental payments",{"v":400,"d":"400 "}," "," "," "," "," "," "," "]
["Operating lease liability",{"v":2083,"d":"$ 2,083"}," "," "," "," "," "," "," "]
["Office Manufacturing And Laboratory Space [Member] | Florham Park New Jersey [Member] | Legacy Celularity [Member]"," "," "," "," "," "," "," "," "]
["Property, Plant and Equipment [Line Items]"," "," "," "," "," "," "," "," "]
["Area of building | ft²"," ",{"v":147215,"d":"147,215 "}," "," "," "," "," "," "]
["Area of building"," ","2036"," "," "," "," "," "," "]
["Option to renew lease term period."," ","5 years"," "," "," "," "," "," "]
["Option to renew lease term period."," ","Mar.  01,  2020"," "," "," "," "," "," "]
["Initial monthly base rent."," ",{"v":230,"d":"$ 230"}," "," "," "," "," "," "]
["Restricted cash"," "," ",{"v":14722,"d":"$ 14,722"}," ",{"v":14722,"d":"$ 14,722"}," ",{"v":14722,"d":"$ 14,722"},{"v":14722,"d":"$ 14,722"}]
["Tenant improvement allowance"," ",{"v":14722,"d":"$ 14,722"}," "," "," "," "," "," "]

{"sheet":"Commitments and Contingencies (","index":73,"n_rows":42,"n_cols":12,"rows_kept":42,"merged":[[0,0,1,0]]}
["Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands",{"$nulls":4},"1 Months Ended","3 Months Ended","5 Months Ended","9 Months Ended","12 Months Ended"]
[null,"May 07, 2024","May 06, 2024","Apr. 17, 2023","May 05, 2021","Dec. 31, 2021","Mar. 31, 2023","Jun. 03, 2024","Sep. 30, 2023","Dec. 31, 2023","Sep. 30, 2024","Dec. 31, 2022"]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Contingent consideration"," "," "," "," "," "," "," "," ",{"v":1606,"d":"$ 1,606"},{"v":1606,"d":"$ 1,606"},{"v":105945,"d":"$ 105,945"}]
["Accrued research and development software"," "," "," "," "," "," "," "," ",{"v":3500,"d":"3,500 "}," ",{"v":7333,"d":"7,333 "}]
["Costs related to straight line basis agreement"," "," "," "," "," "," "," "," ",{"v":8000,"d":"8,000 "}," "," "]
["Evolution [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Litigation settlement, amount awarded to other party",{"v":500,"d":"$ 500"}," "," "," "," "," "," "," "," "," "," "]
["Sale of biomaterial products amount"," "," ",{"v":2350,"d":"$ 2,350"}," "," "," "," "," "," "," "," "]
["License Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Upfront fee"," "," "," "," ",{"v":136,"d":"$ 136"}," "," "," "," "," "," "]
["Annual maintenance fee"," "," "," "," ",{"v":113,"d":"113 "}," "," "," "," "," "," "]
["Clinical and regulatory milestones"," "," "," "," ",{"v":5099,"d":"$ 5,099"}," "," "," "," "," "," "]
["License agreement period"," "," "," "," ","10 years"," "," "," "," "," "," "]
["License agreement period"," "," "," "," ","30 days"," "," "," "," "," "," "]
["Settlement and Release Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Settlement payment"," "," "," "," "," "," ",{"v":3500000,"d":"$ 3,500,000"}," "," "," "," "]
["Settlement and Release Agreement [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Shares issued for piggyback registration rights"," "," "," "," "," "," ",{"v":60584,"d":"60,584 "}," "," "," "," "]
["Settlement and Release Agreement [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Settlement payment"," "," "," "," "," "," ",{"v":3500,"d":"$ 3,500"}," "," "," "," "]
["Settlement and Release Agreement [Member] | Subsequent Event [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Shares issued for piggyback registration rights"," "," "," "," "," "," ",{"v":60584,"d":"60,584 "}," "," "," "," "]
["Palantir Technologies Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Litigation settlement, amount awarded to other party"," ",{"v":3500,"d":"$ 3,500"}," "," "," "," "," "," "," "," "," "]
["Palantir Technologies Inc [Member] | Software Cease Use Costs [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Exit or disposal costs"," "," "," "," "," ",{"v":24402,"d":"$ 24,402"}," ",{"v":24161,"d":"$ 24,161"}," "," "," "]
["Palantir Technologies Inc [Member] | Master Subscription Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Payments for master subscription agreement"," "," "," ",{"v":40000,"d":"$ 40,000"}," "," "," "," "," "," "," "]
["Payment subscription period"," "," "," ","5 years"," "," "," "," "," "," "," "]
["H L I Cellular Therapeutics [Member] | Legacy Celularitys [Member] | L L C And Anthrogenesis [Member]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Contingent consideration"," "," "," "," "," "," "," "," ",{"v":1606,"d":"$ 1,606"},{"v":1606,"d":"$ 1,606"},{"v":105945,"d":"$ 105,945"}]

{"sheet":"Summary of the Warrants (Detail","index":74,"n_rows":92,"n_cols":9,"rows_kept":92,"merged":[[0,1,0,2],[0,4,0,5],[90,0,90,8],[91,0,91,8]]}
["Summary of the Warrants (Details) - $ / shares","Sep. 30, 2024",null,"Mar. 13, 2024","Dec. 31, 2023",null,"Jul. 31, 2023","May 18, 2023","Apr. 10, 2023"]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":10905901,"d":"10,905,901 "},null," ",{"v":7070627,"d":"7,070,627 "},null," "," "," "]
["Exercise price"," ",null,{"v":8.1,"d":"$ 8.10"}," ",null," "," ",{"v":7.5,"d":"$ 7.50"}]
["Expiration date"," ",null," "," ",null," ","May 18,  2028"," "]
["Dragasac Warrant [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":652981,"d":"652,981 "},"[1]"," ",{"v":652981,"d":"652,981 "},"[2]"," "," "," "]
["Exercise price",{"v":2.4898,"d":"$ 2.4898"},"[1]"," ",{"v":67.7,"d":"$ 67.70"},"[2]"," "," "," "]
["Expiration date","Mar. 16,  2025","[1]"," ","Mar. 16,  2025","[2]"," "," "," "]
["Public Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":1437447,"d":"1,437,447 "},"[3]"," ",{"v":1437447,"d":"1,437,447 "},"[4]"," "," "," "]
["Exercise price",{"v":115,"d":"$ 115"},"[3]"," ",{"v":115,"d":"$ 115"},"[4]"," "," "," "]
["Expiration date","Jul. 16,  2026","[3]"," ","Jul. 16,  2026","[4]"," "," "," "]
["Sponsor Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":849999,"d":"849,999 "},"[3]"," ",{"v":849999,"d":"849,999 "},"[4]"," "," "," "]
["Exercise price",{"v":115,"d":"$ 115"},"[3]"," ",{"v":115,"d":"$ 115"},"[4]"," "," "," "]
["Expiration date","Jul. 16,  2026","[3]"," ","Jul. 16,  2026","[4]"," "," "," "]
["May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":405405,"d":"405,405 "},null," ",{"v":405405,"d":"405,405 "},null," "," "," "]
["Exercise price",{"v":3.5,"d":"$ 3.50"},null," ",{"v":3.5,"d":"$ 3.50"},null," "," "," "]
["Expiration date","Oct. 10,  2028",null," ","Oct. 10,  2028",null," "," "," "]
["March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":208485,"d":"208,485 "},null," ",{"v":208485,"d":"208,485 "},null," "," "," "]
["Exercise price",{"v":30,"d":"$ 30"},null," ",{"v":30,"d":"$ 30"},null," "," "," "]
["Expiration date","Mar. 27,  2028",null," ","Mar. 27,  2028",null," "," "," "]
["March Two Thousand Twenty Three Private Investment in Public Equity Warrants, Modified [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":729698,"d":"729,698 "},null," ",{"v":729698,"d":"729,698 "},null," "," "," "]
["Exercise price",{"v":10,"d":"$ 10"},null," ",{"v":10,"d":"$ 10"},null," "," "," "]
["Expiration date","Mar. 27,  2028",null," ","Mar. 27,  2028",null," "," "," "]
["March Two Thousand Twenty Three Loan Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":75000,"d":"75,000 "},"[5]"," ",{"v":75000,"d":"75,000 "},null," "," "," "]
["Exercise price",{"v":5.895,"d":"$ 5.895"},"[5]"," ",{"v":7.1,"d":"$ 7.10"},null," "," "," "]
["Expiration date","Mar. 17,  2028","[5]"," ","Mar. 17,  2028",null," "," "," "]
["April Two Thousand Twenty Three Registered Direct Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":435625,"d":"435,625 "},null," ",{"v":435625,"d":"435,625 "},null," "," "," "]
["Exercise price",{"v":7.5,"d":"$ 7.50"},null," ",{"v":7.5,"d":"$ 7.50"},null," "," "," "]
["Expiration date","Oct. 10,  2028",null," ","Oct. 10,  2028",null," "," "," "]
["April Two Thousand Twenty Three Registered Direct Warrants Modified [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":487451,"d":"487,451 "},null," ",{"v":487451,"d":"487,451 "},null,{"v":487451,"d":"487,451 "}," "," "]
["Exercise price",{"v":3.5,"d":"$ 3.50"},null," ",{"v":3.5,"d":"$ 3.50"},null," "," "," "]
["Expiration date","Oct. 10,  2028",null," ","Oct. 10,  2028",null," "," "," "]
["May Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":581394,"d":"581,394 "},null," ",{"v":581394,"d":"581,394 "},null," "," "," "]
["Exercise price",{"v":10,"d":"$ 10"},null," ",{"v":10,"d":"$ 10"},null," ",{"v":10,"d":"$ 10"}," "]
["Expiration date","May 17,  2028",null," ","May 17,  2028",null," ","May 17,  2028"," "]
["June Two Thousand Twenty Three Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":50000,"d":"50,000 "},"[5]"," ",{"v":50000,"d":"50,000 "},null," "," "," "]
["Exercise price",{"v":5.895,"d":"$ 5.895"},"[5]"," ",{"v":8.1,"d":"$ 8.10"},null," "," "," "]
["Expiration date","Jun. 20,  2028",null," ","Jun. 20,  2028",null," "," "," "]
["June Two Thousand Twenty Three Loan Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":300000,"d":"300,000 "},null," ",{"v":300000,"d":"300,000 "},null," "," "," "]
["Exercise price",{"v":8.1,"d":"$ 8.10"},null," ",{"v":8.1,"d":"$ 8.10"},null," "," "," "]
["Expiration date","Jun. 20,  2028",null," ","Jun. 20,  2028",null," "," "," "]
["July Two Thousand Twenty Three Registered Direct Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":857142,"d":"857,142 "},null," ",{"v":857142,"d":"857,142 "},null," "," "," "]
["Exercise price",{"v":3.5,"d":"$ 3.50"},null," ",{"v":3.5,"d":"$ 3.50"},null," "," "," "]
["Expiration date","Jan. 31,  2029",null," ","Jan. 31,  2029",null," "," "," "]
["January Two Thousand Twenty Four Pipe Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":535274,"d":"535,274 "},null," "," ",null," "," "," "]
["Exercise price",{"v":2.4898,"d":"$ 2.4898"},null," "," ",null," "," "," "]
["Expiration date","Jan. 16,  2029",null," "," ",null," "," "," "]
["January 2024 Bridge Loan Tranche One Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":1650000,"d":"1,650,000 "},null," "," ",null," "," "," "]
["Exercise price",{"v":2.4898,"d":"$ 2.4898"},null," "," ",null," "," "," "]
["Expiration date","Jan. 16,  2029",null," "," ",null," "," "," "]
["January Two Thousand Twenty Four Bridge Loan Tranche Two Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":1350000,"d":"1,350,000 "},null," "," ",null," "," "," "]
["Exercise price",{"v":2.988,"d":"$ 2.988"},null," "," ",null," "," "," "]
["Expiration date","Jul. 15,  2029",null," "," ",null," "," "," "]
["March 2024 Rwi Forbearance Warrants [Member]"," ",null," "," ",null," "," "," "]
["Accumulated Other Comprehensive Income (Loss) [Line Items]"," ",null," "," ",null," "," "," "]
["Number of shares",{"v":300000,"d":"300,000 "},null," "," ",null," "," "," "]
["Exercise price",{"v":5.895,"d":"$ 5.895"},null," "," ",null," "," "," "]
["Expiration date","Jun. 20,  2028",null," "," ",null," "," "," "]
[]
["[1]In connection with the execution of the January 2024 PIPE\ndescribed above, the Company agreed to reprice 652,981 67.70 2.4898 67.70 80 14,374,478 8,499,999 115.00 14,374,478 8,499,999 115.00 75,000 7.10 50,000 8.10 5.895"]

{"sheet":"Summary of the Warrants (Deta_2","index":75,"n_rows":38,"n_cols":8,"rows_kept":38,"merged":[[0,1,0,2],[0,5,0,6],[36,0,36,7],[37,0,37,7]]}
["Summary of the Warrants (Details) (Parenthetical) - $ / shares","Sep. 30, 2024",null,"Mar. 13, 2024","Jan. 12, 2024","Dec. 31, 2023",null,"Apr. 10, 2023"]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price"," ",null,{"v":8.1,"d":"$ 8.10"}," "," ",null,{"v":7.5,"d":"$ 7.50"}]
["Starr Forbearance Agreement [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price"," ",null,{"v":7.1,"d":"$ 7.10"}," "," ",null," "]
["Number Of warrants repriced"," ",null,{"v":75000,"d":"75,000 "}," "," ",null," "]
["C V Starr Co Inc [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price"," ",null,{"v":5.895,"d":"$ 5.895"}," "," ",null," "]
["Number Of warrants repriced"," ",null,{"v":50000,"d":"50,000 "}," "," ",null," "]
["Two Thousand Twenty Four Warrant Repricing [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price"," ",null," ",{"v":2.4898,"d":"$ 2.4898"},{"v":67.7,"d":"$ 67.70"},null," "]
["Number Of warrants repriced"," ",null," ",{"v":652981,"d":"652,981 "}," ",null," "]
["Dragasac Warrant [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price",{"v":2.4898,"d":"$ 2.4898"},"[1]"," "," ",{"v":67.7,"d":"67.70"},"[2]"," "]
["Public Warrants [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price",{"v":115,"d":"$ 115"},"[3]"," "," ",{"v":115,"d":"$ 115"},"[4]"," "]
["Warrants outstanding",{"v":14374478,"d":"14,374,478 "},null," "," ",{"v":14374478,"d":"14,374,478 "},null," "]
["Sponsor Warrants [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price",{"v":115,"d":"$ 115"},"[3]"," "," ",{"v":115,"d":"$ 115"},"[4]"," "]
["Warrants outstanding",{"v":8499999,"d":"8,499,999 "},null," "," ",{"v":8499999,"d":"8,499,999 "},null," "]
["Common Class A [Member] | Two Thousand Twenty Four Warrant Repricing [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price"," ",null," ",{"v":67.7,"d":"$ 67.70"}," ",null," "]
["Common Class A [Member] | Dragasac Warrant [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price",{"v":67.7,"d":"$ 67.70"},null," "," ",{"v":67.7,"d":"$ 67.70"},null," "]
["Warrants per share, percentage"," ",null," "," ",{"v":0.8,"d":"80%"},null," "]
["Common Class A [Member] | Sponsor Warrants [Member]"," ",null," "," "," ",null," "]
["Class of Stock [Line Items]"," ",null," "," "," ",null," "]
["Exercise price",{"v":115,"d":"$ 115"},null," "," ",{"v":115,"d":"$ 115"},null," "]
[]
["[1]In connection with the execution of the January 2024 PIPE\ndescribed above, the Company agreed to reprice 652,981 67.70 2.4898 67.70 80 14,374,478 8,499,999 115.00 14,374,478 8,499,999 115.00"]

{"sheet":"Equity (Details Narrative)","index":76,"n_rows":291,"n_cols":25,"rows_kept":291,"merged":[[0,0,1,0],[0,16,0,17],[0,18,0,19]]}
["Equity (Details Narrative) $ / shares in Units, $ in Thousands",{"$nulls":13},"1 Months Ended","3 Months Ended","9 Months Ended",null,"12 Months Ended"]
[null,"Nov. 25, 2024 $ / shares","Mar. 13, 2024 USD ($) Integer $ / shares shares","Feb. 16, 2024 USD ($)","Feb. 15, 2024 USD ($)","Jan. 12, 2024 USD ($) $ / shares shares","Jul. 31, 2023 USD ($) $ / shares shares","May 18, 2023 USD ($) $ / shares shares","Apr. 10, 2023 USD ($) $ / shares shares","Mar. 20, 2023 USD ($) $ / shares shares","Mar. 14, 2023 $ / shares","Sep. 08, 2022 USD ($)","May 18, 2022 USD ($) $ / shares shares","Mar. 01, 2022 USD ($) $ / shares shares","Jul. 31, 2023 USD ($) $ / shares shares","Mar. 31, 2024 shares","Sep. 30, 2024 USD ($) $ / shares shares","Sep. 30, 2023 USD ($) $ / shares shares","Dec. 31, 2023 USD ($) $ / shares shares","Dec. 31, 2022 USD ($) $ / shares shares","Mar. 12, 2024 $ / shares","Feb. 22, 2024 $ / shares","Sep. 14, 2023 $ / shares shares","Dec. 31, 2021 USD ($)","Jul. 14, 2021 shares"]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, shares authorized"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":730000000,"d":"730,000,000 "}," ",{"v":730000000,"d":"730,000,000 "},{"v":730000000,"d":"730,000,000 "}," "," "," "," ",{"v":110000000,"d":"110,000,000 "}]
["Common stock, par value | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "]
["Common stock, voting rights"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","common stock are entitled to one vote per share"," ","common stock are entitled to one vote per share"," "," "," "," "," "," "]
["Preferred stock, shares authorized"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":10000000,"d":"10,000,000 "}," ",{"v":10000000,"d":"10,000,000 "},{"v":10000000,"d":"10,000,000 "}," "," "," "," "," "]
["Preferred stock, shares outstanding"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," ",{"v":857142,"d":"857,142 "}," ",{"v":923077,"d":"923,077 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," "," ",{"v":892856,"d":"892,856 "}," "," "," "," "," "," "," ",{"v":892856,"d":"892,856 "}," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," ",{"v":8.34,"d":"$ 8.34"}," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "," "," "," "," "]
["Aggregate purchase price | $"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":6000,"d":"$ 6,000"},{"v":12750,"d":"$ 12,750"},{"v":12750,"d":"$ 12,750"},{"v":30000,"d":"$ 30,000"}," "," "," "," "," "]
["Exercise price | $ / shares"," ",{"v":8.1,"d":"$ 8.10"}," "," "," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," "," "," "," "," "," ","May 18,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Fair value of the warrant liability | $"," "," "," "," "," ",{"v":2645,"d":"$ 2,645"}," ",{"v":4280,"d":"$ 4,280"}," "," "," "," "," ",{"v":2645,"d":"$ 2,645"}," ",{"v":4259,"d":"$ 4,259"}," ",{"v":3784,"d":"$ 3,784"},{"v":3598,"d":"3,598 "}," "," "," ",{"v":25962,"d":"$ 25,962"}," "]
["Reduced exercise price | $ / shares"," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Additional warrant liability | $"," "," "," "," "," "," "," ",{"v":1389,"d":"1,389 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants or rights outstanding"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":10905901,"d":"10,905,901 "}," ",{"v":7070627,"d":"7,070,627 "}," "," "," "," "," "," "]
["Warrant liabilities | $"," "," "," "," "," ",{"v":511,"d":"$ 511"}," "," "," "," "," "," "," ",{"v":511,"d":"$ 511"}," ",{"v":4403,"d":"$ 4,403"}," ",{"v":4359,"d":"$ 4,359"},{"v":3598,"d":"$ 3,598"}," "," "," "," "," "]
["Fair value of modified warrant, incremental expense | $"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":402,"d":"$ 402"}," ",{"v":402,"d":"$ 402"}," "," "," "," "," "," "]
["Proceeds from the exercise of warrants | $"," "," "," "," "," ",{"v":3000,"d":"$ 3,000"}," ",{"v":6000,"d":"$ 6,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrant term"," "," "," "," "," ","5 years"," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument payment | $"," "," "," "," "," ",{"v":2740,"d":"$ 2,740"}," ",{"v":5505,"d":"$ 5,505"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock shares issued"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":21984614,"d":"21,984,614 "}," ",{"v":19378192,"d":"19,378,192 "},{"v":14892129,"d":"14,892,129 "}," "," "," "," "," "]
["Common stock shares outstanding"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":21984614,"d":"21,984,614 "}," ",{"v":19378192,"d":"19,378,192 "},{"v":14892129,"d":"14,892,129 "}," "," "," "," "," "]
["Daily interest accruing rate"," "," "," "," ",{"v":0.18,"d":"18%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["C V Starr Co Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants repriced"," ",{"v":50000,"d":"50,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares",{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares",{"v":2.85,"d":"$ 2.85"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of credit percentage",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Two Thousand Twenty Four Warrant Repricing [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," ",{"v":2.4898,"d":"$ 2.4898"}," "," "," "," "," "," "," "," "," "," "," "," ",{"v":67.7,"d":"$ 67.70"}," "," "," "," "," "," "]
["Number of warrants repriced"," "," "," "," ",{"v":652981,"d":"652,981 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrant expiration date"," "," "," "," ","Mar. 16,  2025"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Two Thousand Twenty Four Warrant Repricing [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," ",{"v":2.4898,"d":"$ 2.4898"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants repriced"," "," "," "," ",{"v":652981,"d":"652,981 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["January Two Thousand Twenty Four Pipe Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," ",{"v":67.7,"d":"$ 67.70"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants repriced"," "," "," "," ",{"v":652981,"d":"652,981 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Proceeds from private placements | $"," "," "," "," ",{"v":909,"d":"$ 909"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Fair value of warrant modification | $"," "," "," "," ",{"v":524,"d":"$ 524"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Chief Administrative Officer [Member] | Amended Employment Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Base salary | $"," "," ",{"v":500,"d":"$ 500"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Chief Administrative Officer [Member] | Subsequent Event [Member] | Amended Employment Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Base salary | $"," "," ",{"v":425,"d":"425 "},{"v":500,"d":"$ 500"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Private Placement [Member] | January Two Thousand Twenty Four Pipe Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," ",{"v":1.25,"d":"$ 1.25"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Aggregate purchase price | $"," "," "," "," ",{"v":6000,"d":"$ 6,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Private Placement [Member] | January Two Thousand Twenty Four Pipe Warrants [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Aggregate purchase price | $"," "," "," "," ",{"v":6000,"d":"$ 6,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Legacy Celularity [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1328138,"d":"1,328,138 "}," "," "," "," "," "," "," "," "," "," "," "]
["Number of shares issued"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1328138,"d":"1,328,138 "}," "," "," "," "," "," "," "," "," "," "," "]
["Payments of stock issuance costs | $"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":15985,"d":"$ 15,985"}," "," "," "," "," "," "," "," "," "," "," "]
["Minimum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "," "," "," "," "]
["Minimum [Member] | Investor Rights Agreement [Member] | Dragasac Limited [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of partial liquidating damages"," "," "," "," ",{"v":0.01,"d":"1%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Minimum [Member] | Chief Administrative Officer [Member] | Amended Employment Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Base salary | $"," "," ",{"v":425,"d":"$ 425"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Minimum [Member] | Legacy Celularity [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":35,"d":"$ 35"}," "," "," "," "," "," "," "," "," "," "," "]
["Maximum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," "," "," ",{"v":83.43,"d":"$ 83.43"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "," "," "," "," "," ",{"v":7.5,"d":"7.50"}," "," "," "," "," "," "," "," "," "," "]
["Maximum [Member] | Investor Rights Agreement [Member] | Dragasac Limited [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of partial liquidating damages"," "," "," "," ",{"v":0.06,"d":"6%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Maximum [Member] | Legacy Celularity [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":75.3,"d":"$ 75.30"}," "," "," "," "," "," "," "," "," "," "," "]
["Preferred Stock [Member] | Minimum [Member] | Legacy Celularity [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of shares required for voting"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.5,"d":"50%"}," ",{"v":0.5,"d":"50%"}," "," "," "," "," "," "]
["May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","Oct. 10,  2028"," ","Oct. 10,  2028"," "," "," "," "," "," "]
["Reduced exercise price | $ / shares"," "," "," "," "," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "," "," "," "," "]
["Amended termination date description"," "," "," "," "," "," "," ","date to five and one-half\nyears following the closing of the offering"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants or rights outstanding"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":405405,"d":"405,405 "}," ",{"v":405405,"d":"405,405 "}," "," "," "," "," "," "]
["May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member] | Private Placement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Aggregate purchase price | $"," "," "," "," "," "," "," "," "," "," "," ",{"v":30000,"d":"$ 30,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Net related cost | $"," "," "," "," "," "," "," "," "," "," "," ",{"v":27396,"d":"27,396 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Reduction to additional paid in capital | $"," "," "," "," "," "," "," "," "," "," "," ",{"v":2604,"d":"2,604 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Proceeds from issuance of private placement in additional paid in capital, net | $"," "," "," "," "," "," "," "," "," "," "," ",{"v":7651,"d":"$ 7,651"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," "," "," "," "," "," "," ",{"v":82.5,"d":"$ 82.50"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," "," "," "," "," "," "," "," "," "," "," ","May 20,  2027"," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)"," "," "," "," "," "," "," "," "," "," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights issued closing date"," "," "," "," "," "," "," "," "," "," "," ","May 20,  2022"," "," "," "," "," "," "," "," "," "," "," "," "]
["Fair value of the warrant liability | $"," "," "," "," "," "," "," "," "," "," "," ",{"v":19745,"d":"$ 19,745"}," "," "," "," "," "," "," "," "," "," "," "," "]
["May 2022 Private Investment In Public Equity Warrants Modified [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants or rights outstanding"," "," "," "," "," ",{"v":405405,"d":"405,405 "}," "," "," "," "," "," "," ",{"v":405405,"d":"405,405 "}," "," "," "," "," "," "," "," "," "," "]
["April Two Thousand Twenty Three Registered Direct Warrants Modified [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","Oct. 10,  2028"," ","Oct. 10,  2028"," "," "," "," "," "," "]
["Number of warrants or rights outstanding"," "," "," "," "," ",{"v":487451,"d":"487,451 "}," "," "," "," "," "," "," ",{"v":487451,"d":"487,451 "}," ",{"v":487451,"d":"487,451 "}," ",{"v":487451,"d":"487,451 "}," "," "," "," "," "," "]
["At the Market Sales Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Sales agents commission rate"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.03,"d":"3%"}," ",{"v":0.03,"d":"3%"}," "," "," "," "," "," "]
["Gross proceeds from issuance of common stock | $"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":141,"d":"141 "},{"v":141,"d":"$ 141"}," "," "," "," "," "," "]
["Net proceeds from sale of common stock | $"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":136,"d":"$ 136"},{"v":136,"d":"$ 136"}," "," "," "," "," "," "]
["March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," "," "," "," ",{"v":938183,"d":"938,183 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Aggregate purchase price | $"," "," "," "," "," "," "," "," ",{"v":9000,"d":"$ 9,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":30,"d":"$ 30"}," ",{"v":30,"d":"$ 30"}," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","Mar. 27,  2028"," ","Mar. 27,  2028"," "," "," "," "," "," "]
["Term (years)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ","5 years"," "," "," "," "," "," "]
["Reduced exercise price | $ / shares"," "," "," "," "," "," "," "," "," ",{"v":10,"d":"$ 10"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants or rights outstanding"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":208485,"d":"208,485 "}," ",{"v":208485,"d":"208,485 "}," "," "," "," "," "," "]
["Adjusted advance notice period"," "," "," "," "," "," "," "," ","61 days"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Premium paid for private placement purchase | $"," "," "," "," "," "," "," "," ",{"v":1650,"d":"$ 1,650"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member] | Private Placement [Member] | Chairman And Chief Executive Officer [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Aggregate purchase price | $"," "," "," "," "," "," "," "," ",{"v":2000,"d":"$ 2,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["May Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Aggregate purchase price | $"," "," "," "," "," "," ",{"v":3750,"d":"$ 3,750"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," "," "," ",{"v":10,"d":"$ 10"}," "," "," "," "," "," "," "," ",{"v":10,"d":"$ 10"}," ",{"v":10,"d":"$ 10"}," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," "," "," "," "," "," ","May 17,  2028"," "," "," "," "," "," "," "," ","May 17,  2028"," ","May 17,  2028"," "," "," "," "," "," "]
["Term (years)"," "," "," "," "," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants or rights outstanding"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":581394,"d":"581,394 "}," ",{"v":581394,"d":"581,394 "}," "," "," "," "," "," "]
["Adjusted advance notice period"," "," "," "," "," "," ","61 days"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2141098,"d":"2,141,098 "}," "," "," ",{"v":405406,"d":"405,406 "}," "," "," "," "," "]
["Common Stock [Member] | Warrant [Member] | RWI Forbearance Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," ","Jun. 20,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock [Member] | Warrant [Member] | Subsequent Event [Member] | RWI Forbearance Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," ","Jun. 20,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock [Member] | Warrant [Member] | March Two Thousand Twenty Three Loan Warrants [Member] | Loan Agreement [Member] | C V Starr Co Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," ",{"v":8.1,"d":"$ 8.10"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock [Member] | Warrant [Member] | March Two Thousand Twenty Three Loan Warrants [Member] | Forbearance Agreement [Member] | Loan Agreement [Member] | C V Starr Co Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":7.1,"d":"$ 7.10"}," "," "," "," "]
["Warrant expiration date"," ","Mar. 17,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock [Member] | Warrant [Member] | June Two Thousand Twenty Three Loan Warrants [Member] | Forbearance Agreement [Member] | Loan Agreement [Member] | C V Starr Co Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," ",{"v":5.895,"d":"$ 5.895"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrant expiration date"," ","Jun. 20,  2028"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock [Member] | Maximum [Member] | Warrant [Member] | RWI Forbearance Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants repriced"," ",{"v":300000,"d":"300,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock [Member] | Maximum [Member] | Warrant [Member] | Subsequent Event [Member] | RWI Forbearance Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of warrants repriced"," ",{"v":300000,"d":"300,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Equity Purchase Agreement [Member] | Yorkville [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Payments of stock issuance costs | $"," ",{"v":125,"d":"$ 125"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Sale of stock, maximum average daily traded amount (in percent)"," ",{"v":1,"d":"100%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days | Integer"," ",{"v":5,"d":"5 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Sale of stock, percentage based on volume weighted average price"," ",{"v":0.97,"d":"97%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Cash due diligence fee"," ",{"v":25000,"d":"25,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Commitment fee in shares"," ",{"v":16964,"d":"16,964 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Equity Purchase Agreement [Member] | Yorkville [Member] | Convertible Promissory Notes [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Line of credit percentage"," ",{"v":0.18,"d":"18%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Equity Purchase Agreement [Member] | Subsequent Event [Member] | Yorkville [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Sale of stock, maximum average daily traded amount (in percent)"," ",{"v":1,"d":"100%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days | Integer"," ",{"v":5,"d":"5 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Sale of stock, percentage based on volume weighted average price"," ",{"v":0.97,"d":"97%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days | Integer"," ",{"v":3,"d":"3 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Cash due diligence fee"," ",{"v":25000,"d":"25,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Commitment fee in shares"," ",{"v":16964,"d":"16,964 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["May Two Thousand Twenty Two Private Investment In Public Equity Warrant [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Amended termination date description"," "," "," "," "," "," "," ","date to five and one-half years following the closing of the\noffering"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, shares authorized"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":730000000,"d":"730,000,000 "}," ",{"v":730000000,"d":"730,000,000 "},{"v":730000000,"d":"730,000,000 "}," "," "," "," "," "]
["Common stock, par value | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"}," "," "," "]
["Purchase and sale of shares"," "," "," "," "," ",{"v":857143,"d":"857,143 "}," ",{"v":923076,"d":"923,076 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," "," ",{"v":857142,"d":"857,142 "}," ",{"v":923076,"d":"923,076 "}," "," "," "," "," ",{"v":857142,"d":"857,142 "}," ",{"v":10905901,"d":"10,905,901 "}," ",{"v":7070627,"d":"7,070,627 "}," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," ",{"v":6.5,"d":"$ 6.50"}," "," "," "," "," ",{"v":3.5,"d":"$ 3.50"}," "," "," "," "," "," "," "," "," "," "]
["Common stock shares issued"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":21984614,"d":"21,984,614 "}," ",{"v":19378192,"d":"19,378,192 "}," "," "," "," "," "," "]
["Common stock shares outstanding"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":21984614,"d":"21,984,614 "}," ",{"v":19378192,"d":"19,378,192 "}," "," "," "," "," "," "]
["Common Class A [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.0001,"d":"$ 0.0001"}," "," "," "]
["Common Class A [Member] | Two Thousand Twenty Four Warrant Repricing [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," ",{"v":67.7,"d":"$ 67.70"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | Private Placement [Member] | January Two Thousand Twenty Four Pipe Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares"," "," "," "," ",{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," ",{"v":2141098,"d":"2,141,098 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," ",{"v":2.4898,"d":"$ 2.4898"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," "," "," "," ","Jan. 16,  2029"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)"," "," "," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights issued closing date"," "," "," "," ","Jan. 16,  2024"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | Private Placement [Member] | January Two Thousand Twenty Four Pipe Warrants [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares"," "," "," "," ",{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," ",{"v":2141098,"d":"2,141,098 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Exercise price | $ / shares"," "," "," "," ",{"v":2.4898,"d":"$ 2.4898"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights outstanding, expire date"," "," "," "," ","Jan. 16,  2029"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Term (years)"," "," "," "," ","5 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants and rights issued closing date"," "," "," "," ","Jan. 16,  2024"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | Legacy Celularity [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Proceeds from the exercise of warrants | $"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":46485,"d":"$ 46,485"}," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | Maximum [Member] | Private Placement [Member] | January Two Thousand Twenty Four Pipe Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," ",{"v":535274,"d":"535,274 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | Maximum [Member] | Private Placement [Member] | January Two Thousand Twenty Four Pipe Warrants [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," ",{"v":535274,"d":"535,274 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," "," "," "," "," "," ",{"v":82.5,"d":"$ 82.50"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member] | Private Placement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," "," "," "," "," "," "," ",{"v":405405,"d":"405,405 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," "," "," "," "," "," "," "," ",{"v":405405,"d":"405,405 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," "," "," "," "," "," ",{"v":74,"d":"$ 74"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member] | Minimum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," "," "," "," "," "," ",{"v":7.5,"d":"7.50"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member] | Maximum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," "," "," "," "," "," ",{"v":82.5,"d":"$ 82.50"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | May 2022 Private Investment In Public Equity Warrants Modified [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," "," ",{"v":892857,"d":"892,857 "}," "," "," "," "," "," "," ",{"v":892857,"d":"892,857 "}," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," "," "," "," ",{"v":938184,"d":"938,184 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":729698,"d":"729,698 "}," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":30,"d":"$ 30"}," "," "]
["Common Class A [Member] | March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member] | Private Placement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," "," "," ",{"v":1.25,"d":"$ 1.25"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member] | Maximum [Member] | Private Placement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," "," "," "," "," ",{"v":938183,"d":"938,183 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | May Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," "," ",{"v":581394,"d":"581,394 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase aggregate shares"," "," "," "," "," "," ",{"v":581394,"d":"581,394 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," ",{"v":5.2,"d":"$ 5.20"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | May Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member] | Private Placement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase price of per share | $ / shares"," "," "," "," "," "," ",{"v":1.25,"d":"$ 1.25"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | Equity Purchase Agreement [Member] | Yorkville [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, shares authorized"," ",{"v":10000,"d":"10,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares"," ",{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Consideration shares of common stock | $"," ",{"v":10000,"d":"$ 10,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | Equity Purchase Agreement [Member] | Subsequent Event [Member] | Yorkville [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, shares authorized"," ",{"v":10000000,"d":"10,000,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, par value | $ / shares"," ",{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Consideration shares of common stock | $"," ",{"v":10000,"d":"$ 10,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Class A [Member] | May Two Thousand Twenty Three Private Investment In Public Equity Warrant [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," "," ",{"v":581395,"d":"581,395 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock [Member] | At the Market Sales Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":13296,"d":"13,296 "},{"v":13296,"d":"13,296 "}," "," "," "," "," "," "]
["Aggregate offering price | $"," "," "," "," "," "," "," "," "," "," ",{"v":150000,"d":"$ 150,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Average price per share | $ / shares"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":10.6,"d":"$ 10.60"},{"v":10.6,"d":"$ 10.60"}," "," "," "," "," "," "]

{"sheet":"Schedule of Weighted Average Gr","index":77,"n_rows":7,"n_cols":5,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)","9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Share-Based Payment Arrangement [Abstract]"," "," "," "," "]
["Risk-free interest rate",{"v":0.045,"d":"4.50%"},{"v":0.041,"d":"4.10%"},{"v":0.041,"d":"4.10%"},{"v":0.027,"d":"2.70%"}]
["Expected term (in years)","5 years 6 months","5 years 7 months 6 days","5 years 7 months 6 days","5 years 10 months 24 days"]
["Expected volatility",{"v":1.108,"d":"110.80%"},{"v":0.865,"d":"86.50%"},{"v":0.865,"d":"86.50%"},{"v":0.771,"d":"77.10%"}]
["Expected dividend yield",{"v":0,"d":"0%"},{"v":0,"d":"0%"}," "," "]

{"sheet":"Schedule of Stock Option Activi","index":78,"n_rows":35,"n_cols":6,"rows_kept":35,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[1,1,1,2],[33,0,33,5],[34,0,34,5]]}
["Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands","9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024",null,"Dec. 31, 2023","Dec. 31, 2022","Sep. 30, 2023"]
["Two Thousand And Twenty One And Two Thousand And Seventeen Equity Incentive Plan [Member]"," ",null," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," ",null," "," "," "]
["Options beginning balance",{"v":2820187,"d":"2,820,187 "},null,{"v":2514452000,"d":"2,514,452,000 "}," "," "]
["Weighted Average Exercise Price, beginning balance",{"v":40.16,"d":"$ 40.16"},null,{"v":49.08,"d":"$ 49.08"}," "," "]
["Weighted Average Contract Term","6 years","[1]","5 years 7 months 6 days","6 years 1 month 6 days"," "]
["Aggregate Intrinsic Value",{"v":115,"d":"$ 115"},"[1]"," ",{"v":7851,"d":"$ 7,851"}," "]
["Options Granted",{"v":879664,"d":"879,664 "},null,{"v":741634000,"d":"741,634,000 "}," "," "]
["Weighted Average Exercise Price, Granted",{"v":3.76,"d":"$ 3.76"},null,{"v":5.35,"d":"$ 5.35"}," "," "]
["Options Exercised"," ",null,{"v":-108637000,"d":"(108,637,000)"}," "," "]
["Weighted Average Exercise Price, Exercised"," ",null,{"v":2.8,"d":"$ 2.80"}," "," "]
["Options Forfeited/Expired",{"v":-289802,"d":"(289,802)"},null,{"v":-327262000,"d":"(327,262,000)"}," "," "]
["Weighted Average Exercise Price, Forfeited/Expired",{"v":31.47,"d":"$ 31.47"},null,{"v":42.23,"d":"$ 42.23"}," "," "]
["Options ending balance",{"v":3410049,"d":"3,410,049 "},"[1]",{"v":2820187,"d":"2,820,187 "},{"v":2514452000,"d":"2,514,452,000 "}," "]
["Weighted Average Exercise Price, ending balance",{"v":31.51,"d":"$ 31.51"},"[1]",{"v":40.16,"d":"$ 40.16"},{"v":49.08,"d":"$ 49.08"}," "]
["Options Vested and expected to vest",{"v":3410049,"d":"3,410,049 "},null,{"v":2820187000,"d":"2,820,187,000 "}," "," "]
["Weighted Average Exercise Price, Vested and expected to vest",{"v":31.51,"d":"$ 31.51"},null,{"v":40.16,"d":"$ 40.16"}," "," "]
["Weighted Average Contract Term, Vested and expected to vest","6 years",null,"5 years 7 months 6 days"," "," "]
["Options Exercisable",{"v":2513584,"d":"2,513,584 "},null,{"v":2025287000,"d":"2,025,287,000 "}," "," "]
["Weighted Average Exercise Price, Exercisable",{"v":38,"d":"$ 38"},null,{"v":46.01,"d":"$ 46.01"}," "," "]
["Weighted Average Contract Term Exercisable","4 years 10 months 24 days",null,"4 years 6 months"," "," "]
["Aggregate Intrinsic Value"," ",null,{"v":7851,"d":"$ 7,851"}," "," "]
["Options Exercised"," ",null,{"v":108637000,"d":"108,637,000 "}," "," "]
["Aggregate Intrinsic Value",{"v":115,"d":"$ 115"},"[1]"," ",{"v":7851,"d":"$ 7,851"}," "]
["Aggregate Intrinsic Value Vested and expected to vest",{"v":115,"d":"115 "},null," "," "," "]
["Aggregate Intrinsic Value Exercisable",{"v":113,"d":"$ 113"},null," "," "," "]
["2021 And 2017 Plan [Member]"," ",null," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," ",null," "," "," "]
["Options outstanding including awards",{"v":1979953,"d":"1,979,953 "},null," "," ",{"v":1475096,"d":"1,475,096 "}]
["Twenty Twenty One Plan [Member]"," ",null," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," ",null," "," "," "]
["Options outstanding including awards",{"v":45000,"d":"45,000 "},null," "," "," "]
[]
["[1]Options outstanding\nat September 30, 2024 under the 2021 Plan and 2017 Plan were 1,979,953 1,475,096 45,000"]

{"sheet":"Schedule of Activity Related to","index":79,"n_rows":13,"n_cols":3,"rows_kept":13,"merged":[[0,0,1,0]]}
["Schedule of Activity Related to RSU Stock-Based Payment Awards (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023"]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "]
["Number of Shares opening balance",{"v":823332,"d":"823,332 "},{"v":227013000,"d":"227,013,000 "}]
["Weighted Average Grant Date Fair Value, beginning balance",{"v":13.77,"d":"$ 13.77"},{"v":73.35,"d":"$ 73.35"}]
["Number of Shares Granted"," ",{"v":954931000,"d":"954,931,000 "}]
["Weighted Average Grant Date Fair Value, Granted"," ",{"v":6.29,"d":"$ 6.29"}]
["Number of Shares Released",{"v":-395996,"d":"(395,996)"},{"v":-83759000,"d":"(83,759,000)"}]
["Weighted Average Grant Date Fair Value, Released",{"v":11.5,"d":"$ 11.50"},{"v":65.05,"d":"$ 65.05"}]
["Number of Shares Forfeited",{"v":-99977,"d":"(99,977)"},{"v":-274853000,"d":"(274,853,000)"}]
["Weighted Average Grant Date Fair Value, Forfeited",{"v":13.24,"d":"$ 13.24"},{"v":21.37,"d":"$ 21.37"}]
["Number of Shares ending balance",{"v":327359,"d":"327,359 "},{"v":823332,"d":"823,332 "}]
["Weighted Average Grant Date Fair Value, ending balance",{"v":16.68,"d":"$ 16.68"},{"v":13.77,"d":"$ 13.77"}]

{"sheet":"Schedule of Stock-based Compens","index":80,"n_rows":13,"n_cols":7,"rows_kept":13,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[0,5,0,6]]}
["Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands","3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"," "," "," "," "," "," "]
["Stock-based compensation expense",{"v":2672,"d":"$ 2,672"},{"v":3598,"d":"$ 3,598"},{"v":8628,"d":"$ 8,628"},{"v":11442,"d":"$ 11,442"},{"v":15017,"d":"$ 15,017"},{"v":15856,"d":"$ 15,856"}]
["Cost of Sales [Member]"," "," "," "," "," "," "]
["Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"," "," "," "," "," "," "]
["Stock-based compensation expense",{"v":90,"d":"90 "},{"v":166,"d":"166 "},{"v":285,"d":"285 "},{"v":462,"d":"462 "},{"v":580,"d":"580 "},{"v":410,"d":"410 "}]
["Research and Development Expense [Member]"," "," "," "," "," "," "]
["Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"," "," "," "," "," "," "]
["Stock-based compensation expense",{"v":182,"d":"182 "},{"v":379,"d":"379 "},{"v":903,"d":"903 "},{"v":1384,"d":"1,384 "},{"v":1832,"d":"1,832 "},{"v":2118,"d":"2,118 "}]
["Selling, General and Administrative Expenses [Member]"," "," "," "," "," "," "]
["Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"," "," "," "," "," "," "]
["Stock-based compensation expense",{"v":2400,"d":"$ 2,400"},{"v":3053,"d":"$ 3,053"},{"v":7440,"d":"$ 7,440"},{"v":9596,"d":"$ 9,596"},{"v":12605,"d":"$ 12,605"},{"v":13328,"d":"$ 13,328"}]

{"sheet":"Stock-Based Compensation (Detai","index":81,"n_rows":98,"n_cols":13,"rows_kept":98,"merged":[[0,0,1,0],[0,4,0,5],[0,6,0,7],[0,8,0,9],[0,10,0,11]]}
["Stock-Based Compensation (Details Narrative) - USD ($)",{"$nulls":3},"1 Months Ended",null,"3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Aug. 16, 2023","Nov. 01, 2022","Aug. 16, 2022","Jul. 31, 2023","Sep. 30, 2021","Sep. 30, 2024","Sep. 30, 2023","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022","Jul. 31, 2021"]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Expected dividend yield"," "," "," "," "," "," "," ",{"v":0,"d":"0%"},{"v":0,"d":"0%"}," "," "," "]
["Weighted average grant-date fair value of stock options granted"," "," "," "," "," "," "," ",{"v":3.1,"d":"$ 3.10"},{"v":0.39,"d":"$ 0.39"},{"v":5.35,"d":"$ 5.35"},{"v":5.43,"d":"$ 5.43"}," "]
["Stock-based compensation expense"," "," "," "," "," ",{"v":2672000,"d":"$ 2,672,000"},{"v":3598000,"d":"$ 3,598,000"},{"v":8628000,"d":"$ 8,628,000"},{"v":11442000,"d":"$ 11,442,000"},{"v":15017000,"d":"$ 15,017,000"},{"v":15856000,"d":"$ 15,856,000"}," "]
["Aggregate intrinsic value, stock option exercised"," "," "," "," "," "," "," "," "," ",{"v":0,"d":"$ 0"},{"v":7997000,"d":"$ 7,997,000"}," "]
["Expected volatility"," "," "," "," "," "," "," ",{"v":1.108,"d":"110.80%"},{"v":0.865,"d":"86.50%"},{"v":0.865,"d":"86.50%"},{"v":0.771,"d":"77.10%"}," "]
["Risk-free interest rate"," "," "," "," "," "," "," ",{"v":0.045,"d":"4.50%"},{"v":0.041,"d":"4.10%"},{"v":0.041,"d":"4.10%"},{"v":0.027,"d":"2.70%"}," "]
["Expected term (in years)"," "," "," "," "," "," "," ","5 years 6 months","5 years 7 months 6 days","5 years 7 months 6 days","5 years 10 months 24 days"," "]
["Stock based compensation"," "," "," "," "," "," ",{"v":0,"d":"0 "}," ",{"v":0,"d":"$ 0"}," "," "," "]
["Share-Based Payment Arrangement, Option [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Stock-based compensation expense"," "," "," "," "," ",{"v":2077000,"d":"2,077,000 "},{"v":2255000,"d":"2,255,000 "},{"v":6306000,"d":"$ 6,306,000"},{"v":6952000,"d":"6,952,000 "},{"v":9293000,"d":"$ 9,293,000"},{"v":10702000,"d":"$ 10,702,000"}," "]
["Estimated weighted-average amortization period"," "," "," "," "," ",{"v":8370000,"d":"8,370,000 "}," ",{"v":8370000,"d":"$ 8,370,000"}," ",{"v":13449000,"d":"$ 13,449,000"}," "," "]
["Estimated weighted-average amortization period"," "," "," "," "," "," "," ","2 years 7 months 13 days"," ","2 years 7 months 2 days"," "," "]
["Awards With Performance Conditions [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Expected dividend yield"," "," "," "," "," "," "," ",{"v":0,"d":"0%"}," ",{"v":0,"d":"0%"}," "," "]
["Stock-based compensation expense"," "," "," "," "," "," "," "," "," ",{"v":0,"d":"$ 0"},{"v":881000,"d":"881,000 "}," "]
["Estimated weighted-average amortization period"," "," "," "," "," "," "," "," "," ",{"v":1175000,"d":"$ 1,175,000"}," "," "]
["Vested options to acquire shares"," "," ",{"v":105000,"d":"105,000 "}," "," "," "," "," "," "," "," "," "]
["Vested options to acquire per share"," "," ",{"v":29.9,"d":"$ 29.90"}," "," "," "," "," "," "," "," "," "]
["Stock option vesting"," "," ",{"v":80000,"d":"80,000 "}," "," "," "," "," "," "," "," "," "]
["Expected volatility"," ",{"v":0.799,"d":"79.90%"}," "," "," "," "," "," "," "," "," "," "]
["Risk-free interest rate"," "," "," "," "," "," "," ",{"v":0.0295,"d":"2.95%"}," ",{"v":0.0295,"d":"2.95%"}," "," "]
["Expected term (in years)"," "," "," "," "," "," "," ","5 years"," ","5 years"," "," "]
["Number of shares remaining stock options forfeited",{"v":60000,"d":"60,000 "}," "," "," "," "," "," "," "," "," "," "," "]
["Awards With Performance Conditions [Member] | Initial Tranche [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Vested options to acquire shares"," "," ",{"v":25000,"d":"25,000 "}," "," "," "," "," "," "," "," "," "]
["Awards With Performance Conditions [Member] | Second Tranche [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Vested options to acquire shares"," ",{"v":20000,"d":"20,000 "}," "," "," "," "," "," "," "," "," "," "]
["Awards With Market Conditions [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Vested options to acquire shares"," "," "," "," ",{"v":246928,"d":"246,928 "}," "," "," "," "," "," "," "]
["Vested options to acquire per share"," "," "," "," ",{"v":63.2,"d":"$ 63.20"}," "," "," "," "," "," "," "]
["Vesting description"," "," "," "," "," "," "," ","vest\nin up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the\neffective date"," ","vest\nin up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the\neffective date"," "," "]
["Stock based compensation"," "," "," "," "," "," "," "," "," "," ",{"v":1167000,"d":"1,167,000 "}," "]
["Reversed stock based compensation expenses"," "," "," "," "," "," "," "," "," "," ",{"v":1681000,"d":"1,681,000 "}," "]
["Restricted Stock Units (RSUs) [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Options vesting period"," "," "," "," "," "," "," ","2 years"," ","2 years"," "," "]
["Stock-based compensation expense"," "," "," "," "," ",{"v":595000,"d":"595,000 "},{"v":1343000,"d":"$ 1,343,000"},{"v":2322000,"d":"$ 2,322,000"},{"v":4490000,"d":"$ 4,490,000"},{"v":5724000,"d":"$ 5,724,000"},{"v":4787000,"d":"$ 4,787,000"}," "]
["Estimated weighted-average amortization period"," "," "," "," "," ",{"v":4086000,"d":"4,086,000 "}," ",{"v":4086000,"d":"$ 4,086,000"}," ",{"v":7732000,"d":"$ 7,732,000"}," "," "]
["Estimated weighted-average amortization period"," "," "," "," "," "," "," ","2 years 2 months 12 days"," ","2 years 21 days"," "," "]
["Number of Shares Granted"," "," "," "," "," "," "," "," "," ",{"v":954931000,"d":"954,931,000 "}," "," "]
["Weighted Average Grant Date Fair Value, Granted"," "," "," "," "," "," "," "," "," ",{"v":6.29,"d":"$ 6.29"}," "," "]
["Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Vesting percentage"," "," "," "," "," "," "," ",{"v":0.25,"d":"25%"}," ",{"v":0.5,"d":"50%"}," "," "]
["Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Two [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Vesting percentage"," "," "," "," "," "," "," "," "," ",{"v":0.5,"d":"50%"}," "," "]
["Performance Shares [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Estimated weighted-average amortization period"," "," "," "," "," "," "," "," "," ",{"v":871000,"d":"$ 871,000"}," "," "]
["Estimated weighted-average amortization period"," "," "," "," "," "," "," "," "," ","1 year 9 months 14 days"," "," "]
["Stock based compensation"," "," "," "," "," "," "," "," "," ",{"v":0,"d":"$ 0"}," "," "]
["Number of Shares Granted"," "," "," ",{"v":174500,"d":"174,500 "}," "," "," "," "," "," "," "," "]
["Weighted Average Grant Date Fair Value, Granted"," "," "," ",{"v":5,"d":"$ 5"}," "," "," "," "," "," "," "," "]
["Market Condition Stock Unit [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Estimated weighted-average amortization period"," "," "," "," "," ",{"v":145833000,"d":"$ 145,833,000"}," ",{"v":145833000,"d":"$ 145,833,000"}," "," "," "," "]
["Stock based compensation"," "," "," "," "," "," "," ",{"v":28667000,"d":"$ 28,667,000"}," "," "," "," "]
["Number of Shares Granted"," "," "," ",{"v":174500,"d":"174,500 "}," "," "," "," "," "," "," "," "]
["Weighted Average Grant Date Fair Value, Granted"," "," "," "," "," "," "," ",{"v":5,"d":"$ 5"}," "," "," "," "]
["Maximum [Member] | Performance Shares [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Options vesting period"," "," "," ","3 years"," "," "," "," "," "," "," "," "]
["Maximum [Member] | Market Condition Stock Unit [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Options vesting period"," "," "," ","3 years"," "," "," "," "," "," "," "," "]
["Minimum [Member] | Performance Shares [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Options vesting period"," "," "," ","1 year"," "," "," "," "," "," "," "," "]
["Minimum [Member] | Market Condition Stock Unit [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Options vesting period"," "," "," ","1 year"," "," "," "," "," "," "," "," "]
["Two Thousand And Twenty One [Equity Incentive Plan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of shares issued from outstanding capital stock, maximum"," "," "," "," "," "," "," ",{"v":0.04,"d":"4%"}," ",{"v":0.04,"d":"4%"}," "," "]
["Two Thousand And Twenty One [Equity Incentive Plan [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of shares remaining available for future grant"," "," "," "," "," ",{"v":1254803,"d":"1,254,803 "}," ",{"v":1254803,"d":"1,254,803 "}," ",{"v":821789,"d":"821,789 "}," ",{"v":2091528,"d":"2,091,528 "}]
["Number of shares issued for future issuance automatic increase period"," "," "," "," "," "," "," ","10 years"," ","10 years"," "," "]
["2017 Equity Incentive Plan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Number of shares remaining available for future grant"," "," "," "," "," ",{"v":3234204,"d":"3,234,204 "}," ",{"v":3234204,"d":"3,234,204 "}," ",{"v":3234204,"d":"3,234,204 "}," "," "]
["Percentage of fair market value"," "," "," "," "," "," "," "," "," ",{"v":1,"d":"100%"}," "," "]
["2017 Equity Incentive Plan [Member] | Maximum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Stock option, expiration period"," "," "," "," "," "," "," ","10 years"," ","10 years"," "," "]
["Options vesting period"," "," "," "," "," "," "," ","4 years"," ","4 years"," "," "]
["2017 Equity Incentive Plan [Member] | Minimum [Member]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Options vesting period"," "," "," "," "," "," "," ","3 years"," ","3 years"," "," "]

{"sheet":"Schedule of Disaggregated Reven","index":82,"n_rows":13,"n_cols":7,"rows_kept":13,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[0,5,0,6]]}
["Schedule of Disaggregated Revenue by Product And Services (Details) - USD ($) $ in Thousands","3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Disaggregation of Revenue [Line Items]"," "," "," "," "," "," "]
["Total net revenues",{"v":9296,"d":"$ 9,296"},{"v":3786,"d":"$ 3,786"},{"v":36088,"d":"$ 36,088"},{"v":10659,"d":"$ 10,659"},{"v":22771,"d":"$ 22,771"},{"v":17975,"d":"$ 17,975"}]
["Product [Member]"," "," "," "," "," "," "]
["Disaggregation of Revenue [Line Items]"," "," "," "," "," "," "]
["Total net revenues",{"v":3393,"d":"3,393 "},{"v":1684,"d":"1,684 "},{"v":26199,"d":"26,199 "},{"v":3633,"d":"3,633 "},{"v":13149,"d":"13,149 "},{"v":3749,"d":"3,749 "}]
["Service [Member]"," "," "," "," "," "," "]
["Disaggregation of Revenue [Line Items]"," "," "," "," "," "," "]
["Total net revenues",{"v":1292,"d":"1,292 "},{"v":1427,"d":"1,427 "},{"v":3857,"d":"3,857 "},{"v":4062,"d":"4,062 "},{"v":5441,"d":"5,441 "},{"v":5512,"d":"5,512 "}]
["License Royalty And Other [Member]"," "," "," "," "," "," "]
["Disaggregation of Revenue [Line Items]"," "," "," "," "," "," "]
["Total net revenues",{"v":4611,"d":"$ 4,611"},{"v":675,"d":"$ 675"},{"v":6032,"d":"$ 6,032"},{"v":2964,"d":"$ 2,964"},{"v":4181,"d":"$ 4,181"},{"v":8714,"d":"$ 8,714"}]

{"sheet":"Schedule of Changes in Deferred","index":83,"n_rows":9,"n_cols":9,"rows_kept":9,"merged":[[0,0,1,0],[0,1,0,4],[0,5,0,8],[1,1,1,2],[1,3,1,4],[1,5,1,6],[1,7,1,8],[7,0,7,8],[8,0,8,8]]}
["Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) - USD ($) $ in Thousands","9 Months Ended",{"$nulls":3},"12 Months Ended"]
[null,"Sep. 30, 2024",null,"Sep. 30, 2023",null,"Dec. 31, 2023",null,"Dec. 31, 2022"]
["Revenue from Contract with Customer [Abstract]"," ",null," ",null," ",null," "]
["Beginning Balance",{"v":6020,"d":"$ 6,020"},null,{"v":4492,"d":"$ 4,492"},null,{"v":4492,"d":"$ 4,492"},null,{"v":4067,"d":"$ 4,067"}]
["Deferral of revenue",{"v":3931,"d":"3,931 "},"[1]",{"v":4579,"d":"4,579 "},"[1]",{"v":6266,"d":"6,266 "},"[2]",{"v":5004,"d":"5,004 "},"[2]"]
["Recognition of unearned revenue",{"v":-3619,"d":"(3,619)"},"[3]",{"v":-3514,"d":"(3,514)"},"[3]",{"v":-4738,"d":"(4,738)"},null,{"v":-4579,"d":"(4,579)"}]
["Ending Balance",{"v":6332,"d":"$ 6,332"},null,{"v":5557,"d":"$ 5,557"},null,{"v":6020,"d":"$ 6,020"},null,{"v":4492,"d":"$ 4,492"}]
[]
["[1]Deferral of revenue includes\n$ 3,736 3,818 2,271 2,274"]

{"sheet":"License and Distribution Agre_2","index":84,"n_rows":36,"n_cols":14,"rows_kept":36,"merged":[[0,0,1,0],[0,11,0,12]]}
["License and Distribution Agreements (Details Narrative) - USD ($) $ in Thousands",{"$nulls":8},"3 Months Ended","9 Months Ended","12 Months Ended"]
[null,"Dec. 11, 2023","Aug. 25, 2023","Jul. 31, 2023","Apr. 13, 2023","Apr. 10, 2023","Mar. 17, 2023","Sep. 01, 2021","May 07, 2021","Mar. 31, 2024","Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022","Sep. 30, 2023"]
["Deferred revenue"," "," "," "," "," "," "," "," "," ",{"v":3736,"d":"$ 3,736"}," "," ",{"v":3818,"d":"$ 3,818"}]
["Issuance of common stock"," "," "," "," "," "," "," "," "," "," "," ",{"v":7651,"d":"$ 7,651"}," "]
["Purchase and sale of shares"," "," ",{"v":857142,"d":"857,142 "}," ",{"v":923077,"d":"923,077 "}," "," "," "," "," "," "," "," "]
["Common Stock [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issuance of common stock"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase and sale of shares"," "," "," "," "," "," "," "," ",{"v":2141098,"d":"2,141,098 "}," "," ",{"v":405406,"d":"405,406 "}," "]
["Regeneron Research Collaboration Services Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Service agreement term"," ","5 years"," "," "," "," "," "," "," "," "," "," "," "]
["License agreement notice period"," ","30 days"," "," "," "," "," "," "," "," "," "," "," "]
["Deferred revenue"," "," "," "," "," "," "," "," "," ",{"v":750,"d":"750 "},{"v":750,"d":"$ 750"}," "," "]
["Arthrex Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Supply and distribution agreement period"," "," "," "," "," "," "," ","6 years"," "," "," "," "," "]
["Supply and distribution agreement renewal term"," "," "," "," "," "," "," ","2 years"," "," "," "," "," "]
["Supply and distribution agreement non-renewal notice period"," "," "," "," "," "," "," ","12 months"," "," "," "," "," "]
["Discount percentage payment for invoices within ten days"," "," "," "," "," "," "," ",{"v":0.02,"d":"2%"}," "," "," "," "," "]
["Payment term net"," "," "," "," "," "," "," ","45 days"," "," "," "," "," "]
["Material breach contract terminated term"," "," "," "," "," "," "," ","30 days"," "," "," "," "," "]
["Evolution Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Supply and distribution agreement period"," "," "," "," "," "," ","3 years"," "," "," "," "," "," "]
["Supply and distribution agreement period"," "," "," ","Apr. 13,  2023"," "," "," "," "," "," "," "," "," "]
["Outstanding invoice amount refused"," "," "," ",{"v":2350,"d":"$ 2,350"}," "," "," "," "," "," "," "," "," "]
["Pulthera Llc Binding Term Sheet [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Payment of option fee in cash"," "," "," "," "," "," "," "," "," ",{"v":3000,"d":"3,000 "},{"v":3000,"d":"3,000 "}," "," "]
["Pulthera Llc Binding Term Sheet [Member] | Research and Development Expense [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Option fee expense"," "," "," "," "," ",{"v":3000,"d":"$ 3,000"}," "," "," "," "," "," "," "]
["Pulthera Llc Binding Term Sheet [Member] | Common Stock [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issuance of common stock"," "," "," "," "," "," "," "," "," ",{"v":1000,"d":"$ 1,000"},{"v":1000,"d":"$ 1,000"}," "," "]
["Purchase and sale of shares"," "," "," "," "," ",{"v":169492,"d":"169,492 "}," "," "," "," "," "," "," "]
["License Agreement With Biocellgraft Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Option fee expense","4 years"," "," "," "," "," "," "," "," "," "," "," "," "]
["Commercial license to dental products agreement renewal term","2 years"," "," "," "," "," "," "," "," "," "," "," "," "]
["License fee expense",{"v":5000,"d":"$ 5,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["License fees payment period","2 years"," "," "," "," "," "," "," "," "," "," "," "," "]
["License fee payment",{"v":300,"d":"$ 300"}," "," "," "," "," "," "," "," "," "," "," "," "]

{"sheet":"Benefit Plan (Details Narrative","index":85,"n_rows":5,"n_cols":3,"rows_kept":5,"merged":[[0,0,1,0],[0,1,0,2]]}
["Benefit Plan (Details Narrative) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2023","Dec. 31, 2022"]
["Retirement Benefits [Abstract]"," "," "]
["Contributions made to the plan",{"v":198,"d":"$ 198"}," "]
["Accrued amount but not made matching contribution to the plan"," ",{"v":1159,"d":"$ 1,159"}]

{"sheet":"Schedule of Current and Deferre","index":86,"n_rows":10,"n_cols":7,"rows_kept":10,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[0,5,0,6]]}
["Schedule of Current and Deferred Tax Provision (Details) - USD ($) $ in Thousands","3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Income Tax Disclosure [Abstract]"," "," "," "," "," "," "]
["Federal"," "," "," "," "," "," "]
["State"," "," "," "," ",{"v":10,"d":"10 "},{"v":13,"d":"13 "}]
["Total current income tax expense"," "," "," "," ",{"v":10,"d":"10 "},{"v":13,"d":"13 "}]
["Federal"," "," "," "," ",{"v":1,"d":"1 "},{"v":1,"d":"1 "}]
["State"," "," "," "," ",{"v":-1,"d":"(1)"},{"v":-1,"d":"(1)"}]
["Total deferred tax expense"," "," "," "," "," "," "]
["Total expense from income taxes"," "," "," "," ",{"v":10,"d":"$ 10"},{"v":13,"d":"$ 13"}]

{"sheet":"Schedule of Reconciliation of_2","index":87,"n_rows":13,"n_cols":3,"rows_kept":13,"merged":[[0,0,1,0],[0,1,0,2]]}
["Schedule of Reconciliation of the U.S federal statutory income tax (Details)","12 Months Ended"]
[null,"Dec. 31, 2023","Dec. 31, 2022"]
["Income Tax Disclosure [Abstract]"," "," "]
["Federal statutory income tax rate",{"v":0.21,"d":"21%"},{"v":0.21,"d":"21%"}]
["State income taxes, net of federal benefits",{"v":0.014,"d":"1.40%"},"(38.90%)"]
["Interest accretion expense",{"v":0.11,"d":"11%"},"(186.90%)"]
["Change in valuation allowance","(20.00%)",{"v":2.691,"d":"269.10%"}]
["Mark to market warrant",{"v":0.005,"d":"0.50%"},"(58.50%)"]
["Deferred true-up","(2.40%)",{"v":0.002,"d":"0.20%"}]
["Stock-based compensation","(0.00%)","(8.20%)"]
["Impairment","(12.00%)",{"v":0.053,"d":"5.30%"}]
["Other permanent items",{"v":0.005,"d":"0.50%"},"(3.10%)"]
["Effective income tax rate","(0.00%)","(0.00%)"]

{"sheet":"Schedule of Deferred tax assets","index":88,"n_rows":18,"n_cols":3,"rows_kept":18}
["Schedule of Deferred tax assets and liabilities (Details) - USD ($) $ in Thousands","Dec. 31, 2023","Dec. 31, 2022"]
["Income Tax Disclosure [Abstract]"," "," "]
["Net operating loss carryforwards",{"v":109544,"d":"$ 109,544"},{"v":102723,"d":"$ 102,723"}]
["Research and development tax credit carryforwards",{"v":5674,"d":"5,674 "},{"v":5674,"d":"5,674 "}]
["Stock-based compensation expense",{"v":16539,"d":"16,539 "},{"v":14321,"d":"14,321 "}]
["Startup costs",{"v":498,"d":"498 "},{"v":588,"d":"588 "}]
["Intangible assets",{"v":3442,"d":"3,442 "},{"v":3905,"d":"3,905 "}]
["Deferred revenue",{"v":1441,"d":"1,441 "},{"v":1135,"d":"1,135 "}]
["Unicap",{"v":5,"d":"5 "},{"v":6,"d":"6 "}]
["Imputed interest on contingent payments",{"v":110,"d":"110 "},{"v":5654,"d":"5,654 "}]
["Legal fee capitalization and amortization",{"v":1171,"d":"1,171 "},{"v":1342,"d":"1,342 "}]
["Capitalized research and development",{"v":26613,"d":"26,613 "},{"v":19318,"d":"19,318 "}]
["Other",{"v":4751,"d":"4,751 "},{"v":3121,"d":"3,121 "}]
["Total deferred tax assets",{"v":169788,"d":"169,788 "},{"v":157787,"d":"157,787 "}]
["In-process research and development"," ",{"v":-27271,"d":"(27,271)"}]
["Total deferred tax liabilities"," ",{"v":-27271,"d":"(27,271)"}]
["Valuation allowance",{"v":-169797,"d":"(169,797)"},{"v":-130525,"d":"(130,525)"}]
["Net deferred tax liabilities",{"v":-9,"d":"$ (9)"},{"v":-9,"d":"$ (9)"}]

{"sheet":"Schedule of Unrecognized Tax Be","index":89,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2023","Dec. 31, 2022"]
["Income Tax Disclosure [Abstract]"," "," "]
["Balance beginning",{"v":1028,"d":"$ 1,028"},{"v":1270,"d":"$ 1,270"}]
["Decrease related to current year tax provisions"," ",{"v":-242,"d":"(242)"}]
["Decrease related to current year tax provisions"," ",{"v":242,"d":"242 "}]
["Balance ending",{"v":1028,"d":"$ 1,028"},{"v":1028,"d":"$ 1,028"}]

{"sheet":"Income Taxes (Details Narrative","index":90,"n_rows":11,"n_cols":4,"rows_kept":11,"merged":[[0,0,1,0]]}
["Income Taxes (Details Narrative) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2023","Dec. 31, 2022","Dec. 31, 2021"]
["Effective Income Tax Rate Reconciliation [Line Items]"," "," "," "]
["Valuation allowance increased amount",{"v":39272,"d":"$ 39,272"}," "," "]
["Unrecognized tax benefits",{"v":1028,"d":"1,028 "},{"v":1028,"d":"$ 1,028"},{"v":1270,"d":"$ 1,270"}]
["United States Federal And State [Member]"," "," "," "]
["Effective Income Tax Rate Reconciliation [Line Items]"," "," "," "]
["Net operating loss carryforwards",{"v":109544,"d":"$ 109,544"},{"v":102723,"d":"102,723 "}," "]
["Operating loss carryforwards expiration year","2040"," "," "]
["Tax credit carryforwards",{"v":5674,"d":"$ 5,674"},{"v":5674,"d":"$ 5,674"}," "]
["Tax credit carryforwards expiration year","2032"," "," "]

{"sheet":"Schedule of Financial Informati","index":91,"n_rows":51,"n_cols":10,"rows_kept":51,"merged":[[0,0,1,0],[0,1,0,5],[0,6,0,7],[0,8,0,9]]}
["Schedule of Financial Information by Segment (Details) - USD ($)","3 Months Ended",{"$nulls":4},"9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Jun. 30, 2023","Mar. 31, 2023","Dec. 31, 2022","Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Segment Reporting Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Net revenues",{"v":9296000,"d":"$ 9,296,000"},{"v":3786000,"d":"$ 3,786,000"}," "," "," ",{"v":36088000,"d":"$ 36,088,000"},{"v":10659000,"d":"$ 10,659,000"},{"v":22771000,"d":"$ 22,771,000"},{"v":17975000,"d":"$ 17,975,000"}]
["Gross profit"," "," "," "," "," "," "," ",{"v":6755000,"d":"6,755,000 "},{"v":-1690000,"d":"(1,690,000)"}]
["Direct expenses",{"v":16565000,"d":"16,565,000 "},{"v":16212000,"d":"16,212,000 "}," "," "," ",{"v":56143000,"d":"56,143,000 "},{"v":92565000,"d":"92,565,000 "},{"v":81041000,"d":"81,041,000 "},{"v":144198000,"d":"144,198,000 "}]
["Segment contribution",{"v":-11152000,"d":"(11,152,000)"},{"v":-16028000,"d":"(16,028,000)"}," "," "," ",{"v":-27701000,"d":"(27,701,000)"},{"v":-88313000,"d":"(88,313,000)"},{"v":-74286000,"d":"(74,286,000)"},{"v":-145888000,"d":"(145,888,000)"}]
["Indirect expenses",{"v":375000,"d":"375,000 "},{"v":83228000,"d":"83,228,000 "}," "," "," ",{"v":1377000,"d":"1,377,000 "},{"v":117289000,"d":"117,289,000 "},{"v":118001000,"d":"118,001,000 "},{"v":-120288000,"d":"(120,288,000)"}]
["Loss from operations",{"v":-11527000,"d":"(11,527,000)"},{"v":-99256000,"d":"(99,256,000)"}," "," "," ",{"v":-29078000,"d":"(29,078,000)"},{"v":-205602000,"d":"(205,602,000)"},{"v":-192287000,"d":"(192,287,000)"},{"v":-25600000,"d":"(25,600,000)"}]
["Change in fair value of contingent consideration liability"," "," "," "," "," "," ",{"v":-104339000,"d":"(104,339,000)"},{"v":-104339000,"d":"(104,339,000)"},{"v":-126277000,"d":"(126,277,000)"}]
["Goodwill impairment"," ",{"v":82714000,"d":"82,714,000 "},{"v":0,"d":"$ 0"},{"v":29633000,"d":"$ 29,633,000"},{"v":3610000,"d":"$ 3,610,000"}," ",{"v":112347000,"d":"112,347,000 "},{"v":112347000,"d":"112,347,000 "},{"v":3610000,"d":"3,610,000 "}]
["IPR&D impairment"," "," "," "," "," "," ",{"v":107800000,"d":"107,800,000 "},{"v":107800000,"d":"107,800,000 "}," "]
["Change in fair value of contingent stock consideration"," "," "," "," "," "," ",{"v":-159000,"d":"(159,000)"},{"v":-159000,"d":"(159,000)"},{"v":186000,"d":"186,000 "}]
["Cost of revenues (excluding amortization of acquired intangible assets)",{"v":3883000,"d":"3,883,000 "},{"v":3602000,"d":"3,602,000 "}," "," "," ",{"v":7646000,"d":"7,646,000 "},{"v":6407000,"d":"6,407,000 "}," "," "]
["Cell Therapy [Member]"," "," "," "," "," "," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Net revenues"," "," "," "," "," "," "," "," "," "]
["Gross profit"," "," "," "," "," "," "," "," "," "]
["Direct expenses",{"v":3496000,"d":"3,496,000 "},{"v":4887000,"d":"4,887,000 "}," "," "," ",{"v":12383000,"d":"12,383,000 "},{"v":53505000,"d":"53,505,000 "},{"v":28694000,"d":"28,694,000 "},{"v":75379000,"d":"75,379,000 "}]
["Segment contribution",{"v":-3496000,"d":"(3,496,000)"},{"v":-4887000,"d":"(4,887,000)"}," "," "," ",{"v":-12383000,"d":"(12,383,000)"},{"v":-53505000,"d":"(53,505,000)"},{"v":-28694000,"d":"(28,694,000)"},{"v":-75379000,"d":"(75,379,000)"}]
["Goodwill impairment"," "," "," "," "," "," "," ",{"v":112347000,"d":"112,347,000 "}," "]
["Cost of revenues (excluding amortization of acquired intangible assets)"," "," "," "," "," "," "," "," "," "]
["Biobanking [Member]"," "," "," "," "," "," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Net revenues",{"v":1292000,"d":"1,292,000 "},{"v":1427000,"d":"1,427,000 "}," "," "," ",{"v":3857000,"d":"3,857,000 "},{"v":4062000,"d":"4,062,000 "},{"v":5441000,"d":"5,441,000 "},{"v":5512000,"d":"5,512,000 "}]
["Gross profit"," "," "," "," "," "," "," ",{"v":3791000,"d":"3,791,000 "},{"v":1976000,"d":"1,976,000 "}]
["Direct expenses",{"v":353000,"d":"353,000 "},{"v":350000,"d":"350,000 "}," "," "," ",{"v":1216000,"d":"1,216,000 "},{"v":780000,"d":"780,000 "},{"v":1752000,"d":"1,752,000 "},{"v":1699000,"d":"1,699,000 "}]
["Segment contribution",{"v":701000,"d":"701,000 "},{"v":679000,"d":"679,000 "}," "," "," ",{"v":1689000,"d":"1,689,000 "},{"v":1927000,"d":"1,927,000 "},{"v":2039000,"d":"2,039,000 "},{"v":277000,"d":"277,000 "}]
["Cost of revenues (excluding amortization of acquired intangible assets)",{"v":238000,"d":"238,000 "},{"v":398000,"d":"398,000 "}," "," "," ",{"v":952000,"d":"952,000 "},{"v":1355000,"d":"1,355,000 "}," "," "]
["Degenerative Disease [Member]"," "," "," "," "," "," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Net revenues",{"v":8004000,"d":"8,004,000 "},{"v":2359000,"d":"2,359,000 "}," "," "," ",{"v":32231000,"d":"32,231,000 "},{"v":6597000,"d":"6,597,000 "},{"v":17330000,"d":"17,330,000 "},{"v":12463000,"d":"12,463,000 "}]
["Gross profit"," "," "," "," "," "," "," ",{"v":2964000,"d":"2,964,000 "},{"v":-3666000,"d":"(3,666,000)"}]
["Direct expenses",{"v":4187000,"d":"4,187,000 "},{"v":1901000,"d":"1,901,000 "}," "," "," ",{"v":14385000,"d":"14,385,000 "},{"v":6799000,"d":"6,799,000 "},{"v":9720000,"d":"9,720,000 "},{"v":10859000,"d":"10,859,000 "}]
["Segment contribution",{"v":172000,"d":"172,000 "},{"v":-2746000,"d":"(2,746,000)"}," "," "," ",{"v":11152000,"d":"11,152,000 "},{"v":-5254000,"d":"(5,254,000)"},{"v":-6756000,"d":"(6,756,000)"},{"v":-14525000,"d":"(14,525,000)"}]
["Goodwill impairment"," "," "," "," "," "," "," "," ",{"v":3610000,"d":"3,610,000 "}]
["Cost of revenues (excluding amortization of acquired intangible assets)",{"v":3645000,"d":"3,645,000 "},{"v":3204000,"d":"3,204,000 "}," "," "," ",{"v":6694000,"d":"6,694,000 "},{"v":5052000,"d":"5,052,000 "}," "," "]
["Other [Member]"," "," "," "," "," "," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "," "," "," "," "," "]
["Net revenues"," "," "," "," "," "," "," "," "," "]
["Gross profit"," "," "," "," "," "," "," "," "," "]
["Direct expenses",{"v":8529000,"d":"8,529,000 "},{"v":9074000,"d":"9,074,000 "}," "," "," ",{"v":28159000,"d":"28,159,000 "},{"v":31481000,"d":"31,481,000 "},{"v":40876000,"d":"40,876,000 "},{"v":56261000,"d":"56,261,000 "}]
["Segment contribution",{"v":-8529000,"d":"(8,529,000)"},{"v":-9074000,"d":"(9,074,000)"}," "," "," ",{"v":-28159000,"d":"(28,159,000)"},{"v":-31481000,"d":"(31,481,000)"},{"v":-40876000,"d":"(40,876,000)"},{"v":-56261000,"d":"(56,261,000)"}]
["Indirect expenses",{"v":375000,"d":"375,000 "},{"v":83228000,"d":"83,228,000 "}," "," "," ",{"v":1377000,"d":"1,377,000 "},{"v":117289000,"d":"117,289,000 "},{"v":118001000,"d":"118,001,000 "},{"v":-120288000,"d":"(120,288,000)"}]
["Change in fair value of contingent consideration liability"," ",{"v":-39000,"d":"(39,000)"}," "," "," "," ",{"v":-104339000,"d":"(104,339,000)"},{"v":-104339000,"d":"(104,339,000)"},{"v":-126277000,"d":"(126,277,000)"}]
["Goodwill impairment"," ",{"v":82714000,"d":"82,714,000 "}," "," "," "," ",{"v":112347000,"d":"112,347,000 "},{"v":112347000,"d":"112,347,000 "},{"v":3610000,"d":"3,610,000 "}]
["IPR&D impairment"," "," "," "," "," "," ",{"v":107800000,"d":"107,800,000 "},{"v":107800000,"d":"107,800,000 "}," "]
["Amortization",{"v":375000,"d":"375,000 "},{"v":553000,"d":"553,000 "}," "," "," ",{"v":1377000,"d":"1,377,000 "},{"v":1640000,"d":"1,640,000 "},{"v":2193000,"d":"2,193,000 "},{"v":2193000,"d":"2,193,000 "}]
["Total other",{"v":375000,"d":"375,000 "},{"v":83228000,"d":"83,228,000 "}," "," "," ",{"v":1377000,"d":"1,377,000 "},{"v":117289000,"d":"117,289,000 "},{"v":118001000,"d":"$ 118,001,000"},{"v":-120288000,"d":"(120,288,000)"}]
["Change in fair value of contingent stock consideration"," "," "," "," "," "," ",{"v":-159000,"d":"(159,000)"}," ",{"v":186000,"d":"$ 186,000"}]
["Cost of revenues (excluding amortization of acquired intangible assets)"," "," "," "," "," "," "," "," "," "]

{"sheet":"Segment Information (Details Na","index":92,"n_rows":5,"n_cols":4,"rows_kept":5,"merged":[[0,0,1,0]]}
["Segment Information (Details Narrative) $ in Thousands","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024 USD ($) Segment","Dec. 31, 2023 USD ($) Integer","Dec. 31, 2022 USD ($)"]
["Segment Reporting [Abstract]"," "," "," "]
["Number of operating segments",{"v":3,"d":"3 "},{"v":3,"d":"3 "}," "]
["Total assets",{"v":128840,"d":"$ 128,840"},{"v":143889,"d":"$ 143,889"},{"v":401066,"d":"$ 401,066"}]

{"sheet":"Related Party Transactions (Det","index":93,"n_rows":104,"n_cols":19,"rows_kept":104,"merged":[[0,0,1,0],[0,8,0,9],[0,10,0,12]]}
["Related Party Transactions (Details Narrative) - USD ($)",{"$nulls":6},"1 Months Ended","9 Months Ended",null,"12 Months Ended"]
[null,"Mar. 13, 2024","Oct. 12, 2023","Mar. 20, 2023","Jan. 25, 2023","Sep. 01, 2022","Aug. 16, 2022","Sep. 21, 2022","Sep. 30, 2024","Sep. 30, 2023","Oct. 13, 2024","Dec. 31, 2023","Dec. 31, 2022","Sep. 14, 2023","Jul. 31, 2023","Jun. 21, 2023","Apr. 10, 2023","Mar. 17, 2023","Aug. 21, 2003"]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Accrued expenses"," "," "," "," "," "," "," ",{"v":14466000,"d":"$ 14,466,000"}," "," ",{"v":7580000,"d":"$ 7,580,000"},{"v":9069000,"d":"$ 9,069,000"}," "," "," "," "," "," "]
["Proceeds from PIPE financings"," "," "," "," "," "," "," ",{"v":6000000,"d":"$ 6,000,000"},{"v":12750000,"d":"$ 12,750,000"}," ",{"v":12750000,"d":"$ 12,750,000"},{"v":30000000,"d":"30,000,000 "}," "," "," "," "," "," "]
["Warrants to purchase common stock"," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":892856,"d":"892,856 "}," "," "," "," "]
["Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase common stock"," "," "," "," "," "," "," ",{"v":10905901,"d":"10,905,901 "}," "," ",{"v":7070627,"d":"7,070,627 "}," "," ",{"v":857142,"d":"857,142 "}," ",{"v":923076,"d":"923,076 "}," "," "]
["Restricted Stock Units (RSUs) [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Options vesting period"," "," "," "," "," "," "," ","2 years"," "," ","2 years"," "," "," "," "," "," "," "]
["COTA Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Contribution made"," "," "," "," "," "," "," ",{"v":0,"d":"$ 0"},{"v":0,"d":"0 "}," ",{"v":0,"d":"$ 0"},{"v":86000,"d":"86,000 "}," "," "," "," "," "," "]
["Cryoport Systems Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Contribution made"," "," "," "," "," "," "," ",{"v":2000,"d":"$ 2,000"},{"v":33000,"d":"33,000 "}," ",{"v":33000,"d":"$ 33,000"},{"v":70000,"d":"70,000 "}," "," "," "," "," "," "]
["CV Star Loan [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loan agreement"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":5000000,"d":"$ 5,000,000"}," "]
["CV Star Loan [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase common stock"," "," "," "," "," "," "," ",{"v":1528138,"d":"1,528,138 "}," "," ",{"v":125000,"d":"125,000 "}," "," "," "," "," "," "," "]
["Number of shares holding"," "," "," "," "," "," "," "," "," "," ",{"v":764069,"d":"764,069 "}," "," "," "," "," "," "," "]
["CV Star Loan [Member] | Common Class A [Member] | March Two Thousand Twenty Three Loan Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase common stock"," "," "," "," "," "," "," ",{"v":125000,"d":"125,000 "}," "," ",{"v":75000,"d":"75,000 "}," "," "," "," "," "," "," "]
["CV Star Loan [Member] | Common Class A [Member] | June Two Thousand Twenty Three Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase common stock"," "," "," "," "," "," "," "," "," "," ",{"v":50000,"d":"50,000 "}," "," "," "," "," "," "," "]
["Resorts World Inc Pte Ltd [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loan agreement"," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":12000000,"d":"$ 12,000,000"}," "," "," "]
["Resorts World Inc Pte Ltd [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase common stock"," "," "," "," "," "," "," "," "," "," ",{"v":300000,"d":"300,000 "}," "," "," "," "," "," "," "]
["Sorrento Therapeutics Inc [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Contribution made"," "," "," "," "," "," "," "," "," "," ",{"v":0,"d":"$ 0"},{"v":1821000,"d":"1,821,000 "}," "," "," "," "," "," "]
["Chairman And Chief Executive Officer [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," ",{"v":285000,"d":"$ 285,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Chairman And Chief Executive Officer [Member] | Ceo Promissory Note [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Principal amont"," ",{"v":285000,"d":"$ 285,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Interest rate",{"v":0.15,"d":"15%"},{"v":0.15,"d":"15%"}," "," "," "," "," "," "," ",{"v":0.15,"d":"15%"}," "," "," "," "," "," "," "," "]
["March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Proceeds from PIPE financings"," "," ",{"v":9000000,"d":"$ 9,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member] | Common Class A [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Warrants to purchase common stock"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":729698,"d":"729,698 "}," "," "," "," "," "]
["Securities Purchase Agreement [Member] | March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member] | Dr Robert Hariri [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Proceeds from PIPE financings"," "," ",{"v":9000000,"d":"9,000,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Securities Purchase Agreement [Member] | March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member] | Dr Hariri [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Proceeds from PIPE financings"," "," ",{"v":2000000,"d":"$ 2,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loan Agreement [Member] | Chairman And Chief Executive Officer [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument contribution amount"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1000000,"d":"$ 1,000,000"}]
["Loan interest rate"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.15,"d":"15%"}]
["Consulting Agreement [Member] | Dr Andrew Pecora [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related party description"," "," "," "," "," "," "," "," "," "," ","On\nAugust 31, 2022, Dr. Pecora resigned as the Company’s President, and subsequently entered into a consulting agreement with the\nCompany dated September 21, 2022, to receive a $10 monthly fee for an initial six-month term and will be automatically renewed for one\nadditional six- month term if either party does not provide notice of non-renewal."," "," "," "," "," "," "," "]
["Receive for month"," "," "," "," "," "," ",{"v":10000,"d":"$ 10,000"}," "," "," "," "," "," "," "," "," "," "," "]
["Scientific And Clinical Advisor Agreement [Member] | Restricted Stock Units (RSUs) [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["RSUs one-time grant value"," "," "," "," ",{"v":125000,"d":"$ 125,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Scientific And Clinical Advisor Agreement [Member] | Dr Andrew Pecora [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Receive for month"," "," "," "," ",{"v":10000,"d":"$ 10,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Scientific And Clinical Advisor Agreement [Member] | Dr Andrew Pecora [Member] | Restricted Stock Units (RSUs) [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Options vesting period"," "," "," "," ","4 years"," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Advisory Agreement [Member] | Robin L Smith Md [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Receive for month"," "," "," "," "," ",{"v":20000,"d":"$ 20,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Vested options to acquire shares"," "," "," "," "," ",{"v":105000,"d":"105,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["One-time cash bonus"," "," "," "," "," ",{"v":1500000,"d":"$ 1,500,000"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Amount paid"," "," "," "," "," "," "," ",{"v":0,"d":"$ 0"},{"v":20000,"d":"20,000 "}," ",{"v":20000,"d":"$ 20,000"},{"v":80000,"d":"80,000 "}," "," "," "," "," "," "]
["Advisory Agreement [Member] | Robin L Smith Md [Member] | Initial Tranche [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Vested options to acquire shares"," "," "," "," "," ",{"v":25000,"d":"25,000 "}," "," "," "," "," "," "," "," "," "," "," "," "]
["Advisory Agreement [Member] | Robin L Smith Md [Member] | Share-Based Payment Arrangement, Tranche Two [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Vested options to acquire shares"," "," "," "," ",{"v":20000,"d":"20,000 "}," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Dr Robert Hariri [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Accrued expenses"," "," "," "," "," "," "," ",{"v":1432,"d":"1,432 "}," "," ",{"v":1088,"d":"1,088 "}," "," "," "," "," "," "," "]
["Securities purchase agreement date"," "," "," ","Jan. 12,  2024"," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Dr Robert Hariri [Member] | Securities Purchase Agreement [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid base salary"," "," "," ",{"v":1088000,"d":"$ 1,088,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Net proceeds from offerings of equity securities"," "," "," ",{"v":21000000,"d":"$ 21,000,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of unpaid base salary"," "," "," ",{"v":1.25,"d":"125%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Percentage of base salary"," "," "," ",{"v":0.85,"d":"85%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Bonus program effective date"," "," "," ","Feb. 16,  2024"," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Annual rate of base salary"," "," "," ",{"v":180000,"d":"$ 180,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Bonus program effective date"," "," "," ","Jan.  01,  2025"," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Employment Of Immediate Family Member [Member] | Ms Hariri [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Base salary"," "," "," "," "," "," "," ",{"v":265000,"d":"$ 265,000"},{"v":265000,"d":"$ 265,000"}," ",{"v":265000,"d":"$ 265,000"},{"v":216000,"d":"$ 216,000"}," "," "," "," "," "," "]

{"sheet":"Schedule Of Antidilutive Securi","index":94,"n_rows":16,"n_cols":5,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details) - shares","9 Months Ended",null,"12 Months Ended"]
[null,"Sep. 30, 2024","Sep. 30, 2023","Dec. 31, 2023","Dec. 31, 2022"]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":15929600,"d":"15,929,600 "},{"v":13740797,"d":"13,740,797 "},{"v":11263827,"d":"11,263,827 "},{"v":5342746,"d":"5,342,746 "}]
["Share-Based Payment Arrangement, Option [Member]"," "," "," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":3455049,"d":"3,455,049 "},{"v":2961438,"d":"2,961,438 "},{"v":2820187,"d":"2,820,187 "},{"v":1239219,"d":"1,239,219 "}]
["Restricted Stock Units (RSUs) [Member]"," "," "," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":327359,"d":"327,359 "},{"v":878555,"d":"878,555 "},{"v":823332,"d":"823,332 "},{"v":128590,"d":"128,590 "}]
["Warrant [Member]"," "," "," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":10905901,"d":"10,905,901 "},{"v":7070627,"d":"7,070,627 "},{"v":7070627,"d":"7,070,627 "},{"v":3345836,"d":"3,345,836 "}]
["Convertible Debt Securities [Member]"," "," "," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "," "," "]
["Anti-dilutive securities",{"v":1241291,"d":"1,241,291 "},{"v":2830177,"d":"2,830,177 "},{"v":549681,"d":"549,681 "},{"v":629101,"d":"629,101 "}]

{"sheet":"Schedule of Reconciliation of_3","index":95,"n_rows":8,"n_cols":4,"rows_kept":8,"merged":[[0,0,1,0],[0,2,0,3]]}
["Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details) - USD ($) $ in Thousands","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Subsequent Events [Abstract]"," "," "," "]
["Beginning balance",{"v":2072,"d":"$ 2,072"},{"v":2514,"d":"$ 2,514"}," "]
["Net transfers into (out of) Level 3"," "," "," "]
["Purchases settlements and other net",{"v":-2072,"d":"(2,072)"}," "," "]
["Fair value adjustments"," ",{"v":-104339,"d":"(104,339)"},{"v":-126277,"d":"(126,277)"}]
["Ending balance"," ",{"v":2072,"d":"$ 2,072"},{"v":2514,"d":"$ 2,514"}]

{"sheet":"Schedule of Reconciliation of W","index":96,"n_rows":8,"n_cols":4,"rows_kept":8,"merged":[[0,0,1,0],[0,2,0,3]]}
["Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands","9 Months Ended","12 Months Ended"]
[null,"Sep. 30, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Subsequent Events [Abstract]"," "," "," "]
["Fair value, Beginning Balance",{"v":3784,"d":"$ 3,784"},{"v":3598,"d":"$ 3,598"},{"v":25962,"d":"$ 25,962"}]
["January 2024 Bridge Loan - Tranche #2 warrant issuance",{"v":1858,"d":"1,858 "}," "," "]
["Gain recognized in earnings from change in fair value",{"v":1587,"d":"1,587 "},{"v":-6164,"d":"(6,164)"},{"v":-42109,"d":"(42,109)"}]
["Reclassification of warrants from liability classified to equity classified",{"v":-2970,"d":"(2,970)"}," "," "]
["Fair Value, Ending Balance",{"v":4259,"d":"$ 4,259"},{"v":3784,"d":"$ 3,784"},{"v":3598,"d":"$ 3,598"}]

{"sheet":"Schedule of January 20224 Bridg","index":97,"n_rows":16,"n_cols":4,"rows_kept":16,"merged":[[0,0,0,1],[14,0,14,2],[15,0,15,2]]}
["Schedule of January 20224 Bridge Loan (Details) - January Two Thousand Twenty Four Bridge Loan Tranche Two Warrants [Member]",null,"Jul. 15, 2024 $ / shares","Jan. 16, 2024 $ / shares"]
["Class of Warrant or Right [Line Items]",null," "," "]
["Common share price",null,{"v":3.19,"d":"$ 3.19"},{"v":2,"d":"$ 2"}]
["Term to initial exercise date (years)","[1]"," ","6 months"]
["Term (years)",null,"5 years","5 years"]
["Measurement Input, Expected Dividend Rate [Member]",null," "," "]
["Class of Warrant or Right [Line Items]",null," "," "]
["Warrant and right outstanding measurement input",null,{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Measurement Input, Risk Free Interest Rate [Member]",null," "," "]
["Class of Warrant or Right [Line Items]",null," "," "]
["Warrant and right outstanding measurement input",null,{"v":4,"d":"4 "},{"v":3.9,"d":"3.90"}]
["Measurement Input, Price Volatility [Member]",null," "," "]
["Class of Warrant or Right [Line Items]",null," "," "]
["Warrant and right outstanding measurement input",null,112.5,107.5]
[]
["[1]As discussed further\nin Note 7, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July 15, 2024,\nthe warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the Company’s\nown stock. As such, the warrants were marked to fair value as of the initial exercise date and then reclassified from liability classified\nto equity classified."]

{"sheet":"Schedule of Debt (Details)","index":98,"n_rows":21,"n_cols":5,"rows_kept":21}
["Schedule of Debt (Details) - USD ($) $ in Thousands","Sep. 30, 2024","Jul. 29, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Line of Credit Facility [Line Items]"," "," "," "," "]
["Total short-term debt - unaffiliated",{"v":3695,"d":"$ 3,695"}," ",{"v":19331,"d":"$ 19,331"}," "]
["Short-term debt - other"," "," ",{"v":2108,"d":"2,108 "}," "]
["Total short-term debt - related parties",{"v":38915,"d":"38,915 "}," ",{"v":19909,"d":"19,909 "}," "]
["Total debt",{"v":42610,"d":"42,610 "},{"v":42700,"d":"$ 42,700"},{"v":39240,"d":"39,240 "}," "]
["CV Starr Bridge Loan Net Of Discount [Member]"," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "]
["Total short-term debt - related parties",{"v":5640,"d":"5,640 "}," ",{"v":5523,"d":"5,523 "}," "]
["R W I Bridge Loan Net Of Discount [Member]"," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "]
["Total short-term debt - related parties",{"v":29482,"d":"29,482 "}," ",{"v":12967,"d":"12,967 "}," "]
["Ceo Promissory Note [Member]"," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "]
["Total short-term debt - related parties",{"v":3793,"d":"3,793 "}," ",{"v":1419,"d":"1,419 "}," "]
["Yorkville [Member] | Pre Paid Advance Agreement [Member]"," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "]
["Total short-term debt - unaffiliated"," "," ",{"v":17223,"d":"17,223 "}," "]
["Yorkville [Member] | Convertible Promissory Notes [Member]"," "," "," "," "]
["Line of Credit Facility [Line Items]"," "," "," "," "]
["Total short-term debt - unaffiliated",{"v":3695,"d":"$ 3,695"}," "," "," "]

{"sheet":"Schedule of Changes in Deferr_2","index":99,"n_rows":4,"n_cols":3,"rows_kept":4}
["Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical) - USD ($) $ in Thousands","Sep. 30, 2024","Sep. 30, 2023"]
["Subsequent Events [Abstract]"," "," "]
["Deferred revenue",{"v":3736,"d":"$ 3,736"},{"v":3818,"d":"$ 3,818"}]
["Unearned revenue",{"v":2271,"d":"$ 2,271"},{"v":2274,"d":"$ 2,274"}]

{"sheet":"Subsequent Events (Details Narr","index":100,"n_rows":32,"n_cols":9,"rows_kept":32}
["Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands","Nov. 25, 2024","Oct. 09, 2024","Sep. 30, 2024","Mar. 13, 2024","Dec. 31, 2023","Jul. 31, 2023","Apr. 10, 2023","Dec. 31, 2022"]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "]
["Common stock par value"," "," ",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"}," "," ",{"v":0.0001,"d":"$ 0.0001"}]
["Exercise price"," "," "," ",{"v":8.1,"d":"$ 8.10"}," "," ",{"v":7.5,"d":"$ 7.50"}," "]
["Maximum [Member]"," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "]
["Exercise price"," "," "," "," "," ",{"v":7.5,"d":"$ 7.50"}," "," "]
["Subsequent Event [Member]"," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "]
["Proceeds from notes and purchaser warrants",{"v":750,"d":"$ 750"}," "," "," "," "," "," "," "]
["Bearing interest",{"v":0.08,"d":"8%"}," "," "," "," "," "," "," "]
["Increase in bearing interest",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "]
["Common stock par value",{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "," "," "]
["Exercise price",2.85," "," "," "," "," "," "," "]
["Gross proceeds",{"v":2500000,"d":"2,500,000 "}," "," "," "," "," "," "," "]
["Floor price",{"v":1,"d":"$ 1"}," "," "," "," "," "," "," "]
["Warrant outstanding term","5 years"," "," "," "," "," "," "," "]
["Percentage of cash fee equal to aggregate proceeds",{"v":0.07,"d":"7%"}," "," "," "," "," "," "," "]
["Percentage of non-accountable expense fee",{"v":0.01,"d":"1%"}," "," "," "," "," "," "," "]
["Initial retainer fee",{"v":25,"d":"$ 25"}," "," "," "," "," "," "," "]
["Reimbursement of legal expenses",{"v":75,"d":"$ 75"}," "," "," "," "," "," "," "]
["Percentage of exercise price equal to offering price",{"v":1.25,"d":"125%"}," "," "," "," "," "," "," "]
["Subsequent Event [Member] | Maximum [Member]"," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "]
["Notes and purchaser warrants principal amount",{"v":1000,"d":"$ 1,000"}," "," "," "," "," "," "," "]
["Sequence Lifescience Inc [Member] | Subsequent Event [Member]"," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "]
["Consideration paid for assets"," ",{"v":5500,"d":"$ 5,500"}," "," "," "," "," "," "]
["Upfront payment"," ",{"v":1000,"d":"1,000 "}," "," "," "," "," "," "]
["Monthly milestone payments"," ",{"v":4000,"d":"4,000 "}," "," "," "," "," "," "]
["Prior payment to related party"," ",{"v":500,"d":"$ 500"}," "," "," "," "," "," "]
["Net sales percentage"," ",{"v":0.2,"d":"20%"}," "," "," "," "," "," "]